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Thesis Abstract 
The vasculitides are a wide spectrum of disorders which are characterised by vascular 
inflammation.  Endothelial  injury  can  occur  as  a  consequence  of  inappropriate 
inflammation and is central to the pathogenesis of these varied diseases.  This thesis 
documents the development of assays for detection of novel biomarkers of endothelial 
injury and/or activation and subsequent reparative responses in children with primary 
systemic vasculitis.  It focuses in particular on circulating endothelial cells, cellular 
microparticles, growth factors involved in angiogenesis/vasculogenesis and endothelial 
progenitor cells.   
 
Circulating endothelial cells are mature endothelial cells which have become detached 
from the vessel wall and represent a highly damaged vasculature and were found to be 
significantly higher in  children with  active primary systemic vasculitis  compared to 
healthy  child  controls  and  patients  in  remission.    Microparticles  are  released  from 
activated cells, including the endothelium and leukocytes.  In this study endothelial and 
monocyte derived microparticles were found to  be elevated during active vasculitis.  
Growth factors released in response to endothelial injury regulate reparative responses, 
of which endothelial progenitor cells may play a key role.  In this study, patients at 
disease onset prior to treatment were found to have significantly higher levels of growth 
factors  and  endothelial  progenitor  cells,  which  decreased  with  remission  inducing 
therapy.  Overall this thesis has investigated the changes in these interlinked biomarkers 
of injury and repair during active disease, remission and disease flare.  
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1 Introduction 
 
1.1.  The endothelium and its functions 
 
1.2.  Vasculitis – a clinical perspective 
 
1.3.  The pathogenesis of vasculitis 
 
1.4.  Assessment of disease activity in vasculitis – the need for reliable 
biomarkers 
 
1.5.  Aims of this thesis 
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1.1 The endothelium and its functions 
The term “vasculitis” refers to inflammation affecting blood vessels.  The endothelium, 
which forms the inner layer of all blood vessels, is both central to the pathogenesis of 
the disease and can be directly damaged by the inflammatory processes, resulting in 
impairment of function.  This thesis therefore begins with a brief introduction to the 
endothelium, hilighting some of its key functions that are essential for health but may be 
impacted upon in vasculitis.  
 
In  an  adult  human  the  endothelial  monolayer  consists  of  approximately  10
13  cells 
covering an area of 1-7m
2 (Cines et al., 1998).   Endothelial cells are supported by a 
basement membrane that is surrounded by varying thicknesses of smooth muscle and 
connective tissue depending on vessel type and function.  In the microvasculature where 
smooth muscle is absent, pericytes also sit within the basement membrane and surround 
the endothelium with long cytoplasmic processes (Allt and Lawrenson, 2001).  Prior to 
the  discovery  of  the  vasodilator  prostacyclin  in  1976  (Bunting  et  al.,  1976)  the 
endothelium  was  considered  to  be  an  inert  barrier  that  separated  blood  and  tissue.  
However, it is now apparent that the endothelium plays a role in many vital functions 
including:  regulation  of  vessel  tone  and  blood  flow,  fluid  and  solute  exchange, 
haemostasis  and  coagulation,  vasculogenesis  and  angiogenesis  and  inflammatory 
responses.   
 
1.1.1 Control of vessel tone 
In response to stimulation by substances in the blood (e.g. histamine, angiotensin, 5HT) 
or mechanical stimuli endothelial cells can release a number of vasoactive factors that 
relax (e.g. prostacyclin, nitric oxide (NO), hydrogen peroxide (H2O2)) or contract (e.g. 18 
 
thromboxane A2, endothelin, angiotensin II) surrounding smooth muscle (Feletou and 
Vanhoutte, 2006).  Endothelial cells can also signal directly with smooth muscle via 
myoendothelial gap junctions, allowing the spread of membrane potential  and small 
molecules and ions such as calcium (Ca
2+) which in turn can alter vascular tone (Feletou 
and Vanhoutte, 2006).  
 
Global  rise  in  intracellular  Ca
2+  directly  influences  the  contractile  state  of  vascular 
smooth muscle (VSM) (House et al., 2008).  This occurs via its binding of calmodulin 
and subsequent activation of myosin light chain kinase (MLCK), which results in the 
phosphorylation  of  myosin,  allowing  interaction  with  actin  and  the  initiation  of 
contraction  (Rang  et  al.,  1999).    The  ability  of  the  endothelium  to  activate/inhibit 
signalling  pathways  that  crosstalk  with  this  system,  means  that  although  Ca
2+  is 
important for contraction, the relationship between Ca
2+ concentration and the extent of 
contraction is not as clearly defined in VSM as it is in skeletal or cardiac muscle (Rang 
et al., 1999).  
 
1.1.2 Fluid and solute exchange 
The endothelium acts as a semi-permeable barrier and tightly controls the passage of 
large molecules and fluids between the blood and interstitial space.  Small molecules 
such  as  urea,  glucose  and  ions  easily  pass  across  in  a  paracellular  manner  through 
interendothelial gap junctions (Lum and Malik, 1994).   However, larger molecules such 
as  albumin  cannot  do  this  and,  in  the  quiescent  endothelium,  they  pass  in  an 
intracellular  manner  via  vesicular  transport.    Calveolae  (pits)  in  the  surface  of  the 
endothelium, develop into vesicles which pass across the cell, either independently via 
fluid-phase  uptake  or  in  a  receptor  dependent  manner  (Lum  and  Malik,  1994).    In 19 
 
response to certain  stimuli  (such as histamine  or vascular  endothelial  growth factor 
(VEGF)) interendothelial gap junctions become disrupted and larger molecules can pass 
through.  This transvascular flux of liquid and solutes from the circulation can rapidly 
lead to the oedema formation that is often associated with inflammation (Mehta and 
Malik, 2006).     
 
1.1.3 Haemostasis 
Damage to the luminal vessel wall can result in blood loss and haemostasis refers to the 
process by which it is stopped.  It is associated with vasoconstriction, adhesion and 
activation of platelets at the site of injury and a complex enzymatic activation cascade 
which culminates in the formation of a stable fibrin plug, effectively sealing the vessel 
(Hoffman and Monroe, 2007).   
 
Exposure to the blood of tissue factor (TF), the transmembrane receptor for factor VII, 
initiates this proteolytic clotting cascade, which ultimately results in the downstream 
activation of thrombin and its subsequent conversion of fibrinogen to the clot stabilizing 
polymer fibrin.  TF is constitutively expressed on a number of cells in the vessel wall 
(e.g. pericytes, fibroblasts and smooth muscle) (Camerer et al., 1996) but not on the 
endothelium, and thus  under normal  physiological  conditions  clotting should  not  be 
instigated.  However, TF can be expressed on tumour derived endothelium (Engelmann 
et  al., 2003) and on endothelial cells  in  response to  inflammation  (Randolph  et  al., 
1998).  It is also found on activated monocytes and is associated with platelets and 
microparticles in the circulation (Muller et al., 2003).  On microparticles in healthy 
individuals it is thought to be in an inactive form (Furie and Furie, 2008).   
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Platelets are activated on contact with exposed collagen in the vessel wall and along 
with leucocytes form part of the thrombus, propagating the enzymatic cascade by acting 
as a surface upon which TF is exposed and where fibrin generating pathways can occur 
(Hoffman and Monroe, 2007).  Pathological thrombosis can occur in the absence of 
substantial endothelial damage, and platelet activation independent of collagen exposure 
may be an initiating event in this.           
 
During  haemostasis  the  endothelium  acts  to  influence  both  pro  and  anticoagulant 
pathways.  It synthesizes and secretes key components of the clotting cascade (e.g. von 
Willebrand factor (vWF) and plasminogen activator inhibitor-1(PAI-1)) (Becker et al., 
2000).    Conversely  the  endothelium  also  generates  NO  and  prostacyclin  (inhibiting 
platelet  function),  and  activates  a  number  of  anticoagulant  pathways  that  limit  the 
thrombus  formed.    These  anticoagulant  pathways  are  essential  for  preventing 
unnecessary  pathological  haemostasis  and  include  expression  of  the  surface 
glycoprotein  heparan  sulfate,  which  is  a  cofactor  for  the  serine  protease  inhibitor 
antithrombin  III  (which  can  inhibit  many  of  the  clotting  cascade  enzymes)  and 
thrombomodulin, a thrombin receptor which activates the anticoagulant protease protein 
C  (Adams  and  Huntington,  2006).  Tissue  factor  pathway  inhibitor  (TFPI)  is 
constitutively released by the endothelium and interferes in the TF-activated factor VII 
complex (Lwaleed and Bass, 2006) Tissue plasminogen activator, released in response 
to procoagulant activity catalyses the conversion of plasminogen to plasmin  - a key 
player in dissolution of the clot once injury has healed (Emeis, 1992).    
 
1.1.4 Angiogenesis and Vasculogenesis 
Once  haemostasis  has prevented blood loss from the vessel wall,  repair must  occur  to  21 
 
prevent long term dysfunction.  In health, the integrity of the endothelium is maintained 
by a continuous renewal of cells.  Turnover of the endothelium is low, with replication 
rates in the region of 0.1% per day in adults (Hunting et al., 2005), although in healthy 
growing children it could well be higher.  
 
Until relatively recently angiogenesis, whereby mature endothelial cells already present 
within the vessel proliferate and migrate, was considered to be the mechanism by which 
growth, remodeling and repair of damage occurred.  Vasculogenesis, whereupon bone 
marrow derived progenitor cells are recruited to form new vasculature, was considered 
to occur only during early embryonic development.  The concept of post-embryonic 
vasculogenesis gained impetus in 1997 when Asahara et al described a population of 
CD34+ cells which circulated within the peripheral blood, had the potential to form 
endothelial-like cells in vitro and enhanced repair in an ischaemia-reperfusion model 
(Asahara et al., 1997).  These cells were termed endothelial progenitor cells (EPCs) and 
have been the subject of much research in recent years. 
 
Whether EPCs are true endothelial progenitors with the ability to form permanent long 
lasting endothelium is still open to debate a decade later.  One alternative hypothesis is 
that they promote a localized pro-angiogenic state and are only found transiently at sites 
of injury (Fazel et al., 2006), although this requires further confirmation.  Regardless of 
the  exact  mechanisms  which  contribute  to  repair,  the  regulators  of  these  pathways 
(growth factors, chemokines and cytokines) a number of which act directly on or are 
released  from  the  endothelium,  are  frequently  the  same  in  angiogenesis  and 
vasculogenesis  and  thus  these  processes  are  likely  to  be  highly  interdependent. 
Angiogenesis and vasculogenesis are discussed in more detail in subsequent chapters.      22 
 
1.1.5 Inflammatory responses and the endothelium 
The endothelium responds rapidly to pathological conditions being both affected by and 
contributing  to  the  inflammatory  process,  secreting  inflammatory  cytokines  and 
chemokines and upregulating adhesion molecules, facilitating leukocyte recruitment.  In 
health, these responses are reversible and localized, however sustained or inappropriate 
activation is associated with endothelial dysfunction and contributes to the development 
of cardiovascular diseases such as atherosclerosis (Loppnow et al., 2008).   
 
A wide number of cytokines and chemokines can be released from the endothelium in 
response to inflammatory stimuli such as treatment with lipopolysaccharide (LPS) or 
tumour necrosis factor-α (TNFα) in vitro, and shear stress, infection or hypoxia in vivo 
(Krishnaswamy et al., 1999).  These include acute phase response cytokines such as IL-
1 and IL-6, which are responsible for a number of the characteristic manifestations of 
inflammation including fever, generation of acute-phase reactants by hepatocytes and 
activation  of  lymphocytes  (Marceau  et  al.,  1992,Ala  et  al.,  1992).    Chemokines 
produced include IL-8, which can recruit and activate neutrophils (Sica et al., 1990a), 
MCP-1 (monocyte chemoattractant protein-1)  which recruits  monocytes,  activated T 
cells,  dendritic  cells,  and  natural  killer  (NK)  cells  (Sica  et  al.,  1990b)  and 
CCL5/RANTES  (regulated  upon  activation  normal  T  cell  expressed  and  secreted), 
which recruits eosinophils.  Colony stimulating factors (CSF) released from endothelial 
cells such as GM-CSF (granulocyte-macrophage-CSF), M-CSF (macrophage-CSF) and 
G-CSF  (granulocyte-CSF)  alter  the  differentiation,  activation,  proliferation  and 
migration of macrophages and granulocytes and may even promote the in situ longevity 
of these recruited inflammatory cells (Rajavashisth et al., 1990). 
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Leukocyte  recruitment  to  the  tissue  from  the  circulation  requires  cells  to  migrate 
through the vessel wall.  The endothelium plays  a key role in  this  by  upregulating 
adhesion molecules which interact with leukocytes aiding their recruitment.  Endothelial 
E  and  P  selectins  acting  on  their  carbohydrate  ligands  on  leukocytes  result  in  the 
leukocytes slowing down and rolling along the endothelial surface.   Rolling leukocytes 
rapidly become activated via immobilized chemokines on the endothelium (Johnston 
and  Butcher,  2002)  with  upregulation  of  integrins  on  their  surface.      Integrins  on 
leukocytes contribute both to the rolling process (Ley et al., 2007) and to firm adhesion 
by binding members of the immunoglobulin superfamily on endothelial cells such as 
intercellular  adhesion  molecule  1  (ICAM-1)  and  vascular  cell  adhesion  molecule  1 
(VCAM-1)  (Petri  and  Bixel,  2006).  Subsequently  leukocytes  engage  other  adhesion 
molecules  such  as  platelet/endothelial  cell  adhesion  molecule-1  (PECAM-1), 
endothelial  cell-selective  adhesion  molecule  (ESAM),  CD99  and  members  of  the 
junctional adhesion molecule family (JAM) and cross the endothelial layer (Ley et al., 
2007).   
 
Studies  utilizing  neutralising  antibodies  indicate  that  different  adhesion  molecules 
mediate  leukocyte  transmigration  depending  on  stimulus,  leukocyte  cell  type  or 
location.  In rat mesenteric arteries for example IL-1β but not FMLP induced leukocyte 
transmigration can be inhibited by the use of PECAM blocking antibodies (Thompson 
et al., 2000).  Leukocytes can cross the endothelium in a paracellular or transcellular 
manner (Feng et al., 1998). It remains to be determined whether both pathways are of 
equal  physiological  relevance  or  if,  as  has  been  observed  in  vitro,  paracellular 
mechanisms are primary route of migration (Vestweber, 2007). 
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1.1.6 Conclusions 
The  endothelium  is  a  dynamic  and  heterogeneic  organ  system,  with  significant 
differences in response between endothelium of different vessels and even between cells 
in a similar location to certain stimuli.  With such a wide ranging and tightly regulated 
functionality preservation of a healthy endothelium is crucial to the maintenance of 
health  and  normal  physiological  homeostasis.    Inappropriate  and  sustained 
inflammatory  responses  (such  as  those  seen  in  the  vasculitides)  are  associated  with 
endothelial dysfunction.  Endothelial dysfunction is a phenomeneon that is considered 
to be central to the pathogenesis of the vasculitides and hence this group of disorders 
will now be discussed in more detail.  
 
 
1.2 Vasculitis – a clinical perspective 
The vasculitides are a group of disorders characterised by the presence of inflammatory 
cellular infiltrates (neutrophilic, eosinophilic, or mononuclear) in the walls of blood 
vessels, with resultant tissue ischaemia and necrosis. Vasculitis can affect blood vessels 
of all sizes and can occur as the primary disease manifestation or secondary to other 
conditions, such as infection, malignancy or autoimmune diseases such as rheumatoid 
arthritis  (RA),  scleroderma,  Sjogrens  syndrome  and  systemic  lupus  erythematosus 
(SLE) amongst others. 
 
1.2.1 Primary systemic vasculitis 
Classification of the vasculitides has proved difficult because of the absence of sensitive 
and specific diagnostic tests and an incomplete understanding of the aetiology of most 
vasculitic syndromes.  Patients often have constellations of symptoms and findings that 25 
 
overlap the clinical features of the various individual diseases.  Although many attempts 
have been made to  classify primary systemic vasculitis  (PSV) according to type of 
inflammation, causative mechanisms or associated autoantibodies, the most commonly 
used  system  for  classifying  disease  is  based  on  the  size  of  the  smallest  vessel 
predominantly involved  in  the disease process  - the Chapel  Hill Consensus  Criteria 
(Jennette et al., 1994).   
 
While  the  Chapel  Hill  criteria  and  the  American  College  of  Rheumatology  (ACR) 
criteria (Appendix 1) for classification of vasculitis are widely used, they have never 
been validated in children.  In this  context the recently described European League 
Against  Rheumatism  (EULAR)/Paediatric  Rheumatology  European  Society  (PRES) 
endorsed consensus criteria for the classification of childhood vasculitides may be more 
appropriate  (Appendix  1)  (Ozen  et  al.,  2006),  and  are  currently  undergoing  formal 
validation  (Brogan,  personal  communication).    This  is  based  on  the  Chapel  Hill 
consensus  criteria  with  modifications  suggested  by  consensus  relevant  to  paediatric 
disease.    For  the  purposes  of  this  thesis  which  is  focused  on  the  downstream 
consequences of vasculitis (i.e. endothelial injury and repair), classification is perhaps 
somewhat arbitrary as endothelial injury occurs in PSV irrespective of disease aetio-
pathogenesis (Brogan et al., 2004a).  In addition overlap in the size of vessels affected 
occurs (“polyangiitis overlap”), for example in Wegener’s granulomatosis (WG), which 
is classified as a small vessel disease vasculitis can be detected in small and medium-
sized  arteries  and  occasionally  larger  vessels,  including  the  renal  artery  and  aorta 
(Shitrit et al., 2002).  Therefore in this thesis when data was analysed the cohort was 
first examined as a whole, and then by subgroup analysis of individual diseases where 
appropriate.  Diseases were classified predominantly using the Chapel Hill Consensus 26 
 
Criteria, however the ACR and EULAR/PRES consensus criteria were used (out of 
necessity)  as  additional  classification  tools  by  clinicians  experienced  in  the 
classification of vasculitis at Great Ormond Street Hospital (GOSH).   
 
The individual vasculitic diseases of the young which have been studied within this 
thesis will now be described in more detail.  The predominant diseases observed in this 
study  have  been  Polyarteritis  Nodosa  (PAN)  and  Wegener’s  Granulomatosis  (WG), 
followed by Kawasaki disease (KD) and Takayasu’s Disease (TD).  An additional group 
of patients had definite but “unclassified” vasculitis. Epidemiological evidence suggests 
that  KD  and  Henloch  Schönlein-Purpura  (HSP)  are  the  most  common  vasculitic 
diseases of childhood.  In 2002 incidences for KD and HSP were estimated to be 8.2 per 
100 000 children under the age of five (Harnden et al., 2002) and 20.8 per 100 000 
children (Gardner-Medwin et al., 2002) respectively, with 0.24 per 100 000 children for 
all other primary systemic vasculitic conditions (Gardner-Medwin et al., 2002).  This is 
not  reflective  of  the  GOSH  cohort  however,  as  GOSH  is  a  specialist  centre  for 
paediatric vasculitis dealing with more complex cases that are referred from secondary 
and other tertiary care trusts 
 
1.2.2 Polyarteritis Nodosa and associated diseases 
In its  classical form,  PAN, is  a  necrotizing  vasculitis  associated  with  aneurysmal 
nodules along the walls of medium-sized muscular arteries, and was first described in 
detail in 1866 by Kussmaul and Maier (Dillon, 1998).  Although overlap occurs with 
smaller vessel disease, it is distinct from microscopic polyangiitis (see below), and in 
children occurs more commonly than the anti neutrophil cytoplasmic antibody (ANCA) 
associated vasculitides (Brogan and Dillon, 2000b).  The main clinical features of PAN 27 
 
are malaise, fever, skin rash, abdominal pain and arthropathy, although testicular pain, 
myalgia,  hypertension,  neuropathy,  renal  failure,  organic  psychosis  and  myocardial 
ischaemia can also occur (Besbas et al., 2000,Brogan and Dillon, 2000b).  
 
PAN  can  occur  in  a  predominantly  cutaneous  form,  associated  with  painful  skin 
nodules, livedo reticularis, and often following upper respiratory tract infection (Ozen et 
al., 2004).  While cutaneous PAN is generally a milder condition that responds well to 
non-steroidal  anti  inflammatory  drugs  (although  in  some  cases  corticosteroids  are 
necessary) and/or antibiotics if infection is suspected, the cutaneous disease can develop 
into the more serious systemic condition (Till and Amos, 1997).  Relapses are common 
(up  to  25%)  and  prophylactic  penicillin  is  sometimes  used,  as  infection  may  be 
associated  with  relapse.    Those  with  relapsing  disease  may  have  a  higher  risk  of 
developing systemic vasculitis (Till and Amos, 1997). 
 
Microscopic polyangiitis (MPA, formerly microscopic polyarteritis) differs from classic 
PAN by having extensive glomerular involvement and/or pulmonary haemorrhage.  It 
can  be  defined  as  a  small  vessel  vasculitis  with  focal  segmental  pauci-immune 
glomerulonephritis, sometimes with alveolar haemorrhage but without granulomatous 
disease of the respiratory tract (Puechal, 2007).  MPA is one of the ANCA-associated 
vasculitides (AAV), associated with perinuclear ANCA (pANCA) positivity, typically 
directed against myeloperoxidase (MPO-ANCA) (Bosch et al., 2006). 
 
1.2.3 Wegener’s Granulomatosis 
WG  is a necrotizing granulomatous vasculitis of the upper and  lower  respiratory  tract,  28 
 
associated with glomerulonephritis and variable small vessel vasculitis.  Upper airway 
disease can include granulomatous involvement of the trachea leading to stenosis, and 
of the nasal septum, leading to collapse of the bridge of the nose and “saddle nose” 
deformity.  Lower airway disease can often masquearade as infection (Stegmayr et al., 
2000), but it due to necrotising vasculitis of the pulmonary capillaries.  WG is another 
ANCA associated disease, although it is predominantly cytoplasmic ANCA staining 
(cANCA) that is observed (Bosch et al., 2006), typically against proteinase-3 (PR3-
ANCA), although MPO-ANCA are sometimes observed (Brogan, 2007).  
 
1.2.4 Takayasu disease 
World-wide,  TD  is  the  third  commonest  vasculitis  of  childhood,  and  some  have 
suggested that it may be related to tuberculosis infection (Dillon, 1998).  TD is a giant 
cell arteritis, a term that relates to the infiltration of giant cells (multinucleated cells 
formed by the fusion of many cells) seen in biopsies of diseased tissue.  TD causes 
stenosis and aneurysmal  dilatation  of large arteries, such as  the aorta and its  major 
branches. Its clinical features include fever, anorexia, weight loss, arthritis, and later the 
development of hypertension, heart failure and loss of pulse in some limbs (Kerr et al., 
1994).  The disease is often delayed in its diagnosis, especially in the young, and they 
can be confused with other causes of occlusive vasculopathy such as fibromuscular 
dysplasia (Tullus et al., 2008). 
 
1.2.5 Kawasaki disease 
KD was first described in 1967 by Tomisaku  Kawasaki who described 50 Japanese 
children with an illness characterised by fever, rash, conjunctival injection, erythema 
and swelling of hands and feet, and cervical lymphadenopathy (Kawasaki, 1967).  KD 29 
 
is more common in children of oriental background, with peak incidence at around 9-11 
months  of  age  (Newburger  et  al.,  2003).    KD  is  associated  with  development  of 
systemic  vasculitis  complicated  by  coronary  and  peripheral  arterial  aneurysms,  and 
myocardial infarction in some patients.  KD is the commonest cause of acquired heart 
disease in children in the UK and USA (Shulman et al., 1995)   
 
1.2.6 Henoch-Schönlein purpura  
HSP (anaphylactoid purpura) is the commonest vasculitis seen in childhood with peak 
incidence occurring at 4-5 years of age, more commonly in males.  It is a multi-system 
small vessel systemic vasculitis with a prominent cutaneous component, that can also 
affect joints, gastrointestinal tract and the kidney (Yang et al., 2008). Other organs less 
frequently involved include the central nervous system, gonads and the lungs.  HSP 
often occurs following an upper respiratory tract infection and the onset of the disorder 
may  be  accompanied  by  systemic  symptoms  including  malaise  and  mild  pyrexia 
(Saulsbury,  1999).    Of  the  childhood  vasculitides  HSP  has  the  most  favourable 
outcome,  with  the  large  majority  of  children  requiring  no  treatment.  Recurrence  of 
symptoms  occurs  in  around  one  third  of  cases,  generally  within  four  months  of 
resolution  of  the  original  symptoms  and  more  frequently  in  those  with  renal 
involvement (Saulsbury, 1999). 
 
1.2.7 Churg-Strauss syndrome 
Churg-Strauss  syndrome  (CSS)  or  allergic  granulomatosis  is  extremely  rare  in 
childhood  (Boyer  et  al.,  2006).    It  is  described  as  AAV,  although  there  is  no 
predominant  cANCA  or  pANCA  association  (Bosch  et  al.,  2006)  and  in  the  small 
number of published studies in children, frequency of ANCA positivity is lower than in 30 
 
adults (Boyer et al., 2006).   The disease can affect the lungs, GI tract and nervous 
system and often presents initially as severe asthma.  Other clinical features include 
eosinophilia, infiltrates on chest X-ray and extra-vascular granulomata on biopsy (Boyer 
et al., 2006). 
 
1.2.8 Other vasculitic disorders 
According  to  the  EULAR/PRES  consensus  criteria  relating  to  the  classification  of 
paediatric vasculitis the following conditions fall into the category of disease described 
as “other” (Ozen et al., 2006).  No specific definitions are described for these entities in 
the proporsed EULAR/PRES criteria, thus Chapel Hill consensus or ACR criteria were 
applied where appropriate. 
 
1.2.8.1 Behçet’s disease 
Behçet’s disease (BD) occurs rarely in children.  In studies of adults incidence is much 
higher in the Mediterranean, Middle East and Far East compared to Northern Europe 
(Reynolds, 2008). Incidence in adults in Turkey is estimated at 110-370 per 100 000 
(Idil et  al.,  2002,Yurdakul  et  al.,  1988), whereas  in  the UK it is  0.64 per 100 000 
(Chamberlain, 1977).  BD is associated with recurrent oral and genital ulcers, relapsing 
uveitis, skin lesions, arthritis and CNS and GI manifestations.  It is recognised that a 
vasculitic component is an important feature of the disease (Reynolds, 2008,Kutlay et 
al., 2008).   
 
1.2.8.2 Cogan’s syndrome 
Cogan’s syndrome is a rare condition that predominantly affects young adults, although 
has  been reported in  children  (Olfat  and Al-Mayouf, 2001).  The syndrome mainly 31 
 
affects  the  eyes  with  inflammation  of  the  cornea  (keratitis)  leading  to  eye  redness, 
blurred vision, pain and photophobia and the vestibuloauditory system causing tinnitus, 
dizziness, hearing loss and nausea and vomiting.  Systemic vasculitis can also occur, in 
predominantly  large and medium vessels, typically associated with aortic involvement 
(St Clair and McCallum, 1999). 
 
1.2.8.3 Vasculitis secondary to connective tissue diseases 
Secondary systemic vasculitis associated with autoimmune connective tissue diseases is 
a well recognised phenomenon.  The extent to which it occurs at a subclinical level may 
be much more widespread, than previously appreciated, and in children and adults is 
likely  to  have  long  term  implications  relating  to  cardiovascular  outcomes  such  as 
premature atherosclerosis (Bacon et al., 2002).  
 
Autopsy  studies  in  adult  patients  suffering  from  RA  indicate  that  a  significant 
proportion have evidence of systemic vasculitis (ranging from 15-31%) (Bely et al., 
1992,Salvarani et al., 1992,Suzuki et al., 1994) however in living patients detection is at 
much lower levels (<1%) (Watts et al., 2004,Wattiaux et al., 1987,Genta et al., 2006).  
The relationship between rheumatic disease and risk of adverse cardiovascular events 
independent of traditional risk factors is now well recognized.  RA doubles the risk of 
cardiovascular disease and is associated with early mortality (Van et al., 2002,bou-Raya 
and bou-Raya, 2006) while SLE has a 5-6 times higher risk of a significant coronary 
event, rising to up to 50 times higher than the general population in young women 
(Manzi  et  al.,  1997).    The  presence  of  subclinical  vasculitis  in  these  patients  is  an 
attractive hypothesis to explain this phenomenon, however as discussed in more detail 
later in this chapter monitoring disease activity in primary systemic vasculitis is fraught 32 
 
with difficulties in routine clinical practice.  Thus assessing subclinical vasculitis in 
patients with inflammatory disease remains a major challenge, but is likely to be of 
great  importance  in  view  of  the  poor  cardiovascular  outcomes  associated  with 
autoimmune diseases (Bacon et al., 2002).   
 
1.2.8.4  Vasculitis secondary to infection 
Infectious agents such as viruses, bacteria and fungi have been repeatedly proposed as 
triggering agents for vasculitis, and are more frequently associated with conditions that 
are ANCA negative (Pagnoux et al., 2006).  Some infections are directly responsible for 
causing  vasculitis  by  their  action  on  the  endothelium,  either  by  directly  infecting 
endothelial cells or binding to them, resulting in bystander injury to the surrounding 
vessel wall.  Other infections misdirect the host immune response towards self: if the 
infecting  pathogen  expresses  structures  similar  to  that  seen  in  the  endothelium, 
molecular  mimicry  may  occur  whereby  host  responses  are  directed  towards  the 
endothelium  as  well  as  the  pathogen.  Complementary  peptides  (which  contain 
sequences that match the antisense DNA strand of a host peptide) can also induce a host 
autoimmune response (discussed in more detail in the context of AAV) (Pendergraft, III 
et al., 2004).  Superantigens have also been implicated in vasculitis, particularly KD 
(Brogan et al., 2008).  These pathogen derived peptides have the ability to activate large 
proportions of the T cell population (5-30%) by crosslinking MHC class II on antigen 
presenting cells  (APCs) and the T cell receptor (TCR) independent  of conventional 
antigen processing pathways. 
 
Viral infections that have been implicated in vasculitis include hepatitis B, hepatitis C, 
human immunodeficiency virus, erythrovirus B19, cytomegalovirus (CMV), varicella-33 
 
zoster virus (VZV) and human T-cell lymphotropic virus-1 (HTLV-1) (Pagnoux et al., 
2006).  Bacterial  infections  that  have  been  proposed  as  potential  causative  agents 
include strains of Pseudomonas, Legionella, Neisseria, Rickettsiae, Staphylococcus and 
Mycobacterium tuberculosis (Pagnoux et al., 2006).  Fungal infections of the lung can 
mimic WG or Churg Strauss syndrome by causing a granulomata to form in vessel 
walls  (El-Zammar  and  Katzenstein,  2007).    In  a  number  of  these  infection  related 
vasculitides, if the vasculitis is a direct effect of the infective agent (e.g. the necrotizing 
vasculitis of the lung sometimes seen in Pseudomonas aeruginosa infections) rather 
than  as  a  downstream  consequence  after  the  immune  system  has  been  misdirected 
towards self, then effective treatment  of the underlying infection  with  antimicrobial 
agents  is  necessary,  and  may  be  sufficient  without  additional  immunosuppression 
(Pagnoux et al., 2006).   
 
1.2.8.5 Vasculitis secondary to malignancy 
Vasculitis associated with malignancy is extremely rare in children (Pelajo et al., 2007), 
however it can occur and there a number of ways in which this happens.   Vasculitis can 
occur as the result of an infectious complication in an already immunocompromised 
patient.   Vasculitis  can also  be triggered directly  by the presence of malignancy or 
metastases invading blood vessels (Racanelli et al., 2008).  Alternatively, it can occur as 
a  paraneoplastic  phenomenon  as  a  consequence  of  abeherent  immune  responses, 
whereupon  treatment  of  the  inciting  malignancy  can  resolve  the  vasculitis.    Often 
paraneoplastic vasculitis is a cutaneous form that is detected prior to clinical detection 
of the malignancy.  Lastly, it remains possible that both malignancy and vasculitis are 
triggered by the same environmental stimuli in some cases (Racanelli et al., 2008). 
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1.2.9 Treating vasculitis 
Treatment  for  systemic  vasculitis  comprises  aggressive  immunosuppression  and 
consists  of  combined  corticosteroid  and  cytotoxic  agents  such  as  cyclophosphamide 
(oral or pulsed intravenous), azathioprine or methotrexate as well as antiplatelet agents 
(usually  aspirin),  and  in  some  forms  of  vasculitis  pooled  human  intravenous 
immunoglobulin (IVIG, particularly for KD (Newburger et al., 1986)) in an attempt to 
bring the disease into remission (Watts et al., 2005).  Plasma exchange may also prove a 
useful therapy, particularly for severe fulminant forms of small vessel vasculitis (Jayne 
et al., 2007). The exact regime used depends on the disease and the individual patient.  
In some of the milder conditions such as HSP or cutaneous PAN, treatment may only 
consist of symptomatic relief with analgesics or non steroidal anti inflammatory drugs 
(Palit and Inamadar, 2006).   
 
Newer  biological  agents  may  be  necessary  if  conventional  treatment  is  ineffective.  
These  include  (amongst  others)  anti  TNFα  (Burns  et  al.,  2005a,Booth  et  al., 
2004a,Brogan  et  al.,  2009),  anti  IL-1  (Eleftheriou  et  al.,  2009),    B  cell  depletion 
(Eleftheriou  et  al.,  2009)  or  lymphocyte  depletion  using  anti-CD52  (Campath) 
(Lockwood et al., 2003).  These novel approaches have only been used in relatively 
small numbers of patients and thus their usage is based on largely anecdotal evidence.  
That said, biologic therapy holds promise for recalcitrant disease.  If remission is still 
not achieved, autologous stem cell transplantation may be an option and indeed was 
performed successfully in one child included in this thesis.   
 
With the more agressive forms of therapy there is significant morbidity associated with 
long  term  use  of  these  agents  which  includes  diabetes,  infection,  bladder  cancer, 35 
 
haemorrhagic cystitis, bone marrow toxicity and infertility.  Thus treatment should be 
tailored to the minimum required to control disease whilst at the same time limiting 
these  unfavourable  side  effects  (Brogan  and  Dillon,  2000a).    Following  successful 
induction of remission, maintenance of remission is achieved using therapy including 
anti-platelet  doses  of  aspirin  and  low  dose  corticosteroids  combined  with 
immunosuppressants  such  as  azathioprine,  mycophenolate  mofetil,  or  methotrexate 
sometimes for months or years (Brogan and Dillon, 2000a).   
 
Despite these aggressive therapeutic approaches, there is still a significant mortality and 
morbidity  associated  with  PSV,  including  treatment  related  complications  such  as 
opportunistic infections.  However it is worth noting that without treatment mortality is 
extremely high.  Historically for patients with WG there was 80% mortality within the 
first year (Walton E.W, 1958).  Thus treatment outcomes for children and adults with 
vasculitis are vastly improved but require further refinement, a programme of work 
currently being performed by the EUVAS group (European vasculitis study group). 
 
Lastly it is important to emphasise that many of the treatment protocols for PSV in 
children, with the exception of KD are based on evidence from clinical trials in adults.  
Importantly, however for the first time children with ANCA associated vasculitis have 
recently been included in EUVAS trials (Brogan, personal communication).  
 
1.2.10 Prognosis 
Overall  outlook  is  good  for  patients  who  urvive the initial vasculitic insult  and  any 
subsequent  disease  flares,  however  the  long  term  consequences  of  vasculitis  in 
childhood are still not clear.  Recent studies indicate that there is increased subclinical 36 
 
atherosclerosis in adult patients with small vessel vasculitis (Chironi et al., 2007) and 
whether  children  with  these  diseases  have  similar  consequences  remains  to  be 
determined.  Coronary  artery  lesions  (including  aneurysms  and  stenoses)  in  KD 
predispose to premature coronary atherosclerosis, and peripheral arteries remain stiffer 
than  in  healthy  controls  for  years  after  disease  remission  in  PAN,  possibly  being 
indicative of fibrotic changes (Cheung et al., 2002,Suzuki et al., 1986)  and/ or ongoing 
subclinical vascular inflammation (Mitani et al., 2005).   So although now most children 
survive vasculitis, it appears that there could be implications for their cardiovascular 
health in the longer term (Nakamura et al., 2002).    
 
1.2.11 Conclusions relating to clinical perspectives on vasculitis 
There is a wide spectrum of vasculitic disease affecting children.  The distinction from 
other conditions, especially those associated with infection is often difficult, but it is 
possible to categorise the disorders into clinico-pathological entities even though there 
is  a  substantial  degree  of  overlap.  Treatment  for  systemic  disease  is  aggressive 
immunosuppression, aimed at inducing remission, rather than targeting upstream casual 
pathology  (described  in  Section  1.3).    Outlook  for  patients  on  the  whole  is  good, 
however  in  the  long  term,  cardiovascular  complications  may  lead  to  reduced  life 
expectancy, however much work remains to be done in order to identify those patients 
at greatest risk.  
 
 
1.3 The pathogenesis of vasculitis 
In most patients  the definitive upstream  causes  of vasculitis  are unknown, however 
there are a number of well described inflammatory pathways that culminate in injury to 37 
 
the endothelium that are beginning to be understood.  The predominant theory as to how 
vasculitis is initiated is the combination of an environmental trigger occurring in an 
individual with a background genetic susceptibility (Brogan, 2007). 
 
1.3.1 Environmental triggers 
A  number  of  epidemiological  studies  support  the  hypothesis  that  an  environmental 
trigger is involved in the development of vasculitis.  In the two commonest vasculitic 
diseases of childhood, HSP and KD, epidemiological evidence points to an infectious 
cause.  Both conditions have seasonal variations in incidence, with KD peaking in the 
winter and spring months (Bronstein et al., 2000)  and HSP in autumn and winter (Yang 
et al., 2005) often following a respiratory tract infection.  WG occurs more commonly 
in Northern Europe than Southern Europe.  In one study by Watts et al although there 
were significant differences in the incidence of WG between Spain and the UK, there 
was little variation in HLA-DRB1 region genetics (the human leucocyte antigen region 
of the genome which is associated with a number of autoimmune diseases) leading the 
authors to suggest that environmental factors may be more important than genetic risk 
factors for triggering WG (Watts et al., 2001).   
      
While infections and malignancies (discussed above) may be triggers of vasculitis, there 
a  number  of  other  potential  non-infectious  environmental  factors  which  have  been 
implicated  in  disease  onset.    In  2003  Lane  et  al  demonstrated  increased  risk  of 
developing  PSV  (all  forms)  in  Norfolk  with  exposure  to  silica,  solvents  and 
interestingly  farming,  which  undoubtedly  exposes  the  individual  to  many  chemicals 
(pesticides, fertilizers etc) and possible infectious agents from livestock (Lane et al., 
2003).  Other studies have also implicated silica and solvents (Tervaert et al., 1998,Pai 38 
 
et al., 1998) as well as heavy metal exposure (Albert et al., 2004) , a number of different 
vaccinations (including influenza and hepatitis B) (Somer and Finegold, 1995,Schattner, 
2005),  many  different  classes  of  drugs  (Wiik,  2008),  corticosteroid  withdrawal 
(Kinoshita et al., 1999) and allergy desensitisation procedures (Cabrera et al., 1993).  A 
background  of  allergy  or  asthma  is  also  associated  with  increased  risk  of  PSV  (all 
forms) (Lane et al., 2003).  
 
1.3.2 Genetics of vasculitis 
In recent years there have been a number of studies examining the genetic background 
of the different vasculitic diseases.  Table 1.1 (adapted from Brogan, 2007) highlights a 
number of these studies.  What is immediately apparent is that the genetic factors which 
predispose individuals to developing vasculitis are complex and there are a wide variety 
of candidate genes that may be involved.  These genes include those  involved  in  
inflammation  such  as  cytokines, chemokines, and their receptors as well as those 
relating  to  regulation  of  the  vasculature  such  as  growth  factors  and  NO  synthase.  
Caveats to these genetic studies include the large numbers of patients with these rare 
diseases  which  are  required  for  adequate  powering,  and  the  difficulty  of  robust 
classification.  This has resulted in a number of potentially underpowered studies in KD, 
HSP,  BD  and  AAV.    However,  considerable  advances  in  genome  wide  association 
studies hold the promise of major advances in the understanding of complex diseases 
such as the vasculitides if adequate patient numbers can be studied (numbers in the 
1,000s are necessary (McCarthy et al., 2008)).  This will ultimately require international 
cooperation. 
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Table 1-1: Genetic studies in vasculitis 
 
 
Gene of 
interest 
Disease 
studied  Effect 
Angiotensin 
converting 
enzyme 
KD 
 
 
HSP 
 
 
 
BD 
Higher expression of ACE insertion allele associated with increased disease susceptibility 
(Shim et al., 2006) 
 
No association found with ACE, but angiotensinogen (angiotensin precursor) associated with 
disease susceptibility (Ozkaya et al., 2006) 
ACE DD genotype predicts persistent proteinurea (Yoshioka et al., 1998) 
 
Higher expression of ACE deletion allele than in controls (Turgut et al., 2005) 
VEGF 
KD 
 
 
HSP 
Polymorphisms associated with development of disease (Breunis et al., 2006), a more recent 
study demonstrated no associations (Huang et al., 2008) 
 
Polymorphisms associated with development of renal complications (Rueda et al., 2006) 
Nitric oxide 
synthase 
(NOS) 
HSP 
 
 
KD 
Polymorphism in iNOS promotor associated with renal involvement  (Martin et al., 2005) 
although no associations with eNOS polymorphisms (Amoli et al., 2004b) 
 
No  association  of  eNOS  or  iNOS  polymorphisms  with  susceptibility  or  coronary  artery 
lesions (Khajoee et al., 2003) 
IL-1/IL-1Ra 
KD 
 
HSP 
 
 
WG 
Polymorphisms in Il-1ra but not IL-1β associated with susceptibility (Wu et al., 2005) 
 
Polymorphisms in both Il-1ra and  IL-1β associated with renal involvement (Amoli et al., 
2002,Amoli et al., 2004a) 
 
No associations found (Zhou et al., 2004) 
TNFα 
KD 
 
 
WG 
Polymorphisms  associated  with  susceptibility  (Cheung  et  al.,  2008)  and  IVIG  resistance 
(Yang et al., 2003) 
 
Polymorphisms associated with susceptibility (Spriewald et al., 2005) although another study 
showed no association (Huang et al., 2000) 
IL-6 
 
 
KD 
 
HSP 
 
BD 
No associations found (Sohn et al., 2001) 
 
No associations found (Amoli et al., 2007) 
 
Polymorphisms associated with susceptibility (Chang et al., 2005) 
IL-10 
KD 
 
 
AAV 
 
BD 
Association  of  promoter  polymorphism  with  increased  risk  of  coronary  artery  aneurysm 
(Yang et al., 2003) 
 
Polymorphisms associated with CSS but not WG (Wieczorek et al., 2008) 
 
Polymorphism associated with susceptibility in UK patients  (Wallace et al., 2007) 
Inositol 1,4,5-
trisphosphate-3 
kinase C 
(ITPKC) 
KD  Polymorphism in ITPKC ( a negative regulator of T cell signalling) associated with both 
susceptibility to KD and coronary artery lesions (Onouchi et al., 2008) 
CCR5  KD  Polymorphisms in CCR5 and its ligand CCL3LI associated with susceptibility (Burns et al., 
2005b) 
Human 
leucocyte 
antigens 
(HLA) 
AAV 
 
KD 
HLA-DRB4 associated with CSS development (Vaglio et al., 2007) 
 
HLA-B and C polymorphisms associated with susceptibility in Korean cohort  (Oh et al., 
2008). No association with HLA DRB1 (Huang et al., 2007) 
 
Mannose 
binding lectin 
(MBL) 
KD 
 
 
 
AAV 
 
BD 
In  Children  <1  year  old  polymorphisms  in  MBL2  (resulting  in  low  MBL  levels)  were 
associated with increased risk of coronary artery aneurysms, however conversely at >1 year 
of age wild type (normal MBL levels) were at increased risk (Biezeveld et al., 2006) 
 
No associations found (Kamesh et al., 2007) 
 
MBL2 HYPA haplotype associated with severity and susceptibility (Park et al., 2005b) 
Matrix 
metallo-
proteinases 
KD 
MMP3  promotor  (6A/6A)  genotype  associated  with  higher  frequency  of  coronary  artery 
aneurysms,  no  associations  found  with  MMP9  polymorphisms  (Park  et  al.,  2005a).  In  a 
second study no association was found with a different MMP3 promoter polymorphism (-
439C/G) (Hong et al., 2008) 
Proteinase 3 
(PR3)  WG 
Polymorphism in promoter of PR3 associated with WG susceptibility (Gencik et al., 2000) as 
is a polymorphism in the inhibitor of PR3 α-1-antitrypsin which causes deficiency (Elzouki et 
al., 1994) although other studies suggest its influence  is minor (Lhotta et al., 1994) 
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1.3.3 Immunological pathways in vasculitis  
1.3.3.1 Autoantibodies  
Numerous  autoantibodies  are  associated  with  vasculitis,  however  the  pathological 
consequences  of  antineutrophil  cytoplasmic  antibodies  (ANCA)  and  anti-endothelial 
cell antibodies (AECA) have been studied extensively and require mention in detail. 
 
1.3.3.2 Antineutrophil cytoplasmic antibodies 
ANCA are detected in 85-95% of adult patients with MPA, WG, CSS, and the localized 
forms of these diseases (Bosch et al., 2006).  The frequency of ANCA positivity may be less 
for children with these vasculitides however (Akikusa et al., 2007,Belostotsky et al., 2002).  
These  predominantly  IgG  autoantibodies  target  antigens  found  within  neutrophil 
granules and also within the lysosymes of monocytes (Braun et al., 1991).  Although a 
number of other antigenic targets have been identified the most clinically relevant are those 
targeting  PR3  and  MPO.    Typically,  PR3-ANCA  is  seen  as  diffuse  staining    of    the  
neutrophil  cytoplasm  (cANCA)  whereas MPO-ANCA gives a perinuclear staining 
(pANCA) pattern on immunofluorescent microscopy.  Table 1.2 summarises the type of 
ANCA found in the difference ANCA associated vasculitides in adults.   
 
Table 1-2: ANCA distribution in the ANCA associated vasculitides  
 
 Data from (Van Paassen P. et al., 2007) 
Disease 
% of patients with 
MPO-ANCA 
% of patients with 
PR3-ANCA 
Churg Strauss syndrome (CSS)  30-70  <10 
Wegener’s Granulomatosis (WG)  10-30  >70 
Microscopic Polyangiitis (MPA)  30-70  10-30 41 
 
In  comparison  to  patients  positive  for  MPO-ANCA  patients  with  PR3-ANCA  have 
more organs involved, a faster decline in renal function, more frequent relapses of the 
disease, and granulomatous necrotizing inflammation in the airways (Franssen et al., 
2000), suggesting different pathological pathways may be involved. 
 
Development of ANCA 
The upstream events which lead to development of ANCA remain unknown, however 
there are a number of hypothesese as to how ANCA develop.  As AAV can be initiated 
by infection, molecular mimicry is one possibility (Benoist and Mathis, 1998), another 
is autoantigen complementarity a phenomenon described by Pendergraft et al, whereby 
peptides  complementary  to  PR3  (encoded  by  the  corresponding  antisense  strand  of 
DNA) initiate production of antibodies against PR3 (Pendergraft, III et al., 2004).  The 
generation of PR3-ANCA occurs via a 2-stage immune response, the initial response is 
directed  against  the  complementary  peptide,  the  secondary  response  again  the 
antibodies  generated  to  the  complementary  peptide  (these  will  also  act  on  PR3).  
Interestingly  peptides  complementary  to  PR3  are  found  in  a  number  of  infectious 
agents,  including  Staphylococcus  Aureus,  human  herpes  virus  4  and  rickettsia 
prowazekii (Pendergraft, III et al., 2004).   
 
A non-infection related hypothesis for ANCA generation relates to neutrophil apoptosis.  
When  neutrophils  undergo  apoptosis,  their  granule  contents  translocate  to  the  cell 
surface  (Gilligan  et  al.,  1996),  incomplete  or  inappropriate  phagocytosis  may  allow 
exposure of these self antigens to antigen presenting cells (APCs).  However, while 
injection of apoptotic neutrophils into mice (Rauova et al., 2002) or rats (Patry et al., 
2001) induced ANCA expression, neither species developed vasculitis.  Evidence from 42 
 
in-vitro  experiments  is  conflicting.    Although  immature  dendritic  cells  can  take  up 
apoptotic and necrotic neutrophils, with corresponding increases in maturation markers 
such as CD83 and MHC class II, the costimulatory molecules (CD86, CD80 and CD40) 
necessary  for  T  cell  activation  are  downregulated.    Thus  the  overall  effect  of 
apoptotic/necrotic neutrophils in this study is tolerogenic, although this was partially 
reversed by TNFα treatment (Clayton et al., 2003).  Thus the exact mechanisms by 
which defective neutrophil apoptosis could lead to ANCA generation remain poorly 
defined. 
 
Are ANCA pathogenic? 
Regardless of how ANCA production is initiated, there is much evidence to implicate 
this autoantibody in the pathogenesis of vasculitis from observations made in humans 
and  animal  models.    Recently  animal  models  have  provided  some  of  the  most 
compelling evidence that ANCA are indeed directly pathogenic manner, while in vitro 
experiments have provided more details at a cellular level on mechanisms by how this 
can occur.   
 
Proof of concept – do ANCA cause vasculitis in vivo? 
As yet only MPO-ANCA have been shown to induce significant vasculitis in animal 
models.  Studies have been performed using PR3-ANCA however it is apparent that the 
disease pathogenesis in PR3-ANCA associated conditions may be more complicated 
than just an autoantibody mediated vasculitis (Kallenberg, 2008), corresponding with 
the differences observed in disease severity between MPO-ANCA and PR3-ANCA in 
humans (Franssen et al., 2000).   
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Rats injected with human MPO, generate anti-MPO antibodies and developed a small 
vessel vasculitis (Little et al., 2005).  The IgG isolated from these rats was shown (like 
human ANCA) to enhance leukocyte-endothelial interactions in vitro.  In other studies, 
injecting  MPO  knockout  mice  with  mouse  MPO  allowed  generation  of  anti-mouse 
MPO IgG (removing the potential confounding factor of using a human peptide) (Xiao 
et  al.,  2002).    When  these  antibodies  were  injected  into  wildtype  or  recombinase 
activating gene-2 (RAG2-/-) knockout mice (which have no mature B or T cells) they 
developed  a  disease  similar  to  AAV  with  focal  necrotizing  and  crescentic 
glomerulonephritis, and in some mice a systemic small vessel vasculitis (Xiao et al., 
2002).  The presence of disease in RAG-/- mice indicated that T cells were not required 
to induce the acute lesions.  Neutrophils however were necessary as prior injection of a 
neutrophil depleting antibody prevented disease (Xiao et al., 2005). Correspondingly, 
priming neutrophils with LPS prior to the IgG dose exacerbated the disease (Huugen et 
al.,  2005).    Interestingly,  the  non  classical  complement  activation  pathway  is  also 
implicated  in  this  model  as  C4  (classical)  but  not  C5  (common)  or  factor  B  (non-
classical) knockout mice develop disease after transfer of anti-mouse-MPO IgG (Xiao et 
al., 2007a).   
 
In  contrast,  evidence  that  PR3-ANCA  are  directly  pathogenic  is  so  far  conflicting.  
When mice were injected with human PR3-ANCA, they developed antibodies to PR3 in 
a two stage immune  response similar to  that  described  for  complimentary peptides.  
Mice initially develop antibodies to human PR3-ANCA, followed by antibodies against 
these (anti-anti-human-PR3-ANCA) which have the ability to bind PR3 (Tomer et al., 
1995).  These mice developed lung disease but not glomerulonephritis.  However, when 
PR3-ANCA was generated in PR3 knockout mice (using mouse PR3), the injection of 44 
 
these antibodies into wild type mice did not result in spontaneous vasculitis (Pfister et 
al.,  2004).    The  only  difference  observed  was  an  exacerbated  response  to  localised 
TNFα injection (Pfister et al., 2004).   Rats injected with human/mouse chimeric PR3, 
also generated PR3-ANCA, however, despite this being able to bind rat PR3, vasculitis 
did not develop (van der Geld et al., 2007). 
 
Perhaps the most robust evidence yet that ANCA can cause vasculitis in humans comes 
from two reports that have documented trans-placental transfer of IgG MPO-ANCA 
from mothers with active MPA.  The two neonates described developed pulmonary 
renal syndrome soon after birth (Bansal and Tobin, 2004,Schlieben et al., 2005).    
 
How do ANCA cause vascular injury? 
The  predominant  mechanism  by  which  ANCA  induce  endothelial  injury  is  via 
neutrophil  activation  and  adhesion  to  the  endothelium,  followed  by  neutrophil 
degranulation and subseqeunt dyseregulated apoptosis (Bosch et al., 2006).  ANCA can 
also activate other cell types involved in the inflammatory processes, although these 
pathways are less well defined (Ralston et al., 1997).   
 
Although MPO and PR3 are not found on the surface of resting neutrophils (Gilligan et 
al.,  1996),  priming  of  neutrophils  with  substances  such  as  TNFα  or  LPS  (at  a 
concentration  that  does  not  induce  full  activation)  or  even  isolated  purified  ANCA 
results in their translocation to the cell surface (Csernok et al., 1994,Hattar et al., 2001).  
In patients with active AAV circulating neutrophils are primed; they have enhanced 
expression of surface PR3 (Muller Kobold et al., 1998a), the activation markers CD66b, 45 
 
CD63,  and  CD64  (Muller  Kobold  et  al.,  1998b)  and  increased  basal  superoxide 
production (Harper et al., 2001).  
 
When ANCA bind their target antigens on the neutrophil surface, they also crosslink 
with Fc receptors causing cell activation (Porges et al., 1994).  Neutrophil-endothelial 
adhesion changes from rolling to firm in an integrin dependent manner, followed by 
respiratory  burst  and  degranulation.    Degranulation  releases  potentially  damaging 
reactive  oxygen  species,  chemokines,  cytokines  and  proteolytic  enzymes  in  close 
vicinity to the endothelium (Harper et al., 2004). NO generated independent of classical 
NO  synthase  (NOS)  pathways  is  also  released  (Tse  et  al.,  2001),  although  the 
consequences of the increased availability of NO is unclear.  While NO is a potent 
vasodilator and has been shown to reduce neutrophil endothelial interactions, it is also 
cytotoxic,  increases  vascular  permeability,  forms  free  radicals  and  can  modulate 
cytokine production in leucocytes, thus could conceivably be contributing to endothelial 
injury in this context (Tripathi et al., 2007).  
    
Neutrophil activation by ANCA is followed by apoptosis, however in vitro experiments 
indicate this is accelerated and dysregulated; while neutrophils showed typical features 
of  apoptosis  such  as  shrunken  nuclei  and  internucleasomal  cleavage  of  DNA 
phosphatidylserine  (PS)  does  not  become  externalized  (Harper  et  al.,  2000).  The 
externalisation of PS is essential for recognition of apoptotic cells by phagocytes, which 
engulf and safely remove them preventing release of damaging cell contents.  This poor 
clearance  explains  the  leucocytoclasia  (accumulation  of  unscavenged  apoptotic  or 
necrotic neutrophils or their fragmented nuclei in the tissues around the vessels) often 
seen in vasculitic lesions. 46 
 
As well as neutrophil activation ANCA have the potential to initiate endothelial injury 
by other mechanisms.  Both PR3-ANCA and MPO-ANCA can act directly on their 
target enzymes altering their function.  PR3 degrades extracellular matrix proteins such 
as  elastin and collagen  type  IV.   Its  natural  inhibitor is  α1-antitrypsin which forms 
complexes with PR3 causing it extensive structural reorganization and irreversible loss 
of function.  PR3-ANCA inhibits both the proteolytic activity of PR3 and its complex 
formation with α1-antitrypsin (van der Geld et al., 2002,Dolman et al., 1993) which 
may  impair  both  regulation  and  clearance  of  PR3  (Dolman  et  al.,  1993).    MPO  is 
involved in the reaction between hydrogen peroxide and chloride ions which generates 
hypochlorous acid (HOCl), one of the reactive oxygen species that contributes to the 
neutrophil oxidative burst.  In vitro, MPO-ANCA can activate MPO and may directly 
initiate neutrophil oxidative burst, resulting in the release of a number of EC damaging 
ROS (Guilpain et al., 2007).   
 
PR3-ANCA  can  act  directly  on  the  endothelium,  despite  endothelial  cells  not 
expressing it (or MPO either) and the mechanism by which this occurs remains elusive 
(Pendergraft  et  al.,  2000).    Consequences  include  activation  and  upregulation  of 
adhesion molecules such as ICAM-1 (de et al., 1997a) and VCAM-1 (Mayet et al., 
1996), expression of TF and release of IL-1 (de et al., 1997b).  Both PR3-ANCA and 
MPO-ANCA can activate monocytes, resulting in production of IL-8 (Ralston et al., 
1997)  and  increasing  expression  of  CD14  (LPS  receptor)  and  CD18  (a  2  integrin 
receptor)(Nowack  et  al.,  2000).    Interestingly  glomerular  epithelial  cells  are  also 
reported to express PR3 mRNA, raising the possibility of direct glomerular epithelial 
injury by ANCA (Schwarting et al., 2000) 
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1.3.3.3 Anti-endothelial cell antibodies 
A number of autoantibodies directed against the endothelium have been detected in 
vasculitis.  The antigens targeted by AECA encompass a broad spectrum and remain 
poorly identified; AECA positive sera displays a broad reactivity against EC from many 
different locations (Praprotnik et al., 2001) and different species (reacting with bovine 
and murine endothelial cells) (Shoenfeld, 2002) as well as a number of other targets, 
including  extracellular  matrix  (Belizna  and  Tervaert,  1997).    IgG,  IgM,  and  IgA 
isotypes of those antibodies have all been reported (Praprotnik et al., 2001).  
 
AECA from the sera of patients with WG are able to activate endothelial cells directly, 
up-regulating  expression  of  adhesion  molecules  such  as  E-selectin  and  inducing 
production of proinflammatory cytokines and chemokines including IL-1, IL-6, IL-8, 
and MCP-1 (Del et al., 1996) via NFκB activation (Blank et al., 1999). AECA have also 
been  shown  to    induce  apoptosis  of  endothelial  cells  (Bordron  et  al.,  1998)  and 
upregulate TF (Tannenbaum et al., 1986). 
 
Mice immunized with IgG from the sera of patients with WG after any ANCA present 
has  been  depleted,  develop  a  vasculitic  disorder  characterized  by  lymphocytic 
infiltration in vessel walls, particularly in the lungs and kidney (Damianovich et al., 
1996).  As in the previously described ANCA models injection of human IgG results in 
an idiopathic response, whereby antibodies are initially generated against the human 
IgG,  then  a  second  response  generates  antibodies  against  these.    The  second  stage 
antibodies have the ability to bind to the target endothelial antigens. 
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1.3.3.4 T cells 
T  cells  are  activated  when  APCs  present  specific  antigen  to  them  via  the  MHC 
molecules on their surface, in combination with co-stimulatory signals.  T cells can 
broadly  fall  under  the  categories  of  T  helper  cells  (CD4+),  whereby  they  release 
cytokines  promoting  the  immune  response,  cytotoxic  T  cells  (CD8+)  whereby  their 
function is to remove altered-self cells, or regulatory T cells whereupon they suppress 
immune responses (Goldsby RA et al., 2003a).  Memory cells of these subtypes are also 
found, as are natural killer cells, a T cell subtype which recognizes and eliminates host 
cells missing MHC class I molecules (Krzewski and Strominger, 2008).  CD4+ T helper 
cells can secrete different profiles of cytokines. Th1 type cells produce TNFα and IFNγ 
which  are  responsible  for  promoting  the  cellular  immune  system,  activating 
macrophages and cytotoxic cells, whilst Th2 type cells release IL-4, IL-6, IL-10 which 
activates  the  humoral  immune  system,  inducing  B  cell  proliferation  and  antibody 
production (Goldsby RA et al., 2003a).  A recently described population of T helper 
cells,  Th17s  produce  Il-17,  IL-21  and  IL-22.    IL-17  in  particular  is  a  potent 
chemoattractant  of  neutrophils  and  can  induce  production  of  other  inflammatory 
cytokines and chemokines (Kolls and Linden, 2004).  There has been much interest in 
this  novel  T  cell population, with  evidence indicating that  IL-17 is  involved in  the 
pathogenesis of many autoimmune conditions (Bettelli et al., 2007).  
 
In AAV T cells can be activated by MPO and PR3 (King et al., 1998) and in patients 
there is evidence of activated T cells irrespective of phase of disease or therapy as 
demonstrated  by  reduced  CD28  (co-stimulatory  molecule)  and  increased  CD69  (an 
early T-cell activation marker) on CD3 T cells, and CD38 on CD8+ cytotoxic T-cells 
(present on mitogen stimulated T cells) (Christensson et al., 2000).  In WG activated 49 
 
CD4+  cells  have  a  predominantly  Th1  cytokine  profile  (Ludviksson  et  al.,  1998), 
although in disease remission CD4+ cells are skewed towards a Th2, Th17 response 
(Abdulahad  et  al.,  2008).    In  WG  there  is  also  evidence  of  a  PR3  specific  Th17 
population (Abdulahad et al., 2008).  Both CD4+ and CD8+ T cells are found in lesions 
in  AAV,  as  are  the  adhesion  molecules  and  cytokines  that  are  required  for  their 
recruitment.      In  pauci-immune  glomerulonephritis  (so  called  because  of  lack  of 
immune complex deposition) cellular infiltrates at the site of injury include activated T 
cells, indicative of a casual role in this particular disease manifestation (Cunningham et 
al., 1999).   
 
In KD activated T cells have been found in skin biopsies and coronary vascular lesions 
(Terai et al., 1990), however there are conflicting reports regarding whether peripheral 
blood  T cells  are activated in  acute KD.  While some indicate increased activation 
(Barron et al., 1988), others have demonstrated no overall difference from controls, 
although  subfamilies  of  T  cells  bearing  particular  Vβ  segments  may  be  activated 
preferentially (Brogan et al., 2008). 
 
T cells also play a pivotal role in giant cell arteritis (not a disease of childhood, however 
the mechanism bears mention) and are believed to direct a response to arterial antigens - 
T  cells  in  the  arterial  wall  have  identical  sequences  at  the  third  complementary 
determining  region  (CDR3)  of  their  T-cell  receptors  suggesting  a  common  antigen 
(Weyand et al., 1994). 
 
Regulatory T cells are a topic of great interest in the context of autoimmune disease.  
They  are  characterised  by  expression  of  CD4,  CD25,  and  the  transcription  factor 50 
 
FOXP3, are anergic to proliferative responses in vitro and do not express key cytokines, 
such  as  IL-2  or  IFN-γ  in  response  to  stimulation.    Functionally,  they  suppress 
proliferation of effector T cells, which in vitro requires activation and cell contact but is 
not via  IL-4, IL-10, or transforming growth factor-β (TGF-β) production (Torgerson, 
2006).  Studies  in  KD indicate that regulatory  T cells  are reduced in  acute disease 
(Furuno et al., 2004), while in BD (Hamzaoui et al., 2006) and WG they are elevated, 
however their functional capacity to suppress proliferation was found to be decreased in 
WG (Abdulahad et al., 2007).  
 
1.3.3.5 Immune complexes, complement and cryoglobulins 
Immune complexes occur when antibodies bind to soluble antigen – the mechanism of 
type III hypersensitivity reactions.  Once formed immune complexes can be deposited 
in various tissues, instigating an inflammatory response.  Immune complexes are found 
in a number of small vessel vasculitides including HSP, PAN and cryoglobulinaemia 
and are a major cause of associated glomerulonephritis (Guillevin and Dorner, 2007).  
 
Endothelial  injury  mediated  by  immune  complexes  involves  recruitment  of 
inflammatory  cells  and  also  activation  of  classical  complement  pathways  (Claudy, 
1998). C1q, the first component of complement, binds to the Fc portion of IgG or IgM 
antibodies  in  the  deposited  immune  complexes  resulting  in  activation  of  other 
components of the enzymatic cascade which culminates in the formation of a membrane 
attack complex and subsequent cell lysis (Goldsby RA et al., 2003b). Some components 
(such as C5a) have chemotactic properties and can recruit neutrophils, monocytes and 
lymphocytes  (Guo  and  Ward,  2005).    C5a  can  also  activated  neutrophils,  inducing 
oxidative burst and degranulation (Guo and Ward, 2005).  The deposition of immune 51 
 
complexes in the vessel wall can therefore target these activated inflammatory cells to 
the endothelium. 
 
Cryoglubulins  are  immunoglobulins  that  persist  in  the  serum,  precipitate  with  cold 
temperature,  and  resolubilize  when  rewarmed  (Cacoub  et  al.,  2002).    They  are 
associated with some forms of vasculitis and also induce immune complex deposition 
with resultant vascular injury (Cacoub et al., 2002). 
 
1.3.3.6 Endothelial immune interactions – amplifying inflammation? 
As previously mentioned, endothelial cells play a pivotal role in inflammatory processes 
and it is thus not surprising that they can play a role in amplifying the vasculitic process.   
Activation of the endothelium induces upregulation of adhesion molecules to facilitate 
leukocyte recruitment and adhesion (Rao et al., 2007) and release of pro-inflammatory 
cytokines which act in both an autocrine and paracrine manner; increasing endothelial 
activation and activating surrounding cells such as neutrophils to induce further injury 
(Krishnaswamy et al., 1999). 
 
In PAN it has been shown that while early on in lesional formation there is increased 
expression  of  E-selectin  and  VCAM-1  at  the  site  of  lesions,  as  disease  progresses 
adhesion molecules are downregulated in the lesion but upregulated on surrounding new 
formed  microvasculature  (Coll-Vinent  et  al.,  1998).    Interestingly  animal  models 
indicate  that  upregulation  of  adhesion  molecules  occurs  normally  in  newly  formed 
vessels (Vallien et al., 2000).   Thus reparative responses such as angiogenesis could 
exacerbate disease if inflammation is not controlled by facilitating in recruitment of 
more inflammatory cells to the site of injury (Coll-Vinent et al., 1998). 52 
 
1.3.4 Conclusions regarding the pathogenesis of vasculitis 
Complex pathways involving immune cells, immune complexes and pro-inflammatory 
pathways as well as the endothelium itself are involved in the pathogenesis of vasculitis, 
although  the  upstream  mechanisms  which  initiate  and  maintain  endothelial  injury 
remain to be fully elucidated.  Whatever the exact mechanisms involved in different 
vasculitis syndromes, the common end result is injury to the endothelium.  This concept 
will be examined in further detail in the subsequent chapters of this thesis. 
 
 
1.4  Assessment of disease activity in vasculitis – the 
need for reliable biomarkers 
After initial disease is brought into remission, it is not uncommon in a number of the 
vasculitides for repeated recurrent flares of the disease to occur.  This is a particular 
problem  for  PAN  and  the  AAV  (Gayraud  et  al.,  2001).    In  this  context  it  is  thus 
important  clinically  to  be  able  to  distinguish  between  vasculitic  disease  activity  in 
which escalation of immunosuppression is required or treatment related manifestations 
such as  opportunistic infection, where further immunosuppresion  is  unneccessary or 
could be detrimental. 
 
In the late 1990s, an expert working group at the NIH (National Institutes of Health, 
USA) was established to define the concept of biomarkers and their role in defining 
clinical  outcomes  and  endpoints  for  trials.    They  defined  a  biomarker  as:  "a 
characteristic  that  is  objectively  measured  and  evaluated  as  an  indicator  of  normal 
biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention” (Biomarkers definitions working group, 2001). In the context of vasculitis 53 
 
there is great interest in finding novel biomarkers that could be used to routinely assess 
disease activity in a minimally invasive manner, a number of which are discussed in 
detail below.   
 
It would have been virtually impossible to assess all the potential biomarkers described 
herein  within  the  vasculitis  cohort  at  GOSH.    Therefore  this  thesis  focuses  on 
biomarkers  associated  with  endothelial  injury,  a  phenomenon  common  to  all  of  the 
vasculitides, irrespective of causal pathology as discussed in Section 1.3.  Biomarkers 
that reflect  endothelial  activation and injury therefore have the potential  to  monitor 
disease activity over a heterogeneous cohort (Brogan et al., 2004a).  While it is difficult 
to access the tissue directly, any factors released by the endothelium enter the blood, 
thus providing a window to the affected organ.  Before consideration is given to these 
novel biomarkers, some description of routine clinical assessment of vasculitis disease 
activity is required.   
 
1.4.1 Routine clinical tests for diagnosis and assessment of disease activity 
1.4.1.1 Initial diagnosis 
The symptoms of vasculitis are shared with a wide number of other conditions and 
therefore numerous investigations are performed in order to distinguish it from other 
diseases. In the first instance these include haematological tests such as blood counts, 
erythrocyte  sedimentation  rate  (ESR)  and  C-reactive  protein  (CRP),  assessment  of 
renal,  liver  and  thyroid  function,  screens  for  infectious  diseases,  screening  for 
prothrombotic clotting factors and certain genetic mutations as well as a multitude of 
immunological  tests,  including  autoantibodies  (antinuclear  antibodies  (ANA),  anti 
double stranded DNA antibodies (DS-DNA), rheumatoid factor (RF),  antibodies to 54 
 
extractable nuclear antigens such as Ro and La (ENAs), anticardiolipin antibodies, anti-
glomerular basement membrane antibodies (GBM)), immunoglobulins, cryoglobulins, 
factors  involved  in  the  complement  pathways  (MBL,  C3/C4/C5a)  and  cytokines 
(Damianovich et al., 1996,Rees et al., 2007).   Radiological investigations, biopsy and 
further testing to exclude rare conditions (such as malignancy) and to further confirm 
the presence or absence of vasculitis would then be dependent on the individual patient 
symptoms and organ involvement (Rees et al., 2007). 
 
Radiological investigations are most useful in the medium to large vessel vasculitides, 
in smaller vessel diseases the techniques may not be sufficiently sensitive to detect 
abnormalities.  At GOSH digital subtraction arteriography, magnetic resonance imaging 
and angiography (MRI/MRA) and positron emission tomography (PET) may be used 
for  initial  diagnostic  assessment.  Of  these,  arteriography  is  the  most  invasive, 
whereupon a contrast agent is injected into the arteries at the site of interest (selective 
visceral and/or cerebral arteriography), via a catheter and guide wires usually inserted 
through the femoral artery (Brogan et al., 2002).  This allows X-rays to be taken which 
will show changes within the vessel lumen, demonstrating aneurysms occlusions and 
stenosis (Brogan et al., 2002). 
 
MRI and MRA are  relatively  non-invasive  techniques  which  can  provide  additional  
information about the vessel wall (MRI) and lumen (MRA).    MRI can give indication  
of  thickening  of  the  vessel  walls  including  oedema  which  may  be  indicative  of 
inflammation (Pipitone et al., 2008).  MRA is used to assess aneurysms, occlusions and 
stenosis, however it can overestimate the degree of stenosis and thus have higher false 
positives than conventional areriography (Gotway et al., 2005).  Conversely MRA lacks 55 
 
sufficient sensitivity for the detection of changes affecting smaller muscular arteries 
frequently observed in PAN (Brogan et al., 2002). 
 
PET scanning utilizes a radiolabelled glucose analogue (
18fluorodeoxyglucose (
18FDG)) 
to  highlight  cells  which  have  a  higher  level  of  glucose  uptake  due  to  increased 
metabolic activity.  At sites of active vasculitis uptake is high (Belhocine et al., 2003), 
however although it is unlikely to be as large a confounding factor in paediatric cohorts 
as it is in adults, atherosclerotic lesions are also sites of high metabolic activity (Yun et 
al., 2001) and thus great care must be taken when interpreting the scans.  Co-registration 
of PET with computed tomography (PET-CT) vastly improves anatomical resolution 
and is useful for TD, although radiation exposure is very high (Henes et al., 2008).   
 
Evidence of vasculitic disease activity on a tissue biopsy is frequently referred to as the 
“gold standard” for confirming active disease (Mukhtyar et al., 2006).  However due to 
the localised nature of the disease, a negative result on biopsy does not indicate that 
disease  is  absent.    For  example  in  patients  with  well-documented  active  WG,  only 
around 50% of nasal biopsies demonstrated evidence of active vasculitis (Del Buono 
and Flint, 1991).  Ultimately diagnosis is based on the ability to assimilate the evidence 
pointing to vasculitis and to exclude other conditions that may mimic it through a broad  
array of clinical investigations. 
  
1.4.1.2 Routine assessment of disease activity following diagnosis 
As treatment for vasculitis is often toxic, a well defined diagnosis at outset is essential.  
In  addition,  the  ability  to  monitor  disease  activity  is  equally  important  due  to  the 
relapsing nature of a number of the vasculitides and the need for rapid intervention if  or 56 
 
when disease returns.  Careful clinical evaluation of individual patients, with assessment 
of changes in symptoms and biological and radiological markers is the only way in 
which disease activity and response to treatment can be assessed.  This is the principle 
behind the Birmingham Vasculitis Activity Score (BVAS) (Appendix 2, discussed in 
Section 2.2.2) which is now routinely used to quantify disease activity in clinical trials 
and increasingly in routine clinical practice as well (Luqmani et al., 1994). 
 
Commonly used biological markers of inflammation such as ESR and CRP are non 
specific and cannot easily distinguish between infection or disease activity.  During 
active  disease,  levels  of  these  inflammatory  markers  may  also  remain  normal, 
particularly in episodes of localised disease and granulomatous flares (Salvarani et al., 
2003,Sproson  et  al.,  2007),  so  caution  must  be  taken  when  interpreting  such 
information.   
 
In  the  ANCA-associated  vasculitides  routine  monitoring  of  ANCA  levels  is 
commonplace, both PR3 and MPO-ANCA can be detected using ELISA or indirect 
immunofluorescence (Hagen et al., 1996).  However, the usefulness of ANCA as  a 
biomarker  remains  controversial;  while  transient  rises  in  ANCA  often  occur  during 
relapse many patients who have a rise in ANCA remain well (Mukhtyar et al., 2008).  
  
Although  histopathological  evidence  on biopsy  is  a  reliable  confirmation  of  active  
disease in vasculitis, it is not a practical measure for routinely assessing disease activity 
due  to  its  invasive  nature.    The  same  applies  for  radiological  investigations,  while 
changes in radiological images are indicative of ongoing disease activity, the techniques 
can  be  extremely  invasive  and  are  also  expensive,  time  consuming  and  in  some 57 
 
instances  carry  a  significant  radiation  level.    Moreover,  contrast  agents  used  in 
MRI/MRA protocols have recently been associated with nephrogenic systemic fibrosis 
in patients with renal impairment (Agarwal et al., 2008,Penfield, 2008).  Thus it is with 
caution that MRI/MRA should be performed in patients with renal vasculitis.      
 
1.4.2 Novel Biomarkers in vasculitis 
Due  to  the  complexity  of  diagnosing  and  assessing  vasculitis  there  has  been  much 
interest in finding novel biomarkers which may prove useful in this context.  Possible 
biomarkers  for  vasculitis  that  have  been  investigated  range  from  autoantibodies,  to 
soluble adhesion molecules, cytokines, growth factors and cellular fragments.  
 
1.4.2.1 Autoantibodies  
Anti-endothelial cell antibodies  
As described in Section 1.3 AECA may have a pathological role in vasculitis.  AECA 
are commonly detected using a cell based ELISA with HUVEC as the substrate and 
their presence has been observed in a number of the vasculitides, including WG (Savage 
et  al.,  1991), PAN and BD  (Navarro  et  al., 1997), TD  (Park et  al.,  2006) and KD 
(Fujieda et al., 1997).  However some studies completely contradict these findings with 
no difference in the proportion of samples positive for AECA in patients or controls 
(Dinc et al., 2003,Varagunam et al., 1993).  A small number of studies have shown 
AECA levels fluctuate correspondingly with disease activity in vasculitis (Park et al., 
2006), however other groups have shown no such relationship (Sebastian et al., 2007).  
The  discrepancies  in  findings  have  been  in  part  attributed  to  the  non  standardised 
methodologies used to detect AECA; while the majority of groups use variations on 
cellular  ELISA,  flow  cytometry  and  a  number  of  other  methods  have  also  been 58 
 
employed (Belizna and Tervaert, 1997).  While experimental evidence points to AECA 
as  a  potential  mechanism  of  endothelial  activation  both  in  vivo  and  in  vitro,  the 
contrasting observations in patients do not currently support its role as a biomarker of 
disease activity.   
 
Anti-heat shock protein antibodies 
Heat  shock  proteins  (HSPs)  are  highly  evolutionary  conserved  proteins  that  are 
upregulated  in  response  to  a  number  of  environmental  stresses  (including,  hypoxia, 
heat-shock  and  inflammation)  (Tsan  and  Gao,  2004).    Many  family  members  also 
function  constitutively,  acting  as  molecular  chaperones  –  stabilizing  in  folding  and 
assisting  in  the  intracellular  trafficking  of  peptides,  including  complex  formation.  
Under stress,  their increased expression is  protective assisting in  cellular repair  and 
inhibiting a number of apoptotic signalling pathways (Lanneau et al., 2008).   
 
Because of the highly conserved structure of HSPs throughout species, the presence of 
antibodies to bacterial and human homologue HSPs in vasculitis has been proposed as 
evidence of molecular mimicry causing disease, particularly in KD (Sireci et al., 2000) 
and BD (Tanaka et al., 1999).  As HSPs can bind with cell membrane peptides, it has 
been suggested that HSPs may be a target of AECA (Jamin et al., 2005).  As with other 
autoantibodies in vasculitis the evidence regarding anti-HSPs is conflicting, while some 
studies show elevated levels of antibodies to specific HSPs in patients with vasculitis 
such  as  alpha-enolase  in  KD  (Chun  et  al.,  2008)  others  show  no  differences  in 
expression  from  controls  (Sherer  et  al.,  2008).    As  yet  no  study  has  examined  the 
changes in anti-HSPs with treatment and thus the lack of reproducible data and the 59 
 
possibility that it may only be relevant in a small proportion of patients indicates this 
may not prove a suitable biomarker in a varied cohort. 
 
Other autoantibodies 
Other  autoantibodies  that  have  been  shown  to  be  elevated  in  vasculitis  include  
antiphospholipid  antibodies  and  anti  glomerular  basement  membrane  antibodies.  
Neither of these are specific for vasculitis,  nor have been studied in  the  context  of 
disease  progression,  however  both  may  influence  the  type  of  disease  complications 
which occur.  Antiphospholipid antibodies are a heterogenous groups of autoantibodies 
specific for anionic phospolipids  (including anti-cardiolipin,  lupus anticoagulant  and 
anti-β2 glycoprotein), and have been documented in WG (Hergesell et al., 1993) and 
PAN (de la Fuente and Grana, 1994), with a small number of studies suggesting an 
association with adverse thrombotic events (Morelli et al., 1998).  Antibodies targeting 
the glomerular basement membrane are rare, but their presence is associated with renal 
and pulmonary complications (Goodpasture’s disease). While these may not provide a 
direct assessment of disease activity, their presence or absence could provide useful 
insight for treatment in certain vasculitides, albeit the vast minority of cases (Rutgers et 
al., 2005). 
  
1.4.2.2 Soluble adhesion molecules 
Adhesion molecules mediate the attachment of cells to each other, playing a pivotal role 
in the recruitment of inflammatory cells to the site of injury in vasculitis.  Proteolytic 
cleavage of the extracellular portion of cell membrane expressed adhesion molecules 
results in a soluble form being released into the circulation and explains in part the 
transient expression of adhesion molecules on activated cells (Gearing and Newman, 60 
 
1993).  There is also evidence that some adhesion molecules (such as P-selectin) may 
have  alternatively spliced forms  which lack  a trans-membrane domain  and thus  are 
produced in a soluble form (Ishiwata et al., 1994).    
 
L-selectin  is  constitutively  expressed  on  leukocytes, but  is  rapidly shed from the  
surface of activated cells.  In-vitro the soluble form can inhibit lymphocyte-endothelial 
interactions (Schleiffenbaum et al., 1992).  In patients with active AAV (Ara et al., 
2001), PAN (Coll-Vinent et al., 1997) and KD (Takeshita et al., 1997) L-selectin levels 
were lower than in controls, however in KD levels rose during the convalescent stages 
of the disease (Takeshita et al., 1997). 
 
P-selectin is a preformed molecule which is stored in the granules of platelets and the 
Weibel-Palade bodies of the endothelium, and is involved in the interaction between 
platelets,  the  endothelium  and  leukocytes,  thus  playing  a  key  role  in  vascular 
inflammation.    The  soluble  form  has  been  shown  to  be  upregulated  in  active  BD 
(Turkoz et al., 2005), and in the subacute phase of KD, correlating with platelet count 
(Takeshita et al., 1997).  In AAV and PAN P-selectin levels did not differ from controls 
(Ara et al., 2001,Coll-Vinent et al., 1997).  
 
E-selectin  is  highly  selective,  only  being  found  on  activated  endothelial  cells  in  a 
transient manner.  Its soluble form is detected in the supernatants of TNFα and IL-1 
stimulated  ECs  (Pigott  et  al.,  1992).    Correspondingly  it  is  upregulated  in  active 
vasculitis, in AAV (Ara et al., 2001), PAN (Coll-Vinent et al., 1997) and KD (Takeshita 
et  al.,  1997)  and  declines  with  remission  inducing  treatment.    In  KD  it  showed 61 
 
correlation with disease activity and was highest in patients with coronary artery lesions 
(Furui et al., 2002).  
 
 Both ICAM-1 and VCAM-1 are released in a soluble form from activated ECs in vitro 
(Pigott  et  al.,  1992).    Unlike  E-selectin  their  expression  is  not  specific  to  the 
endothelium,  however  they  are  both  upregulated  in  vasculitis  (Wang  et  al., 
2006,Stegeman  et  al.,  1994,Verity  et  al.,  1998)  and  in  some  studies  have  shown 
correlation with disease activity (Stegeman et al., 1994), although not in all (Wang et 
al., 2006,Ara et al., 2001).   
 
While soluble adhesion molecules have been widely studied in the vasculitides the data 
is ambiguous, with good correlation with disease activity reported in some studies(Furui 
et al., 2002,Stegeman et al., 1994), but not in others (Ara et al., 2001).  The predominant 
methodology for detection of these molecules is ELISA, which may not distinguish 
between biologically active and inactive forms of the adhesion molecules and may also 
be detecting adhesion molecules associated with membrane fragments (microparticles) 
rather than true soluble molecules. 
   
1.4.2.3 Other peptides – cytokines, chemokines, clotting and growth factors 
Unsurprisingly   a   number   of   the   vasculitides  are  associated   with   elevations   in  
inflammatory cytokines such as IL-1, TNFα, IFNγ Il-17, Il-23 and Il-6 (Ohlsson et al., 
2004,Chi et al., 2008,Grau et al., 1989) and chemokines such as RANTES, fractalkine, 
eotaxin,  MCP-1 and  IL-8 (Torheim et  al.,  2005,Bjerkeli et  al.,  2007,Dhawan  et  al., 
2006). Both are produced by a wide variety of cell types, including the endothelium and 
recruited leukocytes.  The actual cytokine profile in individual patients is extremely 62 
 
varied and as in the case of elevated ESR and CRP, cytokines and chemokines are not 
specific to vasculitis and can be upregulated in inflammation without the presence of 
active  vasculitic  disease.  Thus  their  use  as  a  biomarker  for  disease  activity  would 
require careful interpretation.  However with the increasing use of biological therapies 
to Il-1 and TNFα in patients refractory to other treatments, the presence of high levels of 
these cytokines may provide valuable clinical insight regarding indication for treatment 
with  these  agents.    Interestingly  in  AAV  at  least,  although  anti-TNFα  therapy 
(infliximab) induced remission in 10 patients with active disease, levels of serum TNFα 
were not significantly different to controls, nor was there a significant change observed 
with  treatment  in individual patients  (Booth  et  al.,  2004b).    Further studies  will be 
necessary to clarify any diagnostic potential of these cytokines.    
   
Von Willebrand Factor (VWf) is released in large amounts from Weibel-Palade bodies 
by activated and damaged endothelium.  It is important in coagulation, binding exposed 
collagen in the vessel wall, platelet receptors to form complexes even under high shear 
stress, and clotting factor VII preventing its inactivation (Ruggeri, 2007).  In vasculitis a 
number of studies have assessed its potential as a biomarker of disease activity with 
promising results.  VWf correlates with disease activity in WG (D'Cruz et al., 1999) and 
HSP (Yilmaz et al., 2005), although in acute KD despite being elevated compared to 
healthy  controls  there  were  no  differences  to  febrile  controls  (Lin  et  al.,  2005) 
suggesting a lack of specificity for vasculitis.  Another peptide involved in haemostasis 
is thrombomodulin which acts as a receptor for thrombin and functions as a natural 
anticoagulant.  It is found on endothelial cells and is cleaved on cellular activation. In 
vasculitis  it  has  been  to  shown  to  correlate  with  disease  activity  in  WG  and  MPA 63 
 
(Hergesell  et  al.,  1996)  (Boehme  et  al.,  1996)  although  like  VWf  is  unlikely  to  be 
specific for vasculitis and is upregulated in infection (Van de Wouwer M. et al., 2004). 
 
In response to vascular injury, the endothelium secretes numerous growth factors to 
assist  in  repair.  This  important  topic is  discussed in  more detail  in  Chapter 5.   In 
vasculitis a number of studies have examined VEGF levels in patient plasma or sera and 
found it to be upregulated in active disease in HSP (Topaloglu et al., 2001), BD (Shaker 
et al., 2007) and in KD (Terai et al., 1999), which decreased on recovery.  Data also 
suggests in KD that high VEGF may be a risk factor for development of coronary artery 
lesions  (Ohno  et  al.,  2000).    Interestingly  in  KD  the  antiangiogenic  growth  factor 
endostatin was shown to be lower in active disease (Takeshita et al., 2005).     
 
1.4.2.4 Cells and cellular fragments 
When cells become activated, membrane blebs or microparticles (MPs) are shed and 
can be detected in the circulation (Piccin et al., 2007).  Thus cellular MPs could provide 
valuable information about activated cell populations and hypothetically may be able to 
predict disease flare prior to significant vascular injury by early detection of activated or 
primed cells before irreversible vascular injury occurs.  MPs are discussed in detail in 
Chapter  4  where  they  are  assessed  as  a  potential  biomarker  of  disease  activity  in 
vasculitis. 
 
If  endothelial  cells  become  sufficiently  activated,  they  may  become  apoptotic  or 
necrotic  and  whole  cells  may  become  detached  from  the  vessel  wall.    Circulating 
endothelial cells (CECs) have been detected in a number of conditions associated with 64 
 
vascular injury (Blann et al., 2005) and are discussed in detail in Chapter 3, where they 
have been assessed as a potential biomarker of vasculitic disease activity.  
 
Conversely  endothelial  injury  must  be  followed  by  endothelial  repair  in  order  to 
maintain  health,  and  markers  of  putative  reparative  response  such  as  endothelial 
progenitor cells (EPCs) and the growth factor signalling pathways involved in their 
recruitment  may  also  provide  insight  into  disease  activity.    This  important  area  is 
discussed in more detail in Chapters 5 and 6.   
 
While these markers of endothelial activation and injury are of particular relevance in 
the  vasculitis  cohort,  they  also  have  significance  in  a  number  of  other  conditions 
affecting the vasculature, including atherosclerosis.  Although this latter condition is not 
so relevant in paediatric cohorts (where atherosclerotic changes are rare), it may be of 
greater significance in adult cohorts.  That said, as will be discussed later in this thesis, 
both  endothelial  MPs  and  CECs  have  been  studied  in  adults  with  vasculitis  with 
promising results (Erdbruegger et al., 2008). 
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1.5 Aims of this thesis 
The aim of this thesis is to evaluate novel putative biomarkers of disease activity in 
primary systemic vasculitis.  As the endothelium is the target organ of the disease, this 
objective has been addressed by focusing on surrogate markers of endothelial activation 
and injury and subsequent reparative responses.  The biomarkers studied in subsequent 
chapters  of  this  thesis  include  circulating  endothelial  cells  and  endothelial 
microparticles,  growth  factors  associated  with  angiogenesis  and  vasculogenesis  and 
endothelial progenitor cells.  A major factor of work involving children is the small 
volumes of blood available on which to perform such tests and thus much care was 
taken to minimise blood volumes necessary for study.        
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2.1 Introduction 
This section details materials and methods which are used in more than one chapter.  
Where methodologies have been adapted or developed specifically for this study, they 
are discussed in greater detail in the relevant chapter. 
 
 
2.2 Patients, vasculitis classification and assessment of 
disease activity 
All patients enrolled in the study were assessed by rheumatologists at GOSH.  Full 
informed consent was obtained for all patients and controls (parental) and children’s 
assent was sought where appropriate on enrolment in the study.   
     
2.2.1 Classification of the vasculitic syndromes 
As discussed in Section 1.2 vasculitis was classified predominantly according to the 
Chapel Hill Consensus Criteria (Jennette et al., 1994), however the American College of 
Rheumatology  (ACR)  criteria  (Fries  et  al.,  1990)  and  the  EULAR/PRES  endorsed 
consensus  criteria  (Ozen  et  al.,  2006)  for  vasculitis  of  the  young  were  applied  as 
additional classification tools.  The Chapel Hill criteria classifies vasculitis on the size 
of the vessel predominantly affected and also forms the basis of the EULAR/PRES 
criteria,  which  contains  further  modifications  relating  to  the  paediatric  population.  
These include; the  exclusion of diseases  not  relevant  in  childhood  and inclusion of 
diseases that are not addressed by the adult system, an extra category of disease entitled 
“other diseases” and the use of vessel “predominantly affected” to categorise patients 
whose disease overlaps vessel sizes (Ozen et al., 2006). Appendix 1 lists all criteria. 68 
 
2.2.2 Assessment of disease activity 
Disease activity was assessed using a modified paediatric version of the Birmingham 
Vasculitis Activity Score (BVAS) (Luqmani et al., 1994), a scoring system that is used 
to give an overall view of disease activity in vasculitis patients (Appendix 2).  It has 
never been formally validated in children.  However, in a previous report from our 
group a modified paediatric version of BVAS was found to significantly correlate with 
the conventional acute phase marker CRP (as in adults) (Brogan et al., 2004a,Luqmani 
et al., 1994).   
 
The aim of the BVAS scoring system is to give a uniform assessment of current disease 
activity in groups of patients with different forms of vasculitis and is not specifically 
designed for any single vasculitic syndrome, although a specific form of BVAS for 
Wegener’s  Granulomatosis  has  been  described  for  use  in  adult  patients  (Jayne, 
2001,Stone et al., 2001).   At time of scoring, disease activity is only considered for 1 
month  previously.    The  score  is  weighted  more  heavily  towards  biochemical  and 
objective evidence of active vasculitis (such as organ involvement e.g. gut or kidneys) 
rather  than  symptoms  which  have  a  subjective  element  (e.g.  myalgia,  arthralgia).  
Despite  the  inherent  potential  limitations  and  scorer  subjectivity  of  the  BVAS  this 
system  does  provide  an  overall  clinical  score  of  vasculitic  disease  activity  and  has 
proved a successful tool for use in clinical trials (Jayne, 2001).  
 
In this study, active vasculitis was defined as a BVAS score greater than 0, where the 
scored criteria were newly appearing or worse in the preceding 4 weeks and attributable 
to  vasculitis,  having  excluded other causes such as  infection.  The maximum  score 69 
 
attainable was 63.  Disease remission was defined as a score of 0/63.   The modified 
BVAS used in this thesis is shown in Appendix 2. 
 
 
2.3   Materials 
2.3.1 Reagents for blood collection 
After blood was obtained it was aliquoted into one or more of the following collection 
bottles  depending  on  use;  1.4ml  3.2%  trisodium  citrate  (Sarstedt),  5ml  EDTA 
(International  scientific  supplies),  5ml  polypropylene  containing  no  anticoagulant  or 
sterile 20ml Universal bottles containing 40µl of preservative-free heparin (Monoparin, 
CP Pharmaceuticals Ltd, 1000 U/ml). 
 
2.3.2 Fluorochrome conjugated antibodies for flow cytometry 
The fluorochrome conjugated antibodies used are listed in Table 2.1.  Antibodies were 
diluted using 0.01M PBS + 0.1% azide for staining of peripheral blood mononuclear 
cells  (PBMCS)  and  Human  umbilical  vein  endothelial  cells  (HUVEC)  and  sterile 
filtered  RPMI  1640  with  5%  FCS  for  staining  of  microparticles  (MPs).    Where 
antibodies were used in whole blood they were added neat to give the final dilution 
given  in  Table  2.1.    All  antibodies  were  titrated  alongside  their  manufacturers 
recommended isotype control to determine their optimal concentration and minimise 
non-specific  binding.  FC  receptor  blocking  reagent  (Miltenyi  biotech)  was  used  to 
further reduce non specific antibody binding. 
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Table 2-1: Fluorochrome conjugated antibodies for flow cytometry 
 
Use in this thesis E = endothelial progenitor cells, C = Circulating endothelial cells, M = 
microparticles, EC = in vitro endothelial activation, N = in vitro neutrophil experiments     
Specificity  Isotype  Conjugate  Clone  Dilution  Source  Usage 
 
 
CD34  IgG1  PERCP  8G12  1:10  BD  E,EC,C 
CD133  IgG1  PE  AC133  1:10  Miltenyi  E 
CD14  IgG1  FITC  Mem-18  1:20  Serotec  E 
CD14  IgG1  PE  Mem-18  1:20/1:15  Serotec  E,M 
CD144  Poly 
IgG 
FITC  -  1:15  Serotec  E 
CD144  IgG1  PE  16B1  1:20/1:15  eBiosciences  E,M 
CD45  IgG1κ  FITC  HI30  1:20  eBiosciences  C 
CD146  IgG1 κ  PE  P1H12  1:20  BD  E,EC,C 
CD3  IgG1  CY  UCHT1  1:20/1:15  BD  E,M 
KDR  IgG1  BIOTIN  KDR-2  1:10  Sigma  E 
CD105  IgG1  PE  SN6  1:15  Serotec  M 
CD62e  IgG1κ  PE  68-5H11  1:15/1:10  BD  M,EC 
CD62p  IgG1κ  PE  AK4  1:15  BD  M 
CD62L  IgG1κ  PE-CY5  DREG-56  1:15/1:20  BD  M, N 
CD11b  IgG1κ  PE  ICRF44  1:15/1:20  BD  M,N 
CD15  IgG1κ  PE  HLDA8  1:15/1:20  Biolegend  M,N 
CD54  IgG1κ  PE-CY5  HA58  1:15  BD  M 
CD66b  IgG1  PE  Birma17C  1:40/1:25  IBGRL  M,N 
CD42a  IgG1κ  Percp  Beb1  1:15  BD  M 
TF  IgG1κ  PE  HTF-1  1:15  BD  M 71 
 
2.3.3 Tissue culture media 
The following tissue culture media was used: RPMI-1640 culture medium containing 
2mM L-glutamine (Invitrogen), MCDB-131 (Invitrogen) and the EGM-2 (endothelial 
growth  media)  bullet  kit  (Cambrex).    The  EGM-2  bullet  kit  consisted  of  EBM-2 
(endothelial basal media) with the following supplementation (concentrations were not 
given)  human  recombinant  Epidermal  Growth  Factor  (hEGF),  human  Fibroblast 
Growth  Factor  -  Basic  (hFGF-B),  Vascular  Endothelial  Growth  Factor  (VEGF),  
Ascorbic Acid (Vitamin C), Hydrocortisone,  Long human Recombinant Insulin-like 
Growth  Factor  (R3-IGF-1),  Heparin,  Fetal  Bovine  Serum  (FBS),  Gentamicin  and 
Amphotericin. 
 
Further supplementation to the culture media depended on the culture conditions as 
described  in  the  individual  methodologies,  however  the  following  were  also  used; 
penicillin  and  streptomycin  (10,000U  and  10,000µg,  diluted  1:100,  Invitrogen), 
antibiotic-antimycotic liquid 100x (10,000U penicillin, 10,000 µg streptomycin, 25 µg 
amphotericin  B,  diluted  1:100,  Invitrogen),  Vascular  Endothelial  Growth  Factor 
(VEGF, R&D), basic human fibroblast growth factor (bFGF, R&D), heparin and fetal 
calf serum (FCS, Invitrogen).  In most experiments FCS was heat inactivated at 56
o C 
for  60  minutes  to  destroy  complement.    Variations  in  batch  quality  of  FCS  can 
dramatically influence  HUVEC  growth,  therefore batches  of FCS used for HUVEC 
culture were tested prior to purchase and bought in large quantities.  To enhance cell 
attachment or to act as a growth scaffold the following were used: Attachment factor 
(PAA systems), fibronectin (100ng/ml, Calbiochem), Matrigel
TM, phenol red free (BD). 
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2.3.4 Cytokine and protein reagents 
The following cytokines were used: recombinant TNF- (100ng/ml, Autogen Bioclear), 
recombinant Il-1β (100ng/ml, Autogen Bioclear).  The following peptides were used: N-
formyl-methyl-leucyl-phenylalanine (FMLP)  (1uM,  Sigma),  LPS  (100ng/ml, Sigma). 
The following fluorochrome-conjugated proteins were used: annexin-V (FITC; 1:100 
dilution,  BD);  Ulex  europaeus  I  Agglutinin  (UEA-I  FITC,  10mg/ml,  Sigma), 
Streptavidin (FITC, 1:150 dilution, Serotec).  Type II collagenase (Sigma) was used for 
isolation of HUVEC from umbilical cords.  Trypsin-EDTA (10x, 0.5%, Invitrogen) was 
used for detachment of HUVEC from culture.   
 
2.3.5 Bead based extraction reagents 
DYNAL bead technology (Invitrogen) was used for isolation of CECs: Dynabeads Pan 
Mouse IgG were labeled with an unconjugated IgG1 antibody to CD146, clone s-endo 1 
(BioCytex). The Dynal MPC-L magnet which holds 1-8ml tubes was also used. 
 
2.3.6 ELISA kits 
The following ELISA kits were used to determine levels of growth factors in patients 
plasma and serum: Angiopoeitin-1 (R&D), Angiopoeitin-2 (R&D), Vascular endothelial 
growth factor VEGF) (R&D), Thymosin β4 (immundiagnostik).  All test kits were used 
as per manufacturer recommendation. 
 
2.3.7 Other reagents 
For  isolation  of  PBMCs  from  blood  samples,  the  density  centrifugation  separation 
reagent Lymphoprep (Axis-Shield) was used.  To isolate neutrophils a similar product 
Polymorphprep  was  used  (Axis-Shield).  The  following  latex  beads  were  used  to 73 
 
investigate forward and side scatter (FSC/SSC) flow cytometric characteristics of small 
particles: 0.3, 0.8, 3µm latex beads, (Sigma).  Countbright beads
TM (Invitrogen) were 
used as in an internal standard for absolute enumeration of circulating endothelial cells 
and endothelial progenitor cells in whole blood samples. 
 
 
2.4 Preparation of blood and tissue samples 
All  human  blood  and  tissue  samples  were  collected  with  full  ethical  approval  and 
informed consent. 
 
2.4.1 HUVEC 
2.4.1.1 Isolation of HUVEC  
Umbilical cords were collected from the maternity unit at the West Middlesex hospital, 
London  with  ethical  approval  and  informed  consent.    HUVEC  were  isolated  from 
freshly collected cords in the following manner:  Using tweezers cords were removed 
from the collection bottle (containing RPMI 1640 + 100U/ml Penicillin + 100 µg /ml 
Streptomycin + 0.25 µg/ml Amphotericin) and sprayed liberally with IMS.  Any blood 
inside the cord was squeezed out and discarded.  One end was clamped approximately 
2cm in and the end cut off.  At the other end, a further 1-2cm was removed and a Kwill 
(Universal Hospital Supplies) was inserted into the umbilical vein and clamped into 
position.  A syringe filled with RPMI 1640 (with antibiotics and antimycotic as above) 
was squeezed into the cord via the Kwill and used to fill it.  The clamped end of the 
cord was then released and the vein contents washed out into a clean waste beaker.  The 
vein was then filled with warm (37
oC) collagenase type II solution (0.1%, dissolved in 
RPMI-1640 and passed through a 0.2µm tissue culture filter, aliquoted and stored at -74 
 
20°C).  Both ends were clamped and the cord left for 10 minutes in the incubator.  The 
contents of the vein were then emptied into a sterile collection bottle and a further wash 
through  with  RPMI  (containing  antibiotics  only  +  5%  heat  inactivated  FCS)  was 
performed.  The collected vein contents containing HUVEC were then centrifuged for 8 
minutes at 450g creating a cell pellet. 
 
2.4.1.2 HUVEC culture 
Pelleted  HUVEC  were  resuspended  in  MCDB131  (containing  20%  heat  inactivated 
FCS + antibiotics) and placed in a 25 cm
2 flask, precoated (30 minutes prior to use) with 
attachment factor for optimal cell attachment.  Cells were cultured at 37
oC with 5% CO2 
and inspected each day for growth. The media was changed every 3 days until cells 
were required, passaging as necessary at about 80% confluence.   Initally HUVEC were 
easily identifiable as small clusters of oval adherent cells when inspected under phase-
contrast microscopy (Figure 2.1a).  As they reached confluence their appearance was 
characteristically “cobblestone” (Figure 2.1b).  In some cultures there was significant 
overgrowth of smooth muscle-like or fibroblast-like cells (which are characteristically 
spindle-shaped),  cultures  containing  these  and  those  that  had  not  grown  well  were 
discarded. 
 
2.4.1.3 HUVEC culture passage 
HUVEC that were near-confluent were washed three times in warmed PBS to remove 
non-adherent cells and any FCS. Cells were then washed once in 0.5ml 0.05% Trypsin-
EDTA solution (per 25 cm
2 flask) which was then removed and a further 1ml Trypsin- 
EDTA solution added. Cells were inspected under phase-contrast microscopy, and when 
rounding  and  becoming  dislodged  (typically after 30 seconds),  the  flask  was  tapped 75 
 
Figure 2-1: Cultured HUVEC  phenotype 
 
 
 
 
 
Figure  2.1a:  Soon  after  they  were  placed  in  culture  HUVEC  were  easily  identifiable  as  small 
clusters of oval adherent cells when inspected under phase-contrast microscopy.   Figure 2.1b: As 
HUVEC reached confluence their appearance was characteristically “cobblestone” .  Scale bars 
represent 50µm  
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against the bench top to aid removal.  If cells did not detach, flasks were placed in the 
incubator for a further 30 seconds. The detached cells were quickly resuspended in 
warmed HUVEC culture medium and transferred to a 50-ml sterile conical tube. These 
were  then  seeded  into  6  or  12  well  flat-bottom  tissue  culture  plates,  precoated  in 
attachment factor. Tissue culture plates were then incubated as before. 
 
When cord supply was  plentiful HUVEC at passage 1 and 2 were frozen down, to 
provide a continous supply of endothelial cells if fresh cords were unavailable.  After 
passage, viable HUVEC were counted with trypan blue (to exclude dead cells) in a 
haemocytometer.  A minimum of 5 x 10
6 cells were resuspended in heat inactivated 
FCS  containing  10%  DMSO  and  frozen  in  a  freezing  container  placed  in  a  -80
oC 
freezer.   For use, cells were defrosted rapidly at 37
oC and decanted straight into a T25 
flask precoated with attachment factor and containing EGM-2 media with all additives. 
 
Details  of  specific  conditions  used  to  grow  HUVEC  for  various  experimental 
procedures  are  described  in  the  relevant  sections  in  subsequent  chapters.  HUVEC 
morphology and phenotype, especially in terms of induction of cell adhesion molecules 
in response to pro-inflammatory stimuli may alter after serial passages. The cells used 
throughout this study were therefore always first to third sub-culture passage.  
 
2.4.1.4 Spiking of whole blood samples and PBS with HUVEC  
In these experiments HUVECs at passage 1 or 2 were detached as described above 
using 0.05% trypsin-EDTA and resuspended in PBS + 5% heat inactivated FCS + 0.1% 
azide.    Cells  were  centrifuged  to  a  pellet,  resuspended  in  a  small  volume  of  PBS 
(additives as above) and counted as described above.  The HUVEC were serially diluted 77 
 
to give stock concentrations from which 100l of cells could be added to 1ml blood or 
1ml PBS.  Whole blood or PBS was spiked with 0, 100, 1000, 10000 and 100000 
HUVECs/ml.  Cells  were  carefully  mixed  in  the  blood  or  PBS  sample  by  gentle 
pipetting.  Equal volumes of spiked whole blood or PBS were used for flow cytometry 
or  immunomagnetic  bead  extraction  in  the  comparative  experiments  described  in 
Chapter 3.     
 
2.4.2 Isolation of PBMCS 
PBMCs  were  isolated  using  density  gradient  media  (Lymphoprep).    10ml  of  blood 
collected in preservative free heparin was mixed with 10ml RPMI 1640 containing L-
glutamine with added antibiotics (penicillin 100U/ml and streptomycin 100g/ml) and 
layered  over  10ml  of  lymphoprep  in  a  50ml  conical  tube.    The  sample  was  then 
centrifuged at room temperature for 25 minutes at 700g with no brake.   A wide tipped 
Pasteur pipette was used to aspirate PBMCs from the buffy coat layer formed into a 
fresh  50ml  conical  tube,  which  was  then  washed  with  RPMI  1640  containing  L-
glutamine  (with  10%  heat  inactivated  FCS  and  antibiotics  as  before).    Cells  were 
centrifuged at 500g for 10 minutes and the pellet re-suspended in RPMI 1640 (with FCS 
and antibiotics). Cells were counted as described previously.  To allow batch analysis 
aliquots of cells (concentration 5-10x10
6 cells/ml) were resuspended in heat inactivated 
FCS with 10% DMSO and frozen in a freezing container placed in a -80
oC freezer for 
use in later experiments.  
 
2.4.3 Isolation of neutrophils 
Neutrophils were also isolated using density gradient media (Polymorphprep). 6ml of 
blood  was  layered  directly  over  6ml  of  polymorphprep  in  a  15ml  falcon  tube.  The 78 
 
sample was then centrifuged at 500g for 30minutes.  The different gradient preparation 
resulted in a separation of 2 bands of cells, the lower of which constituted neutrophils 
with the upper band corresponding to PBMCs.  A wide tipped Pasteur pipette was used 
to remove the upper band first, allowing better access to the lower band of interest, 
which was then removed in the same way.  To reduce neutrophil activation, cells were 
resuspended in PBS and kept on ice until use. 
 
2.4.4 Separation of platelet poor plasma 
Blood  collected  in  3.2%  trisodium  citrate  was  spun  at  5000g  for  5  minutes  in  a  
microcentrifuge in 1.5ml polypropylene tubes.  The supernatant was decanted and then 
respunded in order to obtain platelet poor plasma (PPP).  The PPP was then aliquoted 
and stored at -80
oC until use.  PPP was used for detection of microparticles as described 
in 2.5.3 and in ELISAs for detection of Angiopoetin-1 and Angiopoetin-2. 
 
2.4.5 Separation of serum  
Uncoagulated  blood  was  allowed  to  stand  for  2-4  hours.    The  sample  was  then 
centrifuged at 1500g for 10mins, the supernatant aliquoted and samples stored at -80
oC 
until future use.   Serum was used in ELISAs for detection of VEGF and Thymosin β4. 
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2.5 Assessment of endothelial activation and injury 
2.5.1 Detection  of  circulating  endothelial  cells  using  immunomagnetic 
beads 
2.5.1.1 Preparation of immunomagnetic beads 
Dynabeads  (pan  mouse  IgG)  were  resuspended  and  350µl  was  added  to  a  5ml 
polypropylene tube.  The tube was then placed into the magnet (MPC-L) for 2 minutes 
to allow the beads to attach to the side of the tube.  The supernatant was discarded using 
a Pasteur pipette and the beads resuspended in 1ml PBS (+0.1% BSA).  The tube was 
placed in the magnet again and the supernatant discarded as before.  The beads were 
resuspended in 950ul of PBS (+ 0.1% BSA) and 400ul of s-endo-1 antibody were added 
(25µg/ml concentration).  The tube was sealed and the sample mixed on a roller mixer 
for 2 hrs at 4
oC.   Beads were washed as before three times and resuspended in a final 
volume of 1ml, ready for use. 
 
2.5.1.2 CEC extraction from peripheral blood 
CECs  were  detected  using  the  consensus  protocol  as  described  by  Woywodt  et  al 
(Woywodt et al., 2006a).  Briefly 1ml of venous blood collected into a blood bottle 
containing  EDTA  was  mixed  with  1ml  buffer  (phosphate  buffered  saline  (PBS) 
containing 0.1% bovine serum albumin (BSA) and 0.6% sodium citrate) and 20μl Fc 
receptor (FcR) blocking reagent and incubated for 5 minutes at room temperature. 50μl 
of anti-CD146 coated immunomagnetic beads was then added and the sample incubated 
at 4
oC whilst rotating for 30 minutes. Bead-bound cells were separated using the magnet 
as described above and washed three times with buffer. Cells were then re-suspended in 
100μl of buffer containing 10μl of 2mg/ml FITC labelled Ulex Europeus lectin and 80 
 
incubated in the dark at room temperature for one hour. Cells were then washed again 
three times and re-suspended in a final volume of 200μl buffer. 
 
2.5.1.3 Counting CECS 
CECs  in  the  sample  were  counted  using  a  Nageotte  chamber  on  a  fluorescent 
microscope and were defined as the following;  Ulex bright cells, greater than 10μm in 
size with more than 5 magnetic beads attached, a definition put forward in the 2006 
consensus paper (Woywodt et al., 2006a).  A Nageotte counting chamber is designed 
for counting of rare events and holds 50µl of sample over a grid consisting of 40 lines.  
CECs  were counted over 20 lines of the  grid  (corresponding to  25µl  or 1/8  of the 
sample) if there were high numbers, which made it difficult to count or over all 40 lines 
(corresponding to 50µl or 1/4 of the sample) if there were low numbers.  Counts were 
then multiplied by the appropriate factor to get a total value per ml of whole blood.  
 
2.5.2 Detection of circulating endothelial cells using flow cytometry  
Enumeration  of  CECs  has  been  carried  out  using  both  the  immunomagnetic  bead 
extraction as described above and flow cytometry (FC), however only one publication 
has demonstrated whether they give comparable results and this was not in patients with 
vasculitis  (Goon  et  al.,  2006).    Thus  both  methods  were  used  in  this  thesis  for 
comparison.  The flow cytometric definition of CECs definition of  putative CECs as 
suggested by Goon et al in their comparative paper and other groups was thus: cells 
falling within a mononuclear cell gate that express both CD146 and CD34, but which 
are negative for CD45 (Goon et al., 2006,Bertolini et al., 2006,Del et al., 2004,Khan et 
al., 2005).   
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2.5.2.1 Preparation of blood samples for flow cytometry of CECs 
1ml of blood collected in EDTA was lysed using 10ml of FACS lysis solution (1:10 
dilution of 10x FACS lyse, BD). After centrifugation to a pellet and decantation of the 
supernatant,  non-specific  antibody  binding  was  blocked  using  20l  FcR  blocking 
reagent (Miltenyi) and 200l of mouse serum (Sigma-Aldrich) for 20 minutes at room 
temperature.  Cells were then incubated with the following fluorochrome labelled anti-
human antibodies: CD45 FITC, CD146 PE and CD34 Percp for 30 minutes.  Cells were 
washed once using PBS + 5% heat inactivated FCS + 0.1% azide, centrifuged to pellet 
the cells and then re-suspended in 200l of fixative with 10% formaldehyde and 1% 
azide (BD, cellFIX
tm) and made up to 1ml with buffer immediately prior to FC.  
 
2.5.2.2 Flow cytometry instrument settings 
Samples  were  run  on  a  Becton  Dickinson  FACSCalibur  flow  cytometer.    FC  was 
performed using FSC and SSC instrument settings optimised for detection of PBMCs as 
previously  described  (Goon  et  al.,  2006),  using  a  linear  FSC/SSC  scale  with  FSC 
voltage set at E00.  After the optimisation steps described in Chapter 3 FC was also 
performed as for larger cells such as HUVEC, using a logarithmic FSC scale and a 
linear  SSC,  with  a  FSC  voltage  set  at  E00  as  previously  described  (Brogan  et  al., 
2004b). CECs were gated firstly on their FSC and SSC characteristics and then on cells 
negative for CD45 staining.  CECs were then considered to be all events bright for 
CD146  and  CD34  in  this  region.    Non-stained  samples  and  fluorochrome  matched 
isotype controls (IgG1 FITC (eBiosciences), IgG1 PE (BD) and IgG1 Percp (BD)) 
were used to  define positivity.   The  gating strategy used is  shown in Chapter 3 in 
Figures 3.1 and Figure 3.11.  82 
 
2.5.2.3 Absolute enumeration of CECs using flow cytometry 
In order to obtain absolute CEC counts, samples were either spiked with Countbright
TM 
absolute counting beads as per manufacturer’s instructions, run to completion or had the 
flow rate calculated prior to the sample being run using 3µm latex beads (see below).   
 
To  enumerate  using  countbright
TM  beads  50µl  was  spiked  into  the  sample.    50µl 
contained approximately 50,000 beads (depending on batch).  Therefore absolute cell 
count could be determined by calculating the volume of sample analysed by calculating 
the proportion of beads run through the system using the following equation: 
 
 
 
In order to estimate the flow rate of the machine 3µm latex beads were diluted in sterile 
filtered distilled water to give a final concentration of 20,000 beads/µl.  10 µl of this 
stock was then added to 240µl of distilled water.  The number of beads acquired in a set 
time at a set flow speed (usually medium flow) was used to estimate the flow rate (in 
µl/second) using the following calculation: 
 
 
 
 
 
Once the flow rate was estimated the number of CECs in a sample could be calculated 
by working out the volume of sample that would be run in a set time at that flow rate 
and then calculating how many CECs would be in the whole sample.  
Beads added (50,000) 
Beads counted 
x  CECs counted  =  CECs/ml 
÷  Time (s)  =  Flow rate (µl/s)  Beads counted 
Beads added 
(200,000) 
x  Volume (250µl) 83 
 
2.5.3 Detection of cellular microparticles 
Samples  of  platelet  poor  plasma  (PPP)  were  thawed  rapidly  at  37
oC  and  a  known 
volume was spun at 15000g for 60 minutes to pellet the microparticles (MPs) at room 
temperature in a temperature controlled centrifuge. The supernatant was decanted and 
the MPs resuspended in annexin V buffer (BD).  35µl was then added to wells on a 96 
well plate (polypropylene) containing 5µl of annexin V FITC diluted 1:10 (BD) and 
10µl of a PE conjugated, PerCP conjugated or PE-CY5 conjugated antibody diluted to 
give a final concentration in 50µl as in Table 2.1 (1 in 3 for most antibodies, 1 n 5 for 
CD144 and 1 in 8 for CD66b).  MPs were stained, rocking gently, in the dark at room 
temperature for 10 minutes.  200µl of Annexin V buffer was then added to each well to 
end the incubation and samples were then transferred to FACS tubes.   The FC plans 
used for MP detection are shown in Appendix 3.  A 22 tube plan was used for samples 
with a volume greater than 300µl, while smaller samples were run using 12 tubes. 
 
2.5.3.1 Flow cytometry instrument settings for microparticle detection 
Samples  were  analysed  on  a  BD  Facscalibur,  using  a  logarithmic  scale  with  FSC 
voltage set at E01.  Instrument settings were initially optimised using 0.3, 0.8 and 3µm 
latex beads, this process is described in detail in Chapter 4.  As described previously 
(Combes  et  al.,  1997)  MPs  were  gated  on  their  Annexin  V  (AnV)  positivity  as 
demonstrated in Figure 4.3.  As AnV is a protein and not an antibody, it therefore does 
not have an isotype control so unlabeled MPs were used to establish positivity cutoff.  
In order to determine whether observed noise in the system leading to high event rate in 
some samples had a significant effect on MP detection, MPs were analysed with and 
without a threshold based on AnV binding (discussed in Chapter 4).  Histograms based 
on the gated AnV positive population were obtained for the fluorochrome conjugated 84 
 
antibody  binding  and  positivity  was  defined  by  the  isotype  control  using  2.5  % 
positivity as a cutoff.  
 
2.5.3.2 Absolute enumeration of microparticles 
MP samples were run at a medium flow rate for 45 seconds, with a known number 
(200,000) of 3µm latex beads run for 45 seconds at the same flow rate before and after 
each  patient’s  samples,  allowing  absolute  MP  enumeration.  By  using  the  equation 
below, which incorporates the beads run in 45 seconds and the exact volume of plasma 
used the absolute number of annexin V binding microparticles per ml of plasma was 
determined: 
 
 
 
 
 
2.5.4 Detection of activated parent cells 
When  MPs  were  generated  from  isolated  cell  populations  during  setup  experiments 
activation of the parent cell was confirmed in the following manner.  After the cells 
were pelleted and the supernatant was decanted for MP enumeration, the parent cells 
were resuspended in PBS (containing 0.1% azide and 5% heat inactivated FCS) to a 
concentration of 2 x 10
6 cells/ml.  100µl of cell suspension was added to wells on a 96 
well plate.  The plate was then spun at 500g for 5 minutes at 4
oC.  The supernatant was 
flicked off and the plate blotted.  10µl of diluted antibody or control (final concentration 
as in table 2.1) was added to the pelleted cells.  Cells were stained for 30 minutes at 
4
oC,  then  washed  3  times  with  PBS  using  the  spin  down,  flick  and  blot  technique 
MPs/ml of 
plasma  x  x 
no of FACs tubes 
sample divided into 
Annexin V +ve 
events 
Beads added (200,000) 
Average beads counted  x 
1000 
Vol of plasma  
spun down (µl) 
= 85 
 
described above. After the final wash cells were resuspended in 200µl of Cellfix.  The 
phenotype  of  the  MPs  generated  from  different  cell  populations  and  their  activated 
parent cells is shown in Appendix 4. 
  
 
2.6 Assessment of potential endothelial repair 
responses 
2.6.1 Measurement of endothelial growth factors  
Growth factors associated with endothelial reparative responses were measured using 
then following ELISA kits: VEGF (R&D), Angiopoetin 1 (R&D), and 2 (R&D), and 
thymosin beta 4 (immunodiagnostik).  The three R&D kits were based on the sandwich 
ELISA principle while the thymosin beat  4 kit was  based on a competitive ELISA 
principle. 
 
In a sandwich ELISA a monoclonal antibody specific to the peptide of interest is coated 
onto each well of a 96 well plate.  Standards and samples are then pipetted into the 
wells in duplicate and any peptide of interest becomes immobilised.  Unbound sample is 
then washed away and an enzyme linked secondary monoclonal specific for the peptide 
of interest is added.  This then binds the immobilised peptide and after a wash step, the 
introduction of a substrate for the enzyme allows a colour to develop, the reaction is 
stopped  and  the  plate  then  read  at  a  specific  wavelength  to  determine  the  colour 
intensity (Figure 2.2).  The intensity of colour (measured as optical density (OD)) of the 
standards allows a standard graph to be plotted so the test samples can be compared to it 
and  have  their  concentration  calculated.    Examples  of  the  standard  graphs  obtained 86 
 
using these kits can be seen in Appendix 5.  VEGF was measured in serum (100µl per 
well, undiluted), Angiopoetin 1 was measured in platelet poor plasma (50µl per well, 
diluted 1 in 15) as was Angiopoeitin-2 (50µl per well diluted 1 in 5).   
 
In a competition ELISA (Figure 2.3) the peptide of interest is coated onto the wells of 
the 96 well plate and competes with the peptide in the standards and samples to bind an 
enzyme linked substrate.  In the case of thymosin β4, the substrate was monomeric 
actin.  Thus in samples which have a high OD the substrate had bound the plate and 
thus there was a low concentration of thymosin β4 in the sample, conversely samples 
with low OD have high thymosin β4.  The standards with a known concentration for 
thymosin beta 4 were used to generate a standard curve with which to compare the test 
samples.  Unfortunately although the kit purchased claimed to be fully optimised for 
measurement  of  TB4  in  human  serum,  children  had  in  some  cases  10  fold  high 
thymosin β 4 level than adults and were off the standard curve.  Further dilution of the 
sample  was  necessary  and  demonstrated  that  all  samples  required  a  1  in  5  dilution 
before running on the plate.  Examples of the standard curves generated are in Appendix 
5. 
 
2.6.2 Flow cytometry for detection of endothelial progenitor cells  
Frozen PBMCs were thawed rapidly at 37
oC, then transferred to warmed FCS, to which 
warm RPMI 1640 (with antibiotics) was added to give a final FCS concentration of 10-
20%.  PBMCs were then counted and diluted to 2 x 10
6 cells per ml (in some samples a 
pelleting  step  was  necessary  to  concentrate  cells),  50µl  of  FcR  blocking  agent  was 
added per ml and the cells incubated for 10 minutes at room temperature. 150µl of the 
cell suspension was added to wells on a 96 well plate, subsequently the plates were spun 
at 500g for 5 mins at 4
oC and the supernatant flicked off and the plate blotted. 87 
 
Figure 2-2: Methodology of Sandwich ELISA 
 
   
 
 
 
 
 
 
Figure 2.2:  Sandwich ELISAs for VEGF and Angiopoietins-1 and 2 were performed using the 
above protocol, adapted from R&D instruction manuals. 
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Figure 2-3: Methodology of Thymosin-β 4 competition ELISA 
 
 
 
 
 
 
 
Figure 2.3: Thymosin beta-4 competition  ELISA methodology was performed as described in the 
protocol  above,  adapted  from  Immunodiagnostik  instruction  manual.    Although  the  kit  was 
optimised for adult samples, it became apparent that children have much higher levels of  TB4 and 
thus serum samples had to be diluted 1 in 5 before they could be analysed using this kit  
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Cells were then stained with 10µl of diluted antibody (diluted using PBS + 0.1% azide; 
table 1a) and incubated for 30 minutes at 4
oC.   Cells were washed using 200µl of FACs 
wash  (PBS  +  0.1%  azide  +  5%  heat  inactivated  FCS)  and  spun  down  and  the 
supernatant flicked off as before.  The secondary antibody for KDR, Streptavidin FITC 
was then added to the required wells and incubated for 10mins at 4
oC.  Cells were then 
washed  twice  as  before  and  finally  resuspended  in  150µl  of  fixative  with  10% 
formaldehyde with 1% azide (BD, cellFIX
tm). 
 
Using flow cytometry the endothelial progenitor cell (EPC) markers KDR, CD133 and 
CD34  were  examined  alongside  the  endothelial  markers  CD144,  CD146  and  the 
lymphocyte marker CD3, the monocyte marker CD14 and the pan leukocyte marker 
CD45. Non stained samples and fluorochrome matched isotype controls were used to 
define positivity.  EPCs were expressed as a percentage of the mononuclear cell gate, as 
a  percentage  of  total  CD34+  cells    and  in  the  vasculitis  patients  as  an  estimate  of 
absolute EPC number based on the full blood count obtained from the clinical labs as 
described in Chapter 6.  Briefly the leukocyte count is multiplied by the % of viable 
cells expressing CD34.  It is important to note that this was not used as an absolute 
count  of  EPCs  but  as  a  crude  tool  to  estimate  absolute  EPC  numbers  in  order  to 
determine  whether  trends  observed  in  individual  patients  were  reflected  when  the 
different ways of expressing EPC number were compared.  
 
2.6.3 Endothelial progenitor cell colony culture   
Hill et al described a methodology for counting colonies believed to be derived from 
EPCs.    In  a  large  study  these  colonies  correlated  with  flow  mediated  dilatation  (a 
measure of endothelial function) (Hill et al., 2003).  This technique was thought to be 90 
 
dependent  on  the  batch  of  FCS  used,  which  was  developed  into  the  commercially 
available colony counting assay – Endocult
TM (Stemcell technologies).  This technique 
has now become widely used in clinical studies and is thought to predict cardiovascular 
mortality (Hill et al., 2003).  Work done previously within our group by Dr Francesca 
Arrigoni  had  resulted  in  a  growth  factor  supplemented  media  which  emulated  the 
growth characteristics of endocult, independent of FCS batch.  Thus this media was 
used for assessment of EPC colonies as follows: PBMCs were isolated as described in 
2.4.4  and  5  x  10
6  cells  were  cultured  in  RPMI  1640  (with  20%  FCS  (not  heat 
inactivated) and antibiotics as before) for 2 days per well on a fibronectin coated 6 well 
plate.  The non-adherent cells (hypothesized to contain the non differentiated stem cell 
population) were then removed and replated onto a fibronectin coated 24 well plate at a 
concentration of 1 x 10
6 cells per well.  The replated cells and the adherent population 
remaining on the 6 well plate were cultured in MCDB131 containing the following 
additives  L-glutamine  (50ng/mL),    endothelial  cell  growth  serum  (50µg/ml,Sigma), 
VEGF (20ng/mL), bFGF (5ng/mL), 20% FCS (not heat inactivated), heparin (5U/mL) 
and penicillin (100 U/mL) and streptomycin (100µg/ml).  Media was changed every 3 
days until day 7 when colonies were counted.  Colonies consisted of a central core of 
rounded cells surrounded by spindle like outgrowth cells (Figure 2.4a). 
 
2.6.4 Endothelial progenitor cell outgrowth culture   
Although a number of groups have used colony counting as a measure of EPC function, 
other groups have derived endothelial-like monolayers from adherent cell populations, 
in much longer cultures (20+ days)  and these have been termed late outgrowth EPCs 
(Lin et al., 2000). In line with most studies which have grown these late outgrowths, the 
commercially available endothelial media EGM-2 was used.  PBMCs were isolated as 91 
 
described in Section 2.4.4 and in order to grow late outgrowths 10 x 10
6 cells were 
added to fibronectin coated wells on a 6 well plate.  Cells were cultured in EGM-2 with 
supplements as described in Section 2.3.3. After the first 4 days, media was changed 
every 3 days.  As with the Hill protocol described above colonies formed between 4-7 
days  in  culture  (Figure  2.4b).    In  some  experiments  cells  were  replated  on  fresh 
fibronectin  using  trypsin  as  described  for  passage  of  HUVEC  to  determine  optimal 
conditions for growth of monolayers (Figure 2.4c and d). 
 
2.6.5 Matrigel - assessment of endothelial progenitor cell function 
A number of studies have shown that EPCs can incorporate into tubule networks formed 
by endothelial cells on extracellular matrix formulations (Matrigel
TM) (Bompais et al., 
2004,Hur et  al.,  2004).   The following protocol used for assessing incorporation of 
PBMCs into tubule networks is based on work previously established by Dr Francesca 
Arrigoni and Dr Neil Halliday within the group.   
 
Isolated PBMCs were cultured for 9 days in EGM-2 on a fibronectin coated 24 well 
plate with 5 x 10
6 cells added per well as described above. EGM-2 cultures were thus 
the same age as the non-adherent colony cultures when lifted.  At day 9 cells were 
stained with Di-I-acetylated low density lipoprotein (DiI-AC-LDL) 1.6µl/well for 4 hrs 
at 37
oC.  An hour before the cells were ready, 100µl of defrosted matrigel (defrosted for 
3+ hours at 4
oC) was added using cold (left overnight at -20
oC) pipette tips into each 
well of a cold (-20
oC overnight) 24 well plate on ice, taking care to spread evenly across 
the well.  The matrigel was left to set at room temperature for 1 hour.  After 1 hour, 1ml 
of EGM-2 (without hydrocortisone) was added to each well.  EGM-2 cells and HUVEC 
were then lifted using trypsin as previously described and 4 x 10
4 EGM-2 cells and 4 x 92 
 
Figure 2-4: EPC colony culture 
 
 
 
 
 
 
Figure 2.4a: After 7 days in culture after the preplating step the EPCS had formed colonies which 
consisted of a central cluster of rounded cells surrounded by spindle-like outgrowths. Figure 2.4b: 
cells cultured for 7 days in EGM-2 had a similar phenotype.  Figure 2.4cd: When these EGM-2 cells 
were left for longer, they went on to form “late outgrowth” EPCS which resembled a HUVEC-like 
monolayer at around 18-20 days in culture.  Scale bars represent 50µm. 
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10
4 HUVEC or 4 x 10
4 HUVEC alone were added to each well.  Tubule growth and 
PBMC incorporation was assessed after 18 hours in culture, using the HUVEC alone as 
a control (Figure 2.5ab). 
 
 
 
2.7 Statistics 
A number of parametric and non-parametric statistical analyses were used in this thesis.  
Description of individual tests and their applications is given in the relevant chapters.  
While parametric tests were used whenever possible, there were a number of instances 
where  data  were  not  normally  distributed  (and  could  not  be  easily  transformed  to 
normality)  and  thus  non-parametric  tests  were  used.    Parametric  tests  used  were 
student’s t-test and paired t-tests. Non-parametric tests used were the Kruskall-Wallis 
test, the Wilcoxon signed-ranks test, and Spearman rank correlation coefficient. Bland-
Altman  statistics  were  performed  where  comparison  of  methodology  was  required, 
including assessment of interuser variability.  In several chapters of this thesis multiple 
comparisons were performed simultaneously, so in order to reduce the risk of falsely 
finding tests positive a post-hoc Holm-Bonferroni correction was performed.   Graphs 
were plotted using Microsoft Excel 2007 and Graphpad Prism version 4. All statistics 
were calculated using Microsoft Excel 2007, and SPSS versions 15. 
 
As the cohort described herein is highly heterogenous, data was colour coded dependent 
on  disease  classification,  in  all  the  graphs  within  this  thesis  the  following  coding 
applies:  
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Figure 2-5: Matrigel, incorporation of PBMCS into HUVEC tubules 
 
 
 
 
 
 
Figure 2.5a: When HUVEC alone are cultured on matrigel, they form characteristic lattices. Scale 
bar represents 100µm. Figure 2.5b: When cells cultured for 9 days in EGM-2 are added alongside 
HUVEC they adhere/incorporate in the tubules formed the extenct of incorporation is assesssed 
using  DiI  acetylated  LDL  to  visualise  these  cells.    Scale  bar  represents  50µm. 95 
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3.1 Summary 
As  discussed  in  the  introduction  to  this  thesis,  assessment  of  disease  activity  in 
vasculitis  can  be  challenging.    The  gold  standard  technique  for  detecting  active 
inflammatory  disease  (tissue  biopsy)  is  invasive  and  impractical  for  repeated 
assessment, particularly due to the patchy nature of the disease where false negative 
results can occur.   This chapter describes the methodology used to detect circulating 
endothelial cells (a novel biomarker of endothelial injury) and demonstrates which of 
the two commonly used techniques is more appropriate for patients with vasculitis.  The 
latter part of this chapter then examines the relationship between circulating endothelial 
cells and disease activity in children with primary systemic vasculitis.  Some of the data 
presented herein are now published (Clarke et al., 2008,Shantsila and Lip, 2008).    
 
 
3.2 Introduction 
Circulating endothelial cells (CECs) are mature endothelial cells which have become 
detached from the vessel wall.  In health, these cells are found in low levels in the 
circulation  and  are  believed  to  represent  physiological  endothelial  turnover 
(Erdbruegger et  al.,  2006), however in  conditions  associated with  endothelial injury 
they are elevated (Woywodt et al., 2006a). 
 
3.2.1 Detecting CECs 
The concept that mature endothelial cells can be detected within peripheral blood is not 
new.    CECs  were  first  described  in  the  1950s  in  blood  smears  (Li  et  al., 
1958,Shanberge,  1955)  and  were  considered  likely  to  be  the  result  of  traumatic 
venepuncture and not of pathological consequence.  The CECs described by Li et al 97 
 
occurred both singly and in sheets of cells and their detection relied on observations of 
morphology and size under light microscopy.  In the early 1970s the link between these 
CECs  in  blood  smears  and  vascular  injury  was  proposed  and  these  cells  were 
subsequently identified in various conditions including myocardial infarction (Hladovec 
et al., 1978) and hypertension (Hladovec and Prerovsky, 1989).  All these early studies 
were reliant on morphology alone and were technically difficult and subjective.   
 
Further refinement of the blood smear methodology included the use of fluorescent 
antibodies to endothelial markers such as Von Willebrand factor (VWf) or cell adhesion 
molecules (Percivalle et al., 1993).  However there remained a lack of specificity of cell 
surface  antigens  and  the  use  of  more  specific  intracellular  antigens  required  cell 
permeabilisation, which increased the potential for cell loss from samples.  By the early 
1990s  antibodies  to  more  specific  surface  markers  for  ECs  had  been  developed, 
including the monoclonal S-endo-1 against CD146, a highly expressed constitutive EC 
cell surface marker associated with the cytoskeleton.  CD146 is more specific for ECs 
(although it is found on some activated T cells and melanoma cells) than other EC 
surface  markers  such  as  CD31  (PECAM-1,  also  found  on  platelets,  monocytes, 
neutrophils and T cells), CD54 (ICAM-1, also found on monocytes and lymphocytes) or 
CD105 (endoglin, also  found on activated monocytes,  macrophages  and erythrocyte 
precursers)  and  soon  became  the  antibody  of  choice  for  CEC  detection.    Its  high 
expression on most ECs importantly allowed the use of immunomagnetic beads for 
enrichment of CECs from blood samples (George et al., 1992). 
 
In 2006 Woywodt et al described a consensus protocol for detection of CECs using 
immunomagnetic bead extraction (IBE) and it is described in detail in Section 2.5.1 98 
 
(Woywodt et al., 2006a).  After CECs are extracted from peripheral blood using CD146 
bound to immunomagnetic beads they are stained with a fluorescently labelled lectin 
Ulex Europeus (Ulex).  Ulex selectively binds alpha-L-fucose containing glycoproteins, 
that can be found on the surface of human ECs and is more sensitive than vWF as it can 
bind ECs shown to be vWF negative (Holthofer et al., 1982).  As with CD146, Ulex is 
not  endothelial  specific  and  has  been  shown  to  bind  many  cell  types  including  gut 
epithelial cells (Narita and Numao, 1992) and megakarocytes (Liu and Liu, 1990) as 
well as the blood type H(O) antigen on red blood cells (Ito et al., 1990).   Therefore 
CECs must be identified by the expression of both of these two endothelial markers to 
discriminate from  other cell populations.   Microscopy  also  allows discrimination of 
CECs based on size and morphology from smaller cells such T cells (which can express 
CD146)  and  endothelial  progenitor  cells  (EPCs)  (CD146  and  ULEX  can  both  stain 
EPCs) (Delorme et al., 2005,Porat et al., 2006).       
 
Using the IBE methodology high levels of CECs have been detected in a number of 
conditions  associated  with  vascular  injury  including  vasculitis  in  adults,  as 
demonstrated in Table 3.1.  In AAV, CECs correlated with disease activity (BVAS 
score) (Woywodt et al., 2003b) and in studies in patients with coronary artery disease it 
was noted that the highest levels of CECs occurred in those patient with the most severe 
and acute disease (Mutin et al., 1999).  Low levels have been documented in healthy 
individuals of all ages in all studies, suggesting that high levels of CECs may be a 
marker of extreme EC injury.    
 
A commonly used alternative methodology to IBE for enumeration of CECs uses flow 
cytometry (FC),  although  as  yet the consistent reproducibility seen with  IBE  has  not  99 
 
Table 3-1: CEC detection in human disease 
 
Median CEC value (range used where given) 
 
been demonstrated with this technique.  Widely differing reference ranges have been 
reported in healthy individuals across different laboratories (Table 3.1) and moreover no 
consensus has been reached for FC methodology, including the choice of cell surface 
markers examined to evaluate CECs.  FC quantification, however, offers a number of 
potential  advantages  over  IBE  including:  multiple  CEC  surface  markers  can  be 
Condition  Method  Case  Control  Study 
Sickle cell anaemia  IBE  13.2-22.8  2.6  (Solovey et al., 1997) 
Septic Shock  IBE  30  2  (Mutunga et al., 2001) 
Rickettsial infection  IBE  5-1600  <3  (George et al., 1993) 
Renal transplantation  IBE  24-72  6  (Woywodt et al., 2003a) 
Bone marrow transplantation  IBE  16-44  8  (Woywodt et al., 2004) 
Acute MI  IBE  7.5  0  (Mutin et al., 1999) 
Diabetes  IBE  35-126  10  (McClung et al., 2005) 
Stroke  IBE  10.8-20.7  2.7  (Nadar et al., 2005), 
Hypertension  IBE  10  7  (Boos et al., 2007) 
AAV  IBE  20-5700  5  (Woywodt et al., 2003b) 
KD  IBE  15  6  (Nakatani et al., 2003) 
Breast cancer 
& lymphoma 
FC 
6800-
39100 
1200-
7900 
(Mancuso et al., 2001) 
Systemic sclerosis  FC  243-375  69-110  (Del et al., 2004) 
SLE  FC  89  10  (Rajagopalan et al., 2004) 
Acute coronary syndrome  FC  8-20  6-10  (Goon et al., 2006) 
Breast cancer  FC  6-16  6-10  (Goon et al., 2006) 100 
 
examined  simultaneously;  exclusion  of  leukocytes  using  the  pan  leukocyte  marker 
CD45; and further characterisation of sub-populations of CECs such as those in either 
an activated, or apoptotic state.  Consequently attempts to optimise FC methodology for 
CEC  detection  in  different  health  and  disease  states  are  clearly  of  considerable 
importance.    In  this  context,  a  recent  FC  protocol  for  CEC  enumeration  has  been 
described  that  demonstrated  agreement  between  CEC  counts  measured  using  FC 
methodology and IBE in healthy adults and patients with primary breast cancer and 
acute coronary syndromes (Goon et al., 2006). 
  
In order to determine which methodology would be most appropriate for the paediatric 
vasculitis cohort, both the IBE consensus protocol (Woywodt et al., 2006a) and an FC 
protocol based on the aforementioned paper (Goon et al., 2006) was established.  As 
described in the methods chapter, the FC definition of a CEC that was used has been 
described by a number of studies: cells that express both CD146 and CD34, but are 
negative for CD45 (Del et al., 2004,Goon et al., 2006,Bertolini et al., 2006,Khan et al., 
2005) (Figure 3.1a-c).  The definition of a CEC using IBE was as follows; Ulex bright 
cells, greater than 10m in size with more than 5 CD146 conjugated magnetic beads 
attached, (Figure 3.1d-f) (Woywodt et al., 2006a). 
 
3.2.2 Where do CECs come from and does this influence phenotype? 
CECs can be detected in both the arterial and venous circulation without significant 
differences  in  values  obtained  (Woywodt  et  al.,  2006a).    This  observation  raises 
interesting questions as to the origins of CECs and whether  they  can  pass  through  the 
capillary beds (unlikely, in the opinion of this author, when considering the size of the 
capillary lumen and the size of CECs), or whether CECs represent widespread (arterial 101 
 
Figure  3-1:  Flow  cytometric  (FC)  and  immunomagnetic  bead  (IBE) 
definitions of CECs 
 
 
 
Figure 3.1a-c: CECs as defined by FC are mononuclear cells (figure 3.1a, R1) which are negative 
for CD45, (figure 3.1b, R2) and positive for CD34 and CD146 (figure 3.1c, R3).  FC data shown is 
from a patient with active Wegener’s Granulomatosis.  Figure 3.1d-f CECs as defined by IBE are 
ULEX bright, have greater than 5 beads attached and are greater than 10µm in size. These CECs 
are from 2 patients with active disease, the first (figure 3.1d) with Wegener’s granulomatosis, the 
second (figure 3.1e) with PAN. Figure 3.1f Demonstrates how several CECs may clump together.  
Although it is apparent that a number of cells make up this sheet, it is still only counted as 1 CEC.  
This CEC is from the same patient with PAN in (figure 3.1e).   102 
 
and venous) or whether CECs represent widespread (arterial and venous) endothelial 
dysfunction or even elevated systemic turnover originating from a localised disease.  
Interestingly the vessel site of origin of CECs may vary between different conditions.  A 
number  of  studies  have  used  the  proposed  microvascular  specific  antigen  CD36 
(Solovey et al., 1997,Swerlick et al., 1992) to assess the extent to which CECs have 
come  from  microvasculature.    In  healthy  adult  controls  half  the  CECs  had  a 
microvascular  phenotype,  whereas  in  sickle  cell  anaemia  this  was  higher  at  78% 
(Solovey et al., 1997).  Interestingly in acute coronary syndrome no CD36 staining was 
observed, suggesting a  macrovascular origin  (Mutin  et  al.,  1999).  Neither of these 
findings in disease is unexpected when the nature of the two diseases is considered. 
 
CECs have also been shown to have widely differing phenotypes.  Relating to size and 
morphology  CECs  consist  of  both  sheets  of  cells  or  individual  cells,  and  in  some 
samples there are numerous brightly staining fragments, which are too small to consider 
whole  cells  but  are  of  endothelial  origin  (Woywodt  et  al.,  2006a).    As  Figure  3.2 
demonstrates such findings have all been demonstrated in the GOSH vasculitis cohort 
described  in  this  thesis.    The  majority  of  CECs  detected  using  IBE  in  adults  with 
vasculitis  are  of  a  necrotic  or  apoptotic  nature  (Woywodt  et  al.,  2003b).    In  other 
conditions this may not be the case.  Both Lin et al and Mutunga et al were able to 
culture  CD146+  CECs  isolated  from  peripheral  blood  from  healthy  controls  and 
Mutunga et al demonstrated that CECs from a proportion of patients with septic shock 
could also be cultured (Lin et al., 2000,Mutunga et al., 2001).   
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Figure 3-2: Phenotype of CECs in vasculitis 
 
 
 
 
 
Figure 3.2a: CECs from patients with PSV can include sheets of many endothelial cells.  Figure 
3.2b: CECS were also seen as single cells Figure 3.2cd: Frequently samples from PSV patients 
contain many CD146 bead bound and Ulex bright events that were too small to be counted as CECs 
- shown at low magnification (figure 3.2c: arrows indicate bright events large enough to be counted 
as CECs) and at higher magnification (figure 3.2d).  These may be fragments of whole cells or 
endothelial microparticles. 
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3.3 Detection of CECs using immunomagnetic bead 
extraction  
CECs were isolated and stained as described in Chapter 2.5.1.  Each sample where 
practical, was counted by two individuals blinded to the patients clinical state.  CEC 
enumeration is reliant on user observation and therefore has an element of subjectivity.  
Whilst  strict  counting  guidelines  as  described  above  will  minimize  this,  duplicate 
counting by two independent  observers is  advised, particularly for validation of the 
technique.   
 
3.3.1 Reproducibility of the technique 
In order to evaluate the reproducibility of the IBE technique, CECs from 1 healthy adult 
control and 1 patient with active WG were prepared from 3 individual 1ml samples.  As 
a positive control, blood was spiked with 1000 HUVEC/ml and again 3 samples were 
prepared from this.  Figure 3.3 demonstrates that there was greater variation in count for 
samples with high CECs (i.e. from the HUVEC spiked into blood and from the patient) 
and little variation in absolute CEC count in healthy adult control samples.  Despite this 
variation at high counts, results were all consistantly high and thus a single sample was 
considered a sufficiently robust representation of clinical CEC counts from patients in 
subsequent studies. 
 
3.3.2 Interobserver variability 
As  mentioned  previously,  due  to  subjectivity  in  CEC  counting  bias  relating  to 
interobserver variability could occur.  In samples counted by more than one observer, 
Bland-Altman   analysis  was   performed  to  determine   the  degree   of  interobserver  105 
 
Figure 3-3: Reproducibility of IBE for detection of CECs  
 
 
 
 
 
 
Figure  3.3:  Blood  samples  from  1  healthy  adult  control  and  1  patient  with  active  Wegener’s 
granulomatosus were divided into 3 and CECs enumerated in each sample.  As a further positive 
control a sample of the healthy control blood was spiked with 1000 HUVEC/ml.    The mean CEC 
count in the healthy adult control was 1 CECs/ml  SD 2;  in the patient with active Wegener’s 
granulomatosis the mean was 768 CECs/ml SD 128; and in the HUVEC spiked sample the mean 
was 757 CECs/ml SD 72.  
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variability between myself and four other individuals who had been trained to count 
CECs.    Figure  3.4a  demonstrates  that  there  was  greater  interobserver  variability 
between samples which had high CEC counts (overall mean difference -26.7, 95% CI 
+/- 331.5), however this is undoubtedly influenced by the multiplication factor used as 
part of the nageotte chamber counting protocol.   
 
As described in Chapter 2 (section 2.5.1.3) when samples have high CECs less lines are 
counted  on  the  nageotte  chamber  (since  counting  the  full  40  lines  would  be 
prohibitively time consuming and impractical for routine clinical used) and therefore the 
multiplication factor is greater.  Thus in figure 3.4b when the absolute nageotte count 
was  considered,  the  interobserver  variability  was  low,  the  mean  difference  was  0.2 
CECs counted (95% CI, +/- 36.2).  While there was higher interobserver variability at 
the  high  range  of  the  CEC  counts,  the  ability  to  enumerate  exactly  in  this  disease 
context  is  somewhat  less  relevant  than  the  ability  to  distinguish  between  grossly 
elevated and low CEC counts, where agreement was much better.  Particularly when 
monitoring individuals for disease activity in clinical studies. 
 
3.3.3 The effect of traumatic venepuncture 
As  has  previously  been  documented  (Woywodt  et  al.,  2006a)  if  venepuncture  is 
traumatic then CECs may appear falsely elevated.  This is of particular relevance in 
paediatric cohorts as it is often technically more difficult to obtain peripheral blood 
from small children than from adults.  In order to reduce the effect of venepuncture, 
many groups discard the first 5ml of blood taken, however this may not be appropriate 
or possible for paediatric samples, which are typically of smaller volume.  The influence 
of traumatic venepuncture was investigated in 1 healthy adult control (a sample size of 3  107 
 
Figure 3-4: Bland-Altman plots for testing interobserver variability of IBE 
for detection of CECs 
 
 
Figure  3.4a  Primary  observer  (LC  =  myself)  CEC  counts  compared  to  4  different  individuals 
trained to count CECs. Each different observer is indicated by a different coloured cross. CECs 
were  counted  in  18  patients  with  vasculitis  and  13  healthy  child  controls.    Overall,  the  mean 
difference between the CEC counts I obtained and those obtained by others was -26.7, 95% CI +/- 
331.5.  Notably levels of agreement was better at low CEC counts and the wide confidence interval 
influenced by 3 outliers. This analysis does not take into account differences in the multiplication 
factor used to calculate the final count, therefore any differences are amplified in samples with high 
CEC counts.  Figure 3.4b thus compares absolute nageotte count which gives a mean difference of 
0.2, 95% CI +/- 36.3.  108 
 
would  have  been  desirable,  however  volunteers  were  not  forthcoming)  with  ethical 
approval and informed consent.  Blood was collected first using 3 x 5ml syringes from 
the  control  arm.    Traumatic  venepuncture  was  then  achieved  in  the  other  arm  by 
scraping the needle backwards and forwards in the vessel, once it had been inserted.  As 
in the contralateral control arm, blood was then collected in 3 x 5ml syringes.  
 
Although  traumatic  venepuncture  elevated  CECs  from  the  16  cells/ml  seen  in  the 
contralateral arm to a maximum of 128 cells/ml (Figure 3.5),  CECs did not increase to 
the levels observed in adult active vasculitis patients (up 5,000 CECs/ml) (Woywodt et 
al., 2003b).  It was therefore concluded that as long as child controls were age matched 
the effect of the more traumatic venepuncture expected in children would not detract 
from  the  elevations  seen  in  active  disease,  although  could  account  for  more 
“background noise” in both paediatric controls and vasculitis patients.  Also it can be 
seen  in  this  individual  that  discarding  the  first  5mls  of  blood  after  traumatic 
venepuncture did not make a difference to the CEC count as both the second and third 
syringes of blood gave a similar CEC count to the first 5mls sampled (Figure 3.5).  
However, this may have been a consequence of the excessive trauma occurring in this 
individual case.  Thus in line with other studies (Woywodt et al., 2006a) for all future 
blood samples the first 5mls of blood were not used for CEC quantification (where 
possible)  but  rather  for  other  assays  described  in  this  thesis,  minimizing  waste  of 
precious paediatric blood samples. 
 
3.3.4 The effect of storage and time to preparation on CEC enumeration 
In the same individual who had kindly agreed to consent to traumatic venepuncture, 
after  the  1ml  of blood required for IBE was  removed  the  remainder of the  first  5ml 109 
 
Figure 3-5: Factors influencing CEC counting – traumatic venepuncture. 
 
   
 
 
 
 
 
 
Figure 3.5 demonstrates the effect of traumatic venepuncture on CEC enumeration in 1 individual. 
15 mls of blood was taken in 3 x 5ml syringes from both arms.  In the second arm, venupuncture was 
traumatic.      CEC  count  was  much  higher  under  traumatic  conditions  than  in  the  control  arm, 
however notably, discarding the first 5 mls of blood would not have made a difference to the CEC 
count under highly traumatic conditions as the second and third samples from each arm were of 
similar levels to the first.  
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sample was divided into 2 and left at RT or 4
oC.  CECs were then counted in 0.5ml of 
blood at 2hrs, 4hrs and 24hrs to demonstrate any alterations in CEC count caused by 
sample storage time (Figure 3.5a and b, represented by diamonds).   
 
The same time course experiment was also performed on 3 vasculitis patient samples 
(Figure 3.5 a and b, represented by crosses).  As can be seen in Figures 3.6 a and b, as 
has previously been described CEC  counts had declined by 24hrs in all individuals 
studied (Woywodt et al., 2006a).  The temperature at which the sample was stored did 
not appear to influence this, although room temperature samples were more difficult to 
read, with higher background noise possibly due to greater fragmentation/degradation of 
cells  than  samples  stored  at  4
oC.    Thus,  where  possible  all  bloods  were  processed 
immediately, usually within a 2 hour window and kept cold at 4
oC if they could not be 
processed straight away.   
 
 
 
3.4 Detecting CECS using flow cytometry  
For the purposes of this thesis the methodology as described by Goon et al was closely 
followed, as described in Section 2.5.2. (Goon et al., 2006)  
 
3.4.1 The effect of lysis on staining of CD34/CD146/CD45 
In  the  protocol  described  by  Goon et al, 1ml  of whole blood underwent red cell lysis 
prior  to  addition  of  antibodies (to  reduce  the  volume  of  antibody  required for each 
sample).  This is a recognized but uncommon methodology for whole blood FC and 
thus in order to make sure the cells were stained optimally experiments were performed 111 
 
Figure 3-6: Factors influencing CEC counting – sample storage time and 
storage temperature 
 
 
 
Figure 3.6a and b: 3 samples of blood from active vasculitis patients and one from the healthy adult 
control who had undergone traumatic venupuncture were left at room temperature (Figure 3.6a) or 
4
oC (Figure 3.6b) for 0, 2, 4 and 24 hrs before they were prepared for CEC detection.  By 24 hrs  
CEC counts were decreased in all individuals. Thus blood was prepared as close to time of sampling 
as possible for all future clinical studies.  112 
 
to  determine  whether  the  lysis  step  was  influencing  staining  of  these  cell  surface 
markers.  Figures 3.7a-c demonstrate that there were no significant differences in the 
percentage expression of CD45, CD146 or CD34 within the FC mononuclear cell gate 
in 3 patients if cells were stained before or after lysis confirming the validity of this 
methodology.  
 
3.4.2 Using endothelial cells as a positive control for CECs 
HUVEC had provided a useful positive control while establishing the IBE assay.  It was 
therefore  ascertained  whether  HUVEC  could  be  used  as  a  positive  control  in  FC 
protocols  for  CEC  detection.  Unfortunately  HUVEC  detached  from  cultured 
monolayers and resuspended in PBS as described in section 2.4.3 could not be detected 
using the previously published flow cytometric instrument settings for CECs.  This was 
because HUVEC had greater forward and side scatter (FSC and SSC) than peripheral 
blood mononuclear cells.  However when gated optimally HUVEC were detected by FC 
and were negative for the pan leukocyte marker CD45 (Figure 3.7d) and expressed high 
levels of CD146 (Figure 3.7e) and at first passage CD34 (although this diminished with 
later passage) (Figure 3.7 f and g).  Thus HUVEC could be used as a positive control for 
assessment of sensitivity and reproducibility of FC as long as the FSC SSC setting were 
optimized to incorporate them.  This important observation has significant implications 
for the detection of CECs using FC (Clarke et al., 2008) and will be discussed in more 
detail later in this chapter. 
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Figure 3-7: The effect of red cell lysis  on flow cytometric protocols for 
HUVEC detection 
 
 
 
Figure 3.7 a-c demonstrates that the pre-staining red cell lysis protocol as described by Goon et al, 
does  not  significantly  alter  the  %  of  monunuclear  cells  expressing  the  3  CEC markers:  CD45, 
CD146 and CD34.  Figure 3.7 d-g demonstrates that HUVEC can be used as a positive control for 
the CECs described by Goon et al, as they are negative for CD45 (Figure 3.7d) and express high 
CD146 (Figure 3.7e).  HUVEC only express CD34 when examined at early passage (Figure 3.7f), 
by P3 HUVEC are negative for CD34 (Figure 3.7g).  
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3.4.3 Using counting beads to determine absolute cell number  
In the paper from Goon et al, (Goon et al., 2006) the flow rate of the flow cytometer 
was determined prior to each sample being run using a sample spiked with a known 
number of latex counting beads, a standard technique for cell counting using FC.  This 
allowed a calculation of the quantity of sample analysed in a set time and thus could be 
used to calculate an absolute CEC number.  However, samples have to be run for a long 
period of time as CECs are rare events in peripheral blood and thus variations in flow 
rate may occur, which could significantly affect the result.   
 
To  determine  whether  this  would  alter  results  significantly  an  experiment  was 
performed that enumerated HUVEC spiked into whole blood using different methods 
for  calculating  absolute  HUVEC  counts.  Whole  blood  was  spiked  with  100,000 
HUVEC/ml and comparative experiments (n=3) were performed.  In these experiments 
three  different  counting  strategies  were  investigated:  1.  Samples  were  run  to 
completion. 2. The flow rate was  calculated prior to  samples  being run using latex 
beads.    3.  An  internal  standard  counting  bead  was  used  (Countbright
tm  beads, 
Invitrogen).  These methods are described in Chapters 2.5.2 and 2.5.3.   
 
Figure 3.8 demonstrates that enumerating samples using Countbright
tm beads resulted in 
a higher (but non-statistically significant) percentage recovery than calculating the flow 
rate prior to running the samples (NS, p=0.06).  Running samples to completion also 
gave better recovery than calculating flow rate from latex beads, however this technique 
would not be practical for routine clinical studies - the data files produced were large 
and in order to run a 1ml sample to completion dry it took over an hour, even at a high 
flow  rate.    This  experiment  confirmed  that  the  use  of  an  internal  standard  such  as 115 
 
Countbright
TM beads was more accurate over the long period of time required to collect 
sufficient sample for rare event analysis and therefore would be the methodology of 
choice for future studies relating to FC for CEC analysis in this thesis.   
 
3.4.4 Reproducibility of flow cytometry for endothelial cell enumeration 
As  described  previously  whole  blood  was  spiked  with  100,000  HUVEC/ml.    The 
sample was then divided into 3 and the number of HUVEC in each sample was again 
enumerated using Countbright
tm beads.  The mean recovery of HUVEC was 53% (range 
51-56%) demonstrating the reproducibility of the technique.  However this recovery of 
53% of spiked HUVEC was low.  The reasons for this are explained in more detail later 
in this chapter, but are due to poor optimisation of the FC technique for this particular 
experimental  setup.    As  the  aim  of  this  series  of  preliminary  experiments  was  to 
evaluate the previously published FC methodology in vasculitis patients we deliberately 
did not change the methodology from that described by Goon et al before evaluating it 
in  patients  (other  than  to  utilize  countbright
TM  for  enumeration  as  opposed  to  a 
calculated flow rate) (Goon et al., 2006).      116 
 
Figure 3-8:  Absolute enumeration of HUVEC spiked into whole blood 
 
 
 
 
 
 
 
Figure 3.8 demonstrates the % recovery of 100,000 HUVEC spiked into samples of healthy adult 
controls blood.  Samples were enumerated by 1. Running to completion.  2.By calculating the flow 
rate prior to running the sample using latex beads 3. By using an internal standard added to the 
sample to calculate the proportion run (Countbright 
TM beads).  Countbright 
TM beads as an internal 
standard gave the best % recovery compared to the other two techniques (NS, vs completion p=0.11 
and vs calculated flow p=0.06).  While not statistically significant, this difference could be clinically 
relevant and thus Countbright 
TM beads were used for CEC enumeration in future FC studies.    117 
 
3.5 Clinical study comparing two different methods of 
CEC quantification 
3.5.1 Patients and methods 
3.5.1.1 Patients 
25 children with primary systemic vasculitis were studied for this part of the study. 
These included 12 males and 13 females of median age 13.1 years (range 2.3  -16.4 
years). The vasculitis type (using the Chapel Hill Consensus Criteria) (Jennette et al., 
1994) was PAN n=9, WG n=4, MPA n= 1 and unclassified vasculitis n=11. Disease 
activity was assessed using a modified paediatric Birmingham Vasculitis Activity Score 
(BVAS), with a value of 0/63 defining clinical remission (no clinical disease activity) as 
previously described (Brogan et al., 2004a,Luqmani et al., 1994) (Appendix 2).  To 
establish if the assays compared performed similarly in health and disease, in addition 
to the 25 vasculitis patients 20 healthy adult controls were also recruited (2 males, 18 
females, age range 24-40 years).  All blood used for analysis was drawn using a 21 
gauge needle with minimal trauma and with the first 5 mls discarded  if possible as 
previously described (Woywodt et al., 2006a). Blood was processed immediately after 
collection as described below.  
 
3.5.1.2 Detection of CECs using IBE and FC 
This  was  performed  as  describe  in  Chapter  2  (sections  2.5.1  and  2.5.2).    The  IBE 
methodology was identical to the previously published consensus paper (Woywodt et 
al., 2006a).  FC was performed using forward and side scatter (FSC/SSC) instrument 
settings optimised for detection of peripheral blood mononuclear cells (PBMCs; Figure 
3.1) as previously described (Goon et al., 2006) (PBMC-FC).  A second FC protocol 
was designed to optimally capture larger cells such as human umbilical vein endothelial 118 
 
cells  (HUVEC)  as  previously  described  (Brogan  et  al.,  2004b).    This  is  hereafter 
referred to as the EC-optimised-FC gating protocol.   
 
As previously described, CECs were gated firstly on their FSC/SSC characteristics and 
then on cells negative for CD45 (Figure 3.1).   Non-stained samples and fluorochrome 
matched isotype controls (IgG1 FITC, eBiosciences; IgG1 PE, BD; and IgG1 Percp, 
BD) were used to define positivity. All FC instrument settings were optimised using 
detached HUVEC or pulmonary artery ECs (PAECs) in PBS, or whole blood spiked 
with 100000/ml HUVEC.  The PAECs (first passage) were obtained from the main 
pulmonary artery of the explanted lungs of a child with pulmonary hypertension and 
were a kind gift from Dr Sue Hall (Institute of Child Health, UCL). 
 
3.5.1.3 Statistics 
The Mann-Whitney U test (non-paired samples) or Wilcoxon signed rank test (paired 
samples) were used to compare CEC counts between experiments. Levels of agreement 
for CEC counts between different methodologies were summarised using Bland-Altman 
plots  (Bland  and  Altman,  1986).  All  blood  spiking  experiments  were  repeated  in 
triplicate,  unless  otherwise  stated.  All  statistical  analyses  were  performed  in  SPSS 
version 15.0. Statistical significance was set at p<0.05. 
 
 
 
 
 
 119 
 
3.5.2 Results 
3.5.2.1 Agreement between IBE and PBMC-FC  
The overall median IBE CEC count in vasculitis patients (n=25) and controls (n=20) 
combined was 32 CECs/ml, range 0-800. In contrast the PBMC-FC CEC count in the 
same individuals (n=45) was significantly lower at 26 CECs/ml, range 0-326 (p=0.014); 
paired analyses in 45 individuals.  The Bland-Altman plot in Figure 3.9 summarises the 
levels of agreement between IBE and PBMC-FC for vasculitis patients (n=25, denoted 
as crosses) and controls (n=20, denoted as circles).  Overall there was poor agreement 
between  IBE  and  PBMC-FC  based  on  these  45  paired  observations  in  the  45 
individuals: the mean difference between the two methods (IBE - PBMC-FC) was 78 
CECs/ml, 95% confidence interval of the difference +/-365 CECs/ml. 
 
Subgroup analysis of these 45 paired analyses revealed that most of this poor agreement 
arose in the vasculitis patients. Measurements from paired samples in these patients 
(n=25; 10 with active vasculitis [BVAS>0]; 15 with vasculitis in remission [BVAS=0]) 
demonstrated significantly higher numbers of CECs with the IBE method than with 
PBMC-FC:  with IBE the median CEC count in the vasculitis patients was 80 CECs/ml, 
range  0-800,  and  the  corresponding  median  CEC  count  using  PBMC-FC  was  31 
CECs/ml, range 4-326 (p=0.004).  Subgroup analysis of healthy adult controls (n=20) 
showed that agreement between IBE and PBMC-FC was better, but remained weak: the 
mean difference in CEC count between the two methods (IBE – PBMC-FC) was 17 
CECs/ml, 95% CI +/-127 CECs/ml.  
 
 
 120 
 
Figure 3-9: Bland-Altman statistics for testing agreement between IBE and 
PBMC-FC for CEC enumeration 
 
 
 
 
 
 
 
Figure 3.9 is a Bland Altman plot to assess the agreement between the two methodologies described 
for detection of CECs.  25 vasculitis patients (denoted as crosses) and 20 healthy adult controls 
(denoted as circles) were studied.  Overall there was poor agreement between IBE and PBMC-FC 
based on these 45 paired observations in the 45 individuals: the mean difference between the two 
methods (IBE - PBMC-FC) was 78 CECs/ml, 95% confidence interval of the difference +/-365 
CECs/ml.    121 
 
3.5.2.2 Optimisation of flow cytometric gating for detection of endothelial cells 
Having  demonstrated  consistently  higher  CEC  counts  with  IBE  compared  to  FC  in 
patients with vasculitis, it was decided to investigate whether the mononuclear gate used 
in  the  FC  protocol  was  optimal  for  detection  of  CECs.    As  had  previously  been 
observed HUVEC have different FSC SSC characteristics to mononuclear cells, thus in 
order to determine whether CECS might also have different FSC SSC characteristics 
their size was compared to both HUVEC and a second cultured primary endothelial cell 
- pulmonary artery ECS (PAEC) which had been explanted from the pulmonary artery 
of the lungs of a child with pulmonary hypertension.  
 
Cultured ECs are of similar size to CECs obtained from patients with vasculitis 
Phase  contrast  and  immunofluorescent  microscopy  of  HUVEC  and  PAECs  isolated 
using IBE from spiked whole blood or PBS was performed. This demonstrated that 
these  cultured  ECs  overlapped  in  size  and  exhibited  similar  morphology  to  CECs 
extracted from the peripheral blood of patients with active vasculitis (Figure 3.10a-e).  
The diameter of CECs from patients was determined by measurement of all the CECs in 
5 random fields from 5 patients with active vasculitis (WG=3, PAN=2).  In contrast, 
CD146+  cells  extracted  from  isolated  PBMCs  using  immunomagnetic  beads  were 
significantly smaller than CECs (median diameter of CD146+ PBMCs and CECs were 
6.8m  versus  21.5m  respectively  (p<0.0001;  Figure  1a).    These  observations 
emphasised  the  significant  difference  in  size  and  morphology  between  CECs  and 
CD146+ PBMCs as defined by light and fluorescent microscopy, which would be likely 
to influence the flow cytometric FSC/SSC characteristics of these cell populations.  
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Figure 3-10: Comparison of cell size CECs vs ECs 
 
 
 
 
Figure  3.10a-e:  CECs  were  compared  to  pulmonary  artery  endothelial  cells  (PAECs),  venous 
endothelial cells (HUVEC) and peripheral blood mononuclear cells (PBMCs) isolated from spiked 
blood samples using immunomagnetic beads coated with CD146. Figure 3.10a: Demonstrates the 
comparative cell diameter of CD146+ PBMCs, PAECs, CECs from vasculitis patients (5 children, 5 
random fields, all CECs counted in field) and HUVEC.  Of note was the wider range in diameter of 
CECs compared with detached cultured ECs, overlapping both HUVEC and PAECs.  Figure 3.10b: 
Fluorescent  microscopy  of  a  single  CD146+  PBMC  (arrowed)  bound  to  CD146-coated 
immunomagnetic  beads;  Figure  3.10c:  PAEC  with  rosette  of  CD146-coated  immunomagnetic 
beads; Figure 3.10d: CEC from a child with active PSV.  CECs are characterised by rosetting of 
immunomagnetic  beads  and  uptake  of  FITC  labelled  lectin  from  Ulex  europaeus  and  are 
significantly  larger  than  PBMCs  at  approximately  20-40m  in  size.  Figure  3.10e:  HUVEC 
demonstrating similar size to CECs (scale bar, 20m).  
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EC forward and side scatter characteristics    
The FSC/SSC characteristics of detached  cultured PAECs and HUVEC were examined 
using  the  previously  described  PBMC-FC  instrument  settings  (Goon  et  al.,  2006). 
(Figure  3.1)  Using  these  settings  the  majority  of  these  ECs  (>80%  PAEC,  >95% 
HUVEC) were detected outside of the previously proposed CEC gate (Figure 3.11). 
Therefore,  having  demonstrated  that  CECs  from  patients  were  of  similar  size  and 
morphology as both PAECs and HUVEC (Figure 3.10), the FC instrument settings were 
optimised to capture both EC populations and mononuclear events, in order to recover 
all possible CEC events. The EC-optimised-FC gating strategy is illustrated in Figure 
3.11. 
 
3.5.2.3 Comparison of EC-optimised-FC with PBMC-FC  
When the EC-optimised-FC gating strategy was compared with PBMC-FC to detect 
CECs  in  children with vasculitis  (paired observations  in  n=25 patients) and healthy 
controls (paired observations in n=20 subjects) greater numbers of CECs were detected 
using the EC-optimised protocol: the median EC-optimised-FC count was 39 CECs/ml, 
range 5-331; versus PBMC-FC CEC count 26 CECs/ml, range 0-326 (p=0.000).  There 
was correspondingly poor agreement between the two FC protocols as indicated in the 
Bland-Altman plot in Figure 3.12a.  Mean difference between the two techniques (EC-
optimised-FC – PBMC- FC) was 18 CECs/ml, 95%CI +/-63 CECs/ml.  
 
3.5.2.4 Comparison of EC-optimised-FC with IBE for enumeration of CECs 
The  median  CEC  value  obtained  with  the  EC-optimised-FC  protocol  from  all  45 
subjects (25 vasculitis patients; 20 healthy adult controls) was comparable to IBE: the 
the two methods on Bland- Altman analysis: the mean difference (IBE – EC-optimised- 124 
 
Figure  3-11:  FSC/SSC  characteristics  of  ECs  and  optimisation  of  flow 
cytometric gating to detect ECs 
 
 
 
 
Figure 3.11a demonstrates the FSC SSC profile of whole blood and the mononuclear cell gate.   
When pulmonary artery ECs (PAECs) (Figure 3.11b) and  HUVEC (Figure 3.11c) were examined 
using the same instrument settings the majority of all ECs (>80% PAECs, >95% HUVEC) fall 
outside the previously proposed CEC gate.  Figure 3.11d: EC-optimised-FC gate using logarithmic 
FSC/SSC settings.  When 100000 HUVEC were spiked into whole blood they formed a discrete 
population distinguishable from blood cells. The FC instrument settings were thus adjusted to design 
a  FSC/SSC  gate  that  was  optimised  to  capture  endothelial  cells  for  both  HUVEC  (arrowed, 
H=HUVEC); and PAECs(data not shown).  N=neutrophils, M=monocytes, L=lymphocytes.  125 
 
IBE median count was 32 CECs/ml, range 0-800; versus EC-optimised-FC CEC count 
of 39 CECs/ml range 5-331(p=0.25).  Despite this, overall agreement was poor between 
FC) was 60 CECs/ml, 95% CI +/-374 CECs/ml, figure 3.12b. Again much of this poor 
agreement  arose  from  the  children  with  active  vasculitis  and  high  CEC  counts 
(CECs>100/ml) as shown in the Bland-Altman plot (Figure 3.12b).  
 
When  the  optimised  FC  gating  strategy  was  used  to  detect  CECs  in  children  with 
vasculitis (n=24 patients) greater numbers of CECs were detected (median count 39 
CECs/ml, range 9-330) (p=0.023).  However these values remained considerably lower 
than those obtained concurrently using IBE (median count 84 CECs/ml, range 0-800 
CECs/ml) (p=0.018). Again, lower levels of agreement were observed in children with 
more active vasculitis and high CEC counts (CECs > 100/ml) with better agreement 
between the two methods noted at lower CEC counts as shown in the Bland-Altman 
plot (Figure 3.12b).  In healthy adult controls consistently higher numbers of CECs 
were recovered using the optimised FC gating  strategy  (median count  36 CECs/ml, 
range 5-166) (p = 0.001).  Again there was no significant difference between this and 
the results obtained using IBE (p=0.179).  
 
3.5.2.5 Factors influencing the sensitivity of IBE and FC for recovery of ECs 
A series of in vitro experiments were undertaken to investigate further why there was 
poor  agreement  between  IBE  and  FC  (PBMC-FC  and  EC-optimised-FC)  CEC 
enumeration in the clinical samples, particularly in those patients with active vasculitis. 
PBS  or  whole  blood  was  spiked  serially  with  100-100000  HUVEC/ml  and  the 
sensitivity of EC recovery using IBE or FC was evaluated under different experimental 
conditions.  Using HUVEC spiked into WB was a better model of CEC enumeration, as 126 
 
Figure 3-12: Bland-Altman analysis of agreement between EC-optimised 
FC and PBMC-FC and IBE for CEC enumeration  
 
 
 
Figure 3.12a: shows the agreement between EC-optimised-FC (with FSC/SSC optimised to gate on 
ECs) compared to the previously published PBMC-FC protocol.  The mean difference between EC-
optimised-FC  and  PBMC-FC  was  18  CECs/ml,  95%  CI  +/-63  CECs/ml.  Figure  3.12b:  IBE 
compared  to  EC-optimised-FC.    Again  levels  of  agreement  between  IBE  and  FC  were  poor, 
particularly in patients with high CEC counts. Mean difference between IBE and EC-optimised-FC 
was 60 CECs/ml, 95% CI +/-374 CECs/ml.   127 
 
it would mean that confounding cell populations and non specific binding relevant in 
both FC and IBE would also be present.  However there was concern that the HUVEC 
might suffer complement mediated degradation and thus the PBS control was necessary.  
As expression of CD34 on HUVEC is low (Muller et al., 2002) and also dependent on 
passage (Figure 3.7f and g) all CD45-/CD146+ events were considered to be EC in 
these experiments.    
 
Effect of EC numbers on quantification accuracy of IBE and FC 
The PBMC-FC gating protocol (Goon et al., 2006) failed to detect any ECs when 100 
HUVEC/ml  were  added  to  whole  blood  (Figure  3.13a).  EC  recovery  using  this  FC 
protocol was also low when between 1000-100 000 EC were added to whole blood: 
mean  EC  recovery  (n=3  experiments)  was  0.2-0.9%  (Figure  3.13a).  Detection  of 
HUVEC  was  similar  in  both  PBS  and  whole  blood  using  these  instrument  settings 
(Figure 3.13b).   
 
Using the EC-optimised-FC protocol to recover cultured ECs from PBS or whole blood 
resulted  in  greater  recovery  of  CD45-/CD146+  cells  (Figure  3.13a  and  b).  Larger 
numbers of HUVEC (100000 HUVEC/ml) added to whole blood were easily identified 
as a distinct population from both the lymphocyte and monocyte populations (Figure 
3.11d)  although  recovery  was  low  with  a  mean  of  38%  (range  8-56%,  n=5 
experiments).  Recovery using EC-optimised-FC was greatest at 1000 HUVEC/ml with 
mean recovery of 72% (range 21-154%, n=5 experiments; Figure 4).  However, when 
fewer HUVEC (100 HUVEC/ml) were added considerable variation in recovery (36-
708%) was observed indicating sub-optimal sensitivity and specificity at this level of 
detection. Recovery of spiked HUVEC from PBS using the EC-optimised-FC protocol 128 
 
was better than from whole blood with mean recovery of 63% for 1000 HUVEC/ml, 
90% for 10000 HUVEC/ml and 70% for 100000 HUVEC/ml (n=3 experiments).   
    
In contrast, the sensitivity of EC recovery using IBE in these experiments was between 
25%-112% of the cells added to both whole blood and PBS, with greatest sensitivity at 
1,000  cells  per  ml  in  WB  (80%  recovery  from  whole  blood,  range  69-94%,  n=3 
experiments) and at 100 cells/ml in PBS (101%, range 88-112%).  IBE demonstrated 
lower recovery at higher EC counts: when 10000 HUVEC/ml were added, recovery was 
44% in WB, (range 27-56%) and 43% in PBS (range 41-47%); and was even lower for 
100000 HUVEC/ml at 28% in WB, range 14-37% and 45% in PBS (range 30-55).  
 
Flow cytometric resolution: counting of rare events and effect of sample dilution 
In order to determine whether the flow cytometer was “missing” HUVEC events in 
whole  blood  because  of  a  phenomenon  known  as  coincidence  the  final  volume  of 
sample  for  FC  analysis  was  diluted  to  obtain  a  lower  event  acquisition  rate.  
Coincidence occurs if the sample is too concentrated and the total cell events acquired 
per second are too great to resolve all individual rare events (Jaroszeski and Radcliff, 
1999).  In case the presence of enumeration beads was influencing this, samples were 
run to completion to evaluate its effect.  As Figure 3.11d demonstrated HUVEC are 
easily distinguished from whole blood on their CD146 expression alone, so in these 
experiments HUVEC were defined as CD146-high cells.  Diluting the final flow volume 
to a concentration of 1/2 or 1/5, then running tubes to completion at medium flow rate 
increased the recovery of CD146-high HUVEC from spiked blood (100,000 cells/ml; 
Figure 3.14).   However, by increasing the final volume of sample the time taken to 
acquire the data was considerably increased, up to 90 minutes.  129 
 
Figure 3-13: The effect of EC number on recovery - sensitivity  
 
 
 
Figure 3.13ab: Whole blood (figure 3.13a) and PBS (figure 3.13b) were spiked with HUVEC and 
the cells recovered using IBE (grey bars, n=3 experiments) and the two different FC protocols (EC-
optimised-FC, black bars, n=5 experiments; or PBMC-FC, white bars, n=3 experiments).  Using FC 
HUVEC were defined as CD45-/CD146+. On the whole HUVEC recovery from whole blood or PBS 
using IBE was comparable to EC-optimised-FC across the range of cells added. EC-optimised-FC 
HUVEC recovery was sub-optimal at 100 HUVEC/ml, however, since the percentage recovery was 
>100% in some experiments. Of note, previously proposed PBMC-FC strategies failed to detect any 
CD45-/CD146+ cells in these experiments. Error bars demonstrate the standard error of the mean.  130 
 
Figure 3-14: Resolution – sample dilution improves recovery  
 
 
 
 
 
 
 
 
 
 
Figure 3.14: Diluting the final flow volume of blood spiked with HUVEC (100,000 cells/ml of blood) 
resulted in increased HUVEC recovery.  This is due to the phenomenon known as coincidence, 
events are missed because the flow cytometer is unable to resolve them as flow rate is too fast.  
Dilution of the sample improved this.  Error bars demonstrate standard error of the mean.  Mean 
recovery of neat sample was 43% which increased to 63% when dilute 1in2 and 66% when diluted 1 
in 5.    
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 Lysis of ECs in flow cytometric protocols limits CEC recovery from vasculitis patients.  
When samples from patients with active vasculitis (n=3) were treated with FC red cell 
lysis buffer prior to enumeration using IBE there was a  significant reduction in the 
number of CECs recovered.  This reduction was observed using both BD FACS lyse, 
and a non-fixative ammonium chloride lysis buffer in 3 individual patients with active 
vasculitis.  The median IBE CEC count from these patients for the non-lysed sample 
was  376 CECs/ml (range 216-552) which fell to  152 CECs/ml (range  144-168) for 
samples pre-treated with BD FACS lyse; and 120 CECs/ml (range 64-176) for samples 
pre-treated  with  ammonium  chloride  lysis  buffer  (Figure  3.15ab).  Repeating  these 
experiments using detached HUVEC added to  PBS revealed that pre-treatment with 
lysis buffer did not reduce EC recovery Figure 3.15c.  
 
 
3.6 Conclusions of methodological experiments 
As  this  series  of  experiments  has  demonstrated,  considerable  optimization  of  FC 
protocols is still required in order to detect CECs with accuracy.  Technical factors 
inherent to FC which influence CEC quantification include FSC/SSC gating strategy 
which necessarily require optimisation for EC capture; limited FC reliability of rare 
event measurement; variations in FC flow rate during long sample acquisition and loss 
of activated and necrotic CECs during the lysis and washing steps in preparation for FC.    
 
For  the  purposes  of  this  thesis  it  was  concluded  that  detection  of  CECs  using  IBE 
methodology as described by Woywodt et al in their 2006 consensus paper (Woywodt 
et al., 2006a) would the most appropriate methodology for enumeration of CECs in the 
GOSH vasculitis cohort, described in Section 2.5. 
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Figure 3-15: The effect of lysis on CEC recovery  
 
 
 
Figure 3.15ab: When blood samples taken from children with active vasculitis (n=3) were lysed 
using BD FACs lyse (Figure 3.15a) or an ammonium chloride based lysis (AC lysis) (Figure 3.15b) 
prior to IBE there was a reduction in the number of cells recovered that was not seen when viable 
cells such as HUVEC were lysed prior to IBE at all concentrations of spiked HUVEC (Figure 
3.15c).  133 
 
3.7 Evaluation of CECs in vasculitis 
As  described  previously,  CECs  obtained  from  patients  with  active  vasculitis  were 
affected by the lysis stages necessary for flow cytometry.   Thus in this thesis CECs as a 
biomarker of endothelial injury in children with vasculitis were evaluated using IBE.  
 
3.7.1 Patients and methods 
3.7.1.1 Patients 
42 children with primary systemic vasculitis were studied. These included 18 males and 
24 females of median age 10.8 years (range 0.3 -16.6 years). The vasculitis type (using 
the  Chapel  Hill  Consensus  Criteria)  (Jennette  et  al.,  1994)  was  polyarteritis  nodosa 
(PAN) n=18, Wegener’s granulomatosis (WG) n=8, microscopic polyangiitis (MPA) n= 
1, Kawasaki’s disease (KD) n = 6, Takayasu’s disease (TD) n = 3, Beçhets disease (BD) 
n  = 1 and unclassified vasculitis n=5. Disease activity was assessed using a modified 
paediatric BVAS (Appendix 2).   25 healthy child controls (6 males, 19 females, median 
age 8.9 years, range 1.5-15.8),  13 febrile controls (7 males, 6 females, median age 7.3 
years range 1.5- 14.0) and 20 healthy adult controls were also recruited (2 males, 18 
females, age range 24-40 years).  The febrile control group consisted of patients with a 
variety of autoimmune or other inflammatory disorders (including infection) without the 
presence of vasculitis. 
 
3.7.1.2 Methods 
CECS were isolated from EDTA coagulated peripheral venous blood as described in 
section 2.5.1.  All blood used for analysis was drawn using a 21 gauge needle with 
minimal trauma and where possible the first 5 mls of blood were discarded (and used in 
 other assays).  Blood was processed immediately after collection. 134 
 
3.7.1.3 Statistics 
Median CEC counts were compared between groups using a Kruskall Wallis test to 
check for overall differences.  Individual Mann Whitney U tests for non-parametric data 
were used for specific inter-group comparisons.  The Wilcoxon signed rank test was 
performed  to  compare  groups  with  paired  samples.    Spearman  Rank  correlation 
coefficiants were examined to determine the levels of correlation between CECs and 
other markers of clinical disease activity.  In all data graphs patient classification was 
denoted using colour coding as indicated below: 
 
 
  
 
3.7.2 Results 
3.7.2.1 CECs are elevated during active disease and decline with treatment 
Kruskall Wallis testing indicated there was an overall significant differences between 
test  groups  (p<0.0001).    CECs  were  significantly  higher  in  32  children  with  active 
vasculitis (as defined by a BVAS score >0, median value 208 CECs/ml) compared to 13 
febrile  disease  controls  (non-syndromic,  inflammatory  disorders,  median  value  36 
CECs/ml, p=0.0009), 25 healthy child controls (median value 32 CECs/ml, p<0.0001) 
and 20 healthy adult controls (median value 20 CECs/ml, p<0.0001).  There were no 
significant differences between 28 patients with inactive vasculitis (median value 32 
CECs/ml) and these control groups.   135 
 
Notably,  there  were  a  number  of  individual  patients  whose  disease  was  considered 
clinically inactive, yet had elevated CECs, possibly indicative of subclinical endothelial 
injury (Figure 3.16a).  The data shown in Figure 3.16a includes paired samples between 
individual patients with active and inactive disease and thus these groups could not be 
compared without their exclusion.  Only the first observation made in each individual 
patient was included in this analysis. CECs were significantly higher in 32 patients with 
active vasculitis compared to 11 patients in remission (p<0.0001, median CEC count 
was 208 CECs/ml vs 16 CECs/ml).  
 
In 19 individual patients with paired analyses (active vasculitis vs inactive vasculitis), 
CECs  were  significantly  higher  during  active  disease  compared  to  when  they  were 
considered to be clinically in remission (BVAS score = 0, median time to remission 3.5 
months, p=0.01, Figure 3.16b). Of these 19 patients, 16 had frequent and detailed follow 
up  over  time  for  up  to  18  months  from  disease  onset  and  pre-treatment  (prior  to 
immunomodulatory therapy) or from a flare of their disease while on treatment (10 
patients were followed up from disease onset - solid line, 6 from a disease flare - dotted 
line).  Ultimately CEC numbers declined in all individuals although in some patients 
this took longer than in others (Figure 3.17).  At median followup of 3 and 12 months 
from pretreatment at disease onset (10 individuals) CECs were significantly lower than 
at onset (p=0.005 and p=0.014).  At 12 months 2 patients had flared, with corresponding 
elevation in CEC number (Figure 3.17). 
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Figure 3-16: CECs in vasculitis 
 
  
 
 
Figure  3.16a: Circulating endothelial cells were significantly higher in 32 children with active 
vasculitis  compared  to  13  febrile  disease  controls  (non  syndromic,  inflammatory  disorders) 
(p=0.0009), 25 healthy child controls (p<0.0001) and 20 healthy adult controls (p<0.0001).  There 
were no significant differences between 28 patients with inactive disease and these control groups, 
however  it  is  notable  that  there  are  a  number  of  individual  patients  with  inactive  disease  and 
elevated CECs, possibly indicative of subclinical endothelial injury. Figure 3.16b: In 19 individual 
patients  with  paired  analysis,  CECs were  significantly  higher  when  patients  had active  disease 
compared to when they were considered inactive (median time to remission 3.5 months, p=0.01).   
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Figure 3-17: CECs in vasculitis – response to treatment 
 
 
 
 
 
 
Figure 3.17:16 individual patients had their circulating endothelial cells measured from initiation of 
treatment after disease onset or flare  (dotted lines indicate patients followed from a flare while on 
treatment, solid lines indicate patients who were observed from pre-treatment). At median followup 
of 3 and 12 months from pre-treatment CECs were significantly lower than at onset (p=0.005 and 
p=0.014).  At 12 months 2 patients had flared, with corresponding elevation in CEC number.  
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3.7.3 Correlation between CECs and disease activity 
Spearman Rank correlation coefficiant analysis was performed between CEC count and 
the traditional markers of active disease; BVAS, ESR, CRP, platelet count, albumin and 
white cell count.  Correlations were performed on all values obtained from the cohort of 
44  patients.    Table  3.2  summarises  the  results.    CECs  in  vasculitis  correlated 
significantly  with  disease  activity  as  determined  using  a  paediatric  modified  BVAS 
scoring  system,  although  not  significantly  with  other  markers.    Figure  3.18 
demonstrates the relationship between CECs, BVAS , ESR and CRP visually.  As can 
be seen in Figure 3.18a-c there were a number of patients with low ESR or CRP and 
low  disease activity as  defined by  BVAS that had high CEC  levels,  again  possibly 
indicative ongoing subclinical endothelial injury (Figure 3.18).  
 
Table  3-2:  Spearman  Rank  correlation  coefficiants  between  CECs  and 
conventional markers of disease activity 
 
Marker of disease activity  vs CECs    Marker of disease activity  vs CECs 
BVAS  r = 0.48 
p<0.0001 
n = 110  
  Platelet count  r = 0.059 
p = 0.556 
n = 102  
ESR  r = 0.12 
p = 0.23 
n = 101  
  Albumin  r  = -0.160 
p = 0.11 
n = 99 
CRP  r = 0.134 
p = 0.17 
n = 107  
  White cell count  r = 0.117 
p = 0.233 
n = 105  
 
Significant correlations highlighted in blue 
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Figure 3-18: Correlation with disease activity 
 
 
 
Figure  3.18a:  Circulating  endothelial  cells  correlated  with  disease  activity  in  vasculitis  as 
determined using a paediatric modified BVAS scoring system  (p<0.0001, R=0.47) based on 105 
measurements in 42 patients.  Figure 3.18b and c CECs did not correlate significantly with ESR 
(p=0.09, based on 98 measurements in 41 patients) or CRP  (p=0.2, based on 102 measurements in 
42 patients), as the graphs show there are a number of patients with low inflammation as determined 
by ESR or CRP or disease activity as defined by BVAS that have high CEC levels, indicative of 
subclinical  endothelial injury.  
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Of the 16 patients who had detailed repeated measurements over time, a number had 
flares of active disease during the study period.  Figures 3.19-3.22 hilight 4 interesting 
cases, the first three are patients studied from disease onset, the fourth a patient who 
underwent autologous stem cell transplantation.  Figure 3.19 a-d shows the changes in 
CEC count alongside ESR, CRP and BVAS over time from treatment in a 12 year old 
female with WG.  As can be seen she had a disease flare (arrowed) in which CECs 
mirrored the more traditional methods used for assessing disease activity.  In Figure 
3.20 a-d an 11 year old female with WG was also followed up over time, unfortunately 
her CECs were not observed at the onset of her disease, however she entered an episode 
of severe, localized and (presumed) granulomatus flare (orbital mass) and as can be seen 
her CECs rose, but did not rise to the high levels seen in severe active systemic disease 
(Figure 3.20).  In Figure 3.21 a-d a 10 year old female with PAN was followed closely 
at the initiation of disease.  After initially entering remission her ESR and CRP became 
elevated, however her CECs remained normal.  This was subsequently proven not to be 
a flare of her disease but an associated urinary tract infection. Figure 3.22 a-d shows the 
changes in CEC number that occured in one individual who underwent autologous stem 
cell transplantation for recalcitrant vasculitic disease occurring secondary to a familial 
fever.    CEC  numbers  declined  from  3,136  to  20  after  a  week  of  pre-conditioning 
treatment  (Campath®).    CEC  numbers  remained  low  after  the  transplant,  until  the 
patient contracted a cytomegalovirus (CMV) infection, which corresponded with a rise 
in CEC count.  CECs infected with CMV have been documented by a number of groups 
in patients with CMV infections (Pooley, Jr. et al., 1999,Percivalle et al., 1993).  Other 
examples of the changes in CECs in individual patients with other markers of disease 
activity over time from treatment are found in Appendix 6. 
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Figure 3-19: Patient with WG - CECs and disease activity – predictive of 
disease flare? 
 
 
 
Figure 3.19a indicates the change in CEC number over time from treatment in a 12 year old female 
with  WG.  Figures 3.19 b-d  indicate  the  changes  in  disease  activity  as  determined  using  BVAS 
scoring and the changes in the inflammatory markers ESR and CRP.  CEC levels mirrored the 
changes seen in the more traditional clinical methods of assessing disease activity in this individual. 
Rx = treatment, BVAS = Birmingham vasculitis activity score, ESR = erythrocyte sedimentation 
rate, CRP = c reactive protein. 142 
 
Figure  3-20:  Patient  with  WG  –  CECs  and  disease  activity  in  orbital 
granuloma  
 
 
 
Figure 3.20a indicates the change in CEC number during a granulomatus flare in an 11 year old 
female with WG. Figures 3.20 b-d indicates the changes in disease activity as determined using 
BVAS  scoring  and  the  changes  in  the  inflammatory  markers  ESR  and  CRP.  Although  CECs 
increased slightly, they were within the healthy child range. 
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Figure 3-21: Patient with PAN – CECs and disease activity 
 
 
 
 
 
Figure 3.21a-d indicates the changes in CEC number and traditional markers of disease activity 
after treatment in a 10 year old female with PAN. At 6 months into her disease she experienced a 
spike in ESR and CRP (Figures c and d) subsequently proven to be due to a urinary tract infection 
(UTI), not active disease – BVAS and CECS remained low.  
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Figure 3-22: CECs during autologous stem cell transplantation 
 
 
 
 
Figure 3.22a-d indicates the changes in CEC number and traditional markers of disease activity in 
a patient who underwent autologous stem cell transplantation for recalcitrant vasculitic disease 
occurring secondary to a familial fever.  CECs were high, prior to Campath® pre-conditioning and 
remained low during the transplant, until the patient contracted a CMV infection.  Unfortunately 
ESR and CRP were not measured as frequently in this patient as the research bloods as they are not 
part of the routine bloods performed in transplantation patients.  145 
 
3.7.4 CECs in individual vasculitic syndromes 
When  the  combined  cohort  of  vasculitis  patients  was  subdivided  into  individual 
diseases, the results, although based on small numbers were worthy of some comment.  
During active disease patients with KD and TD (diseases predominantly affecting large 
and  medium  vessels)  had  lower  CECs  than  patients  with  PAN  or  WG  (disease 
predominantly  affecting  small  to  medium  vessels)  (Figure  3.22a).    This  interesting 
result which warrants  further investigation, could  indicate that this  biomarker  could 
depend on how widespread the overall surface area of the endothelium affected by the 
disease is.  Bearing in mind that by far the largest surface area of endothelium is made 
up of smaller vessel endothelium (Ganong WF, 2001) this explanation may not be an 
oversimplification. During clinically defined remission (BVAS =0, Figure 3.22b) the 
majority of patients had low CECs.  There were two notable exceptions: in the WG 
group, three patients had high CECs despite clinical remission; the single patient with 
KD had coronary artery aneurysms and although systemic inflammation had subsided, 
was likely to be undergoing extensive vascular remodeling.   
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Figure  3-23:  Subdivision  into  individual  diseases  -  CECs  in  different 
vasculitic conditions 
 
 
 
Figure  3.23a:  When  the  patient  cohort  was  divided  into  the  different  disease  classifications, 
although the numbers were low, patients with Takayasu’s disease (TD) and Kawasaki disease (KD) 
had lower levels of CECs in active disease than those patient with Polyarteritis nodosa (PAN) or 
Wegener’s granulomatosis (WG). Figure 3.23b: Interestingly in those patients in clinical remission, 
the group with the highest proportion of individuals who had elevated CECs was the WG group, a 
disease  affecting  predominantly  small  vessels  and  notorious  for  its  relapsing  nature  and  poor 
clinical outcome. 
Active 
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3.8 Discussion 
Circulating endothelial cells are elevated at times of active disease in PSV and correlate 
with  disease  activity  although  inconsistently  with  routine  clinical  markers  of 
inflammation.  In  individual  patients,  CECs  were  elevated  during  active  disease  and 
declined over time with remission inducing treatment (Figures 3.16 and 3.17).  CECs 
tended to be higher in patients with diseases affecting predominantly smaller vessels, 
although  this  observation  was  preliminary  (Figure  3.18).    In  the  small  number  of 
patients who entered a flare of systemic vasculitic disease while on treatment, CECs 
correspondingly increased (Figure 3.19, Appendix 6 patients 3,4,7,10 and 13), although 
in localised flare this was not to the high levels seen in systemic disease (Figure 3.20, 
Appendix 6 patients 6 and 8), a finding that has also been observed in adults with WG 
(Woywodt et al., 2006b).   
 
The  significant  differences  in  CEC  number  between  active  disease  and  healthy  age 
matched and febrile controls, suggest that CECs may be a reliable marker of active 
vasculitis and endothelial injury.  Vasculitis patients are a highly heterogeneous group 
and it is thus not surprising that some patients with active disease do not have high 
elevation of CECs, perhaps related to the time of sampling in relation to initiation of 
treatment and the location and extent (systemic versus localised) of the vasculitic injury.  
As  discussed  in  the  introduction  to  this  chapter,  it  remains  unclear  where  CECs 
originate and how they enter the venous circulation.  Of some concern in this patient 
population was the small number of patients who had elevated levels of CECs but no 
clinical  signs  of  disease  activity.    It  may  be  that  this  is  indicative  of  an  increased 
endothelial turnover and vascular remodeling rather than acute injury, an hypothesis that 
makes sense considering the time it takes CECs to return to normal levels in some 148 
 
individual patients, despite bringing the inflammation under control.  A less optimistic 
hypothesis, however is that in these patients endothelial injury is ongoing, despite the 
clinical impression of disease remission.  
 
The  poor  correlation  with  clinical  markers  of  inflammation  is  consistant  with  the 
conflicting results observed in previous studies in adult, whereby strong correlations 
have been observed between CECs and BVAS in ANCA associated disease (Woywodt 
et al., 2003b,Woywodt et al., 2006b) but only a weak correlation was been observed 
with CRP (Woywodt et al., 2006b).  As discussed in the introduction to this thesis, 
levels  of ESR and CRP may  remain normal  during active vasculitis,  particularly in 
episodes of localised disease and granulomatous flares (Salvarani et al., 2003,Sproson et 
al.,  2007)  and  thus  this  result  is  unsurprising,  indicating  as  mentioned  above  that 
endothelial injury can occur in the absence of inflammation.      
 
Unfortunately the technique used in this thesis for detection of CECs is not yet suitable 
for large scale automated routine clinical testing, because of its time consuming nature 
and the training required to reliably read samples.  Development of a flow cytometry 
based assay optimised for detection of necrotic cell populations was not a direction in 
which this project went due to time constraints and the availability of a well established 
and  reproducible  assay  for  reliable  detection  of  CECS.      However  flow  cytometry 
protocols can be relatively simply automated and future work based on this would be of 
considerable interest.  A multiparametric approach for detection of CECs would allow a 
much more defined population,  that  could  provide more understanding  of the exact 
nature of CECs.  149 
 
As red cell lysis used in FC was one of the major causes of loss of the fragile CEC 
population, the use of similar techniques to those used for examination of apoptotic and 
necrotic cells using FC such as no wash/no lyse protocols (Darzynkiewicz et al., 1997) 
could  overcome  this  limitation.    However  without  red  cell  lysis  there  is  much 
background noise due to non removal of red cells, and in order to distinguish cells of 
interest from erythrocytes, a threshold based on fluorescence must be used.  As yet 
these techniques are only described for rare event analysis based on very bright staining 
populations with metabolic dyes rather than antibody staining (Rehse et al., 1995) and 
thus  may  not  be  suitable  for  detection  of  CECs.    Another  potential  method  for 
overcoming these problems (in order to benefit from the multiparametric potential of 
FC) would be to enrich the CEC population prior to preparation for FC, thus removing 
the majority of superfluous cells and much of the background noise.  This could be done 
using  FC  compatible  magnetic  beads  as  described  recently  by  Widemann  et  al.  
Interestingly, although this protocol gave comparable values to  IBE, statistically the 
results were consistently higher when healthy individuals, patients who had undergone 
coronary angioplasty or renal transplantation were studied  (Widemann et al., 2008).  
The authors attributed this to the loss of fragile cells populations during the washing 
steps required for IBE and thus this finding is extremely promising for future studies in 
vasculitis,  whereby  conventional  FC  methodology  resulted  in  considerable  loss  on 
handling of CECs (Clarke et al., 2008).   
 
An alternative multiparameter identification technique which has been developed into a 
commercially  available  CEC  counting  system  involves  automated  microscopy 
(Celltracks endothelial cell kit, Immunicon). CECs are isolated from peripheral blood 
using CD146 immunomagnetic beads then stained with DAPI, anti-CD105-PE and anti-150 
 
CD45-APC.  The stained cells are transferred to a counting chamber and are scanned 
with an automated microscope.  Events positive for DAPI and CD105 and negative for 
CD45  have  composite  images  taken  which  an  operator  can  then  distinguish  on 
morphology.  Not surprisingly the setup costs for this kind of system are prohibitively 
expensive.  However, with the right software and using a microscope with a motorised 
stage and filter set, it may be possible to emulate the technology at a fraction of the cost.  
Unfortunately time restraints did not permit the development of either of these avenues 
of  work  and  thus  for  the  purposes  of  this  thesis  and  to  examine  CECs  within  the 
vasculitis patient cohort, IBE as described by the 2006 consensus paper was therefore 
the methodology of choice (Woywodt et al., 2006a).   
 
While IBE has proved to be more reproducible and robust than FC for assessment of 
CECs in vasculitis, excluding a single study in KD (Nakatani et al., 2003) this is the 
first study to examine a paediatric cohort with necrotising vasculitis in detail.  Thus 
potential paediatric related sources of error needed to be considered.  In particular the 
effect of traumatic venepuncture and the inability to guarantee that all samples would 
have the first 5 mls of blood discarded due to the small samples typically obtained for 
research in children.  Although the data is preliminary, due to lack of willing volunteers, 
traumatic venepuncture did considerably elevate the CECS in a single healthy adult 
volunteer  above  the  median  values  normally  obtained  in  healthy  adult  controls  (20 
CECs/ml in this study, comparable with previous studies of around 10-20 CECs/ml) 
(Blann  et  al.,  2005).    However  the  range  seen  in  active  AAV  (20-5700  CECs/ml) 
(Woywodt et al., 2003b) was much higher than this and the experimental venepuncture 
performed in this study was far more traumatic than would be hoped under normal 
conditions.   Interestingly discarding the first 5 mls of blood in this individual, would 151 
 
not  have  influenced  the  CECs  enumerated.    Although  it  is  difficult  to  draw  firm 
conclusions from these preliminary findings, as long as the same conditions are applied 
to  the  control  group  as  to  the  patient  group  it  is  possible  that  these  child  related 
confounding issues will not affect our the results, because CECs are so grossly elevated 
in children and adults with active vaculitis.  
 
In  conclusion  it  appears  that  in  vasculitis  in  children  CECs  reflect  the  extreme 
endothelial damage associated with this condition and are a useful tool for assessing 
disease activity.  Further development of the methodology towards a routine clinical test 
would be an obvious future direction of this work. 
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4.1 Summary 
This chapter describes the methodology used to detect cellular derived microparticles.  
Like  CECs  this  technique  can  provide  insight  into  the  activation  state  of  the 
endothelium,  and  may  be  an  appropriate  biomarker  of  disease  activity  in  vaculitis.  
However, due to the multiparametric nature of the technique used, insight can be gained 
at  the  same  time  relating  to  the  activation  state  of  a  number  of  different  cells  (eg 
neutrophils, monocytes) which are also pivotal to disease activity in vasculitis.  The 
latter part of this chapter examines in detail the relationship between microparticles and 
disease activity in children with primary systemic vasculitis and further expands on 
previously published data from the group (Brogan et al., 2004a).  
  
 
4.2 Introduction 
Microparticles (MPs) are membrane derived vesicles 0.1-2µm in size that are released 
during physiological or pathological cell or platelet activation (Piccin et al., 2007).  MPs 
can express surface markers of their cell of origin and in contrast to quiescent cells can 
express  phosphatidylserine  (PS)  on  their  outer  leaflet  (Hugel  et  al.,  2005),  a 
consequence of the membrane remodelling or in more pathological situations the loss of 
integrity necessary for their formation.   
 
4.2.1 Formation of MPs 
Cellular and platelet plasma membranes  consist of a phospholipid bilayer, which in 
unstimulated  cells  has  an  asymmetrical  distribution  of  its  components.    Uncharged 
phospholipids  such  as  phophatidylcholine  (PC)  and  sphyingomyelin  (SM)  are 
predominantly expressed on the outer leaflet and negatively charged phospholipids such 154 
 
as  PS  and  phosphatidylethanolamine  (PE)  found  on  the  inner  leaflet.    Membrane 
remodelling and subsequent PS expression on the outer leaflet of cells promotes the 
activation  of  clotting  factors  (Bevers  et  al.,  1982)  and  recognition  of  the  cell  by 
phagocytes and is considered to be a key stage in apoptosis (Fadok et al., 1992).   
 
Membrane composition is tightly regulated by enzymes, known as flippases, floppases 
and scramblases (Piccin et al., 2007).  Flippases inwardly direct the negatively charged 
phospholipids  in  an  ATP  dependent  manner,  whereas  floppases  act  in  an  outward 
manner (Daleke, 2003).  Scramblases degrade the bilayer phospholipid gradients, acting 
in both directions.  A Ca
2+ activated scramblase has been described which plays an 
important  role  in  membrane  reorganization  in  response  to  cell  stimulation  (Daleke, 
2003), the resultant membrane disorganisation results in PS expression on the surface of 
the cell.  As transient rises in Ca
2+ can alter the membrane asymmetry and activate 
enzymes involved in cytoskeleton remodeling, such as calpain, it is believed to play a 
key role in MP formation (Wiedmer et al., 1990). Thus Ca
2+ ionophores can be used to 
generate MPs.   
 
In vitro it is relatively easy to stimulate isolated cell populations to generate MPs by the 
use  of  cytokines  of  ionophores.    In  vivo  the  stimuli  which  generate  MPs  and  their 
functions remains unclear, however it is apparent that they are a consequence of cell 
activation, apoptosis and necrosis and are the product of remodeling of the cytoskeleton 
and loss of membrane asymmetry.    
 
4.2.2 Detection of MPs 
The majority of studies which have detected MPs have used flow cytometry (FC) based  155 
 
protocols.  This allows for a multi-parameter based assessment of the MP population. 
However there is much variation in methodology and no consensus protocol has been 
described  (Enjeti  et  al.,  2007).    An  alternative  technique  utilizes  sandwich  ELISA, 
whereupon MPs are immobilized on the ELISA plate by PS binding.  However this does 
not provide as much information relating to phenotype as FC allows, and also does not 
allow analysis of PS negative MPs.  Thus in this thesis FC was employed to study MPs. 
 
4.2.3 Function of MPs 
The phenotype and function of MPs from different cellular origins remains to be fully 
elucidated, however it is apparent that different cellular MPs and the circumstances 
under  which  they  are  generated  can  exert  different  functional  effects.  MPs  are 
generated in response to numerous stimuli and while some groups hypothesise that their 
role is in inter-cellular signaling, others suggest it is a consequence of cell survival.  The 
expression of high levels of PS on the outer surface of all phenotypes of MPs indicates 
widespread procoagulant potential, as PS promotes the coagulation cascade (Hugel et 
al.,  2005,Toti  et  al.,  1996).    Elevated  levels  of  MPs  from  endothelium,  platelets, 
mononuclear  cells  and  neutrophils  have  been  documented  in  a  number  of  diseases 
associated with cardiovascular injury, including vasculitis in both adults (Daniel et al., 
2006,Erdbruegger et al., 2008) and children (Brogan et al., 2004a) and will now be 
discussed in more detail.  
  
4.2.4 Endothelial MPs 
Endothelial  MPs  (EMPs)  were  first  described  by  Hamilton  et  al  in  1990,  being 
produced  in  response  to  complement  mediated  attack  on  HUVEC  (Hamilton  et  al., 
1990).  The resultant MPs generated were less than 1µm in size and bound activated 156 
 
factor V a key component of the coagulation pathway (Hamilton et al., 1990).  Cultured 
ECs  have  subsequently  been  shown  to  produce  MPs  in  response  to  various  stimuli 
including inflammatory cytokines such as TNFα (Combes et al., 1999) and IL-1α (bid 
Hussein et al., 2003), CRP (Wang et al., 2007), thrombin (Sapet et al., 2006) and serum 
from patients with antiphospholipid syndrome (APS) (Combes et al., 1999), thrombo-
cytopenic purpura (Jimenez et al., 2001) and multiple sclerosis (Minagar et al., 2001).   
 
Elevated levels of EMPS have been detected in many diseases associated with vascular 
injury including vasculitis (Brogan et al., 2004a), acute coronary syndrome (Bernal-
Mizrachi et al., 2003), multiple sclerosis (Minagar et al., 2001) and type 2 diabetes 
where they are predictive of associated coronary artery disease  (Koga et al., 2005).  
Thus are not specific to the vasculitides, but reflect activation and injury.   
 
4.2.4.1 Phenotype of EMPs 
There is no agreed consensus as to what defines an EMP other than the presence of 
endothelial cell membrane antigens on the surface of a MP.  More often than not MPs 
are  defined  by  the  presence  of  PS  (shown  by  binding  of  AnnexinV  (AnV))  on  the 
surface  of  particles  with  low  FSC,  however  some  groups  consider  AnV  negative 
populations  as  well. EC  markers that have been examined on MPs  include CD144, 
CD146 (Faure  et  al.,  2006), CD31, CD105, CD51,  ICAM-1, E-selectin and CD106 
(Jimenez et al., 2003). 
 
Jimenez  et al  demonstrated that when ECs were deprived of growth factors  to induce  
apoptosis  the  MPs  generated  expressed  CD31  and  CD105  (Jimenez  et  al.,  2003), 
however  after  cellular  activation  with  TNFα  the  MPs  produced  had  much  higher 157 
 
expression of the inducible activation markers E-selectin, ICAM-1 and CD106 (Jimenez 
et  al.,  2003).  Thus examining a combination of markers may  give insight  into the 
circumstances  of  MP  generation.    For  the  purposes  of  this  thesis,  the  constitutive 
endothelial markers CD144 and CD105 and the inducible endothelial markers ICAM-1 
and E-selectin were examined.   
 
CD144 is specific for ECs in adults, however can be found on haematopoeitic stem cells 
in the foetus (Kim et al., 2005) and endothelial progenitor cells post-natally (Rehman et 
al., 2004).  It is involved in maintaining the tight cell-cell contact between ECs, thus 
significant EC disruption would necessitate it being exposed.  CD105 or endoglin is part 
of the TGFβ receptor complex on endothelial cells and like CD144 it is not frequently 
found on cells circulating in the blood, other than leukaemic cells (Duff et al., 2003).  It 
is upregulated in hypoxia (Sanchez-Elsner et al., 2002) and on proliferating ECs (Duff 
et al., 2003).  Although CD31 and CD146 are alternative EC constitutive markers, they 
are found on haematopoietic cell types which are more prevalent and may generate MPs 
in inflammatory conditions; CD146 is found on activated T cells and CD31 is found on 
platelets, neutrophils, T cells and NK cells.  E-selectin is highly specific for activated 
ECs and has only been observed on other cell types in vitro; TNFα stimulated foetal 
astrocytes  (Hurwitz  et  al.,  1992)  or  on  CD4+  T  cells  after  antibody  stimulation  of 
membrane-bound TNF (Harashima et al., 2001).  In vitro its expression is transient, 
peaking  at  4hrs  after  stimulation  (Pober  et  al.,  1986).    ICAM-1  is  constitutively 
expressed  on  EC,  but  is  also  upregulated  on  activation,  peaking  at  4hrs  after  IL-1 
stimulation (Dustin et al., 1986).  It is less EC specific though and is also expressed on 
activated leucocytes. 
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4.2.4.2 Functional significance 
Microparticles generated in vitro from cultured endothelial cells such as HUVEC or 
microvascular endothelial cells (MVEC) have been shown to activate monocytes (Jy et 
al., 2004b) and enhance monocyte-endothelial adhesion (Huber et al., 2002), suppress 
HUVEC growth in a matrigel angiogenesis assay (Mezentsev et al., 2005) and promote 
coagulation in vitro and in vivo (bid Hussein et al., 2008).  In isolated perfused human 
microvessels,  the  addition  of  EMPs  reduced  acetylcholine  induced  endothelium 
dependent vasodilation and in the same study, when EMPs were injected into both rats 
and mice acute lung injury occurred (Densmore et al., 2006).   
 
4.2.5 Platelet MPs 
Platelet MPs (PMPs) are the population which have been most extensively studied to 
date and make up the predominant MP population in healthy individuals (Diamant et al., 
2004).  Stimulation of platelets by a wide variety of agents (such as thrombin, collagen 
or ADP) induces the aggregation necessary for haemostasis and can also result in MP 
release  (Diamant  et  al.,  2004).    PMPs  are  also  released  in  vitro  by  shear  stress 
(Miyazaki et al., 1996).   
 
Elevated levels of PMPs have been found in patients suffering thrombotic complications 
or  vascular  injury  including  acute  myocardial  infarction  (Matsumoto  et  al.,  2002), 
peripheral  arterial  disease  (Zeiger  et  al.,  2000),  vasculitis  (Brogan  et  al.,  2004a), 
hypertension (Preston et al., 2003) and in malignancy (Kim et al., 2003).  Conversely 
patients  with  bleeding  disorders,  such  as  Castamann’s  disease  have  reduced  PMPs 
(Castaman et al., 1997) and in the rare genetic disease Scott’s syndrome where PS is 159 
 
unable to be exposed on the surface of cells, PMPs cannot be generated at all (Toti et 
al., 1996). 
 
4.2.5.1 Phenotype of PMPs     
As  with  EMPS,  PMPs  have  been  assessed  based  on  their  expression  of  PS  in 
combination  with  a  platelet  surface  marker  such  as;  CD42a,  CD42b,  CD41,  CD61, 
CD63 or P-selectin (Piccin et al., 2007).  For the purposes of this thesis CD42a, which 
is  constitutive  and  selectively  expressed  on  platelets  and  the  adhesion  molecule  P-
selectin which is found on platelets although less selectively (it is also expressed on 
endothelial cells (Merten and Thiagarajan, 2004)) were chosen.  CD42a or glycoprotein 
IX is part of the vWF receptor complex (consisting of 4 subunits – gp1bα and β, gpIX 
and gpV) which is involved in mediating the tethering of platelets to exposed vWF on 
the  subendothelium.    The  complex  also  interacts  with  thrombin,  P-selectin  and 
coagulation factors (Du, 2007).   P-selectin mediates rolling of platelets and leukocytes 
on activated endothelium and intereactions between platelets and leukocytes (Merten 
and Thiagarajan, 2004).  
 
4.2.5.2 Function of PMPs 
In vitro PMPs have been shown to initiate and propagate coagulation (Warkentin et al., 
1994),  activate  neutrophils  (Jy  et  al.,  1995),  monocytes  (Barry  et  al.,  1998)  and 
endothelial cells (Barry et al., 1997) and mediate the cell-cell interactions between them 
(Barry et al., 1998).  PMPs have been shown to transfer platelet antigens (Majka et al., 
2007) and other receptors between cell types such as CXCR4, which can make cells 
susceptible to the HIV virus (Rozmyslowicz et al., 2003). In lung cancer PMPs can 
induce  metastasis  (Janowska-Wieczorek  et  al.,  2005).    Conversely  under  some 160 
 
conditions  PMPs  have  demonstrated  anticoagulant  properties,  via  acceleration  of 
inactivation  of  activated  factor  V  by  protein  C  (Tans  et  al.,  1991)  and  by  their 
expression  of  proteins  which  inhibit  coagulation,  such  as  TF  pathway  inhibitor 
(Steppich et al., 2005), suggesting a complex role in the balance of haemostasis.  
  
4.2.6 Leukocyte MPs – Neutrophils, monocytes and lymphocytes 
As neutrophils play a key role in the pathogenesis of AAV, it is perhaps not surprising 
that elevated levels of neutrophil derived MPs (NMPs) have been described in vasculitis 
(Daniel et al., 2006).  Elevated levels of NMPS have been also been documented in 
sepsis (Joop et al., 2001).  Both studies examined the immunoglobulin surface marker 
CD66b.  For the purposes of this thesis CD15, CD11b, and L-selectin were examined in 
addition to CD66b.  CD15 is a constutively expressed adhesion molecule found in high 
levels on neutrophils and is involved in phagocytosis and chemotaxis (Skubitz et al., 
1989).  CD11b is an integrin involved in neutrophil and monocyte adhesion with the 
endothelium and is upregulated on stimulation of neutrophils (Finn et al., 1994).  L-
selectin  is  involved  in  leucocyte-endothelial  interactions  and  is  downregulated  on 
neutrophil stimulation (Finn et al., 1994).   
 
Microparticles derived from monocytes (MMPs) have previously been detected by their 
high expression of CD14 in combination with AnV (Kanazawa et al., 2003). CD14 is 
part of the LPS receptor complex and is found on a small proportion of neutrophils. 
Stimulated  monocytes  can  synthesis  high  levels  of  tissue  factor  (TF).    While  both 
endothelial cells and platelets can release TF from intracellular granules on stimulation, 
it is hypothesized that monocytes may be the predominant source of TF positive MPs, 
which  have  the  potential  to  form  complexes  with  platelets  and  PMPs,  propagating 161 
 
coagulation (Osterud, 2001).  Elevated levels of CD14+ MPs have been documented in 
lung cancer (Kanazawa et al., 2003) and type 2 diabetes (Omoto et al., 2002).  
 
Elevations  in  lymphocyte  microparticles  (LMPs)  have  been  documented  in  pre-
eclampsia (VanWijk et al., 2002) and HIV(Aupeix et al., 1997) and has been postulated 
to be associated with high levels of lymphocyte apoptosis in these conditions.  CD4 and 
CD8 MPs were examined in these studies. For the purposes of this thesis CD3 positive 
MPs were assessed.  CD3 is part of the T cell receptor complex and is constitutively 
expressed on mature T cells (Goldsby RA et al., 2003a).  
 
4.2.6.1 Function of leukocyte MPs 
Leukocyte  derived  MPS  have  been  less  well  studied  than  those  derived  from 
endothelium or platelets.  It is apparent that they are associated with inflammation and 
infection  and  there  is  evidence  accumulating  that  they  may  also  have  functional 
significance.  MMPs express high levels of TF, which can be transferred to other cell 
populations (Osterud, 2001) indicating a role in coagulation.  LMPs have been shown to 
activate monocytes (Scanu et al., 2008) propagating inflammation. The data relating to 
NMPs is more complex; while NMPs can stimulate endothelial cells to release IL-6 
(Mesri and Altieri, 1998), perhaps potentiating inflammatory reponses, conversely they 
can act  in  an anti-inflammatory manner.   In vitro NMPs  generated  from  N-formyl-
methyl-leucyl-phenylalanine (FMLP) stimulated adherent neutrophils (cocultured with 
HUVEC),can inhibit neutrophil-endothelial interactions (Dalli et al., 2008).  In vivo, 
mouse NMPs generated in the same manner (using mouse endothelium) inhibited IL-1β  
induced inflammatory infiltrate in a mouse air pouch model (Dalli et al., 2008). 
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4.2.7 Microparticles in vasculitis 
To date, there have been 3 studies and one case study examining MPs in vasculitis, the 
first by Brogan et al demonstrated an elevation in E-selectin and CD105 expressing 
EMPs and CD42a (although not P-selectin) expressing PMPs in children with active 
PSV compared to healthy controls (Brogan et al., 2004a). Daniel et al demonstrated an 
elevation in NMPs expressing CD66b and PMPs expressing CD41a in adult patients 
with AAV during active disease compared to controls.  During remission patients also 
had  higher  NMPs  than  controls  (Daniel  et  al.,  2006).  Recently  Erdbruegger  et  al 
examined  EMPs  in  adults  with  AAV  and  demonstrated  an  elevation  E-selectin  and 
CD105  EMPs  during  active  disease  compared  to  patients  in  remission  and  healthy 
controls  (Erdbruegger  et  al.,  2008).    The  case  study  described  by  Kumpers  et  al, 
demonstrated eleveated EMPs, PMPs and leucocyte MPs (CD45+) at onset of Churg-
Strauss syndrome that declined with treatment (Kumpers et al., 2008).   
 
While Erdbruegger et al followed changes in EMPs for 6 months from treatment and 
demonstrated a rapid decline, the two other studies only examined a small number of 
patients before and after treatment.  Thus a comprehensive study relating to changes in 
MPs in relation to treatment and disease flare has  yet to be performed.  The study 
described herein will begin to examine MPs in this context. 
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4.3 Detection of MPs – methodological optimisation 
4.3.1 Preparation of samples 
The methodology described is based on work previously optimized and published by 
the  group  (Brogan  et  al.,  2004a)  and  thus  few  changes  to  the  basic  protocol  were 
required.  Platelet poor plasma was generated as described in Section 2.4.7.  Figure 4.1 
demonstrates the extent to which platelets were removed from the sample after each 
spin.  50µl samples of blood prior to spinning, plasma after 1 x 5 mins spin at 5,000g 
and after 2x 5 mins spins at 5,000g were diluted in 200µl of sterile filtered (0.22µm) 
FACS buffer and run for 45 seconds on a BD Facscalibur, using logarithmic instrument 
settings, with FSC amplitude of E01.  As can be seen in Figure 4.1a-c while 1 spin 
removes a large proportion of platelets (Figure 4.1b), 2 spins removes almost all of 
them (Figure 4.1).  The removal of platelets from plasma is an important step in the 
protocol as to (some extent) they have overlapping FSC/SSC profiles to MPs making 
FC analysis more difficult in the presence of platelet contamination.  Moreover, the 
freeze thawing of platelets may disrupt their membrane and could result in false positive 
MP events (see section of effect of freeze-thawing below).    
 
4.3.2 Preparation of positive controls for setup experiments 
In  order  to  detect  the  different  MP  populations  in  vasculitis  patients  MPs  were 
generated  from  activated  parent  cells  of  different  types.    For  EMPs  HUVEC  were 
isolated and cultured as described in section 2.4.1.  After first passage they were grown 
on 6 well plates until 80% confluence, whereupon they were serum starved overnight 
and then stimulated with 100ng/ml TNF for 24hrs.  To generate NMPs neutrophils were 
isolated using polymorphprep as described in section 2.4.5 and stimulated for 30 mins-
4hrs using FMLP (10ng/ml), TNFα (100ng/ml) or  LPS  (10ng/ml)  or  combinations  of 164 
 
Figure 4-1: The removal of platelets for generation of platelet poor plasma 
 
 
 
 
 
 
 
 
Figure 4.1a-c: Using instrument settings  optimised for MP detection (Voltage E01, logarithmic 
scale) the platelet population can be easily seen within whole blood. (Figure 4.1a, circled).  After 1 
and 2 x 5000g spins, 50µl samples of  the plasma obtained  were diluted with 200µl of sterile filtered 
PBS + 0.1% azide and run for 45seconds at low flow. Figure 4.1b: After 1 x 500g spin some 
platelets are removed.  Figure 4.1c:  After 2 spins most platelets are removed.  Absolute platelet 
count dropped from 250 to 27 after the second spin in this representative experiment.  
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FMLP with another reagent.  To generate MMPS and LMPs, PBMCs were isolated as 
described in Section 2.4.4 and stimulated using 100ng/ml TNF for 30 mins-4hrs.  To 
detect  a  mixed  population  of  MPs,  including  platelet,  monocyte,  lymphocyte  and 
neutrophil whole blood was stimulated with LPS 100ng/ml. All stimulation experiments 
of blood and cells in suspension were carried out in polypropylene tubes to prevent MPs 
sticking to the plasticware.  Activation of parent cells was confirmed using FC as 2.5.4.  
The  phenotype  of  the  MPs  generated  and  their  activated  parent  cells  is  shown  in 
Appendix 4. 
 
4.3.3 Staining of MPs for flow cytometry 
A known and exact volume of sample containing MPs – either platelet poor plasma or 
culture media from experiments (which had been centrifuged at 500g for 5 mins to 
remove cells) was  centrifuged at  13000g for 60 mins to  pellet  the MPs.  This  was 
necessary to allow samples to be resuspended in AnV buffer (containing 2.5mM CaCl2) 
as AnV binding is Ca
2+ dependent and thus there must be optimal Ca
2+ present to allow 
binding to occur.  Once the supernatant had been carefully decanted the MPs were 
resuspended in sufficient Annexin V buffer to allow 35µl to be added to wells on a 96 
well plate containing 5 µl of Annexin V FITC and 10 µl of a PE/PE-CY5 or Percp 
conjugated antibody as described in Chapter 2.5.3. After 10mins of staining at room 
temperature 200µl  of Annexin  V buffer was  added to  stop  staining and allow flow 
cytometry of sample.  The full MP staining plan is shown in Appendix 3. 
 
4.3.4 Flow cytometry of MPS 
MPs were analysed on a BD Facscalibur using logarithmic instrument settings with a 
FSC voltage of E01.   166 
 
4.3.4.1 Optimisation of instrument settings using latex beads 
To establish the limits of detection and appropriate instrument settings 0.3, 0.8 and 3µm 
latex counting beads were used.  It is important to note that while these beads give an 
approximate estimate of size they are not directly comparable with MP size as they are 
of different composition and therefore have different optical properties (the refraction 
and reflection of the laser beam in the flow cytometer which contribute to FSC and SSC 
will be different when considering latex particles to cell membranes).  Thus MPs should 
be FSC/SSC gated based on their discrete populations and not based entirely on where 
beads fall on the FC (Furie and Furie, 2006).   As can be seen in Figure 4.2a, 3µm latex 
beads lie within a similar FSC location to platelets when whole blood was examined 
and thus could be used as an approximate upper boundary of the FC region of interest.     
 
In order to investigate the lower limits of detection, 0.8µm, 0.3µm beads and sterile 
filtered water alone were also examined.  Sterile filtered water was used to examine the 
absolute  limits  of  detection.    The  noise  detected  using  0.2µm  filtered  water  was 
presumed  to  be  electrical  noise  and  therefore  a  FSC  threshold  was  established  to 
exclude the peak of this (Figure 4.2b).  Once this threshold was established the 0.8 µm 
and 0.3µm beads were examined.  As can be seen from the histograms, while the 0.8µm 
beads  are  easily  distinguishable  from  noise  (Figure  4.2c)  the  0.3µm  beads  are  not 
(Figure 4.2d).  Thus, as MPs are close to the limits of detection of the flow cytometer, it 
is apparent that they cannot be entirely distinguished from this noise based on their FSC 
and  SSC  characteristics  alone,  emphasizing  the  importance  of  using  AnV  as  a 
constitutive MP marker.  Figure 4.3 shows the gating strategy used for detection of 
MPs. As can be seen a number of events positive for AnV fall within this overlapping 
noise region. 167 
 
Figure 4-2: Optimisation of MP gating using 0.3µm, 0.8µm and 3µm latex 
beads  
 
 
 
 
 
 
Figure 4.2a demonstrates the FSC profile of 3µm latex beads and shows that they sit at the upper 
end of the platelet region that was described in figure 3.16a-c. This was used as the upper limit of 
the region of interest.  Figure 4.2 b indicates the lower limits of detection by using sterile filtered 
distilled water only and highlights the extent of background electrical noise within the system.  The 
blue line indicates the FSC threshold used to remove the peak of the background noise  Figure 4.2c 
shows  that  0.8µm  beads  can  be  easily  distinguished  from  both  the  noise  and  the  3µm  bead 
population.  0.3µm beads however cannot be distinguished from the background noise (figure 4.2d)   
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4.3.4.2 Absolute enumeration of MPs 
As described previously in Chapter 3 there are 3 commonly used methods for absolute 
enumeration  of  flow  cytometric  events:  1.  Allowing  samples  to  run  to  completion; 
2.Using an internal standard such as counting beads; or 3.calculating the flow rate for a 
set collection time prior to running the samples.  While using an internal standard had 
proved  more  accurate  for  enumerating  CECs,  the  presence  of  beads  within  the  MP 
sample  might  influence  the  level  of  back  ground  noise  making  it  more  difficult  to 
reliably count MPs accurately.   Thus this issue needed further clarification.  
 
Optimisation of detection of 3µm latex beads 
In previous studies, 3µm latex beads had been used as an internal standard (Brogan et al., 
2004a).  In the first instance it was important to establish that these counting beads were 
being detected with accuracy.  3µm latex beads were diluted in sterile filtered distilled 
water to give a final concentration of 20,000 beads/µl.  10 µl of this stock (200,000 
beads) was then added to 240µl of sterile filtered water.  Samples (n=3) were then run 
to completion at a medium flow rate using the instrument settings as established in 
Figures 4.2 and 4.3.  Using these instrument settings beads recovery was poor, with 
mean recovery of only 8.9% (range 6.7-11.4%).   
 
The manufacturer’s recommendations for the use of latex beads suggested that the use 
of  a  detergent  may  prevent  beads  clumping  together,  a  phenomenon  which  could 
explain this poor recovery.   Thus an experiment was performed to determine if this 
could be the cause of poor recovery. Bead clumping can occur over time, so all bead 
samples  used  in  these  experiments  were  prepared  immediately  prior  to  use  in  FC 
experiments.  Beads were diluted in sterile filtered distilled water or 0.05 % TWEEN to  169 
 
Figure 4-3: MP gating strategy, based on Annexin V positivity 
 
 
    
 
 
Figure 4.3a shows the FSC vs Annexin V positivity of MPs from a patient with active vasculitis.  The 
MPs form a discrete population at the lower end of the FSC axis that can be gated on, notably a 
number of events fall within the electrical noise region described in Figure 4.2.  When a histogram 
is drawn based on this gating, (figure 4.3b) this gated MP populations sample can be seen to have 
high  numbers  of  CD144  positive  MPs.  The  black  line  represents  the  negative  isotype  control 
antibody,  and the red line the CD144 antibody staining.  The marker was set at 2.5% positivity of 
the isotype control alone, the non-specific 2.5% being subtracted from the CD144% staining to 
obtain the final value of 38% in this example. 
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give a stock solution of 20,000 beads/µl.  10µl of each stock solution (200,000) was 
then added to 240µl of sterile filtered distilled water, 0.05% TWEEN or AnV buffer.  
As Figure 4.4b demonstrates the recovery of beads was poor under all conditions, which 
indicated that bead clumping may not be the reason for poor recovery.  Alternative 
explanations thus included suboptimal instrument settings.   
 
The aforementioned phenomenon of flow cytometric “coincidence”, whereby too many 
individual  events  are  occurring  simultaneously  to  detect  with  accuracy,  could 
conceivably influence recovery.   As Figure 4.4a demonstrates, the flow cytometric 
instrument settings are at the limits of detection and there is much background noise 
(circled)  which  contributes  to  the  events  occuring.    In  order  to  determine  if  this 
phenomenon  was  influencing  the  ability  to  recover  beads  a  FSC  threshold  was  set 
(Figure 4.4c). As Figure 4.4d shows, this increased the average bead recovery from 
8.9% to 111% (range 89-133%).  Thus in order to enumerate counting beads accurately 
the instrument settings must be optimised to the counting beads.  This was problematic 
as using the FSC threshold show in figure 4.4c would mean that the majority of the MPs 
would go undetected: as can be seen in figure 4.3a the MP population has a low FSC.  
Thus it was apparent that the use of these 3µm beads as an internal standard was not 
appropriate in this experimental setting for reliable MP quantification.   
 
As the background noise was having such a detrimental effect on bead enumeration 
(possibly  via  coincidence  or  another  undefined  mechanism)  this  observation  raised 
questions regarding the effect of “noise” on MP counts.  MPs are detected using AnV 
positivity to define them, so using a threshold based on the MP AnV phenotype could 
reduce  background  noise and may allow a FITC labeled counting bead to be used as an  171 
 
Figure 4-4: Recovery of 3µm counting beads 
 
  
 
 
 
Figure 4.4: When 200,000 latex beads were spiked into 240µl of sterile distilled water and acquired 
using MP flow cytometric instrument setting (Figure 4.4a) recovery was poor with mean recovery 
8.9% (range 6.7-11.4%).  To assess if this was due to bead clumping the stock sample of beads was 
diluted in the presence of detergent as recommended by the manufacturer (0.05% TWEEN)  - white 
bars (Figure 4.4b) and spiked into distilled water, Annexin V buffer or more detergent.  This had no 
affect on bead recovery.   There was much background noise in the sample (circled in Figure 4.4a) 
so a FSC threshold to cut out the noise was set (Figure 4.4c).  This resulted in good recovery of 
beads (Figure 4.4d, white bar) mean recovery 111% (range 89-133%).  
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internal standard.  As had been established for the non-labelled latex counting beads it 
was important to determine that the FITC labelled beads (3µm flouresbrite yellow green 
microparticles, Polysciences) were being recovered with accuracy.  As before the beads 
were diluted in sterile distilled water to give a final concentration of 20,000 beads/µl, of 
which 10µl (200,000 beads) was added to 240µl of sterile filtered distilled water.   
 
Figure  4.5a-c  demonstrates  that  when  instrument  settings  were  optimised  to  beads 
(figure 4.5a) and noise (circled) was excluded using an FL1 threshold (figure 4.5b) bead 
recovery was good (mean recovery 106%, range 96-111%) (figure 4.5c).  In order to 
determine if this could be used as an internal standard 10µl of the stock solution was 
added to 240µl of a sample containing MPs stained with AnV only.  As Figures 4.6a 
and b indicate, the bright fluorescence of the beads required the FL1 voltage to be 
decreased, making the MP population appear compressed (Figure 4.6b).  Thus it was 
decided that the most appropriate method for MP enumeration was to use the 3µm latex 
counting beads with FSC threshold applied (as in Figure 4.4c) to determine the flow rate 
of the FACS machine before and after each patient sample was run and thus calculate a 
mean value.   
 
While fluoresbright beads could not be used as an internal standard due to their high 
signal  when  compared  to  MPs,  in  order  to  determine  whether  the  use  of  an  FL1 
threshold improved the recovery of AnV positive MPs, all samples were run using the 
previously published instrument settings (Brogan et al., 2004a) and then again using an 
FL1 threshold.  Figure 4.7 demonstrates the total Annexin V MP results obtained in 20  
healthy child controls.   173 
 
Figure 4-5: Detecting Flouresbrite beads – recovery of beads alone 
 
  
 
 
Figure 4.5a-c demonstrates that when FC instrument settings were optimised to include fluoresbrite 
beads (figure 4.5a) and the noise (circled) was excluded using an FL1 threshold (figure 4.5b) bead 
recovery was good  (mean value 106%, range 96-111%) (figure 4.5c).  
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Figure 4-6:Fluoresbrite beads in relation to MPs 
 
 
 
  
 
 
 
Figure 4.6: When beads were used as an internal standard in the presence of Annexin V positive 
MPs, if instrument settings were optimised to the MPs the beads were off the FL1 scale (Figure 
4.6a, arrowed).  In order to recover beads at the same time as MPs FL1 voltage was reduced 
(Figure 4.6b, beads circled).  However this shifted the MP population considerably. 
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Figure 4-7:Using an FL1 threshold for MP enumeration 
 
 
  
 
 
 
Figure 4.7: When an FL1 threshold was used to remove background noise from the system, (figures 
4.7a and b) the calculated number of Annexin V positive MPs per ml of plasma was increased 
(figure 4.7c).  Figure 4.7c shows the recovery of AnnexinV MPs in 20 healthy child controls.  When 
an FL1 threshold was used, the total number of MPs recovered was significantly higher   
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It is apparent that the use of an FL1 threshold increases the sensitivity of the technique 
by removing the majority of the noise within the system.  It does however prevent 
analysis of AnV negative events.  While phosphatidylserine (PS) is widely thought to be 
found  on  all  MPs  it  has  been  suggested  that  there  are  large  populations  within  the 
circulation which do not express PS (Horstman et al., 2004).  Therefore for the purposes 
of this thesis it was decided to enumerate MPs using a modification of the settings 
described by Brogan et al, with the addition of an FL1 threshold as described above.  
However data was also collected using the previously published instrument settings to 
allow  future  study  of  the  AnV  negative  population  (Brogan  et  al.,  2004a).  Use  of 
fluorescence thresholds have been previously described by others for detection of MPs 
(Jimenez et al., 2001). 
 
It  is  important  to  note  that  these  instrument  settings  are  entirely  dependent  on  the 
particular flow cytometer (in this case a FACscalibur, BD) used for assaying these MPs.  
It is possible that the use of a different machine would not need all of the rigorous steps 
taken above to reduce background noise.  However, when MP samples were run on a 
second flow cytometer (FACSscan, BD) to investigate this, it was found that the use of 
an FL1 threshold still increased the number of AnV positive events recovered and thus 
hilighted that the steps taken to optimize this assay are of important consideration when 
performing rare event analysis under any circumstances. 
 
4.3.5 The effect of plasma freeze-thaw on MP quantification 
As mentioned previously the removal of platelets from plasma is an important step in 
the  protocol  as  all  samples  were  frozen.    While  desirable  (and  possible  with  this 177 
 
technique) to get same day results, the staining process is time consuming, and storage 
of frozen plasma for analysis in batches is more efficient.  
 
In  order  to  determine  if  freeze-thawing  altered  the  MPs  obtained  from  patients  a 
comparison between fresh and frozen platelet poor plasma was performed.  As figure 
4.8 demonstrates there was no difference between fresh and frozen total MP number 
based on experiments in 5 samples.  MPs were stained and enumerated as described 
above and in chapter 2.5.3, but only with AnV.  This finding is in keeping with other 
groups who found no difference due to freeze thaw (Enjeti et al., 2007).  There is one 
study that indicates the freeze thaw process may be detrimental to EMPs  (Jy et al., 
2004a), however in order to establish this finding with certainty a much greater sample 
size, including different MP generation conditions, different MP populations and the 
concentrations frozen must be considered.  Time restraints meant that this investigation 
could not be performed to such a detailed level.   
 
4.3.6 Reproducibility of the technique from different plasma volumes 
Platelet poor plasma from 1 healthy adult control was frozen in 3 separate aliquots, each 
with a different volume (range 150-500µl).  As Figure 4.9 demonstrates each aliquot 
gave similar mean results for total MP enumeration (based on 5 sample tubes analysed 
using flow cytometry as described above), verifying acceptable reproducibility of the 
technique of different volumes of frozen plasma.  
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Figure 4-8: The effect of freeze thaw on MP enumeration 
 
 
 
 
 
 
 
Figure  4.8:  MPs were  enumerated  from  5  individual  patients,  on  freshly  isolated  platelet  poor 
plasma and platelet poor plasma that had been frozen for 24hrs at -80
oC.   Freeze thawing of 
platelet poor plasma gave no significant differences in absolute Annexin V positive MP number 
(n=5). 
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Figure 4-9: Reproducibility of MP enumeration  
 
 
 
 
 
 
 
 
 
Figure 4.9: Platelet poor plasma was obtained from one healthy individual.  3 plasma aliquots of 
different sizes (range 150-500µl) were frozen down and the MPs enumerated, based on 5 individual 
flow cytometric sample readings. There was no significant difference between the samples for total 
AnnexinV positive MP events.  
   180 
 
4.4 Conclusions of methodological experiments 
What is apparent from this series of experiments is that detection of MPs is fraught with 
problems relating to the sensitivity of FC, as it involves using the machine at the limits 
of its detection. However, MP populations can be detected and phenotyped with careful 
and systematic optimisation of FC instrument settings.  
 
To determine whether the MP populations of interest could be detected by FC, MP 
controls from different parent populations as positive controls were generated. For all 
the  cell  surface  markers  used  in  this  study  MPs  expressing  them  were  able  to  be 
generated in vitro (staining profiles are in Appendix 4), thus if they were present in 
patients, then their expression should be detectable.  However, the MPs thus generated 
may not be representative of pathophysiological conditions and thus may not be entirely 
representative  results  of  the  MPs  found  within  the  peripheral  blood  in  health  and 
disease.  While this is a point for consideration it does not detract from the validity of 
the FC work as FC is the only technique with which a multiparametric approach can be 
taken to enumerate subtypes of MPs and has been used widely in different states of 
health and disease.  
 
For the purposes of this thesis MP samples were run twice, once using an FL1 threshold 
to reduce background noise, (the data which is presented in the next section of chapter) 
and once using previously published instrument settings (Brogan et al., 2004a) so that 
they could be compared with previously published data from within our group (this data 
is not included within this thesis). 
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4.5 Evaluation of cellular MPs in vasculitis 
4.5.1 Patients and methods 
4.5.1.1 Patients 
40 children with primary systemic vasculitis were studied.  These patients were the 
same individuals described in Chapter 3, allowing MPs to be compared to CECs.  These 
included 17 males and 23 females of median age 11.1 years (range 1 -16.6 years). The 
vasculitis type (using the Chapel Hill Consensus Criteria) (Jennette et al., 1994) was 
polyarteritis nodosa (PAN) n=18, Wegener’s granulomatosis (WG) n=8, microscopic 
polyangiitis  n=  1,  Kawasaki’s  disease  =  5,  Takayasu’s  disease  (TD)  =  2,  Beçhets 
disease  = 1 and unclassified vasculitis n=5. Disease activity was again assessed using a 
modified  paediatric  BVAS  (Appendix  2).      20  healthy  child  controls  (8  males,  12 
females, median age 8.5 years, range 1.5-15.8),  10 febrile controls (6 males, 4 females, 
median age 6.8 years, range 1.5-13.5) and 20 healthy adult controls were also recruited 
(2  males,  18  females,  age  range  24-40  years).    As  with  the  vasculitis  patients,  the 
control individuals were the same as those studied in Chapter 3.   
 
4.5.1.2 Methods 
MPs were analysed as described above and in Chapter 2.5.3.  Depending on the volume 
of platelet poor plasma obtained samples were either analysed using the 22 tube FC plan 
or the 12 tube FC plan shown in Appendix 3.  As platelet and endothelial microparticles 
have particular relevance in the vasculitides, these were prioritised in the 12 tube plan.  
Other markers are less well defined in MP populations and thus these were analysed in a 
smaller cohort, where plasma sample size was  not a limiting factor.  Adult healthy 
controls were only analysed on the 12 tube plan due to time constraints. 182 
 
4.5.1.3 Statistics 
Median MP counts were compared between groups using the Kruskall Wallis test to 
check for overall differences.  Individual Mann Whitney U tests for non parametric data 
were performed to compare between specific groups.  The Wilcoxon signed rank test 
was  performed to  compare medians  of paired samples.   Spearman Rank correlation 
coefficiants were performed to assess correlation between MPs and other markers of 
disease activity, including CECs.  In all data graphs patient classification was denoted 
using colour coding as indicated below: 
 
 
 
4.5.2 Results 
4.5.2.1 Total Annexin V positive MPs  
These data are presented in Figure 4.10a-c.  Kruskall Wallis testing indicated there was 
an overall significant difference between groups (p=0.005).  Total AnnexinV positive 
MPs were significantly higher in 30 patients with active vasculitis (median value 0.98 x 
10
6 MPs/ml) compared to 20 healthy child controls (median value 0.65 x 10
6 MPs/ml, 
p=0.03) and 20 healthy adult controls (median value 0.30 x 10
6 MPs/ml, p<0.001), 
although there was no significant difference compared 10 febrile controls (median value 
0.70 x 10
6 MPs/ml p=0.09).   There were no significant differences between 27 patients 
with  inactive  vasculitis  (median  value  0.65  x  10
6  MPs/ml)  and  febrile  controls  or 
healthy child controls.  Healthy adults also had significantly lower MPs than children 183 
 
with inactive vasculitis (p=0.007) and child controls (p=0.04) (Figure 4.10a).  When 
paired data between active and inactive vasculitis was excluded (the first observation 
made in individual patients was used in this analysis) there was no significant difference 
between 30 patients with active disease and 11 patients in remission (median value 0.86 
x 10
6  MPs/ml,  data not shown).   In 17 individual patients  there was  no significant 
difference between total MP number during active disease and remission (median time 
to remission 4.5 months) (Figure 4.10b). Of these 17 patients, 13 had frequent  and 
detailed follow up for up to 18 months from pre-treatment at disease onset (10 patients, 
solid line) or from flares of their disease (3 patients, dotted line). At median followup of 
3 and 12 months AnV+ MPs were not significantly different from pretreatment levels 
(Figure 4.10c).   
 
4.5.2.2 MPs of endothelial origin 
These data are presented in Figures 4.11-4.14.  Kruskall Wallis testing indicated that 
there was an overall significant difference between groups for MPs expressing CD144 
(p=0.002).  No other endothelial marker showed overall significance, CD105 (p=0.1) E-
selectin (p=0.2), ICAM-1 (p=0.06) (Figure 4.11-4.14a).  Direct comparisons between 
individual patient and control groups will be presented below.   
 
CD144+ EMPs 
MPs expressing the constitutive marker CD144, were significantly higher in 30 patients 
with active vasculitis (median value 0.35 x 10
6 MPs/ml) compared to 20 healthy child 
controls  (median  value  0.09  x  10
6  MPs/ml,  p=0.02)  and  20  healthy  adult  controls 
(median value 0.04 x 10
6 MPs/ml, p=0.007), but were not significantly different when 
compared with 10 febrile controls (median value 0.15 x 10
6 MPs/ml).     184 
 
Figure 4-10: Total AnV MPs  
 
  
Figure  4.10a:  Kruskall  Wallis  testing  indicated  there  was  an  overall  significant  difference  between 
groups (p=0.005).  Total AnnexinV positive MPs were significantly higher in 30 patients with active 
vasculitis  compared  to  healthy  child  controls  (n=20,  p=0.03)  and  healthy  adult  controls  (n=20, 
p<0.001), there were no significant differences compared 10 febrile controls (p=0.09).   There were no 
significant differences between 27 patients with inactive vasculitis disease and febrile controls or healthy 
child controls.  Healthy adults also had significantly lower MPs than patients with inactive vasculitis 
(p=0.007) and child controls (p=0.04).  Figure 4.10b:In 17 individual patients paired analysis revealed 
there  was  no  significant  difference  between  total  AnV+  MPs  during  active  disease  and    remission 
(median time to remission 4.5 months). Figure 4.10c: 13 individual patients were followed from disease 
onset (n=10, solid line) or flare (n=3, dotted line).  At median followup of 3 and 12 months from disease 
onset AnV+ MPs were not significantly different from pretreatment levels. Rx = treatment.  185 
 
There were no significant differences in CD144+ MPs between 27 patients with inactive 
disease (median value 0.03 x 10
6 MPs/ml) and these control groups (Figure 4.11a).  
When  paired  data  between  active  and  inactive  vasculitis  were  excluded  (the  first 
observation made in each individual patient was used in this analysis) there was no 
significant  difference  between  30  patients  with  active  disease  and  11  patients  in 
remission (median value 0.23 x 10
6 MPs/ml, data not shown).  In 17 individual patients 
however, paired analysis revealed CD144 MPs were significantly higher during active 
disease compared to remission (p=0.001, median time to remission 4.5 months, Figure 
4.11b).  Of these 17 patients, 13 were followed up for up to 18 months from initiation of 
treatment at disease onset (10 patients, solid line) or from flare (3 patients, dotted line).  
At median followup of 3 and 12 months from disease onset there was no significant 
difference from pretreatment levels of CD144+ MPs (Figure 4.11c).  
 
CD105+ EMPs 
MPs  expressing  CD105  (endoglin),  were  not  significantly  different  in  the  same  30 
patients with active disease (median value 0.11 x 10
6MPs/ml) compared to 20 healthy 
child controls (median value 0.11 x 10
6MPs/ml), 10 febrile child controls (median value 
0.13 x 10
6MPs/ml or 20 adult controls (median value 0.03 x10
6MPs/ml). However, MPs 
expressing CD105 were significantly higher in 27 patients with inactive disease (median 
value  0.22  x10
6MPs/ml)  compared  to  healthy  child  (p=0.038)  and  adult  (p=0.028) 
controls (Figure 4.12a).  When paired data between active and inactive vasculitis were 
excluded (the first observation made in each individual patient was used in this analysis) 
there  was  no  significant  difference  between  30  patients  with  active  disease  and  11 
patients in remission (median value 0.20 x 10
6 MPs/ml, p=0.09, data not shown).   
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Figure 4-11: MPs of endothelial origin – CD144 
 
 
Figure  4.11a:  Kruskall  Wallis  testing  indicated  there  was  an  overall  significant  difference  between 
groups (p=0.002).  CD144+ MPs were significantly higher in 30 patients with active disease compared 
to healthy child controls (n=20, p=0.02) and healthy adult controls (n=20, p=0.007), but not febrile 
controls (n=10).  Figure 4.11b:  In 17 individual patients, paired analysis revealed CD144 MPs were 
significantly higher during active disease compared to when patients were in remission (p=0.001, median 
time to remission 4.5months). Figure 4.11c: 13 individual patients were followed from disease onset 
(n=10, solid lines) or flare(n=3, dotted lines).  At median followup of 3 and 12 months from disease onset 
(n=10) CD144+ MPs were not significantly different from pretreatment levels. Rx = treatment.    187 
 
Figure 4-12: MPs of endothelial origin CD105 
 
Figure 4.12a: Kruskall Wallis testing indicated that there was no overall significant difference between 
groups  (p=0.1).  However  when  individual  analysis  was  performed  although  CD105+ MPs  were  not 
significantly  different  between  30  patients  with  active  vasculitis  and  control  groups,  they  were 
significantly higher in 27 patients with inactive vasculitis compared to healthy child (n=20, p=0.04) and 
adult controls (n=20, p=0.03) although not febrile controls (n=10).  Figure 4.12b:  In 17 individual 
patients, paired analysis revealed CD105+ MPs were not significantly different during active disease 
compared  to  when  patients  were  in  remission  (p=0.3,  median  time  to  remission  4.5months).  Figure 
4.12c: 13 individual patients were followed from disease onset (n=10, solid lines) or flare (n=3, dotted 
lines).   At  median followup  of 3 and 12 months from disease onset  (n=10) CD105+ MPs were not 
significantly different from pretreatment levels. Rx = treatment.  188 
 
In  17  individual  patients  paired  analysis  revealed  no  significant  difference  between 
active and inactive disease (p=0.3, median time to remission 4.5 months, Figure 4.12b).  
13  of  these  patients  were  followed  up  from  initiation  of  treatment  at  disease  onset 
(n=10, solid line) or from flare (n=3, dotted line). At median followup of 3 and 12 
months from disease onset (n=10) there was no significant difference from pretreatment 
levels of CD105+ MPs (Figure 4.12c).   
 
E-selectin+ EMPs 
MPs expressing the inducible activation marker E-selectin were significantly higher in 
30  patients  with  active  disease  (median  value  0.075  x  10
6MPs/ml)  compared  to  20 
healthy adult controls (p=0.015, median value 0.004 x 10
6MPs/ml), although not child 
controls,  febrile (median value 0.07 x 10
6MPs/ml) or healthy  (median  value 0.04 x 
10
6MPs/ml).    There  were  no  significant  differences  between  patients  with  inactive 
vasculitis and these control groups (Figure 4.13a). When paired data between active and 
inactive vasculitis was excluded (the first observation made in each individual patient 
was used in this analysis) there was no significant difference between 30 patients with 
active disease and 11 patients in remission  (median value 0.049 x 10
6 MPs/ml, data not 
shown).  There was also no significant differences between active and inactive disease 
in  17  individual  patients  where  paired  samples  were  available  for  analysis  (Figure 
4.13b).  13 of these 17 individuals were followed up for up to 18 months from disease 
onset and initiation of treatment (n=10, solid lines) or disease flare (n=3, dotted lines).  
At  median  followup  of  3  and  12  months  from  disease  onset  (n=10)  there  was  no 
significant difference from pretreatment levels of E-selectin+ MPs (Figure 4.13c).   
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Figure 4-13: MPs of endothelial origin – E-selectin 
 
 
 
Figure 4.13a: Kruskall Wallis testing indicated that there was no overall significant difference between 
groups (p=0.1). However when individual analysis was performed E-selectin + MPs were significantly 
higher in 30 patients with active disease compared to 20 healthy adult controls (p=0.015), although not 
child controls, febrile or healthy. Figure 4.13b:  In 17 individual patients paired analysis revealed there 
was no significant differences between active and inactive disease (p=0.17, median time to remission 6 
months). Figure 4.13c: 13 individual patients were followed from disease onset (n=10, solid lines) or 
flare (n=3, dotted lines).  At median followup of 3 and 12 months from disease onset (n=10) E-selectin+ 
MPs were not significantly different from pretreatment levels. Rx = treatment.  190 
 
ICAM-1+ EMPS 
There were no significant differences in MPs expressing the inducible activation marker 
ICAM-1 between 26 patients with active vasculitis (median value 0.05 x 10
6 MPs/ml)  
compared to 20 healthy child controls (median value 0.02 x 10
6 MPs/ml) or 3 febrile 
controls(median  value  0.16  x  10
6  MPs/ml)  .   There  were  no  significant  differences 
between 18 patients with inactive vasculitis (median value 0.06 x 10
6 MPs/ml)   and 
these  controls  groups  either  (Figure  4.14a).    When  paired  data  between  active  and 
inactive vasculitis was excluded (the first observation made in each individual patient 
was used in this analysis) there was no significant difference between 26 patients with 
active disease and 4 patients in remission (median value 0.06 x 10
6 MPs/ml).  Paired 
analysis  in  14  individual  patients  showed  no  significant  differences  between  and 
inactive disease (Figure 4.14b).  13 individuals were followed from pre-treatment at 
disease onset (n=10, solid lines) or diseaseflare (n=3, dotted lines).  At median followup 
of 3 and 12 months from disease onset (n=10) there was no significant difference from 
pretreatment levels of ICAM-1+ MPs (Figure 4.14c).   
 
 
4.5.2.3 MPs of platelet origin 
These data are presented in figures 4.15-16. Kruskall Wallis testing indicated that there 
were  no  overall  significant  differences  between  groups  for  MPs  expressing  CD42a 
(p=0.7)  or  P-selectin  (p=0.4).    Direct  comparisons  between  individual  patient  and 
control groups will be presented below. 
 
CD42a+ PMPs 
When  individual  analysis  was  performed  between  groups  there  were  no  significant 
differences  in  the number of CD42+ MPs between  30  patients  with  active  vasculitis    191 
 
Figure 4-14: MPs of endothelial origin – ICAM-1 
 
 
Figure 4.14a: Kruskall Wallis testing indicated that there was no overall significant difference between 
groups (p=0.06). When individual analysis was performed ICAM-1+ MPs were not significantly different 
between 26 patients with active disease and 20 healthy child controls or 3 febrile controls.  There were 
no  significant  differences  between  inactive  vasculits  and  these  control  groups.Figure  4.14b:  In  14 
individual  patients  paired  analysis  revealed  there  was  no  significant  differences  between  active  and 
inactive disease (p=0.3, median time to remission 6 months). Figure 4.14c: 13 individual patients were 
followed from disease onset (n=10, solid lines) or flare (n=3, dotted lines).  At median followup of 3 and 
12 months from disease onset (n=10) ICAM-1+ MPs were not significantly different from pretreatment 
levels. Rx = treatment.  192 
 
(median value 0.12 x 10
6 MPs/ml) compared to 10 febrile controls (median value 0.04 x 
10
6 MPs/ml), 20 healthy child controls (median value 0.16 x 10
6 MPs/ml) or 20 healthy 
adult controls (median value 0.15 x 10
6 MPs/ml).  There were no significant differences 
between patients with inactive vasculitis (median value 0.18 x 10
6 MPs/ml) and these 
controls groups (Figure 4.15a).  When paired data between active and inactive vasculitis 
was excluded (the first observation made in each individual patient was used in this 
analysis) there was no significant difference between 30 patients with active disease and 
11 patients in remission (median value 0.26 x 10
6 MPs/ml, data not shown).  Paired 
analysis  in  17  individual  patients  showed  no  significant  differences  between  and 
inactive disease (Figure 4.15b).  13 of these 17 individuals were followed up for up to 
18 months from disease onset and initiation of treatment (n=10, solid lines) or disease 
flare (n=3, dotted lines).  At median followup of 3 and 12 months from disease onset 
(n=10) there was no significant difference from pretreatment levels of CD42a+ MPs 
(Figure 4.15c).    
 
 
P-selectin+ PMPs 
There was also no significant differences for P-selectin+ MPs between 26 patients with 
active vasculitis (median value 0 x 10
6 MPs/ml) compared to child controls (3 febrile, 
median value 0 x 10
6 MPs/ml and 20 healthy median value 0 x 10
6 MPs/ml).  There 
were no significant differences between 18 patients with inactive disease (median value 
0.1 x 10
6 MPs/ml) and these control groups (Figure 4.16a). When paired data between 
active  and  inactive  vasculitis  was  excluded  (the  first  observation  made  in  each 
individual patient was used in this analysis) there was no significant difference between 
26 patients with active disease and 4 patients in remission (median value 0.01 x 10
6 
MPs/ml, data not shown).  Paired analysis in 14 individual patients indicated P-selectin+    193 
 
Figure 4-15: MPs of platelet origin – CD42a 
 
Figure 4.15a: Kruskall Wallis testing indicated that there was no overall significant difference between 
groups (p=0.06). When individual analysis was performed ICAM-1+ MPs were not significantly different 
between 26 patients with active disease and 20 healthy child controls or 3 febrile controls.  There were 
no  significant  differences  between  inactive  vasculitis  and  these  control  groups.Figure  4.15b:  In 14 
individual  patients  paired  analysis  revealed  there  was  no  significant  differences  between  active  and 
inactive disease (p=0.3, median time to remission 6 months). Figure 4.15c: 13 individual patients were 
followed from disease onset (n=10, solid lines) or flare (n=3, dotted lines).  At median followup of 3 and 
12 months from disease onset (n=10) CD42a+ MPs were not significantly different from pretreatment 
levels. Rx = treatment.  194 
 
PMPs were signficiantly higher during remission than during active disease (p=0.01, 
Figure 4.16b).  13 of these 17 individuals were followed up for up to 18 months from 
disease onset and initiation of treatment (n=10, solid lines) or disease flare (n=3, dotted 
lines).  At median followup of 3 and 12 months from disease onset (n=10) there was no 
significant difference from pretreatment levels of P-selectin+ MPs (Figure 4.15c). 
 
4.5.2.4 MPs of leukocyte origins 
These data are presented in Figures 4.17-4.23.  Kruskall Wallis testing indicated that 
there was no overall significant differences between groups for MPs expressing the 
neutrophil  markers  CD15  (p=0.3),  CD11b  (p=0.2),  L-selectin  (p=0.4),  or  CD66b 
(p=0.8), the monocyte markers TF (p=0.2) and CD14 (p=0.2) or the T cell marker CD3 
(p=0.1).    Comparison  between  individual  patient  and  control  groups  are  presented 
below.   
 
CD15+ NMPs 
When individual analysis between specific groups was performed CD15+ MPs were not 
significantly different between 26 patients with active vasculitis (median value 0.025 x 
10
6 MPs/ml) and child controls (3 febrile, median value 0.03 x 10
6 MPs/ml and 20 
healthy, median value 0.04 x 10
6 MPs/ml).  There was no significant difference between 
18 patients with inactive vasculitis (median value 0.02 x 10
6 MPs/ml) and these control 
groups (Figure 4.17a).  When paired data between active and inactive vasculitis was 
excluded (the first observation made in each individual patient was used in this analysis) 
there  was  no  significant  difference  between  26  patients  with  active  disease  and  4 
patients  in  remission  (median  value  0.045  x  10
6  MPs/ml,  data  not  shown).  Paired 
analysis in 14 individuals showed no significant difference between active and inactive  195 
 
Figure 4-16 MPs of platelet origin – P-selectin 
 
 
 
 Figure 4.16a: Kruskall Wallis testing indicated that there was no overall significant difference between 
groups  (p=0.06).  When  individual  analysis  was  performed  P-selectin+  MPs  were  not  significantly 
different between 26 patients with active disease and 20 healthy child controls or 3 febrile controls.  
There were no significant differences between inactive vasculits and these control groups.Figure 4.16b:  
In  14  individual  patients  paired  analysis  revealed  P-selectin+  MPs  were  significantly  higher  during 
remission than active disease (p=0.01, median time to remission 6 months). Figure 4.16c:  13 individual 
patients were followed from disease onset (n=10, solid lines) or flare (n=3, dotted lines).  At median 
followup of 3 and 12 months from disease onset (n=10) P-selectin+ MPs were not significantly different 
from pretreatment levels. Rx = treatment.  
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Figure 4-17: MPs of neutrophil origin – CD15 
 
Figure 4.17a: Kruskall Wallis testing indicated that there was no overall significant difference between 
groups (p=0.3). When individual analysis was performed CD15+ MPs were not significantly different 
between 26 patients with active disease and 20 healthy child controls or 3 febrile controls.  There were 
also no significant differences between inactive vasculits and these control groups (AAV patients – red 
dots).  Figure  4.17b:  In  14  individual  patients  paired  analysis  revealed  there  was  no  significant 
differences between active and inactive disease, subgroup analysis of 7 patients with AAV (red lines) also 
showed no significant difference Figure 4.17c:: 13 individual patients were followed from disease onset 
(n=10, solid lines) or flare (n=3, dotted lines).  At median followup of 3 and 12 months from disease 
onset (n=10) CD15+ MPs were not significantly different from pretreatment levels, analysis of 4 patient 
with AAV(red lines) also demonstrated no significant difference at these timepoints. Rx = treatment. 
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disease  (Figure 4.17b).   Subgroup  paired  analysis  of  7  individuals  with  AAV  also 
disease  (Figure 4.17b).   Subgroup  paired  analysis  of  7  individuals  with  AAV  also 
indicated no significant difference between active and inactive disease.  13 of these 17 
individuals were followed up for up to 18 months from disease onset and initiation of 
treatment (n=10, solid lines) or disease flare (n=3, dotted lines).  At median followup of 
3 and 12 months from disease onset (n=10) there was no significant difference from 
pretreatment  levels  of  CD15+  MPs  (Figure  4.15c),  there  was  also  no  differences 
observed in the AAV subgroup (Figure 4.17c, AAV – red lines, n=4). 
 
CD11b+ NMPs 
CD11b+ MPs were not significantly different between 26 patients with active vasculitis 
(median value 0.27 x 10
6 MPs/ml) and child controls (3 febrile, median value 0.37 x 10
6 
MPs/ml and 20 healthy, median value 0.18 x 10
6 MPs/ml).  There was no significant 
difference  between  18  patients  with  inactive  vasculitis  (median  value  0.15  x  10
6 
MPs/ml) and these control groups (Figure 4.18a).  When paired data between active and 
inactive vasculitis was excluded (the first observation made in each individual patient 
was used in this analysis) there was no significant difference between 26 patients with 
active disease and 4 patients in remission (median value 0.26 x 10
6 MPs/ml, data not 
shown).  Paired  analysis  in  14  individuals  showed  no  significant  difference  between 
active and inactive disease (Figure 4.18b).  Subgroup paired analysis of 7 individuals 
with AAV also indicated no significant difference between active and inactive disease.    
13 of these 17 individuals were followed up for up to 18 months from disease onset and 
initiation of treatment (n=10, solid lines) or disease flare (n=3, dotted lines).  At median 
followup  of  3  and  12  months  from  disease  onset  (n=10)  there  was  no  significant 
difference from pretreatment levels of CD11b+ MPs (Figure 4.15c), there was also no 
differences observed in the AAV subgroup (Figure 4.18c, AAV – red lines, n=4). 198 
 
Figure 4-18: MPs of neutrophil origin – CD11b 
 
Figure 4.18a: Kruskall Wallis testing indicated that there was no overall significant difference between 
groups (p=0.2). When individual analysis was performed CD11b+ MPs were not significantly different 
between 26 patients with active disease and 20 healthy child controls or 3 febrile controls.  There were 
also no significant differences between inactive vasculitis and these control groups (AAV patients – red 
dots)..  Figure  4.18b:  In  14  individual  patients  paired  analysis  revealed  there  was  no  significant 
differences between active and inactive disease, subgroup analysis of 7 patients with AAV (red lines) also 
showed no significant difference Figure 4.18c: : 13 individual patients were followed from disease onset 
(n=10, solid lines) or flare (n=3, dotted lines).  At median followup of 3 and 12 months from disease 
onset (n=10) CD11b+ MPs were not significantly different from pretreatment levels subgroup analysis of 
4 patients with AAV (red lines) also demonstrated no significant difference at these timepoints.. Rx = 
treatment.  
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L-selectin+ NMPs 
L-selectin+  MPs  were  not  significantly  different  between  26  patients  with  active 
vasculitis (median value 0.05 x 10
6 MPs/ml) and child controls (3 febrile, median value 
0.08 x 10
6 MPs/ml and 20 healthy, median value 0.02 x 10
6 MPs/ml).  There was no 
significant difference between 18 patients with inactive vasculitis (median value 0.025 x 
10
6 MPs/ml) and these control groups (Figure 4.19a).  When paired data between active 
and  inactive  vasculitis  was  excluded  (the  first  observation  made  in  each  individual 
patient was used in this analysis) there was no significant difference between 26 patients 
with active disease and 4 patients in remission (median value 0.035 x 10
6 MPs/ml, data 
not shown). Paired analysis in 14 individuals showed no significant difference between 
active and inactive disease (Figure 4.19b).  Subgroup paired analysis of 7 individuals 
with AAV also indicated no significant difference between active and inactive disease.    
13 of these 17 individuals were followed up for up to 18 months from disease onset and 
initiation of treatment (n=10, solid lines) or disease flare (n=3, dotted lines).  At median 
followup  of  3  and  12  months  from  disease  onset  (n=10)  there  was  no  significant 
difference from pretreatment levels of L-selectin+ MPs (Figure 4.19c), there was also 
no differences observed in the AAV subgroup (Figure 4.19c, AAV – red lines, n=4). 
 
CD66b+ NMPs 
CD66b+ MPs were not significantly different between 26 patients with active vasculitis 
(median value 0.005 x 106 MPs/ml) and child controls (3 febrile, median value 0 x 106 
MPs/ml and 20 healthy, median value 0 x 106 MPs/ml).  There was  no significant 
difference between 18 patients with inactive vasculitis (median value 0 x 106 MPs/ml) 
and these control groups (Figure 4.20a).  When paired data between active and inactive 
vasculitis was excluded (the first observation made in each individual patient was used 200 
 
Figure 4-19: MPs of neutrophil origin – L-selectin 
 
Figure 4.19a: Kruskall Wallis testing indicated that there was no overall significant difference between 
groups (p=0.4). When individual analysis was performed L-selectin+ MPs were not significantly different 
between 26 patients with active disease and 20 healthy child controls or 3 febrile controls.  There were 
also no significant differences between inactive vasculits and these control groups (AAV patients – red 
dots)..  Figure  4.19b:  In  14  individual  patients  paired  analysis  revealed  there  was  no  significant 
differences between active and inactive disease, subgroup analysis of 7 patients with AAV also showed no 
significant difference (red lines). Figure 4.19c: 13 individual patients were followed from disease onset 
(n=10, solid lines) or flare (n=3, dotted lines).  At median followup of 3 and 12 months from disease 
onset  (n=10)  L-selectin+  MPs  were  not  significantly  different  from  pretreatment  levels,  subgroup 
analysis of 4 patient with AAV (red lines) also demonstrated no significant difference at these timepoints.. 
Rx = treatment.  201 
 
in this analysis) there was no significant difference between 26 patients with active 
disease and 4 patients in remission (median value 0.005 x 106 MPs/ml, data not shown). 
Paired analysis in 14 individuals showed no significant difference between active and 
inactive disease (Figure 4.20b).  Subgroup paired analysis of 7 individuals with AAV 
also indicated no significant difference between active and inactive disease (although 
6/7 patients did have higher CD66b+ MPs during active disease).  
 
13 of these 17 individuals were followed up for up to 18 months from disease onset and 
initiation of treatment (n=10, solid lines) or disease flare (n=3, dotted lines).  At median 
followup  of  3  and  12  months  from  disease  onset  (n=10)  there  was  no  significant 
difference from pretreatment levels of L-selectin+ MPs (Figure 4.19c), there was also 
no differences observed in the AAV subgroup (Figure 4.19c, AAV – red lines, n=4).   
When  10  individuals  were  followed  from  disease  onset,  there  were  no  significant 
differences from pre-treatment to median followup of 3 and 12 months, there was also 
no differences observed in the AAV subgroup (Figure 4.20c, AAV – red lines, n=4). 
 
TF+ MMPS 
TF+ MPs were only observed in a small number of individuals (2 patients with active 
vasculitis, 5 in remission, 1 febrile control and 3 healthy controls).  Hence no significant 
differences were observed between 26 patients with active vasculitis, or 18 patients with 
inactive disease and child controls (3 febrile, 20 healthy, median value for all groups 0 x 
10
6 MPs/ml, Figure 4.21a).  Paired analysis in 14 individuals showed no significant 
differences between active and inactive disease (Figure 4.21b) and when 13 individuals 
were followed from disease onset prior to treatment (n=10, solid lines) or disease flare 
(n=3, dotted lines), only 4 individuals had any detectable TF+ MPs (Figure 4.21c).   202 
 
Figure 4-20:MPs of neutrophil origin – CD66b 
 
 
Figure 4.20a: Kruskall Wallis testing indicated that there was no overall significant difference between 
groups (p=0.8). When individual analysis was performed CD66b+ MPs were not significantly different 
between 26 patients with active disease and 20 healthy child controls or 3 febrile controls.  There were 
also  no  significant  differences  between  inactive  vasculits  and  these  control  groups  (AAV-  red  dots). 
Figure 4.20b:  In 14 individual patients paired analysis revealed there was no significant differences 
between active and inactive disease, subgroup analysis of 7 patients AAV (red lines) also showed no 
significant difference (although 6/7 patients had a increased CD66b+ MPs during active disease) Figure 
4.20c: : 13 individual patients were followed from disease onset (n=10, solid lines) or flare (n=3, dotted 
lines).   At  median followup  of 3 and 12 months from disease onset  (n=10) CD66b+ MPs were not 
significantly different from pretreatment levels, subgroup analysis of 4 patients with AAV also revealed 
no differences at these timepoints. Rx = treatment.  203 
 
Figure 4-21: MPs of monocyte origin – TF 
 
 
Figure 4.21a: Kruskall Wallis testing indicated that there was no overall significant difference between 
groups  (p=0.2).  When  individual  analysis  was  performed  TF+  MPs  were  not  significantly  different 
between 26 patients with active disease and 20 healthy child controls or 3 febrile controls.  There were 
also no significant differences between inactive vasculits and these control groups.  The majority fo 
individuals  had  no  detectable  TF+  MPs.  Figure  4.21b:  In  14  individual  patients  paired  analysis 
revealed  there  was  no  significant  differences  between  active  and  inactive  disease  Figure  4.21c:  13 
individual patients were followed from disease onset (n=10, solid lines) or flare (n=3, dotted lines).  TF+ 
MPs were only detected in 4 individuals. Rx = treatment.  
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MPs expressing CD14, were significantly higher in 30 patients with active vasculitis 
(median value 0.51 x 10
6 MPs/ml) compared to 20 healthy child controls (median value 
0.24 x 10
6 MPs/ml, p=0.037) or 20 healthy adult controls (median value 0.17 x 10
6 
MPs/ml, p=0.02), although not 10 febrile controls (median value 0.25 x 10
6 MPs/ml).  
There were no significant differences in CD14+ MPs between 27 patients with inactive 
disease (median value 0.23 x 10
6 MPs/ml) and these control groups (Figure 4.22a).  
When  paired  data  between  active  and  inactive  vasculitis  were  excluded  (the  first 
observation made in each individual patient was used in this analysis) there was no 
significant  difference  between  30  patients  with  active  disease  and  10  patients  in 
remission (median value 0.23 x 10
6 MPs/ml, data not shown).   
 
In 17 individual patients paired analysis also revealed no significant difference between 
active vasculitis and remission (Figure 4.22b)  Of these 17 patients, 13 were followed 
up for up to 18 months, from disease onset (n=10, solid lines) or disease flare (n=3, 
dotted lines) at median followup of 3 and 12 months from disease onset, there was no 
signficant difference from pretreatment levels of CD14+ MPs (Figure 4.22c).    
 
CD3+ LMPs 
CD3+  MPs  were  only  observed  in  a  small  number  of  individuals  (3  patients  in 
remission and 1 healthy child controls), hence no significant differences were observed 
between 26 patients with active vasculitis, or 18 patients with inactive disease and child 
controls (3 febrile, 20 healthy, median value for all groups 0 x 10
6 MPs/ml, Figure 
4.23a).  Paired analysis, demonstrated only 2/14 individuals had any change in their 
CD3+ MPs  (Figure 4.23b)  and when 13 individuals were followed from disease onset  
 205 
 
Figure 4-22: MPs of monocyte origin – CD14 
 
Figure 4.22a: Kruskall Wallis testing indicated that there was no overall significant difference between 
groups (p=0.2). However when individual analysis was performed CD14+ MPs were significantly higher 
in 30 patients with active disease compared to 20 healthy child controls (p=0.038) or 20 adult controls 
(p=0.02), although not 3 febrile controls.  There no significant differences between inactive vasculits and 
these control groups.  Figure 4.22b:  In 14 individual patients paired analysis revealed there was no 
significant differences between active and inactive disease. Figure 4.22c: 13 individual patients were 
followed from disease onset (n=10, solid lines) or flare (n=3, dotted lines).  At median followup of 3 and 
12 months from disease onset (n=10) CD14a+ MPs were not significantly different from pretreatment 
levels. Rx = treatment.  206 
 
Figure 4-23: MPs of lymphocyte origin – CD3 
 
Figure 4.23a: Kruskall Wallis testing indicated that there was no overall significant difference between 
groups (p=0.1). When individual analysis was performed CD3+ MPs were not significantly different 
between 26 patients with active disease and 20 healthy child controls or 3 febrile controls.  There were 
also no significant differences between inactive vasculits and these control groups.  The majority of 
individuals  had  no  detectable  CD3+  MPs.  Figure  4.23b:  In  14  individual  patients  paired  analysis 
revealed  there  was  no  significant  differences  between  active  and  inactive  disease  Figure  4.21c:  13 
individual patients were followed from disease onset (n=10, solid lines) or flare (n=3, dotted lines). 
CD3+ MPs were only detected in 4 individuals. Rx = treatment.  207 
 
 (n=10, solid lines) or flare (n=3, dotted lines), only 4 individuals had any detectable 
CD3+ MPs (Figure 4.23c).   
 
4.5.3 Correlation between MPs and disease activity 
Spearman  Rank  correlation  coefficiant  analysis  was  performed  between  all  the 
phenotypes of MPs assessed and BVAS, CRP, ESR, CEC, white cell count, neutrophil 
count,  platelet  count  and  serum  albumin  levels,  Table  4.1  summarises  the  results  – 
significant correlations are highlighted in blue.   Table 4.2 shows the corrected P-values 
obtained  from  a  post-hoc  Holm-Bonferroni  correction.    The  significant  correlations 
observed  on  individual  tests  did  not  withstand  the  rigours  of  multiple  comparison 
correction  and  thus  no significant  correlations  were  observed  between  different  MP 
phenotypes and other markers of disease activity.     
 
When 16 patients were followed up in detail over time from first initiation of treatment 
a number had periods of disease flare.  While different populations of MPs may not be 
significantly different from healthy controls they did change over time in individual 
patients.  Figures 4.24 - 4.26 highlights some of the changes seen in MP populations 
over time from disease onset and initiation of treatment in the same 3 patients that were 
described earlier in this thesis in the context of CECs. In the two patients who flared 
(Figure 4.24 – systemic flare and figure 4.25, localized granulomatous flare) E-selectin+ 
MPs rose before the flare and prior to CD144 becoming elevated.  In the same patients, 
CD14 MPs also rose prior to flare and were followed by CD15, suggesting that different 
MPs may reflect different stages of disease activity and underlying pathology.  In the 
patient who did not have a flare, but a UTI, there was no rise in EMPs or NMPs and 
MMPS.  These data are very preliminary but warrants further study in a large cohort of 208 
 
patients.  Further examples of changes in MPs and CECs in individual patients are given 
in Appendix 6. 
 
Table  4-1:  Spearman  Rank  correlation  coefficiant  analysis  between  different 
MP phenotypes and other markers of disease activity 
 
 
MP  
population  BVAS  ESR  CRP  WCC  Neutrophil 
count 
Platelet 
count  Albumin  CEC 
count 
Total  AnV 
MP 
r = -0.015 
p = 0.89 
n = 88 
r = -0.072 
p = 0.52 
n = 83 
r = 0.005 
p = 0.97 
n = 88 
r = 0.065 
p = 0.56 
n = 85 
r = 0.065 
p = 0.56 
n = 85 
r = 0.145 
p = 0.19 
n = 82 
r = -0.003 
p = 0.98 
n = 82 
r = 0.081 
p = 0.43 
n = 81 
CD144  r = 0.038 
p = 0.73 
n = 88 
r = -0.001 
p = 0.99 
n = 83 
r = 0.040 
p = 0.71 
n = 86 
r = 0.084 
p = 0.44 
n = 85 
r = -0.006 
p = 0.96 
n = 85 
r = 0.155 
p = 0.17 
n = 82 
r = -0.011 
p = 0.92 
n = 81 
r = 0.232 
p = 0.037 
n = 81 
CD105  r = -0.011 
p = 0.3 
n = 88 
r = -0.21 
p = 0.055 
n = 83 
r =- 0.132 
p = 0.23 
n = 86 
r = -0.111 
p = 0.31 
n = 85 
r = -0.092 
p = 0.40 
n = 85 
r =- 0.026 
p = 0.82 
n = 82 
r = 0.001 
p = 0.99 
n = 81 
r = 0.006 
p = 0.96 
n = 81 
E-selectin  r = 0.121 
p = 0.26 
n = 88 
r = 0.070 
p = 0.53 
n = 83 
r = 0.02 
p = 0.84 
n = 86 
r = -0.001 
p = 0.99 
n = 85 
r = -0.009 
p = 0.94 
n = 85 
r = 0.155 
p = 0.17 
n = 82 
r = -0.051 
p = 0.65 
n = 81 
r = 0.092 
p = 0.41 
n = 81 
ICAM-1  r = -0.138 
p = 0.24 
n = 75 
r = 0.044 
p = 0.72 
n =  72 
r = 0.072 
p = 0.54 
n = 73 
r = 0.077 
p = 0.52 
n = 73 
r = 0.002 
p = 0.99 
n = 73 
r = 0.122 
p = 0.31 
n = 70 
r = -0.060 
p = 0.63 
n = 69 
r = -0.141 
p = 0.25 
n = 68 
CD42a  r = -0.235 
p = 0.029 
n = 87 
r = -0.284 
p = 0.010 
n = 82 
r = -0.245 
p = 0.024 
n = 85 
r = -0.087 
p = 0.43 
n = 86 
r = -0.158 
p = 0.15 
n = 84 
r = 0.072 
p = 0.52 
n = 81 
r = 0.108 
p = 0.34 
n = 80 
r = -0.094 
p = 0.41 
n = 80 
P-selectin  r = -0.136 
p = 0.25 
n = 75 
r = -0.063 
p = 0.60 
n =  72 
r = -0.082 
p = 0.50 
n = 73 
r = -0.29 
p = 0.013 
n = 73 
r = -0.25 
p = 0.033 
n = 73 
r = -0.030 
p = 0.81 
n = 70 
r = 0.181 
p = 0.63 
n = 69 
r = 0.028 
p = 0.82 
n = 68 
CD15  r = 0.073 
p = 0.53 
n = 75 
r = 0.061 
p = 0.61 
n =  72 
r = 0.048 
p = 0.69 
n = 73 
r=-0.217 
p = 0.07 
n = 73 
r = -0.110 
p = 0.354 
n = 73 
r = 0.008 
p = 0.94 
n = 70 
r = -0.075 
p = 0.54 
n = 69 
r = 0.010 
p = 0.93 
n = 68 
CD11b  r = 0.071 
p = 0.54 
n = 75 
r = 0.145 
p = 0.22 
n =  72 
r = 0.176 
p = 0.14 
n = 73 
r= 0.097 
p = 0.42 
n = 73 
r = -0.004 
p = 0.98 
n = 73 
r = -0.026 
p = 0.83 
n = 70 
r = -0.150 
p = 0.22 
n = 69 
r = -0.044 
p = 0.72 
n = 68 
L-selectin  r = 0.078 
p = 0.51 
n = 75 
r = -0.040 
p = 0.74 
n =  72 
r = 0.016 
p = 0.89 
n = 73 
r= 0.148 
p = 0.21 
n = 73 
r = 0.019 
p = 0.88 
n = 73 
r = -0.038 
p = 0.76 
n = 70 
r = -0.174 
p = 0.15 
n = 69 
r = 0.058 
p = 0.63 
n = 68 
CD66b  r = 0.157 
p = 0.18 
n = 75 
r = 0.094 
p = 0.43 
n =  72 
r = 0.077 
p = 0.52 
n = 73 
r = 0.233 
p = 0.047 
n = 73 
r = 0.262 
p = 0.025 
n = 73 
r = -0.042 
p = 0.73 
n = 70 
r = -0.212 
p = 0.081 
n = 69 
r = 0.087 
p = 0.48 
n = 68 
TF  r = 0.057 
p = 0.63 
n = 75 
r = -0.023 
p = 0.84 
n =  72 
r = -0.082 
p = 0.49 
n = 73 
r = -0.341 
p = 0.003 
n = 73 
r = -0.247 
p = 0.035 
n = 73 
r = 0.116 
p = 0.34 
n = 70 
r = 0.042 
p = 0.73 
n = 69 
r = 0.031 
p = 0.80 
n = 68 
CD14  r = -0.003 
p = 0.98 
n = 88 
r = -0.166 
p = 0.13 
n = 83 
r =- 0.096 
p = 0.38 
n = 86 
r = 0.005 
p = 0.96 
n = 85 
r = -0.049 
p = 0.66 
n = 85 
r = 0.161 
p = 0.15 
n = 82 
r = 0.076 
p = 0.50 
n = 81 
r = 0.111 
p = 0.33 
n = 81 
CD3  r = -0.166 
p = 0.16 
n = 75 
r = -0.150 
p = 0.21 
n =  72 
r = -0.049 
p = 0.68 
n = 73 
r = -0.114 
p = 0.34 
n = 73 
r = -0.182 
p = 0.12 
n = 73 
r = -0.061 
p = 0.62 
n = 70 
r = 0.106 
p = 0.39 
n = 69 
r = -0.241 
p = 0.048 
n = 68 
Significant correlations are highlighted in blue 209 
 
Table 4-2: Holm-Bonferroni correction for multiple comparisons 
 
Significant test   P value  Adjusted critical value (Holm-
Bonferroni) 
TF vs WCC  0.003  0.0004464 
CD42a vs ESR  0.01  0.0004505 
P-selectin vs WCC  0.013  0.0004545 
CD42a vs CRP  0.024  0.0004587 
CD66b vs neutrophil count  0.025  0.000463 
CD42a vs BVAS  0.029  0.0004673 
P-selectin vs neutrophil count  0.033  0.0004717 
TF vs neutrophil count  0.035  0.0004762 
CD144 vs CECs  0.037  0.0004808 
CD66b vs WCC  0.047  0.0004854 
CD3 vs WCC  0.048  0.0004902 
 
 
 
4.5.4 MPs in different vasculitic syndromes 
When  the  vasculitis  cohort  was  classified  into  the  different,  there  were  no  obvious 
differences in expression of the different MP populations in active or inactive disease 
between  diseases  as  had  been  for  CECs.    However,  Figure  4.27  demonstrates  the 
expression of EMPs (CD144+, CD105+, E-selectin+, ICAM-1+) during active disease.  
Interestingly, whereas CECs were all low in patients with KD (Figure 3.22), their EMPs 
were high.    210 
 
Figure 4-24: Patient with WG - MPs and disease activity – predictive of 
flare?  
 
 
 
 
 
Figure 4.24a indicates the changes in BVAS anc CEC number over time from intitiation of treatment at 
disease  onset  in  a  12  year  old  female  with  WG  (ANCA+).  Figure  4.24b  indicates  the  changes  in 
endothelial  MPs  (CD144+  and  E-selectin+).    Figure  2.24c  indicates  changes  in  monocytes  and 
neutrophil MPS (CD14+ and CD15+ respectively).  Notably in this individual, E-selectin+ MPs mirrored 
changes in CECs, whilst CD144+ MPs remained high despite clinical remission. 211 
 
Figure 4-25:  Patient with WG - MPs and disease activity – localised flare 
 
 
 
Figure 4.25a indicates the changes in BVAS and CEC number over time from intitiation of treatment at 
disease onset in an 11 year old female with WG (ANCA+) who suffered a granulomatous orbital flare. 
Figure  4.25b  indicates  the  changes  in  endothelial  MPs  (CD144+  and  E-selectin+).    Figure  2.25c 
indicates changes in monocytes and neutrophil MPS (CD14+ and CD15+ respectively).  Notably in this 
individual,  E-selectin+  MPs,  CD14+  MPs  and  CD15+  MPs  rose  prior  to  the  clinical  flare,  whilst 
CD144MPs and CEC rose at the time of clinical detection of flare.  
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Figure 4-26:   Patient with PAN – MPs and disease activity 
 
 
 
Figure 4.26a indicates the changes in BVAS and CEC number over time from intitiation of treatment at 
disease onset in an 12 year old female with PAN.  Figure 4.26b indicates the changes in endothelial MPs 
(CD144+ and E-selectin+).  Figure 2.25c indicates changes in monocytes and neutrophil MPS (CD14+ 
and CD15+ respectively).  Notably in this individual, while CD14+ and CD15+ were elevated prior to 
treatment and fell with treatment, CD144+ and E-selectin MPs rose after initiation of treatment, after 
this CD144+ closely tracked changes in CECs.  There was no elevation in any MP during the patients 
UTI. 
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Figure 4-27: EMPs in different vasculitis syndromes 
 
 
 
 
Figure 4.27a-d: When the patient cohort was divided into the different disease classifications,  although 
very preliminary, patients with KD had higher EMPs than other diseases.  This is in striking contrast to 
their CECs (Chapter 3). 
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4.6 Discussion  
Endothelial (CD144+) and monocyte derived microparticles (CD14+) are elevated at 
times  of  active  vasculitic  disease  activity  as  assessed  by  BVAS  score.  Although 
significant differences in a number of other MP populations between health and disease 
were not observed, preliminary data in individual patients demonstrated that different 
biomarkers altered with changes in disease activity. 
 
The finding that EMPs are elevated during active vasculitis is comparable to the other 
studies,  performed  in  vasculitis  which  examined  EMPs  (Brogan  et  al., 
2004a,Erdbruegger  et  al.,  2008).    However,  these  studies  did  not  use  CD144  as 
endothelial  marker  and  the  data  presented  herein  did  not  reproduce  these  groups 
findings that CD105+ and E-selectin+ MPs were significantly elevated during active 
vasculitis.  Differences in methodology relating to the use of an FL1 threshold in this 
study to enhance sensitivity could account for this, as well as differences in patient 
populations.    Erdbruegger  et  al  examined  adults  with  AAV,  whereas  Brogan  et  al 
examined 29 children with active PSV, 15 of which had KD.  As can be seen in the 
preliminary data presented in Figure 4.27, in this study KD patients appeared to have 
higher EMPs (of all phenotypes) than other vasculitic syndromes which could have 
skewed this previous result.  
 
Both  CD105  (endoglin)  and  CD144  are  considered  to  be  constitutive  endothelial 
markers and it is interesting that they gave completely different results with peaks at 
different time points in some individual patients (appendix 6).  As discussed in the 
introduction to this chapter, these markers have very different roles, CD144 forms part 
of  the  intercellular  EC-EC  contact  complex  and  thus  its  expression  would  require 215 
 
significant  cellular  disruption  to  release  it.    This  could  explain  why  this  showed 
correlation with CEC levels (although this did not withstand the more stringent post-hoc 
testing for multiple comparisons).  CD105 is upregulated on proliferating/angiogenic 
cells and thus may be indicative of a more reparative phase of the disease rather than an 
activatory phase.  The finding that E-selectin+ and ICAM-1+ EMPs were not elevated 
in active disease is perhaps not surprising when the transient nature of their expression 
on activated endothelial cells is considered.   
 
Another  possibility  for  the  differences  in  EMPs  between  this  and  previous  studies 
relates to the observation that of the patients studied there were a number with active 
vasculitis  prior  to  treatment  that  had  very  low  levels  of  endothelial  derived  MPs 
(examples are shown in Figures 4.25-26, and can also be observed in the longitudinal 
studies in Figure 4.11-14).  It may be that EMPs are sequestered out of the plasma by 
binding to activated endothelium, platelets and/or cells of the blood.  This situation has 
been  observed  in  other  diseases  associated  with  severe  endothelial  injury  including 
multiple  organ  dysfunction  associated  with  sepsis  (Joop  et  al.,  2001).    Thus  when 
patients are on treatment and the underlying inflammation is suppressed, MPs may be 
observed in greater numbers and perhaps could provide insightful information regarding 
the risk of relapse prior to overt clinical disease flare.  Although numbers are very 
preliminary, increases in E-selectin+ MPs occurred prior to and during flares in a small 
number of patients (Figure 4.25, and Appendix 6 patients 4, 8 and 12), whilst CD144+ 
MPs  were  elevated  during  active  disease.    In  some  individuals  EMPs  were  higher 
during disease flare than at onset (Figure 4.26, Appendix 6 patients 2,5,8,10 and 13).  
CD14+ and CD15+ MPs were also elevated during disease flare in individual patients 
(Figure 4.25-26, Appendix 6 patients 1,5,8,9,12 and 13)   216 
 
The study by Daniel et al examined CD66b+ neutrophil MPs and CD41a+ platelet MPs 
in adults with AAV (WG, MPA, CSS) (Daniel et al., 2006).  Significant differences 
between healthy children and patients with active vasculitis for any of the NMPs or 
PMPs studied herein were not observed in this study, however there are number of 
differences between this study and the one performed by Daniel et al.   Primarily Daniel 
et al did not discriminate MPs based on phosphatidylserine (PS) expression using AnV 
and so may have included MPs that were excluded herein.  Also the clinical criteria for 
active vasculitis used by Daniel et al was patients prior to cytotoxic treatment with 
BVAS >7.5 - so adults with highly active systemic disease. Unfortunately the rarity of 
the vasculitides in children makes this exclusion criteria inappropriate for this cohort.  
In contrast to the data from Daniel et al, prior to correction for multiple comparisons 
PMPs in this study actually correlated negatively with disease activity, which if is a true 
finding  rather than  a false error could  indicate that PMPs  are sequestered  from  the 
plasma during active disease. 
 
MPs which were observed in very low levels in all cohorts included CD3, however 
other studies had not examined this T cell marker in patients before and it may be that 
this is not expressed on T-cell derived MPs. This finding is supported by an in vitro 
study (Fritzsching et al., 2002) where low levels of CD4 and CD3 were found in MPs 
derived from isolated T cells.  It may be that the MPs produced from activated T cells 
lack PS on their surface and are in the AnV negative fraction of MPs, which were not 
analysed in this study.  In this context another marker that was found in low levels was 
TF, no other study has examined this in vasculitis, however the presence of TF positive 
MPs are associated conditions which are often associated with vascular damage (Morel 
et al., 2006), so this is somewhat surprising, however the antibody was titrated with care 217 
 
and worked well on activated parent cells so it may be a genuine finding within the 
parameters of the cohort analysed. 
 
Another factor which needs to be considered is that these parameters were being tested 
simultanously in the patient populations and therefore there is a risk of identifying false 
positives.  While  correcting  for  multiple  comparisons  may  prevent  the  investigator 
falsely finding significant results it is equally important that the investigator does not 
discredit true findings by over conservative correction of the data.  While the Holm 
Bonferroni is a less conservative variation of the Bonferroni test, it is not without its 
limitations and there are varying opinions on the validity of making such corrections.  
While some statisticians believe that  a correction for multiple comparisons must be 
followed  rigidly,  others  believe  careful  interpretation  of  the  data  is  more  crucial  to 
understanding which results are likely to be true positives.  Especially when there are 
only small numbers in each test group.   In the case of the elevation of CD144+ EMPs 
in this patient population and correlation with other markers of disease activity,  as other 
studies performed have indicated elevation of EMPs in patients with vasculitis it is 
likely that this is a true result and not a false positive. 
 
What is apparent from this study of MPs is that in order to understand the role of 
different  MP  phenotypes  in  the  context  of  vasculitis,  their  assessment  at  several 
timepoints over the disease course in order to examine the subtle changes may provide 
greater information relating to disease activity rather than large cross-sectional studies 
comparing groups of patients either in remission or with active disease. 
 218 
 
As with all methods there are technical pitfalls and scope for further optimization.  One 
major confounder relating to FC for detection of MPs is that it is unlikely that the whole 
MP population is observed.  As MPs range in size from 0.1-2µm in diameter (Piccin et 
al., 2007) it is likely that the smaller MPs are beyond the limits of detection of FC.  
While ultimately it may not be as important in conditions where large elevations of MPs 
are observed, it may give an inaccurate representation of their phenotype and a skewed 
population profile.  For example some cells may have a tendency to produce smaller 
MPs and therefore where a population is not observed by FC, it doesn’t necessarily 
mean it was not present (e.g. CD3 MPs).   
 
If it were not for the time constraints of a PhD study, other methodologies could have 
been employed including pull down ELISA.  However only one parameter could be 
measured using this approach per well on the ELISA plate and thus would not be as 
simple to generate multi-parametric data.  ELISA plates are coated with Annexin V 
which MPs from platelet poor plasma samples bind to.  A secondary antibody to a cell 
surface marker associated with the MP of interest can then be used to enumerate the 
MPs in the sample (Jy et al., 2004a).  However, as the data presented herein indicates, 
MPs  can  express  a  wide  varety  of  cell  surface  markers  and  thus  choosing  a  single 
marker  to  base  the  assay  around  would  not  be  as  informative  as  the  multiparamet 
approach that FC offers.   ELISA can however be used in a more functional capacity to 
investigate the behavior of MPs and in fact there are now commercially available kits to 
examine  the  prothrombotic  potential  of  MPs  (e.g.  ZYMUPHEN  MP-activity  kit, 
Aniara). 
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While the current protocol described had been used previously within the group there is 
still much controversy regarding the centrifugation protocols used for MP enumeration 
within the literature and as yet no consensus has been reached  (Enjeti et al., 2007).   
Some groups centrifuge at a lower speed but for longer to generate platelet poor plasma.  
Some do not pellet the MPs at all.  Feasibly all the spinning protocols particularly those 
associated with genreation of MP pellets could result in damage and loss of fragile MPs.  
Thus a protocol which involves a minimal amount of centrifugation and handling would 
be preferable.  Currently the widespread use of Annexin V for detection of PS on the 
surface and its’ reliance on Ca
2+ for binding necessitates the high speed pelleting spin to 
remove anticoagulated plasma with low Ca
2+ content.  However use of alternative stains 
for PS, such as monoclonal antibodies directed against it (Mourdjeva et al., 2005) may 
allow development of a potentially more robust methodology.   
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5.1 Summary 
As  the  endothelium  is  such  a  dynamic  organ,  it  must  be  protected  from  the 
consequences of injury which could conceivably lead to loss of function.  As has been 
demonstrated in Chapters 3 and 4 during active vasculitis injury and activation of the 
endothelium is significant, thus it is possible that repair mechanisms would be activated 
in these patients.  The concept of endothelial repair in response to injury has rapidly 
gained credence in a number of human diseases, including coronary artery disease.  This 
chapter  examines  some  of  the  important  signals  that  could  provide  evidence  of  an 
attempt of endothelial repair in the face of vasculitic injury.   
 
Growth  factors  released  from  the  endothelium  and  surrounding  cells  are  pivotal  in 
activating the mechanisms by which repair can be instigated, including recruitment of 
endothelial progenitor cells from the bone marrow (discussed in more detail in Chapter 
6)  and  activation  of  angiogenic  pathways  in  the  surrounding  endothelium,  smooth 
muscle and pericytes.  As well as reflecting a potential reparative response they could 
also reflect the extent of injury to the endothelium and as such could be used as a 
surrogate biomarker of disease activity.  This chapter details the assessment of a number 
of growth factors associated with angiogenic and vasculogenic responses in patients 
with vasculitis, and considers their potential for use as a biomarker of disease activity.  
 
 
5.2 Introduction 
Angiogenesis, the remodelling of existing blood vessels to form new ones has been well 
studied in the development of tumour vasculature and is regulated by an extremely 
sensitive  interplay  of  growth  factors  and  inhibitors.    A  number  of  key  signalling 222 
 
pathways have been identified that play a role in the formation of new vessels including 
vascular endothelial growth factor (VEGF) and it’s receptor family; platelet derived 
growth  factor  (PDGF)  and  its  receptor  family;  Delta-notch  signalling  and  the 
angiopoietins (Ang-1-Ang-4) and their receptors Tie1 and Tie2 (Ferrara and Kerbel, 
2005).  Other signalling molecules that can impact on this system include peptides such 
as the thymosins and various cytokines and chemokines.  Vasculogenesis, the de novo 
formation of blood vessels has been studied predominantly in embryonic development 
and perhaps unsurprisingly the same regulatory pathways are involved.  
 
5.2.1 The VEGF family – the major angiogenic signalling pathway 
The mammalian VEGF family consists of five isoforms of VEGF (A-D and placental 
growth  factor  PlGF)  and  three  tyrosine  kinase  receptors  which  are  expressed 
predominantly  in  the  vasculature  (Olsson  et  al.,  2006).  VEGFR1  and  VEGFR2  are 
highly  expressed  by  vascular  endothelial  cells  whereas  VEGFR3  is  prominently 
expressed in lymphatic endothelial cells, although it can also be expressed on activated 
vascular  endothelial  cells.    Other  cell  types  that  VEGFRs  are  found  on  include 
haematopoetic stem cells, monocytes,
 osteoblasts and neurons (Tammela et al., 2005). 
 
The VEGF family is further complicated by the presence of splice variants of each of 
the different ligand isoforms which may have different functional effects depending on 
their  ability  to  interact  with  VEGFR  co-receptors,  one  variant  of  VEGF-A  (VEGF-
A165b) for example is a negative regulator of VEGF activity (Woolard et al., 2004).   The 
VEGF-A165 isoform is the most abundant and widely studied of the VEGF isoforms and 
is principal effector
 of VEGF action (others include VEGF-A189 and VEGF-A206 which 
are  mostly  bound  to  cell  surface  or  extracellular  matrix  and  VEGF-A121  which  like 223 
 
VEGF-A165 is a soluble secreted form) (Tammela et al., 2005).  VEGFR1 is bound by 
VEGF-A, VEGF-B and PlGF, VEGFR2 is bound by VEGF-A and cleaved forms of 
VEGF-C  and  VEGF-D,  while  VEGFR3  is  bound  by  VEGF-C  and  VEGF-D.  
Experimental  data  implicates  it  is  the  interactions  of  VEGF-A  with  VEGFR1  and 
VEGFR2 that are most important  in  embryonic vascular development and postnatal 
angiogenesis and vasculogenesis (Karamysheva, 2008), and it is these pathways that 
most recent research studies have focused on.  A recent publication has implicated a 
novel  role  for  VEGFR3  in  the  early  vessel  sprouting  stages  of  vessel  development 
(Tammela et al., 2008).  
 
Targeted  deletions  of  all  of  the  VEGF  receptors  (VEGFR1-3)  in  mice  results  in 
embryonic lethality associated with defective vasculogenesis and vessel development 
(Olsson  et  al.,  2006).    Whilst  VEGFR2
-/-  is  associated  with  deficiency  in  EC 
development and a lack of vessels (Shalaby et al., 1995), VEGFR1
-/- results in excessive 
endothelial proliferation and obstruction of vessel lumen (Fong et al., 1995).  Knock out 
(-/-) or depletion (+/-) of VEGF-A gives a similar phenotype to the VEGFR2
-/-.  Mice 
which exclusively express individual splice variants of VEGF-A have wide variations in 
phenotype, and studies have implicated VEGF-A164 (Human equivalent is VEGF-A165 
as  mice  VEGF  variants  are  one  amino  acid  residue  shorter  than  the  corresponding 
human isoforms) as the most important isoform as these are normal and healthy (Maes 
et  al.,  2004).  Mice expressing only  VEGF-A120 die soon  after birth  from impaired 
myocardial  angiogenesis  with  reduced  capillary  branching  (Carmeliet  et  al., 
1999,Ruhrberg et al., 2002) whilst those expressing VEGF-A188 have stunted growth 
due to defects in bone formation and vascularisation (Maes et al., 2004).  Conversely 
overexpression of VEGF-A also results in embryonic lethality (Miquerol et al., 2000), 224 
 
highlighting  the  essential  role  of  tightly  regulated  VEGF-A  interactions  in  early 
developmental angiogenesis and vasculogenesis.   
 
Knockouts of other VEGF isoforms are viable, but with the exception of VEGF-D
-/- all 
have significant defects; VEGF-B
-/- have reduced heart size with dysfunctional coronary 
vasculature and an impaired recovery from induced myocardial infarction (Bellomo et 
al., 2000) although a later study suggested phenotype was less severe and limited to 
impaired  atrial  conduction  (Aase  et  al.,  2001).    PlGF
-/-  which  also  interacts  with 
VEGFR1  has  a  vascular  phenotype  with  impaired  angiogenesis  and  wound  healing 
(Carmeliet  et  al.,  2001).    VEGF-C
-/-  mice  have  defective  lymphatic  development 
(Karkkainen et al., 2004). 
 
On ligand binding VEGFR form homo or heterodimers which allow their signal to be 
transduced via activation of receptor tyrosine kinases.  Activated tyrosine kinases recruit 
and activate  an array of second messengers including the mitogen  activated protein 
kinases  (MAPK) phosphoinositide  -3 kinases  (PI3K) and phospholipase Cγ (PLCγ), 
which  in  turn  activate  numerous  signaling  cascades  and  complex  crosstalk  between 
them (Olsson et al., 2006).  Negative regulation of the signal is important for limiting 
the  target  cell  responses  and  phosphotyrosine  phosphatases  such  as  src-homology 
phosphatases (SHP1 and 2) which dephosphorylate and deactivate the tyrosine kinase 
signaling are involved (Guo et al., 2000), as is receptor internalization and degradation 
(Singh et al., 2005).   
 
Neuropilins (NRP1 and NRP2), another family of transmembrane receptors can also 
interact with VEGF although their intracellular domain is short and they do not signal 225 
 
(Takahashi  and  Shibuya,  2005).    Knockout  studies  indicate  that  while  NRP1  is 
important in vascular development (Kawasaki et al., 1999) NRP2 is important in the 
lymphatic  system  (Yuan  et  al.,  2002)  and  this  reflects  their  expression  profile 
(Karamysheva,  2008).    In  vitro  studies  show  that  NRP1  complexes  with  VEGFR2, 
enhancing the proliferation and migration of cells in response to VEGF (Whitaker et al., 
2001).   
 
Pathways that VEGF signaling have been implicated in postnatally include endothelial 
cell  proliferation,  survival,  motility  and  migration,  vascular  permeability  and 
recruitment of bone marrow derived stem cells.  VEGFR signaling is dependent on the 
availability of the VEGF ligands, which can be released from a number of different cell 
types  including  epithelial  cells,  tumour  cells  and  macrophages  (Berse  et  al.,  1992), 
smooth  muscle  cells  (Ferrara  et  al.,  1991),  fibroblasts  (Pertovaara  et  al.,  1994), 
neutrophils (Gaudry et al., 1997) and from the endothelium itself (Lee et al., 2007).  
Interestingly  the  autocrine  VEGF  signal  is  necessary  for  endothelial  cell  survival 
although not  for angiogenesis, demonstrated in  endothelial specific VEGF knockout 
mice where marked endothelial apoptosis and thromboembolic events were observed, 
yet overall vascular branched structure was no different to wildtype (Lee et al., 2007).   
 
VEGF  is  upregulated  by  a  variety  of  stimuli,  including  hypoxia,  growth  factors, 
cytokines, oestrogen, nitric oxide and mutations in its promoter associated with tumours 
(Takahashi  and  Shibuya,  2005).    Circulating  VEGF  is  upregulated  in  pathological 
conditions  associated  with  vascular  injury  and  dysfunction  including  myocardial 
infarction (Seko et al., 1997), diabetes and sickle cell aneamia (Solovey et al., 1999) and  226 
 
has previously been observed in active vasculitis in  HSP  (Topaloglu et al., 2001), 
Behçet’s disease (Shaker et al., 2007) and in KD (Terai et al., 1999).     
 
5.2.2 NOTCH-delta signaling – giving endothelial cells direction 
The  Notch  family  consist  of  4  transmembrane  receptors  (Notch  1-4)  and  their 
membrane bound ligands Delta-like-1, -3 and -4 and Jagged-1 and -2.  While VEGF 
directly  stimulates  the  endothelium  in  angiogenesis  and  promotes  the  direction  of 
migration, the response cannot be identical in all cells, otherwise new vessel formation 
would not be able to occur in the directional manner that it does.  So called “tip cells” 
which form the tip of the sprouting blood vessel are necessary and signaling between 
Delta-like ligand-4 (Dll4) and Notch receptors 1 and 4 have been shown to be important 
in their selection, allowing the VEGF gradient to direct new vessel formation (Thurston 
and Kitajewski, 2008).   
 
Notch signaling occurs in many cell types and has a fundamental role in determining the 
differentiation patterns of individual cells in close proximity.  One mechanism by which 
this occurs is lateral inhibition, whereby one cell presents a Notch ligand (Delta or 
Jagged) to  an adjacent  Notch receptor  expressing  cell, resulting in activation of the 
Notch pathway in one cell and suppression in the adjacent cell.  Notch 1 knockout is 
embryonically  lethal  in  mice  and  is  associated  with  defective  angiogenic  vascular 
remodeling.  Mice develop early vessels (the primary vascular plexus) suggesting it is 
not influencing vasculogenesis, however these do not develop further into a complex 
organized  network  of  vessels  (Krebs  et  al.,  2000).    Mice  lacking  Notch  4  develop 
normally, however dual Notch 1/Notch 4 knockouts often have a more severe vascular 
phenotype (some can lack entire major vessels) than the Notch 1 knockout (Krebs et al., 227 
 
2000) and overexpression of Notch 4 results in embryonic lethality (Uyttendaele et al., 
2001).    Thus  appropriate  Notch  4  signalling  is  also  necessary.    Dll4  knockout  is 
embryonic lethal and the majority of heterozygous knockouts do not survive (Gale et 
al., 2004).  
 
5.2.3 PDGF – stabilizing new vessels 
The PDGF family consists of 4 ligands (PDGFA-D) which form functional hetero or 
homodimers and 2 receptors (α and β).  PDGFs form part of the same receptor/ligand 
family as VEGFs, it is generally accepted that the PDGFs influence mesenchymal cells, 
whereas VEGFs influence endothelial cells and both PDGFS and VEGFS are selective 
for their own receptors.  However a recent publication has demonstrated that VEGF-A 
can bind
 to and activate PDGF receptors in bone-marrow-derived mesenchymal
 stem 
cells and thus this long held view that the growth factors do not cross-signal has become 
further complicated (Ball et al., 2007).   
 
PDGFs  act  in  a  paracrine  manner,  in  angiogenesis  PDGF-B  is  highly  secreted  by 
endothelial cells, particularly those in the tip region and influences the recruitment of 
pericytes  and  vascular  smooth  muscle  (VSM)  cell  precursors  expressing  PDGFR-β
 
(Hellstrom et al., 1999) which will stabilise the newly formed vessel.  Knockouts of 
both PDGF-B and PDGFR-β result in pericyte and VSM cell deficiency seen from early 
in embryonic development.  While the cells develop, they do not spread along newly 
developed vessels and the result is embryonic lethality due to vascular defects including 
endothelial  hyperplasia,  abnormal  junctions,  and  excessive  luminal  membrane  folds 
(Hellstrom  et  al.,  2001).    The  stabilization  of  newly  formed  vessels  by  pericytes 
involves  their  release  of  TGFβ  which  inhibits  further  endothelial  proliferation  and 228 
 
migration, downregulates VEGFR2 expression and promotes differentiation of pericyte 
progenitors (Karamysheva, 2008). In vitro this occurs on contact between endothelial 
cells and pericytes (Sato and Rifkin, 1989). 
 
5.2.4 Angiopoietins 
The  angiopoietin  family  (Angiopoietins-1,-2,-3  and  -4  (Ang-1-4)),  like  the  VEGF 
family, bind to receptor tyrosine kinases (RTK) – namely Tie-1 and Tie-2 (Fiedler and 
Augustin, 2006).  The Tie receptors are predominantly expressed within the vasculature 
and haematopoeitic stem cells, although Tie-2 expression can be detected on a subset of 
monocytes (Venneri et al., 2007).  The known functional effects of the angiopoietins are 
predominantly mediated via Tie-2, as yet Tie-1 signalling pathways have been poorly 
elucidated  and  it  was  considered  an  orphan  receptor.    Yuan  et  al  have  recently 
demonstrated that Ang-1 can induce Tie1 signalling, although this is dependent on Tie2 
expression, its consequence is a down regulation of the Tie2 dependent EC survival 
(Yuan et al., 2007). 
 
Deletion of Tie-2 in mice results in embryonic lethality that is associated with reduction 
in vascular complexity and branching (Sato et al., 1995).  A similar phenotype is seen 
when  Ang-1  (Suri  et  al.,  1996)  is  deleted,  or  when  Ang-2  is  overexpressed 
(Maisonpierre  et  al.,  1997),  indicating  that  Ang-2  acts  as  an  antagonist  of  Ang-1 
signalling via the Tie-2 receptor (at least in embryonic development).  Deletion of Ang-
2 gives a relatively mild phenotype at birth, although mice usually die within 2 weeks 
due to severe chylous ascites (lymph fluid leaking into the peritoneal cavity) due to 
defective lymphatic development (Gale et al., 2002).  Embryonic vascular development 
is relatively normal, however postnatal angiogenesis is defective, indiciating a key role 229 
 
for  Ang-2  in  remodeling  of  the  vasculature  (Gale  et  al.,  2002).    While  Ang-1  is 
constitutively expressed by many cell types including smooth muscle, fibroblasts and 
some tumor cells, Ang-2 is expressed predominantly by endothelial cells (as well as 
some tumour cells and retinal cells) (Fiedler and Augustin, 2006).   
 
Ang-1 acting on Tie-2, induces phosphorylation of the receptor, resulting in activation 
of a complex cascade of second messengers, including PI3K and Akt (DeBusk et al., 
2004).  Akt promotes cell survival and inhibits the action of the forkhead transcription 
factor  FKHR-1,  which  induces  Ang-2  production  (Daly  et  al.,  2004).    Thus  Ang-1 
signalling  inhibits  production  of  its  antagonist  Ang-2.    It  also  reduces  vascular 
permeability, inhibits NFkB activation and thus suppresses inflammation (Hughes et al., 
2003) and promotes association between pericytes and the endothelium helping stabilize 
vessels.  The constitutive agonist action of Ang-1 on Tie-2 is considered to be crucial to 
maintaining the endothelium in a non-activated quiescent state (Fiedler and Augustin, 
2006).   
 
Stimulation of the endothelium results in release of Ang-2 from Weibel-palade bodies, 
resulting  in  disruption  of  the  resting  state  of  the  endothelium  and  priming  it  for 
angiogenesis  or  inflammation  (Fiedler  and  Augustin,  2006).    Ang-2  also  enhances 
TNFα induced leukocyte endothelial interactions via increased upregulation of adhesion 
molecules (Fiedler et al., 2006).  The action of Ang-2 is altered by the presence of 
VEGF, in its absence Ang-2 contributes to vascular regression, but in its presence Ang-
2 stimulates angiogenesis  (Maisonpierre  et  al.,  1997).   In vitro, Ang-2 treatment  of 
human microvascular endothelial cells (HMECs) disrupts barrier function, promoting 
actin stress fibre formation, resulting in intercellular gaps and increased permeability 230 
 
(Parikh et al., 2006).  While antagonism of Ang-1 Tie2 signalling may explain some of 
these responses, it is also conceivable that Ang-2 may also signal by alternative as yet 
unknown pathways.   
 
Elevated Ang-2 is associated with conditions of inflammation and cardiovascular injury 
including sepsis (Siner et al., 2008), hypertension (Patel et al., 2008), diabetes (Lim et 
al., 2005) and acute coronary syndromes (Lee et al., 2004). After trauma Ang-2 can be 
elevated in circumstances when VEGF is not (Ganter et al., 2008).  At the time of study 
no groups had examined Angiopoietin levels in patients with vasculitis.  However a 
recent publication has indicated that Ang-2 levels are a potential biomarker of disease 
activity in adults with AAV (Kumpers et al., 2009). 
 
5.2.5 Thymosin β4 
The Thymosins are a family of peptides which were first isolated from the thymus 
(Hannappel, 2007).  They were originally thought to be thymic hormones, however it 
has become apparent that they are ubiquitously expressed.  The β-thymosins sequester 
G-actin, regulating its phosphorylation and thus cytoskeletal remodeling (Hannappel, 
2007).    Thymosin  β4  (Tβ4)  is  the  most  abundant  member  in  most  cell  types, 
representing approximately 70–80% of total beta thymosins and has been implicated in 
angiogenic and vasculogenic pathways (Smart et al., 2007b). 
 
Tβ4 has been shown to influence VEGF levels, act as an endothelial chemoattractant 
and regulate a number of genes which can influence angiogenesis and cell motility, 
including  matrix  metalloproteinases,  adhesion  molecules  and  cytoskeletal  related 
peptides (Smart et al., 2007b).  In tissues with high Tβ4, VEGF levels are also elevated 231 
 
(Cha et al., 2003), correspondingly in tissues where Tβ4 has been knocked out, VEGF 
expression is also low (Smart et al., 2007a).  Whether this is a direct interaction between 
Tβ4  and  VEGF  or  whether  Tβ4  influences  an  upstream  inducer  of  VEGF  such  as 
hypoxia inducible factor (HIF) remains unknown.  Another member of the thymosin 
beta family, Tβ10 which has anti-angiogenic effects reduces VEGF levels (Mu et al., 
2006).  A small number of studies have examined plasma or serum levels of  Tβ4 in 
humans, Tβ4 increases in rhinovirus infection (Hsia et al., 1989), interestingly is lower 
in serum extracted from umbilical cords than from adults (Weller et al., 1988) and a 
recent study has indicated it is elevated in patients with psoriasis (Plavina et al., 2008).  
 
In this chapter the growth factors which have been shown to directly drive angiogenesis 
(VEGF,  Ang-1,  Ang-2  and  Tβ4)  as  opposed  to  those  described  which  are  more 
important  in  influencing  direction  and  vessel  stabilisation  have  been  measured  in 
patients with vasculitis.  Many of these studies (Ang-1, Ang-2 and Tβ4) represent data 
which have hitherto not been reported in paediatric vasculitis.  At the time of writing, of 
these 3 growth factors only Ang-2 has been reported in adults with AAV (Kumpers et 
al., 2009). 
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5.3 Evaluation of growth factors in vasculitis 
5.3.1 Patients and methods 
5.3.1.1 Patients 
40  children  with  primary  systemic  vasculitis  were  studied.  The  majority  of  these 
patients (n=36) were the same individuals described in Chapters 3 and 4, allowing GFs 
to be compared with CECs and MPs.  These included 16 males and 24 females of 
median age 9.8 years (range 0.1 -19.0 years). The vasculitis type (using the Chapel Hill 
Consensus  Criteria)  (Jennette  et  al.,  1994)  was  polyarteritis  nodosa  (PAN)  n=17, 
Wegener’s  granulomatosis  (WG)  n=9,  microscopic  polyangiitis  (MPA)  n=1, 
Kawasaki’s disease (KD) n=5, Takayasu’s arteritis (TD) n=2, Beçhets disease (BD) n=1 
and  unclassified  n=6.    Disease  activity  was  assessed  using  a  modified  paediatric 
Birmingham Vasculitis Activity Score (BVAS), as described previously.  18 healthy 
child controls (4 males, 14 females), 14 febrile controls (6 males, 8 females with  a 
variety  of  autoimmune  or  other  inflammatory  disorders  without  the  presence  of 
vasculitis) and 20 healthy adult controls were also recruited (2 males, 18 females, age 
range 24-40  years). As with the vasculitis patients, the control individuals were the 
same as those studied in Chapters 3 and 4.    
 
5.3.1.2 Methods 
Platelet poor plasma and serum were collected and stored as described in section 2.4.  
Platelet poor plasma was used in ELISA for Ang-1 and Ang-2, using ELISA kits from 
R&D as per manufacturer’s instructions (as described in section 2.6.1).  Serum was 
used in ELISA for detection of VEGF-A165 using an ELISA kit from R&D as described 
in section 2.6.1  Serum was also used for detection of Tβ4 using an ELISA kit from 
immunodiagnostik (as described in section 2.6.1).  Samples were defrosted at room 233 
 
temperature while the ELISA kit reagents were being prepared.  Ang-1 required a 1 in 
15 dilution of sample, Ang-2 required a 1 in 5 dilution of samples (as per manufacturers 
instructions). VEGF serum was used neat and Tβ4 was diluted 1 in 5 before addition to 
the test plate.    As Ang-1 levels were frequently falling below the detection limit of the 
kit and the high level of dilution was necessary to prevent Ang-1 complex formation 
(R&D,  technical  support,  personal  communication)  fewer  samples  had  their  Ang-1 
detected than Ang-2.  Examples of calibration curves are given in Appendix 5.   
  
5.3.1.3 Statistics 
Median growth factor levels were compared between groups using the Kruskall Wallis 
test  to  check  for  overall  differences.    Individual  Mann  Whitney  U  tests  for  non 
parametric data were performed to compare between specific groups.  The Wilcoxon 
signed rank test was performed to compare medians of paired samples.  Spearman Rank 
correlation coefficiants were performed to assess correlation between growth factors 
and  other  markers  of  disease  activity,  including  CECs.    In  all  data  graphs  patient 
classification was denoted using colour coding as indicated below: 
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5.3.2 Results 
5.3.2.1 VEGF 
Kruskall Wallis testing indicated there were significant differences between test groups 
(p=0.04). Individual analysis between groups revealed VEGF was significantly higher 
in 20 patients with active vasculitis (median value 579pg/ml) compared to 22 healthy 
child controls (median value 194pg/ml, p=0.02) and 9 healthy adult controls (median 
value 231pg/ml, p=0.03).  There were no significant differences between patients with 
active vasculitis and 9 febrile controls (median value 395 pg/ml) or 17 patients with 
inactive disease (median value 241pg/ml) and these control groups.  The data presented 
in  Figure 5.1a represents  the overall vasculitis cohort and when tested a significant 
difference between patients with active and inactive vasculitis (p=0.04) was observed, 
however  this  analysis  includes  paired  data.  When    paired  data  between  active  and 
inactive vasculitis was excluded (the first observation made in each individual patient 
was  used  in  this  analysis)  the  difference  between  18  patients  with  active  disease 
(median value 578 pg/ml) and 6 patients in remission (median value 137pg/ml) was no 
longer significant (p=0.07).  As before the colour of symbols and lines indicates disease 
classification of individual patients. 
 
In 13 individual patients VEGF levels were significantly higher during active disease 
than when patients were in remission (p=0.013) (median time to remission 3 months) 
(Figure  5.1b).    10  patients  were  followed  over  time  from  initiation  of  treatment  at 
disease onset, at median follow up of 3 and 12 months VEGF was significantly lower 
than at onset than at followup (p=0.02 and p=0.047 respectively, Figure 5.1c).  
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Figure 5-1: Serum levels of VEGF in vasculitis 
 
 
Figure 5.1a:VEGF was significantly higher in 20 patients with active vasculitis compared to 22 healthy 
child controls (p=0.02), 9 healthy adult controls (p=0.03) and 17 patients with inactive disease (p=0.04).  
There were no significant differences between patients with active disease and 9 febrile controls or 17 
patients with inactive disease and any of the control groups. Figure 5.1b: In 13 individual patients VEGF 
levels were significantly higher during active disease compared to remission (p=0.025, median time to 
remission 3 months). Figure 5.2c:  13 individual patients were followed from initiation of treatment , at 
median followup of 3 months VEGF was significantly lower than at onset (p=0.015) although not at 12 
months (p=0.06).  Symbol and line colours reflect individual patients disease classification.   236 
 
5.3.2.2 Angiopoietin-1 
Kruskall Wallis testing indicated there were no overall significant differences between 
test groups (p=0.07).  When test groups were considered individually Ang-1 was not 
significantly different in 13 patients with active vasculitis (median value 2670 pg/ml) 
compared to 14 healthy child controls (median value 835pg/ml, p=0.1) and 3 healthy  
adult controls (median value 0pg/ml, not enough data to compare statistically).  There 
were no significant differences between 12 patients with inactive vasculitis (median 
value 1051pg/ml) and these control groups (Figure 5.2a.  Ang-1 was comparable with 
reference  ranges  for  the  kit  in  adult  controls.  The  data  presented  in  Figure  5.2a 
represents  the  overall  vasculitis  cohort,  when  tested  no  significant  difference  was 
observed between patients with active and inactive vasculitis (p=0.5).  There were not 
enough samples to exclude paired data between the two test groups.  As before the 
colour of symbols and lines indicates disease classification of individual patients. 
 
In 12 individual patients Ang-1 levels were not significantly different between active 
disease and remission (p=0.6) (median time to remission 3.5 months, Figure 5.2b).  12 
individual patients were followed from initiation of treatment at disease onset or flare 
(dotted  lines  indicate  flare).    In  11  patients  followed  over  time  from  initiation  of 
treatment, at median follow up of 3 and 12 months Ang-1 was not significantly different 
to levels at onset (p=0.3 and p=0.2 respectively, Figure 5.2c). 
 
5.3.2.3 Angiopoeitin-2  
Kruskall Wallis testing indicated there were no overall significant differences between 
the test groups (p=0.2).  When test groups were considered individually Ang-2 was not  
significantly different between 23 patients with active vasculitis (median value 1739 pg/  237 
 
Figure 5-2:Plasma Angiopoeitin-1 levels in vasculitis 
 
 
Figure 5.2a: Ang-1 levels were not significantly different in 12 patients with active vasculitis compared 
to 14 healthy child controls (p=0.07), 11 patients with inactive vasculitis (p=0.5) and 3 healthy adult 
controls (not enough data to compare).  There were no significant differences between patients with 
inactive vasculitis and these control groups. Figure 5.2b: In 13 individual patients Ang-1 levels were not 
significantly  different  between  active  disease  and  remission  (p=0.44)  (median  time  to  remission  3.5 
months). Figure 5.2c: 12 patients were followed over time from initiation of treatment, at median follow 
up  of  3  and  12  months  Ang-1  was  not  significantly  different  to  levels  at  onset  (p=0.3  and  p=0.2 
respectively).  Symbol and line colours reflect individual patients disease classification. 238 
 
ml) compared to 12 febrile controls (median value 1798pg/ml, p=0.27), 19 healthy child 
controls  (median  value  1512  pg/ml,  p=0.15)  and  20  healthy  adult  controls  (median 
value 1382pg/ml, p=0.167, comparable with reference ranges for the kit).  There were 
no significant differences between 25 patients with inactive vasculitis and healthy child 
controls or adult controls however Ang-2 was significantly higher in febrile controls 
(p=0.04).  The data in figure 5.3a represents the whole vasculitis cohort, on testing no 
significant differences were observed between active and inactive disease.  When paired 
samples between these groups were excluded there remained no significant difference 
between 23 patients with active vasculitis and 10 in remission (p=0.2). As before the 
colour of symbols and lines indicates disease classification of individual patients. 
 
In 17 individual patients Ang-2 was significantly higher during active disease than in 
remission (p=0.045, median time to remission 5.5 months, Figure 5.3b).  13 patients 
were followed over time from initiation of treatment at disease onset (solid lines) or 
during flare  (dotted lines), at median follow up of 3 and 12 months from  disease  onset  
and initiation of treatment Ang-2 was significantly lower than at onset (p=0.001 and 
p=0.04 respectively,  Figure 5.3c). 
 
5.3.2.4   Thymosin β4 
Kruskall Wallis  testing indicated no overall significant differences between the test 
groups  (p=0.2).    When  test  groups  were  considered  individually  Tβ4  was  not 
significantly different between 17 patients with active vasculitis (median value 5.87 
µg/ml) compared to 5 febrile controls (median value 6.7µg/ml p=0.56), 9 healthy child 
controls  (median  value  8.61µg/ml  p=0.78)  or  8  healthy  adult  controls  (median 
value3.84µg/ml, p=0.07).  There were no significant differences between patients with 
inactive vasculitis and any of these controls groups or with patients with active disease   239 
 
Figure 5-3: Plasma Angiopoeitin-2 levels in vasculitis 
 
 
Figure 5.3a: Ang-2 was not significantly different between 23 patients with active vasculitis compared to 
12 febrile controls, 19 healthy child controls and 20 healthy adult controls.  There were no significant 
differences between patients with inactive disease and healthy child controls or adult controls however 
Ang-2 was significantly higher in febrile controls (p=0.04). Figure 5.3b: In 17 individual patients, Ang-2 
was significantly higher during active disease than in remission (p=0.045, median time to remission 5.5 
months)  Figure 5.2c: In 12 patients followed over time from initiation of treatment, at median follow up 
of  3  and  12  months  Ang-2  was  significantly  lower  than  at  disease  onset  (p=0.001  and  p=0.04 
respectively). Symbol and line colours reflect individual patients disease classification. 240 
 
(this analysis included paired data between active and inactive disease as there was not 
enough data for statistical analysis otherwise).  Healthy child controls had significantly 
higher levels of Tβ4 than healthy adult controls (p=0.022, Figure 5.4a).     
 
In 12 individual patients there were no significant differences in Tβ4 between active and 
inactive disease (p= 0.7, median time to remission 3 months) (Figure 5.4b).  11 patients 
were followed over time from initiation of treatment at disease onset (solid line) or flare 
(dotted line).  In 10 patients at median follow up of 3 and 12 months from disease onset 
there were no significant differences from initiation of treatment (p=0.8 and p=0.19, 
Figure 5.4c). 
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Figure 5-4: Serum levels of Thymosin Beta 4 in vasculitis 
 
 
Figure 5.4a: Tβ4 was not significantly different between 17 patients with active vasculitis and 5 febrile 
controls, 9 healthy child controls or 8 healthy adult controls.  There were no significant differences 
between patients with inactive vasculitis and any of these controls groups.  Healthy child controls had 
significantly higher levels of  Tβ4 compared to  healthy adult controls (p=0.022).  Figure 5.4b: In 12 
individual  patients  there  were  no  significant  differences  in  Tβ4  between  active  and  inactive  disease 
(median time to remission 3 months) Figure 5.4c: 11 patients were followed over time from initiation of 
treatment at disease onset (solid lines) or flare (dotted lines).  At median follow up of 3 and 12 months 
there  were  no  significant  differences  from  initiation  of  treatment.  Symbol  and  line  colours  reflect 
individual patients disease classification.   242 
 
5.3.3 Correlation between growth factors and disease activity 
Spearman Rank correlation coefficiant analysis was performed between the 4 growth 
factors  assessed  and  the  traditional  markers  of  active  disease;  BVAS,  CRP,  ESR, 
platelet count, albumin, white cell count as well as the previously demonstrated novel 
markers of endothelial injury and cellular activation CEC count, EMPs and PMPs in 
patients  with  vasculitis.    Table  5.1  summarises  the  results.  Table  5.2  shows  the 
corrected  P-values  obtained  from  a  post-hoc  Holm-Bonferroni  correction.    In  this 
instance a number of the significant correlations observed on individual tests withstood 
the  rigours  of  multiple  comparison  correction  and  therefore  are  likely  to  be  true 
significant results and not false positives. 
 
Serum VEGF and Plasma Ang-2 both correlated significantly with the inflammatory 
markers ESR and CRP, as well as the BVAS score of disease activity. Interestingly 
neither  growth  factor  correlated  with  circulating  endothelial  cells.    Although  the 
following  did  not  withstand  correction  for  multiple  comparisons  Ang-2  correlated 
inversely  with  EMPs  (CD105+) Ang-1  correlated with  platelet count  and TB4 only 
correlated  with  VEGF.    Importantly  VEGF  did  not  correlate  with  platelet  count  or 
PMPS.  Both can act as stores of VEGF and thus platelet degranulation may influence 
serum levels (Jelkmann, 2001), however this did not appear to affect this result.    
 
5.3.4 Influence of treatment on growth factor responses 
The result that growth factors did not correlate with endothelial injury as assessed by 
CECs or EMPs was unexpected, especially as both VEGF and Ang-2 correlated with 
the inflammatory markers ESR and CRP and the clinical score of disease activity.  As 
immunosuppression influences the release of chemokines and cytokines from a number 243 
 
Table  5-1:  Spearman  Rank  correlation  coefficiants  of  growth  factors  and 
markers of disease activity in vasculitis. 
 
 
Marker  of 
disease activity 
VEGF  ANG-1  ANG-2  TB4 
BVAS  r = 0.329 
p = 0.018* 
n = 51 
r = 0.158 
p = 0.34 
n = 38 
r = 0.344 
p = 0.002* 
n = 76 
r = 0.22 
p = 0.2 
n = 33 
ESR  r = 0.529 
p<0.001* 
n = 48 
r = 0.035 
p = 0.83 
n = 38 
r = 0.432 
p <0.001* 
n = 74 
r = 0.140 
p = 0.45 
n = 31 
CRP  r = 0.460 
p = 0.001* 
n = 49 
r = 0.086 
p = 0.6 
n = 38 
r = 0.503 
p <0.001* 
n = 75 
r = 0.27 
p = 0.14 
n = 32 
WCC  r = 0.508 
p <0.001* 
n = 50 
r = 0.034 
p = 0.84 
n = 39 
r = 0.137 
p = 0.24 
n = 75 
r = 0.337 
p = 0.055 
n = 33 
Platelet count  r = 0.274 
p = 0.06 
n = 47 
r = 0.44 
p = 0.006* 
n = 37 
r = -0.015 
p = 0.9 
n = 72 
r = 0.215 
p = 0.245 
n = 31 
Albumin  r = -0.502 
p <0.001* 
n = 46 
r = -0.190 
p = 0.266 
n = 36 
r = -0.370 
p = 0.001* 
n = 72 
r = -0.027 
p = 0.09 
n = 31 
CEC count  r = 0.150 
p = 0.35 
n = 41 
r = 0.182 
p = 302 
n = 34 
r = 0.016 
p = 0.89 
n = 70 
r = 0.058 
p = 0.765 
n = 29 
EMP (CD144+)  r = 0.061 
p = 0.69 
n = 44 
r = 0.127 
p = 0.428 
n = 41 
r = -0.148 
p = 0.2 
n = 76 
r = 0.109 
p = 0.55 
n = 32 
EMP (CD105+)  r = 0.047 
p = 0.76 
n = 44 
r = -0.62 
p = 0.7 
n = 41 
r = -0.308 
p = 0.007* 
n = 76 
r = -0.22 
p = 0.23 
n = 32 
EMP (eselectin+)  r = 0.217 
p = 0.16 
n = 44 
r = 0.025 
p = 0.88 
n = 41 
r = -0.103 
p = 0.378 
n = 76 
r = 0.132 
p = 0.47 
n = 32 
PMP (CD42a+)  r = -0.235 
p = 0.13 
n = 43 
r = -0.056 
p = 0.73 
n = 41 
r = -0.214 
p = 0.066 
n = 75 
r = 0.137 
p = 0.46 
n = 32 
Total MP  r = -0.111 
p = 0.473 
n = 44 
r = -0.129 
p = 0.42 
n = 41 
r = -0.067 
p = 0.566 
n = 76 
r = -0.022 
p = 0.9 
n = 32 
VEGF    r = 0.315 
p = 0.09 
n = 30 
r = 0.306 
p = 0.039* 
n = 46 
r = 0.369 
p = 0.023* 
n = 38 
ANG-1  r = 0.315 
p = 0.09 
n = 30 
  r = 0.032 
p = 0.84 
n = 30 
r = 0.178 
p = 0.38 
n = 26 
ANG-2  r = 0.306 
p = 0.039* 
n = 46 
r = 0.032 
p = 0.84 
n = 30 
  r = 0.269 
p = 0.13 
n = 33 
TB4  r = 0.369 
p = 0.023* 
n = 38 
r = 0.178 
p = 0.38 
n = 26 
r = 0.269 
p = 0.13 
n = 33 
 
Significant correlations are highlighted in blue 
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Table  5-2:  Holm-Bonferroni  correction  for  multiple  comparisons  relating  to 
correlations of growth factors and other markers of disease activity 
 
Significant Test  P value  Adjusted critical value 
(Holm-Bonferroni) 
WCC vs VEGF  <0.001  0.000925926 
Albumin vs VEGF  <0.001  0.000943396 
ESR vs ANG-2  <0.001  0.000961538 
CRP vs ANG-2  <0.001  0.000980392 
ESR vs VEGF  0.001  0.001 
CRP vs VEGF  0.001  0.001020408 
Albumin vs ANG-2  0.001  0.001041667 
BVAS vs ANG-2  0.002  0.00106383 
Platelet count vs ANG-1  0.006  0.001086957 
EMP (CD105+) vs ANG-2  0.007  0.001111111 
BVAS vs VEGF  0.018  0.001136364 
TB4 vs VEGF  0.023  0.001162791 
ANG-2 vs VEGF  0.039  0.001190476 
 
of cell types, we hypothesised that treatment might be influencing the release of growth 
factors and thus the data was reanalysed to take this into account.  29 individual patients 
whose  growth factors had been measured and had active disease as defined via clinical  
scores (BVAS) were then divided into two subgroups: those who were treatment naive 
 (i.e.  had  received  no  treatment,  n=  13),  and  those  who  had  flared  while  on 
immunosuppressive  treatment  (n=16).    In  those  individuals  who  had  had  repeated 
measurements taken while disease was still active, it was the first sample that was used 
in this analysis.    245 
 
There were no significant differences in markers of endothelial injury/activation (CECs 
and EMPs) between 9 patients who were treatment naive and 12 patients who were on 
immunosuppressive treatment (Figures 5.5a and b).  Patients who were treatment naive 
had significantly higher BVAS scores (p=0.03) and CRP (p=0.01) although not ES). 
(Figures 5.5c-e)  Correspondingly the treatment naive patients also had significantly 
higher levels of VEGF (p=0.007), Ang-1 (p=0.03) and Ang-2 (p=0.0003), than those 
who were on immunosuppressive therapy. This may indicate that immunosuppressive 
treatment influences release of these growth factors in response to disease activity.   
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Figure  5-5:  Influence  of  treatment  on  endothelial  injury  markers  and 
clinical parameters  
 
 
 
Figure 5.5a-e: When patients with active disease had their treatment status considered (treatment naive 
or  on  treatment),  there  was  no  significant  differences  in  CECs  or  EMP  between  patients  who  were 
treatment naive (no Rx) or on immunosuppressive therapy (on Rx) when they flared (Figure 5.5a and b).  
There were significant differences between the two groups when clinical parameters were considered: 
BVAS  (p=0.01,  Figure  5.5c)  and  the  inflamamotry  markers  CRP  (p=0.005,  Figure  5.5d)  and  ESR 
(p=0.02, Figure 5.5e) were significantly higher in patients who had not yet received treatment Rx = 
treatment.  Symbol and line colour reflect individual patients disease classification (colour coded as in 
previous figures) 247 
 
Figure 5-6: Influence of treatment on growth factors 
 
 
Figure 5.6a-d:When patients  with active vasculitis had their treatment status considered  there were 
significant differences in growth factor levels between patients who were treatment naïve (Rx naïve) and 
those who were on immunosuppressive therapy (on Rx) when they flared.  Figure 5.6a:  VEGF was 
significantly higher in 12 treatment naive patients compared to 7 on immunosuppression (p=0.03) Figure 
5.6b  Ang-1  was  not  significantly  different  between  10  treatment  naive  patients  compared  to  4  on 
immunosuppression  (p=0.1),  however  this  comparison  was  underpowered    Figure  5.6c  Ang-2  was 
significantly higher in 12 treatment naive patients compared to 13 on immunosuppression (p=0.002) .  
Figure  5.6d:  there  were  no  signficant  differences  in  Tβ4  between  treatment  naïve  and  those  on 
immunosuppression.  Symbol  and  line  colour  reflect  individual  patients  disease  classification  (colour 
coded as in previous figures) 248 
 
5.4 Discussion 
Growth factors regulate the angiogenic and vasculogenic pathways that are necessary 
for vascular repair and thus monitoring of their levels may provide insight into potential 
reparative response.  Like CECs and EMPs, they can be expressed as a consequence of 
endothelial injury and it was with this in mind that this study was undertaken, to assess 
their potential as an indicator of active disease in vasculitis.   
 
The preliminary observations made are interesting and warrant further investigation, 
however it is difficult to draw firm conclusions from them since patient numbers are 
small.  Although VEGF and Ang-2 in particular correlate with a number of markers of 
disease  activity,  responses  may  be  influenced  by  treatment.    Thus  their  use  as 
biomarkers in a highly heterogenous cohort on widespread immunosuppression may not 
be  appropriate.    The  complexity  of  the  results  is  perhaps  not  surprising  when  it  is 
considered that growth factors form part of extensive regulatory networks and could 
conceivably  be  contributing  to  the  pathological  processes  involved  in  vascular 
inflammation as well as promoting repair.   
 
None of the growth factors examined herein correlated with CECs or EMPs.  VEGF and 
Ang-2 did however correlate with clinical scores of disease activity (BVAS) as well as 
non specific markers of inflammatory disease activity such as ESR and CRP.  This 
could  be  indicative  of  the  upstream  signalling  required  to  release  them:  VEGF  is 
produced by monocytes which are integral to the inflammatory process and although 
Ang-2 is relatively endothelial specific, it is released from the Weibel-palade bodies in 
response  to  inflammatory  stimuli.    Perhaps  these  growth  factors  are  upregulated  in 
reponse  to  inflammatory  stimuli  that  are  not  sufficient  to  induce  EC  detachment 249 
 
(forming CECs).  VEGF also correlated with Tβ4 levels (although this did not withstand 
the  rigours  of  correction  for  multiple  comparisons),  corresponding  with  previously 
published reports that in animal models high Tβ4 in isolated organs is associated with 
elevated VEGF (Cha et al., 2003).  
 
The concept that growth factors may be more closely linked with inflammation than as 
a  direct  consequence  of  endothelial  injury  was  further  reinforced  by  the  effect  of 
therapy on levels of VEGF, Ang-2 and Ang-1 (although this latter observation was 
underpowered and lacked statistical significance).  Routine maintenance therapy (in the 
majority of cases corticosteroids, with azathioprine) dampened down the elevations seen 
in these growth factors when patients had flares of their disease.  While it would be easy 
to suggest that patients on maintenance therapy do not have such extensive disease 
activity in flare and that is why their response is dampened, CECs and EMPS (which 
reflect  the  extensiveness  of EC injury  and activation) were unaffected  by treatment 
status in patients with active disease.   The pathways upstream of VEGF and ANG-2 are 
complicated,  a  number  of  mediators  can  influence  their  production  and  thus  it  is 
conceivable  that  inhibition  of  several  immune  pathways  by  treatment  such  as 
corticosteroids  and  cytotoxic  immunosuppressants  could  impact  on  growth  factor 
release.   
 
The recently published data from Kumpers et al on Ang-2 levels in adults with AAV, is 
similar to that described herein, Ang-2 levels were elevated at disease onset, declined 
with therapy and correlated strongly with BVAS and (in contrast to the data presented 
herein) CEC number (Kumpers et al., 2009).  Their interpretation of the usefulness of 
Ang-2  as  a  biomarker  of  disease  activity  in  vasculitis  is  more  optimistic  than  the 250 
 
conclusion  reached  in  this  study  as  they  did  not  observe  that  immunosuppressive 
treatment could be influencing the growth factor responses.  While this could be due to 
differences between adult and child physiology, it may be that the inclusion criteria of 
the patients studied is the cause.   Of the 15 patients with active disease studied by 
Kumpers et al, 8 were treatment naive and the remainder were off immunosuppressive 
therapy or on <7.5mg/day prednisolone (exact numbers were not stated).  If the majority 
of patients were in fact not on any immunosuppressive therapy then this interesting 
observation may well have gone undetected in their cohort. Regardless of the status of 
patients included in these studies, both remain preliminary as the datasets are small and 
a larger scale study is necessary to assess the potential of Ang-2 as a biomarker of 
disease activity, and if indeed its levels are influenced by treatment status.  
 
The implications of the apparent growth factor suppression by treatment in children 
may  not  necessarily  be  a  bad  thing.  VEGF  is  a  well  known  mediator  of  vascular 
permeability and elevations of this could be contributing to oedema formation often 
associated with inflammation (Mehta and Malik, 2006).  Furthermore, as discussed in 
the introduction to this chapter, newly formed vessels may amplify and target vascular 
inflammation.  Indeed, one line of argument has regarded angiogenic signals as a means 
of amplifying vasculitic injury (Cid, 2002).   In healthy individuals growth factors act in 
a  localised  manner  to  control  angiogenesis  and  vasculogenesis,  processes  reliant  on 
concentration  gradients  to  direct  tightly  regulated  changes  in  vessel  behaviour.  
Therefore  large  changes  in  growth  factors  could  in  fact  be  pathological  and  not 
indicative of a reparative response but of a “growth factor storm” propagating further 
disruption of endothelial cells and injury.     
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In conclusion, children with active vasculitis demonstrate significant angiogenic and 
vasculogenic signals in peripheral blood at a time when their vasculitis is most active.  
Although  routine  clinical  testing  of  growth  factors  in  vasculitis  would  be  a  simple 
clinical test, the influence of treatment, the inconsistent results observed (particularly 
for Ang-1 and Tβ4) and the complexity associated with growth factor responses and 
effects suggest that the growth factors assessed in this study may not be an appropriate 
biomarker  of  disease  activity  for  clinical  monitoring  of  disease  activity.    These 
observations, particularly in relation to the finding of elevated VEGF and Ang-2 in 
active  vasculitis  (albeit  influenced  by  treatment),  do  however,  provide  impetus  for 
further study of endothelial progenitor cell reponses in relation to vasculitis disease 
activity.  EPCs are the subject of Chapter 6. 
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6.1 Summary 
Endothelial progenitor cells (EPCs) are bone marrow derived cells which migrate to 
sites  of  endothelial  injury  and  assist  in  repair.    Whether  this  occurs  is  via  EPCs 
differentiating  down  an  endothelial  lineage  or  by  orchestrating  a  localised 
proangiogenic environment is unclear.  As has been discussed in Chapter 5, growth 
factors which promote angiogenesis have been implicated in recruitment of EPCs from 
the  bone  marrow  and  I  previously  demonstrated  elevations  of  VEGF  and  Ang-2  in 
children with active vasculitis.  This chapter describes EPCs in children with vasculitis 
and changes with treatment.  
 
 
6.2 Introduction 
Endothelial repair is integral to maintaining health, however the exact mechanisms by 
which this occurs remain as yet unclear. As mentioned in the introduction to this thesis, 
angiogenesis was considered to be the mechanism by which the endothelium repaired 
itself until relatively recently, when Asahara et al introduced the concept of postnatal 
vasculogenesis and endothelial progenitor cells (EPCs) (Asahara et al., 1997).    
 
The EPCs described by Asahara et al were a population of CD34+ cells.  CD34+ cells 
are  routinely  used  in  stem  cell  transplantation  and  can  reconstitute  all  blood  cell 
lineages  (Cheng  et  al.,  1996).    CD34  is  found  on  mature  endothelium  and 
haematopoietic progenitor cells (of myeloid and lymphoid lineages) although is lost 
during  the  latters  maturation.    Vasculogenesis  studies  in  embryonic  development, 
indicate that both the cells forming the vasculature and those that form the cells of the 
blood are derived from a common progenitor – known as the haemangioblast (Vogeli et 254 
 
al., 2006).  Haematopoeitic cells are continually repopulated throughout life and thus 
the concept that EPCs also remain involved in vascular repair and remodeling is an 
attractive hypothesis.   
 
While the work of Asahara et al may have been the first description of EPCs, evidence 
had accumulated for many years previously that circulating cells could repopulate the 
endothelium.  As early as 1932 Hueper and Russell had found capillary like tubule 
formations in cultures of leukocytes and continuation of their work by Parker in 1934 
demonstrated that leukocytes require a base of red blood cells and platelets in order to 
form these structures (Parker, 1934).  By 1963 the concept of fallout endothelialisation 
had  been  described,  whereby  synthetic  grafts  implanted  into  animals  showed  re-
endothelialisation which was not derived from infiltrating surrounding endothelium (Shi 
et al., 1994,Stump et al., 1963).  In 1998 Shi et al demonstrated that these circulating 
cells  originated  from  bone  marror  as  donor  derived  cells  were  found  to  be  the 
predominant endothelial cell on reendothelialised grafts implanted after transplantation 
in dogs (Shi et al., 1998).   
 
6.2.1 EPCs influence in vivo endothelial repair 
Since  the  discovery  of  EPCs  by  Asahara  et  al  numerous  studies  involving  animal 
models  of  acute  vascular  injury,  transplantation  and  atherosclerosis  have  been 
described, indicating a role for EPCs in reparative responses.  The exact phenotype of 
EPCs  is  a  controversial  subject  and  as  yet  no  specific  combination  of  markers 
conclusively defines the EPC population (Hirschi et al., 2008).  Most in-vivo studies 
where EPCs have been perfused into subjects (animals and human) have used mixed 
populations  of cells  which include EPCs;  some studies  have used CD34+ or whole 255 
 
mononuclear fractions of freshly isolated peripheral blood.  In animal models culture 
modified  mononuclear  cells  have  also  been  used.    In  a  number  of  studies 
pharmacological  agents  such  as  G-CSF  have  been  used  to  mobilise  bone  marrow 
progenitors.  These will now be discussed in more detail. 
 
6.2.1.1  EPCs in animal models 
In a series of vein graft transplant studies in transgenic mice, Xu et al demonstrated that 
circulating cells from the recipient rapidly repopulate the vein graft endothelium, about 
a third of which are bone marrow derived cells (Xu et al., 2003).  In apolipoprotein E
−/− 
(ApoE-/-) knockout mice, which have reduced circulating EPCs, regeneration of the 
endothelium is  delayed  and development  of atherosclerotic lesions in  the vein  graft 
accelerated (Xu et al., 2003).   ApoE1-/- are a well established model of atherosclerosis 
and develop spontaneous disease, the progression of which can be decreased with the 
infusion of EPCs  from younger mice, not yet exhibiting atherosclerotic changes, but 
not EPCs from older sick mice (Rauscher et al., 2003).  In this study cells isolated from 
bone marrow and cultured for up to 2 weeks were used.  Interestingly other studies have 
demonstrated that EPC infusion is detrimental in this model when combined with an 
ischaemic  injury  possibly  due  to  an  inflammatory  role.    Although  EPC  infusion 
improved ischaemia reperfusion injury in 2 studies, it also accelerated atherosclerotic 
plaque development and instability (Silvestre et al., 2003), which was associated with 
higher serum IL-6 and MCP-1 (George et al., 2005).  However both these latter studies 
used uncultured cells isolated from bone marrow. 
  
In  arterial  balloon injury  models in rats, mobilization of  EPCs using G-CSF enhances  256 
 
repair and reduces associated hyperplasia of the intima and smooth muscle (Kong et al., 
2004a).  The same group demonstrated that in a similar model in rabbits, modification 
of  cultured  autologous  EPCs  to  overexpress  eNOS  further  enhanced  the  reparative 
response and suppression of hyperplasia (Kong et al., 2004b).  While in these models of 
vascular injury, EPCs suppressed hyperplasia, the opposite effect was observed when 
experimental stents coated with anti-CD34 to promote EPC recruitment were implanted 
in pigs.  While endothelialisation of coated stents was more rapid than in controls, it 
was also associated with excessive intimal hyperplasia  (Rotmans et al., 2005). 
 
In induced myocardial infarction in both mice and rats, transplantation of bone marrow 
mononuclear  cells  into  the  heart  improves  recovery  and  function,  associated  with 
enhanced  angiogenesis  (Zhang  et  al.,  2004)  with  increased  IL-10  production  and 
reduced  T  cell  infiltration,  indicating  a  possible  anti-inflammatory  role  for  EPCs 
(Burchfield  et  al.,  2008).    Similarly  enhanced  angiogenic  responses  and  improved 
function are also seen in hindlimb ischaemia models by injection of autologous and 
donor animal bone marrow mononuclear cells (Asahara et al., 1997) and even human 
circulating PBMCs (into athymic rats) (Iba et al., 2002). 
 
While  there  is  wide  variation  in  the  methods  employed  in  these  animal  studies, 
particularly relating to the phenotype of cells considered to be EPCs and their isolation 
and culture (in some studies), it is apparent that EPCs do promote neovascularisation.  
The extent of incorporation of EPCs into the newly formed vasculature is extremely 
variable  (0-90%,  (Ward  et  al.,  2007)  and  recently  there  has  been  much  interest  in 
understanding the paracrine effects of these cells.   Some in vivo studies have implied 
that EPC recruitment to the site of injury is a transient response and hypothesise that the 257 
 
major role of EPCs is to provide a localized pro-angiogenic environment facilitating 
repair (Fazel et al., 2006).   
 
6.2.1.2 EPCs in human clinical trials   
Despite  many  unanswered  questions  relating  to  function,  phenotype  and  possible 
detrimental effects of EPC infusions, there have been a small number of groundbreaking 
studies  that  have  taken  EPC  therapy  into  humans.    The  majority  of  studies  have 
involved patients with myocardical infarction and while safety has not been an issue in 
the studies performed, efficacy has been questionable (Jujo et al., 2008).   
 
The majority of studies undertaken have used infusions of freshly isolated mononuclear 
cells,  from  either  blood  (Assmus  et  al.,  2002,Wollert  et  al.,  2004)  or  bone  marrow 
(Lunde et al., 2008,Janssens et al., 2006) rather than a selected population.  A small 
number of studies have examined the effects of isolated CD34+(Balogh et al., 2007) or 
CD133+ populations (Bartunek et al., 2005).  Overall it appears that localized infusion 
into the coronary arteries or myocardium during bypass surgery of either mononuclear 
cells, CD133+ or CD34+ cells can result in a mild to moderate improvement in cardiac 
function and/or reduction in infarct size, although these are inconsistent findings, with 
some studies indicating no improvement (Jujo et al., 2008).  This is in contrast to the 
promising  and  significant  differences  seen  in  the  aforementioned  animal  models.  
However, the small human studies so far performed have been underpowered, and the 
methodologies  variable,  particularly  the  timing  of  EPC  infusions  post  injury;  the 
harvesting of cells and types of cell populations infused (Jujo et al., 2008).  Thus it is 
not surprising that the results obtained so far are inconsistent.  Only a longer clinical 
trial  or  metanalaysis of similar trials with common  treatment  protocols, will  establish  258 
 
whether this is truly a therapeutic option for the future.   
 
Clinical trials of G-CSF mobilisation of autologous bone marrow stem cells have so far 
demonstrated no efficacy, and concerns have been raised over the risk associated with 
mobilization of inflammatory  cells  using this  approach  (Ward et  al.,  2007).   In the 
context  of  vasculitis,  G-CSF  has  been  implicated  in  experimental  models  of 
glomerulonephritis;  mice  in  which  GM-CSF  or  G-CSF  has  been  knocked  out  are 
protected  from  a  neutrophil  driven  glomerulonephritis  (although  not  T-cell  driven 
disease) (Kitching et al., 2002) and when rats with glomerulonephritis were treated with 
G-CSF, the condition was exacerbated (Futamura et al., 2002).  
 
6.2.2 Detecting EPCs 
Alongside the studies that implicate EPCs in endothelial reparative responses, there has 
been much interest in assessing their levels and functional capacity in different human 
diseases.  In various conditions it has been demonstrated that EPCs may be impaired or 
reduced in number, which in the context of vasculitis could conceivably be contributing 
to the disease.  As mentioned above, the exact phenotype of EPCs is unclear, however 
there are several methodologies by which putative EPCs have been enumerated, and in 
many studies these do appear to correlate with parameters relating to endothelial health.  
To date putative EPCs have been enumerated using cell culture techniques and flow 
cytometry.  Both techniques will now be described in detail.  
 
6.2.2.1 Cultured EPCs 
There are a number of different protocols described that use cell culture techniques to 
evaluate  EPCs.    A  number  of  studies  have  evaluated  EPC  colonies,  which  can  be 259 
 
derived from PBMCs or CD34+ enriched populations.  Colonies are clusters of cells, 
consisting  of  a  central  core  of  small  rounded  cells  surrounded  by  spindle-like 
outgrowths (examples of which can be seen in section 2.6) and are formed after 5-7 
days of culture in media optimised for endothelial cell growth.  Cells are grown on an 
attachment  scaffold  such  as  fibronectin  or  collagen,  and  protocols  may  or  may  not 
involve a pre-plating step, whereby the non-adherent population is removed after 1-2 
days and replated (in order to remove possible contamination by mature endothelial 
cells (Hill et al., 2003)).  
 
Although colonies derived using different protocols look similar (Section 2.6, Figure 
2.4ab), their phenotype and cellular composition may well vary.  This is highlighted by 
two large studies from Hill et al and Xiao et al which have compared EPC colonies with 
cardiovascular  risk  factors.    The  EPC  colonies  in  these  studies  were  grown  using 
different culture media -  Hill et al used Medium 199 (Gibco) supplemented with 20% 
fetal  calf  serum  (FCS)  and  antiobiotics,  whilst  Xiao  et  al  used  the  commercially 
available  endothelial  optimised  culture  media  EGM-2.    While  Hill  et  al  counted 
colonies derived from non-adherent pre-plated cells, Xiao et al did not pre-plate their 
EPCs.  Hill et al, demonstrated an inverse correlation with Framingham risk factors of 
cardiovascular disease and a positive correlation with flow mediated dilatation (FMD) 
(Hill  et  al.,  2003),  whilst  Xiao  et  al  in  contrast  observed  no  correlation  with 
cardiovascular risk factors (Xiao et al., 2007b).     
 
The methodology described by Hill et al, has led to a commercially available colony 
counting media – Endocult
TM which has been widely used to study putative EPC colony 
forming  units  (known  henceforth  as  Hill-CFU).    The  colonies  formed  consist  of  a 260 
 
central  core  of  haematopoeitic  cells,  which  includes  myeloid
  progenitor  cells, 
monocytes, and T lymphocytes and macrophage/monocyte derived outgrowths (Yoder 
et al., 2007).  While the outgrowths have been shown to express endothelial markers, 
produce nitric oxide and angiogenic growth factors they also have the ability to ingest 
bacteria – reflective of their myeloid lineage.  Moreover, when implanted in vivo they 
do  not  incorporate  in  de  novo  vessels,  they  have  low  proliferative  capacity  and  if 
continued in culture after colony formation do not form endothelial-like monolayers, 
thus it is hypothesized that these colonies are not endothelial progenitors per se but pro-
angiogenic cells of a myeloid lineage (Yoder et al., 2007).  Regardless of which cell 
population Hill-CFUs represent, it is apparent that they are a reflection of endothelial 
health (Hill et al., 2003), in a more recent study by Werner et al in individuals with 
coronary artery disease increased levels of Hill-CFUs were accompanied by decreasing 
risk of death from cardiovascular cause (Werner et al., 2005). 
 
Whilst Hill-CFUs may reflect endothelial health, the colonies described by Xiao et al 
which  did  not  reflect  cardiovascular  risk  may  in  fact  contain  the  elusive  EPC 
population.  Longer term continuation (20+ days) of (non pre-plated) adherent colony 
cultures in EGM-2 can lead to the development of endothelial-like monolayers, known 
as  late  outgrowth  EPCs  (Lin  et  al.,  2000,Ingram  et  al.,  2004),  although  not  in  all 
individuals.  In contrast to Hill-CFUs this population of cells is highly proliferative, do 
not express haematopoetic markers such as CD45, CD14, or CD115 and do not ingest 
bacteria.    More  importantly  when  implanted  in  mice  this  population  spontaneously
 
forms blood vessels that incorporate with murine vessels (Yoder et al., 2007).   
 
Using  cell  sorted  umbilical cord blood, it has been  demonstrated  that  late  outgrowth  261 
 
EPCs derive from a CD14 negative (Gulati et al., 2003) small CD34+ CD45 negative 
subset that expresses VEGFR2 but not CD133 (Timmermans et al., 2007), whereas the 
early colonies that form prior to late-outgrowth EPCs (the population examined by Xiao 
et al) are derived from a haematopoeitic source including CD34+CD45+ (Timmermans 
et al., 2007) and CD14+ cells (Gulati et al., 2003). 
 
Other cell culture techniques that have been used to examine EPC number and function, 
include the counting of cells staining for both DiI-acetylated
 low-density lipoprotein and 
Ulex europaeus (endothelial markers) after 4-5 days in EGM-2 culture; the assessment 
of  cultured  cells  ability  to  adhere  to  endothelial  cells  (such  as  HUVEC);  or  their 
incorporation into HUVEC tubules in extracellular matrix formulations (Matrigel
TM).  
As  with  colony  cultures  a  number  of  protocols  are  described  and  the  exact  cell 
populations  which  orchestrates  these  observations  is  unknown.    Most  experiments 
relating to EPCs adherence/incorporation with HUVEC have used the aforementioned 
adherent cell colonies cultured in EGM-2.  As described above, despite the study by 
Xiao et al demonstrating that these colonies do not reflect cardiovascular risk factors, 
this is the culture which can go on to form late-outgrowth EPCs. 
 
The major restriction relating to EPC cell culture assays in children is the large volumes 
of blood required to obtain enough PBMCs for culture.  As described in the methods 
chapter the initial cultures require a minimum of 5 x 10
6 cells per well for the Hill-CFU 
assay (preferably in duplicate) and 5 x 10
6 cells per well for culturing of outgrowth 
monolayers or for Matrigel
TM.  To perform each assay in triplicate would require 30 x 
10
6 cells or a minimum of 30mls of blood (conceivably more in an immunosuppressed 
patient).   Thus for the purposes of this thesis it was decided to focus on development of 262 
 
flow cytometric assays for detection of EPCs in vasculitis patients and to examine the 
culture methods in healthy adults to determine if it was possible to reduce blood volume 
required for these assays to ultimately apply to the vasculitis cohort. 
 
6.2.2.2 Flow cytometry of EPCs 
The flow cytometric markers used for EPC enumeration are based on the hypothesis 
that  a  putative  circulating  endothelial  progenitor  (adult  angioblast)  would  share  a 
combination  of  cell  surface  markers  found  on  both  embryonic  angioblasts  and 
haematopoeitic cells (Asahara et al., 1997).  The most commonly used are combinations 
of CD34 (found on angioblasts, haematopoietic progenitors and mature endothelium), 
VEGFR2  (found  on  angioblasts  and  mature  endothelium)  and  CD133  (found  on 
angioblasts and haematopoietic progenitors), with or without other endothelial markers 
such as CD31, CD144 or CD146 (Hirschi et al., 2008).  Some groups have defined 
EPCs as cells which stain for CD34, VEGFR2 and CD133 (Kondo et al., 2004)while 
others  have  used  combinations  of  only  2  markers  as  these  represent  a  larger  cell 
population: CD34+CD133+ (Allanore et al., 2007), CD34+VEGFR2+ (George et al., 
2006),  CD34+CD144+  (Redondo  et  al.,  2008),  CD133+VEGFR2+  (Brunner  et  al., 
2008) and CD133+CD144+(Rehman et al., 2004) have all been called EPCs.  While it is 
apparent that these populations do indeed correlate with a wide number of conditions 
associated with  vascular injury or cardiovascular disease, it is  unclear whether they 
reflect a true EPC population, and use of these different EPC definitions means that 
direct comparison between studies is problematic.   
 
When  CD34+VEGFR2+CD133+  cells  are  isolated  and  cultured  they  do  not  form 
colonies or late outgrowth endothelial-like cells (Case et al., 2007) and neither do they 263 
 
correlate with Hill-CFUs in healthy individuals (George et al., 2006).  However, as 
colonies have been shown to primarily consist of haematopoeitic cells, it is unsurprising 
that  these  methods  are  not  comparable  and  that  isolated  populations  do  not  form 
colonies alone.  The work of Timmermans et al indicates that late outgrowth EPCs may 
derive from the CD34+ VEGFR2+ population and so this combination of cell surface 
markers may be indicative of a true EPC.  However as these markers are both expressed 
on mature endothelium they cannot be used alone to define EPC populations and further 
phenotypic clarification is still required (Timmermans et al., 2007).   For the purposes 
of this thesis, as both in vivo and in vitro evidence indicate that the CD34+ population 
contains  true  EPCs,  subpopulations  of  CD34+  cells  were  examined  using  flow 
cytometry. 
 
To date putative EPCs have been enumerated using flow cytometry from either whole 
blood or isolated PBMCs.  While using whole blood has the benefit that only small 
volumes of sample are necessary, the assay must be performed on the day of sampling; 
requires lysis which may remove fragile cell populations; and has a much higher level 
of non specific antibody binding.  In contrast isolated PBMCs can be stored (-80
oC) 
allowing batch analysis, and as well as having overall less background noise neutrophils 
and red blood cells are removed without the need for lysis, thereby further increasing 
the signal to noise ratio.  Putative EPCs are rare events in the circulation and therefore 
careful consideration of the flow cytometric methodology is required to optimize their 
detection. Optimisation of flow cytometry for rare event analysis has been described in 
detail in Chapters 3 and 4, the principles of which remain the same when considering 
EPCs. 
 264 
 
6.2.3 EPCs in health and disease 
While the exact phenotype of EPCs remains unclear, the field of EPC research has 
expanded rapidly since the early publications and much work has been done examining 
these putative EPC populations in health and disease.  As previously described care 
must  be  taken  when  comparing  different  studies  as  there  is  much  heterogeneity  in 
methods employed including cell surface markers examined.  In general, EPC numbers 
(as defined by both colony formation and by flow cytometry) appear to be lower in 
conditions associated with vascular risk and dysfunction including rheumatoid arthritis 
(Egan  et  al.,  2008a),  SLE  (Moonen  et  al.,  2007),  acute  stroke  (Chu  et  al.,  2008), 
diabetes mellitus (Egan et al., 2008b), hypertension (Umemura et al., 2008) and in the 
presence of cardiovascular risk factors such as smoking (Kondo et al., 2004).  EPCs can 
be  mobilized  using  GM-CSF  (granulocyte  macrophage  colony  stimulating 
factor)(Takahashi et al., 1999), on exercise (Laufs et al., 2005) and in response to acute 
vascular injury such as acute myocardial infarction (Shintani et al., 2001) or in burns 
victims (Fox et al., 2008). 
 
EPC number and function declines with age (Heiss et al., 2005,Vasa et al., 2001) and 
children have higher levels of EPCs and haematopoeitic stem cells (CD34+) than adults 
(Jie et al., 2008).  This observation may explain in part why EPC therapy in young 
healthy animal models has proved more effective than in older, sick human patients. 
 
6.2.4 EPCs in vasculitis 
In adults with PR3-ANCA+ WG the number of Hill-CFUs is lower in active disease 
than in remission or in healthy controls (Holmen et al., 2005).  In a recent study in  
AAV, Hill-CFUs were again found to be decreased in patients compared to healthy 265 
 
controls, although not compared to patients on hemodialysis (without vasculitis) or with 
peripheral arterial occlusive disease (Zavada et al., 2008) and in contrast to the work of 
Holmen et al, in this study remission inducing treatment did not increase Hill-CFUs 
(perhaps due to the more heterogeneic population studied).  In a recent flow cytometric 
study,  de  Groot  et  al  demonstrated  that  adults  with  active  AAV  have  comparable 
haematopoietic  progenitor  cells  (CD34+)  to  healthy  controls,  however  treatment 
increased numbers (de Groot et al., 2007).  As discussed above changes in CD34+ cells 
are not necessarily representative of an EPC response, but could indicate repopulation 
of  a  number  of  haematopoetic  lineages  (perhaps  not  surprising  after  cytotoxic 
immunosuppression).      
 
EPCs have only been examined in children with KD, although the study performed used 
a bead based isolation protocol, from which no EPCs were observed in healthy controls 
and only 11 out of 20 KD patients had measurable EPCs.  It was therefore concluded 
that EPCs were higher in KD both in the acute and aubacute phase compared to healthy 
child controls (Nakatani et al., 2003).  
 
 
6.3 Optimisation of flow cytometry for detection of 
EPCs  
6.3.1 Optimisation of antibody staining 
3 colour flow cytometry, as described in section 2.6.2 was used to evaluate expression 
of combinations of the most commonly studied EPC markers: VEGFR2, CD133 and 
CD34, with a variety of other cell surface markers.  These included the constitutive 266 
 
endothelial  markers  CD144  and  CD146  (used  in  CEC  enumeration),  the  monocyte 
marker, the pan leukocyte marker CD45 and the T cell marker CD3. 
 
As EPCs are found in low levels in the circulation, there were a number of important 
considerations relating to rare event analysis which had to be taken into account when 
setting up this assay.  Non-specific antibody binding was minimized via use of FC-
receptor  blocking  agents.    Non  stained  samples  and  fluorochrome  matched  isotype 
controls were used to define positivity.  Antibodies were carefully titrated to determine 
optimum concentrations.  In the case of cell surface markers found on the endothelium 
(VEGFR2,  CD144,CD146)  the  antibodies  were  titrated  using  HUVEC.    All  other 
antibodies were titrated using umbilical  cord PBMCs as  cord blood contains higher 
numbers  of  haematopoeitic  progenitor  cells  than  adult  blood  (Watt  and  Contreras, 
2005).     
 
6.3.2 Sample storage - fresh/frozen PBMCS vs whole blood   
To further reduce non-specific antibody binding, isolated PBMCs as opposed to whole 
blood could be used – removing the need for red cell lysis.  Another advantage of this 
approach  is  that  it  would  allow  sample  collection  and  storage  (-80
oC)  while  the 
techniques  were  being  optimized.    In  order  to  determine  if  EPC  enumeration  was 
dramatically affected by the freeze-thaw process, or was considerably different between 
whole blood samples and isolated PBMCs, blood was obtained from 5 healthy adult 
controls and the percentage of mononuclear cells which expressed CD34, CD133 and 
VEGFR2 was determined (Figure 6.1a-d).  As indicated in Figure 6.1 there were no 
significant differences in the proportion of mononuclear cells expressing CD34, CD133 
or  the  combined  triple  positive  cells,  when  whole  blood,  fresh  PBMCs  and  frozen 267 
 
PBMCs were compared.  While there were some wide differences in values observed in 
individual  patients,  there  were  no  overall  directional  trends  observed.    Interestingly 
VEGFR2 staining was higher (although not significantly) in whole blood compared to 
PBMCs (frozen or fresh, Figure 6.1c) however this did not influence the triple positive 
population of interest and was presumably due to non-specific binding of this antibody.  
A larger study may have revealed significant differences, however as all samples from 
patients and controls were to be treated the same, the study examining EPCs in children 
with  vasculitis  was  performed  using  isolated  PBMCs,  frozen  and  stored  at  -80
oC.  
Storage was frequently necessary as it was often not practical to assay EPCs on the 
same day as sampling, and this also allowed convenient batch analysis.   
 
6.3.3 Flow cytometry – instrument settings and gates 
6.3.3.1 FSC/SSC of CD34+CD133+VEGFR2+ cells  
PBMCs isolated from umbilical cord blood were used to determine the FSC/SSC profile 
of  cells  expressing  CD34,  CD133  and  VEGFR2  in  order  to  determine  the  most 
appropriate  gating  strategy  for  enumeration  of  EPCs  in  isolated  PBMCs.    Previous 
studies have used FSC/SSC gates for viable cells based on the lymphocyte population 
alone (Vasa et al., 2001),  an “extended lymphocyte gate” (Laufs et al., 2005) or both 
lymphocytes and monocytes combined (Rustemeyer et al., 2006) and therefore it was 
decided to investigate which strategy would include all putative EPCs  
  
As Figure 6.2 indicates, when cells positive for CD34, VEGFR2 or CD133 were back-
gated their FSC/SSC profiles fell within a similar region to lymphocytes (Figure 6.2a-f).  
However it was notable that both the CD34 and CD133 populations extended beyond 
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Figure  6-1:  %  of  mononuclear  cells  expressing  EPC  markers  in  whole 
blood, fresh or frozen isolated PBMCs 
 
 
 
Figure 6.1a: Blood was obtained from 5 healthy adult controls.  The percentage of mononuclear cells 
(monocytes and lymphocytes expressing of CD34 (figure 6.1a), CD133 (Figure 6.1b), VEGFR2 (Figure 
6.1c)  and  the  combination  of  all  three  markers  (figure  6.1d)  was  determined  in  whole  blood,  fresh 
PBMCs and frozen PBMCs.  There were no  overall significant differences between fresh and frozen 
PBMCs for expression for these markers and only VEGFR2 appeared higher (although not significantly) 
in whole blood from PBMCs (paired analysis vs fresh p=0.12, vs frozen p=0.14)  
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the  lymphocyte  population  (highlighted  in  Figure  6.2g  and  h).    Thus  an  “extended 
lymphocyte gate” might be most appropriate to detect these cells.   
 
However this may be difficult to reproduce between different samples, particularly in 
vasculitis  when  the  populations  gated  on  may  be  activated  or  apoptotic  which  can 
influence their FSC/SSC profile (Darzynkiewicz et al., 1992).  Of particular concern 
was  defining  the  upper  limit  of  the  gate,  between  the  lymphocyte  and  monocyte 
populations.  Thus it was decided that a gate encompassing all PBMCs allowing EPCs 
to be expressed as a percentage of PBMCs would be a more standardized measure in 
this cohort (bold outline in Figure 6.2f).   
 
6.3.3.2 CD34+ cell gating 
Using  a  large  viable  cell  gate  has  disadvantages,  however,  as  cells  from  different 
populations may have slightly different staining intensities and there is a greater risk of 
non  specific  binding.    As  can  be  seen  in  Figures  6.2a  and  b  CD34+  and  CD133+ 
PBMCs isolated from cord blood formed discrete populations.  The same was true for 
the CD34+ population in adult blood (data not shown).   In some individuals while the 
VEGFR2 staining was a much greater percentage of the PBMC gate than the percentage 
of CD34+ cells, there was much variability and discrete populations were not observed.  
It was decided that in order to allow identification of the different populations of CD34+ 
cells, PBMCS could be gated first on their FSC SSC and then on CD34 positivity, to 
further reduce background noise.  The staining of other putative EPC markers can then 
be examined in this population as demonstrated in Figure 6.3a-d.   270 
 
Figure 6-2: FSC SSC characteristics of CD34+, CD133+ and VEGFR+ cells 
 
 
 
Figure 6.2a-h: PBMCs isolated from umbilical cord blood were stained for CD34, CD133 and VEGFR2. 
Cells positive for these markers (Figure 6.2a-c) were gated on, and the FSC/SSC characteristics of these 
populations determined by back-gating (Figure 6.2d-f).  Figures 6.2g - h indicates the combined regions 
that  these  populations  fall  in  (thin  lines)  as  well  as    FSC  SSC  gate  for  EPC  enumeration,  both an 
extended lymphocyte gate (thick line, Figure 6.2g) and a broad mononuclear cell gate (thick line, Figure 
6.2h). 
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Figure 6-3: EPC gating strategy 
 
 
 
 
Figure  6.3:  PBMCs  were  obtained  from  umbilical  cord  blood  and  stained  for  CD34,  CD133  and 
VEGFR2.  Figure 6.3a: PBMCs were gated initially on their FSC SSC characteristics (R1); a large 
mononuclear cell gate incorporating the regions of high staining for CD34 and CD133 as described in 
Figure 6.2. Figure 6.3b: Cells were then gated on CD34 as this marker formed a discrete cell population 
(R2).  Figure  6.3c:  R1  and  R2  were  combined  in  order  to  determine  the  proportion  of  CD34  cells 
expressing CD133 and VEGFR2.   The triple positive population could then be calculated.  Figure 6.3d 
demonstrates the low nonspecific binding of the isotype control for CD34. CD34/VEGFR2/CD133 EPC 
count for this individual would be (0.69-0.04)% x 5.58/100 =  0.036% 
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6.3.3.3 How best to express EPC numbers? 
In the majority of published studies EPCs have been enumerated as a percentage of a 
viable cell gate as described above.  However, as previously discussed this will give 
varying  results  dependent  on  the  size  of  the  gate,  making  it  difficult  to  compare 
different  studies.    Of  perhaps  more  relevance  in  the  vasculitis  cohort  though  is  the 
possibility  that  the  total  number  of  cells  within  the  gated  population  is  changed  in 
disease – for example there may be increased white cell count at disease onset which 
may decrease with immunosuppressive cytotoxic treatment and thus using a percentage 
of this gate may no longer be representative of absolute EPC number (giving falsely 
elevated results in patients with low mononuclear cells). 
 
Absolute enumeration of EPCs using counting beads in whole blood would be one way 
of avoiding this potential pitfall.  However as a number of precious samples had already 
been  stored  prior  to  establishing  the  assay,  and  rare  event  analysis  in  whole  blood 
requires extensive optimization (due to increased background noise and the possibility 
of  lysis  removing  some  of  the  cells  of  interest)  it  was  decided  to  investigate  this 
phenomena concurrently to the aforementioned widely used methodology.  This was 
done by estimating absolute EPC number and evaluating an alternative enumeration 
strategy  which  may  reduce  the  effect  of  this  potential  error  as  described  below 
(summarized in Table 6.1). 
 
Estimating absolute EPC number 
As research bloods were taken from vasculitis patients in the study at the same time as 
routine clinical tests, full blood count as determined by the hospital laboratory could be 
used  to  estimate  absolute  EPC  number.    The  dual  platform  ISHAGE  (International 273 
 
Society of Hematotherapy and Graft Engineering) protocol for enumeration of CD34+ 
cells is routinely performed in hospital laboratories.  This utilizes the leukocyte count 
determined using an automated haematology analyzer and the % of nucleated white 
blood cells (CD45+, including CD45dim cells) expressing CD34, to determine absolute 
CD34  count  in  a  sample,  either  of  peripheral  blood,  bone  marrow  or  leukapheresis 
product (Gajkowska et al., 2006).  It is important to note that applying this principle to 
the patient samples in  his study (as these have undergone density gradient separation to 
isolate PBMCs) does not give an exact measure of CD34+ cells, but can be used as a 
crude tool to estimate EPC levels and determine if trends observed using a percentage of 
the mononuclear gate are reflected when the absolute number of leukocytes is taken into 
account.  Thus validating the use of a percentage of a viable cell gate as an expression 
of EPC number in this cohort. 
 
Alternative gating 
Expressing EPCs as a percentage of the large mononuclear cell gate, gives a very small 
value (in healthy adult controls values were <0.1%, Figure 6.1d), which as discussed 
above could be influenced by changes in cell numbers.  Another approach which has 
been  utilized  in  T  cell  biology  when  examining  rare  populations  is  to  express  the 
population of interest as a percentage of a much more defined, relevant population.  For 
example, the IL-17 producing T cell subset (Th17 cells) is expressed as a percentage of 
CD4+ T cells (Nistala et al., 2008), not as an absolute number or as a percentage of the 
larger total T cell population.  As the CD34+ population can reconstitute all blood cell 
lineages  (Cheng  et  al.,  1996)  and  is  thought  to  contain  the  “true  EPC”  population, 
changes in expression of EPC markers in this cell population, may be an informative 
indicator of a reparative responses -  reflecting changes in haematopoetic progenitor 274 
 
differentiation.  As can be seen in Figure 6.3, while cells expressing CD34, CD133 and 
VEGFR2 are only 0.036% of the mononuclear cell gate, they make up 5.68% of the 
CD34  population.    The  advantages  and  disadvantages  associated  with  each  of  the 
aforementioned methodologies for EPC enumeration is summarised in Table 6.1. 
 
Table 6-1: How best to enumerate and express EPC number 
 
Method  Advantages  Disadvantages 
Whole blood – absolute 
enumeration, using counting 
beads or ISHAGE dual 
platform protocols 
(Gajkowska et al., 2006) 
Only a small volume of blood 
required (<1ml) 
 
Can get an absolute value for 
EPCs per ml of blood 
Much background noise 
 
Lysis is necessary - may 
remove fragile cell 
populations 
 
Samples must be processed 
quickly, cannot be stored 
PBMC – expressing EPCs as 
% of viable cell gate. 
PBMCs can be isolated and 
stored for batch analysis 
 
If same gate is used, studies 
can be easily compared 
 
Variable gating strategy has 
been described in literature 
 
Changes in total 
mononuclear cell number 
with therapeutic intervention 
could influence results 
PBMCs – expressing EPCs 
as a % of CD34 cells 
PBMCs can be isolated and 
stored for batch analysis 
 
Gate is less variable 
 
Changes in total mononuclear 
cell number will have less of 
an affect on population of 
interest 
This methodology has not 
been described in the 
literature for EPC 
enumeration 
 
 
 
 
 
For  the  purposes  of  this  thesis  EPCs  were  enumerated  from  PBMCs  isolated  from 
patient  using  the  two  enumeration  methodologies  described  in  the  above  table.  
Absolute  EPC  number  was  also  estimated  from  the  values  obtained  in  PBMCs  to 
determine  if  either  of  these  two  enumeration  met hodologies  mirrored  the  trends 
observed in absolute number. 
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6.4 EPCs in vasculitis 
6.4.1 Patients and Methods 
6.4.1.1 Patients 
15 children with primary systemic vasculitis were studied.  These patients were the 
same individuals described in Chapters 3, 4 and 5, allowing EPCs to be compared with 
CECs, MPs and growth factors involved in angiogenic/vasculogenic responses.  The 
patients studied included 6 males and 9 females of median age 9.7 years (range 1.0.-
15.3  years).  The  vasculitis  type  was  polyarteritis  nodosa  (PAN)  n=6,  Wegener’s 
granulomatosis  (WG)  n=4,  Kawasaki  disease  (KD)  n=1,  unclassified  n=3.  Disease 
activity was assessed using a modified paediatric BVAS as previously described.  18 
healthy child controls (4 males, 14 female, median age 8.4, range 1.5-14.6), 4 febrile 
controls  (1  male,  3  females  with  a  variety  of  autoimmune  or  other  inflammatory 
disorders without the presence of vasculitis, median age 7.8, range 1.5-12) and 5 healthy 
adult controls were also recruited (1 male, 4 females, age range 24-30 years). As with 
the  vasculitis  patients,  the  control  individuals  were  the  same  as  those  studied  in 
Chapters 3 and 4.    Blood was processed immediately after collection as described in 
Chapter 2.6.   
 
6.4.1.2 Methods 
FC was performed as  described previously  and in  section 2.6.2.   In order to allow 
enough  flow  cytometric  cell  events  for  accurate  rare  event  analysis,  the  number  of 
markers examined was varied so that in individuals where only small numbers of cells 
were obtained, meaningful data could still be acquired (Flow cytometric staining plans 
are listed in Appendix 3).  Putative EPCs were enumerated as a % of total PBMC 
population and as a % of CD34+ cells to determine which was the most appropriate 276 
 
measure in this cohort.  Absolute EPC number was estimated from whole blood counts 
obtained  from  the  hospital  laboratory,  to  determine  if  trends  observed  in  individual 
patients were reflective of absolute EPC number.  
  
6.4.1.3 Statistics 
The Mann-Whitney U test or Wilcoxon signed rank test (paired samples) were used to 
compare EPCs between patient groups (active vs inactive vasculitis – paired samples) 
and controls (unpaired analysis).  As only a small number of patients were studied – the 
majority of the active-inactive vasculitis data was paired and therefore there was not 
enough data to exclude paired events for comparative unpaired analysis between active 
and inactive disease. Spearman rank correlation coefficiants were used to determine 
correlation.  All statistical analyses were performed in SPSS version 15.0. Statistical 
significance was set at p<0.05.   In all data graphs patient classification was denoted 
using colour coding as indicated below: 
 
 
 
6.4.2 Results 
6.4.2.1 CD34+ cells 
Kruskall Wallis testing indicated no overall significant differences in the percentage of 
PBMCs expressing CD34 between test groups (p=0.3).  When individual analysis was 
performed the percentage of PBMCs expressing CD34, was not significantly different 
between 14 patients with active vasculitis (median value 0.198%) and 18 healthy child 277 
 
controls  (median  value  0.161%)  or  4  febrile  controls  (median  value  0.18%).    The 
percentage of PBMCs expressing CD34 was however significantly lower in 5 healthy 
adult controls (median value 0.04%) compared to 18 healthy children (p=0.03) or 14 
children with active vasculitis (p=0.04). There were no significant differences between 
9 patients with inactive vasculitis (median value 0.11%) and any of the control groups.   
(Figure 6.4a).   
 
In  9  individual  patients,  there  were  no  significant  differences  in  the  percentage  of 
PBMCs  expressing  CD34  between  active  vasculitis  and  remission  (median  time  to 
remission 4 months)  (Figure 6.4b).  When 10 individual  patients  were  followed up 
longitudinally from disease onset and initiation of treatment for up to 15 months there 
were no significant differences in CD34+ cells between onset and median followup of 3 
and 12 months (Figure 6.4c).   
 
In order to determine if the % of PBMCs expressing CD34 was comparable to the 
absolute  numbers  of  CD34+  cells  the  changes  in  absolute  CD34+  cell  number  was 
estimated as described above in section 6.6.3.  (Figure 6.5a and b).  Line colour reflects 
individual  patients  disease  classification  and  the  different  line  styles 
(solid/dashed/dotted)  represent  individual  patients.    Notably,  whilst  a  number  of 
patients’  changes  in  absolute  CD34  number  reflected  the  changes  in  %  of  PBMCs 
expressing  CD34,  in  some  individuals  the  trends  went  in  different  directions  (3/10, 
although only 1 – the red dashed line was considerably different), indicating that % of 
PBMCs may not be the most appropriate way of expressing EPC count in this cohort.  
At median followup of 3 and 12 months, there were no significant differences observed 
for either of these measures of CD34 count from pretreatment levels. 278 
 
Figure 6-4:CD34+ cells in vasculitis 
 
 
 
 
 
Figure 6.4a: Kruskall  Wallis testing indicated no overall significant differences between test groups 
(p=0.3).    Individual  analysis  revealed  there  were  no  significant  differences  in  the  %  of  PBMCs 
expressing CD34 between 15 patients with active vasculitis and 4 febrile controls or 18 healthy child 
controls.      However  5  adults  had  significantly  lower  CD34%  compared  to  15  children  with  active 
vasculitis  (p=0.04)  and  18  healthy  child  controls  (p=0.03).    There  were  no  significant  differences 
between 9 patients in remission and these controls groups.  Figure 6.4b:  In 9 individual patients, there 
were  no  significant  difference  in  CD34+  PBMCs  during  active  or  inactive  disease,  median  time  to 
remission 4 months (p=0.08).  
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Figure 6-5: CD34+ cells in vasculitis – responses to treatment 
 
 
Figure  6.5a-b:  Changes  in  the  %  of  PBMCs  expressing  CD34  over  time  from  disease  onset  was 
compared to changes in estimated absolute numbers of CD34+ cells.  Line colour reflects individual 
patients disease classification (as before) and the different line styles (solid/dashed/dotted) represent 
individual patients.  Of the 10 patients followed longitudinally, the changes observed in 7 individuals 
were the same using both enumeration methods.  At median followup of 3 and 2 months, there were no 
significant differences using either technique when compared to pretreatment levels. 280 
 
6.4.2.2 CD34+CD133+ cells 
PBMCs expressing both CD34 and CD133, could be indicative of an early progenitor 
population  (although  not  necessarily  one  of  endothelial  lineage).    Kruskall  Wallis 
testing  indicated  no  overall  significant  differences  in  the  percentage  of  PBMCs 
expressing both CD34 and CD133 between test groups (p=0.13).  Individual analysis, 
however  revealed  that  the  percentage  of  CD34+CD133+  PBMCs  were  significantly 
higher in 15 patients with active vasculitis (median value 0.099%) compared to 18 child 
controls (median value,0.037%, p=0.017), although not 4 febrile controls (median value 
0.056%) or 5 healthy adult controls (median value 0.05%).  There were no significant 
differences between 9 patients in remission (median value 0.057%) and these control 
groups, nor was there any difference using unpaired analysis (although paired data was 
included in this due to small numbers) between active and inactive vasculitis (p=0.08, 
Figure 6.6a).  In 9 individual patients, there appeared to be a trend towards a higher % 
of PBMCs  expressing CD34+CD133+ during active disease compared to remission, 
although this had not reached statistical significance (p=0.054, median time to remission 
4 months) (Figure 6.6b).   
 
When the CD34+CD133+ population was expressed as the percentage of CD34+ cell 
expressing CD133, Kruskall Wallis testing indicated an overall significant difference 
between  populations  (p=0.006).    Individual  analysis  revealed  that  the  percentage  of 
CD34+  cells  expressing  CD133  was  significantly  higher  in  patients  with  active 
vasculitis (median value 53.5%) compared to 18 child controls (median value 28%, 
p=0.005), although not 4 febrile controls (median value 39%) or 4 healthy adult controls 
(median  value  27.5%).    There  was  no  significant  difference  between  9  patients  in 
remission  (median  value  39%)  and  these  control  groups.  Unpaired  analysis  (again 281 
 
paired data was included in this due to small numbers) between active and inactive 
vasculitis  revealed  significantly  higher  CD133+CD34+  cells  in  patients  with  active 
disease (p=0.03, Figure 6.6c).  This finding was also true when paired analysis in 9 
individual patients was performed (p=0.04, median time to remission 4 months). 
 
In order to determine if the % of PBMCs expressing CD34 and CD133 was comparable 
to  the proportion  of CD34+ PBMCs  expressing CD133 or the  absolute numbers  of 
CD34+ CD133+ cells, the changes observed in individual patients using these methods 
of expressing EPC are shown in figure 6.7a-c.   Of the 10 patients followed up from 
disease  onset,  the  changes  in  the  %  of  PBMCs  expressing  CD34  and  CD133  were 
mirrored in 7/10 individuals by the changes in the % of CD34+ expressing CD133 and 
8/10 individuals by changes in the estimate of absolute number.  The changes in the 
estimate of absolute number were mirrored in 9/10 individuals by the proportion of 
CD34+ cells expressing CD133. 
 
When 10 patients were followed up from disease onset, the only significant difference 
observed was between pretreatment levels and median followup of 12 months for the 
absolute estimate of CD34+CD133+ cells.  There were no other significant differences 
in CD34+CD133+ between onset and median followup of 3 and 12 months for any of 
the three ways of expressing cell numbers (Figure 6.5c).  P values for percentage of 
PBMCs were p=0.25 and p= 0.22, for the percentage of CD34+ cells p = 0.054 and p = 
0.16 and for the estimate of absolute number p=0.1, p=0.03 respectively. 
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Figure 6-6: CD34+CD133+ cells in vasculitis 
 
Figure  6.6a:  Kruskall  Wallis  testing  indicated  no  overall  significant  differences  in  the  percentage  of  PBMCs 
expressing  CD34  and  CD133  between  test  groups  (p=0.13).    Individual  analysis  however  revealed  that 
CD133+CD34+ PBMCs were significantly higher in 15 patients with active disease compared to 18 healthy child 
controls (p=0.017) although not 4 febrile controls or 5 healthy adult controls.  There were no significant differences 
between 9 patients in remission and these controls groups.  Figure 6.6b:  In 9 individual patients, there were no 
significant difference in CD34+CD133 PBMCs during active or inactive disease, median time to remission 4 months 
(p=0.054).    Figure  6.6c:  Kruskall  Wallis  testing  indicated  significantly  different  proportions  of  CD34+  cells 
expressing CD133 between test groups (p=0.006).  Individual analysis revealed that the CD133+ proportion of 
CD34+ PBMCs was significantly higher in 15 patients with active disease compared to 18 healthy child controls 
(p=0.005) and 9 patients in remission (p=0.03) although not 4 febrile controls or 18 healthy adult controls.  There 
were no significant differences between 9 patients in remission and these controls groups.  Figure 6.6d:  Paired 
analysis in 9 individual patients, showed that the CD133+ proportion of CD34+ PBMCs was significantly higher 
during active compared to remission (p=0.04, median time to remission 4 months).   
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Figure 6-7:  CD34+CD133+ cells in vasculitis – responses to treatment 
 
Figure 6.7a-c: Changes in the % of PBMCs expressing CD34 and CD133 (Figure 6.7a), the proportion 
of CD34 cells expressing CD133 (Figure 6.7b) and the estimated absolute numbers of CD34+CD133+ 
cells (Figure 6.7c) were observed over time from disease onset in individual patients.   Line colour 
reflects  individual  patients  disease  classification  (as  before)  and  the  different  line  styles 
(solid/dashed/dotted)  represent  individual  patients.    Of  the  10  patients  followed  longitudinally,  the 
changes in the % of PBMCs expressing CD34 and CD133 were mirrored by 7/10 individuals in the 
changes in the proportion of CD34+ expressing CD133 and 8/10 individuals in changes in the estimate of 
absolute number.  The changes in the estimate of absolute number were mirrored in 9/10 individuals by 
changes in the proportion of CD34+ cells expressing CD133.   When values at median followup of 3 and 
12 months, were compared to disease onset, a significant difference was only observed at 12 months 
when the estimate of absolute number was considered (p=0.03).    284 
 
6.4.2.3 CD34+CD133+VEGFR2+ cells 
PBMCs  which  express  CD34,  VEGFR2  and  CD133,  has  been  the  most  widely 
published  description  of  EPCs.    In  this  study  Kruskall  Wallis  testing  indicated  no 
overall significant differences in the percentage of PBMCs expressing CD34, VEGFR2 
and CD133 between test groups (p=0.19).  Individual analysis, however revealed that 
the  percentage  of  CD34+VEGFR2+CD133+  PBMCs  was  significantly  higher  in  15 
patients with active vasculitis (median value 0.027%) compared to 18 child controls 
(median value 0.016%, p=0.04), although not 4 febrile controls (median value 0.027%) 
or  5  healthy  adult  controls  (median  value  0.017%).    There  were  no  significant 
differences between 9 patients in remission (median value 0.023%) and these control 
groups nor was there any difference using unpaired analysis (although paired data was 
included in this due to small numbers) between active and inactive vasculitis (p=0.3, 
Figure  6.8a).    In  9  individual  patients,  paired  analysis  also  revealed  no  significant 
difference  in  the  percentage  of  CD34+VEGFR2+CD133+  PBMCs  between  active 
vasculitis and remission (p=0.4, median time to remission 4 months, Figure 6.8b).   
 
When the CD34+VEGFR2+CD133+ population was  expressed as the  percentage of 
CD34+ cell expressing VEGFR2 and CD133, Kruskall Wallis testing failed to reach 
significance (p=0.052).  Individual analysis  however revealed that the proportion of 
CD34+ cells expressing VEGFR2 and CD133 was significantly higher in patients with 
active vasculitis (median value 28.5%) compared to 18 child controls (median value 
11%, p=0.007), although not 4 febrile controls (median value 12%) or 5 healthy adult 
controls (median value 20%).  There was no significant difference between 9 patients in 
remission (median value 15%) and these control groups.  Unpaired analysis  (again  
paired   data   was   included   due   to   small   numbers)   between  active  and  inactive 285 
 
Figure 6-8: CD34+VEGFR2+CD133+ cells in vasculitis 
 
Figure  6.8a:  Kruskall  Wallis  testing  indicated  no  overall  significant  differences  in  the  percentage  of  PBMCs 
expressing CD34, VEGFR2 and CD133 between test groups (p=0.2).  Individual analysis however revealed that 
CD34+VEGFR2+CD133+ PBMCs were  significantly higher in 15  patients  with active  disease  compared  to 18 
healthy child controls (p=0.04) although not 4 febrile controls or 5 healthy adult controls.  There were no significant 
differences between 9 patients in remission and these control groups.  Figure 6.8b:  In 9 individual patients, there 
were no significant difference in CD34+VEGFR2+CD133+ PBMCs during active or inactive disease, median time 
to remission 4 months (p=0.4).  Figure 6.8c: Kruskall Wallis testing indicated a significantly higher proportion of 
CD34+ cells expressing VEGFR2 and CD133 between test groups (p=0.05).  Individual analysis revealed that the 
VEGFR2+CD133+  proportion  of  CD34+  PBMCs  was  significantly  higher  in  15  patients  with  active  disease 
compared to 18 healthy child controls (p=0.004) although not 9 patients in remission, 4 febrile controls or 18 healthy 
adult controls.  There were also no significant differences between 9 patients in remission and any control group.  
Figure 6.8d:  Paired analysis in 9 individual patients, showed that the VEGFR2+CD133+ proportion of CD34+ 
PBMCs was not significantly different between active vasculitis and remission (p=0.5, median time to remission 4 
months).   286 
 
Vasculitis revealed no significant differences (p=0.3, Figure 6.8c). This finding was also 
true when paired analysis in 9 individual patients was performed (p=0.5, median time to 
remission 4 months, Figure 6.8d). 
 
In order to determine if the % of PBMCs expressing CD34, VEGFR2 and CD133 was 
comparable to the proportion of CD34+ PBMCs expressing VEGFR2 and CD133 or the 
absolute  numbers  of  CD34+  VEGFR2+CD133+  cells,  the  changes  observed  in 
individual patients using the methods of expressing EPC are shown in Figure 6.9a-c.   
Of the 10 patients followed up form disease onset, the changes in the % of PBMCs 
expressing  CD34,  VEGFR2  and  CD133  were  mirrored  in  5/10  individuals  by  the 
changes in the % of CD34+ expressing VEGFR2 and CD133 and 7/10 individuals by 
changes in the estimate of absolute number.  The changes in the estimate of absolute 
number were mirrored in 6/10 individuals by the proportion of CD34+ cells expressing 
VEGFR2 and CD133.    
 
When 10 patients were followed up from disease onset, no significant differences were 
observed between pretreatment levels and median followup of 3 or 12 months for for 
any of the three ways of expressing cell numbers (Figure 6.9a-c).  P values for the 
percentage of PBMCs were p = 0.6 and p = 0.3, for the percentage of CD34+ cells were 
p=0.2 and p=0.3 and for the estimate of absolute number p=0.1, p=0.15 respectively. 
 
6.4.2.4 CD34+ VEGFR2+ cells 
As  discussed  in  the  introduction  to  this  chapter  some  groups  consider  only  the 
CD34+VEGFR2+  population  when  describing  EPCs  using  flow  cytometry.    Using 
Kruskall  Wallis  testing  revealed that the percentage of PBMCs expressing  CD34  and 
VEGFR2 was not significantly different between test groups (p=0.5).   287 
 
Figure 6-9: CD34+VEGFR2+CD133+ cells in vasculitis 
 
Figure 6.9a-c: Changes in the % of PBMCs expressing CD34,VEGFR2 and CD133 (Figure 6.9a), the proportion of 
CD34  cells  expressing  VEGFR2  and  CD133  (Figure  6.7b)  and  the  estimated  absolute  numbers  of 
CD34+VEGFR2+CD133+ cells (Figure 6.7c) were observed over time from disease onset in individual patients.   
Line  colour  reflects  individual  patients  disease  classification  (as  before)  and  the  different  line  styles 
(solid/dashed/dotted) represent individual patients.  Of the 10 patients followed longitudinally, the changes in the % 
of  PBMCs  expressing  CD34,  VEGFR2  and  CD133  were  mirrored  by  5/10  individuals  in  the  changes  in  the 
proportion of CD34+ expressing CD133 and 7/10 individuals in changes in the estimate of absolute number.  The 
changes in the estimate of absolute number were mirrored in 6/10 individuals by changes in the proportion of 
CD34+ cells expressing VEGFR2 and CD133.   When values at median followup of 3 and 12 months, were compared 
to disease onset, no significant differences were observed for any of the methods of enumeration. 288 
 
On individual analysis no significant differences were observed between 15 patients 
with active vasculitis (median value 0.04%)  compared to 18 child controls (median 
value  0.05%),  4  febrile  controls  (median  value  0.09%)  or  5  healthy  adult  controls 
(median  value  0.03%).    There  was  no  significant  difference  between  9  patients  in 
remission (median value 0.05%) and these control groups. Unpaired analysis between 
active  vasculitis  and  patients  in  remission  also  revealed  no  significant  differences 
(Figure 6.10a).  A finding repeated when data pairing was considered in the analysis 
(Figure 6.10b).   
 
When  CD34+VEGFR2+  cells  were  expressed  as  the  proportion  of  CD34+  cells 
expressing  VEGFR2,  Kruskall  Wallis  testing  also  revealed  no  overall  significant 
differences  between  tesr  groups  (p=0.3).    Individual  analysis  again  revealed  no 
significant differences between patients with active vasculitis (median value 43%) or 
those in remission (median value 18%) and any of the control groups (median values 
adults = 21%, healthy children = 29%, febrile controls = 37%) .  Unpaired analysis 
between  active  vasculitis  and  patients  in  remission  also  revealed  no  significant 
differences, however when paired analysis was performed although not yet significant 
there appeared to be a trend with 7/9 patients having lower levels in disease remission 
(p=0.07).   
 
In  order  to  determine  if  the  %  of  PBMCs  expressing  CD34  and  VEGFR2  was 
comparable to the proportion of CD34+ PBMCs expressing VEGFR2 or the absolute 
numbers of CD34+ VEGFR2+ cells, the changes observed in individual patients using 
the methods of expressing  EPCs are shown in  Figure 6.11a-c.   Of the 10 patients 
followed up form disease onset, the changes in the % of PBMCs expressing CD34 and  289 
 
Figure 6-10: CD34+VEGFR2+ cells in vasculitis  
 
Figure  6.10a:  Kruskall  Wallis  testing  indicated  no  overall  significant  differences  in  the  percentage  of  PBMCs 
expressing  CD34  and  VEGFR2  between  test  groups  (p=0.5).    Individual  analysis  also  revealed  no  significant 
differences between 14 patients with active vasculiits and 18 healthy child controls, 4 febrile controls or 5 healthy 
adult controls.  There were no significant differences between 9 patients in remission and these control groups.  
Figure 6.10b:  In 9 individual patients, there was a trend towards a decrease in CD34+VEGFR2+ PBMCs during 
remission, however this had not reached significance (p=0.07, median time to remission 4 months).  Figure 6.10c: 
Kruskall  Wallis  testing  indicated  no  overall  significant  difference  in  the  proportion  of  CD34+  cells  expressing 
VEGFR2  between  test  groups (p=0.3).    Individual analysis  also  revealed  no  significant  differences between  14 
patients with active vasculiits and 18 healthy child controls, 4 febrile controls or 5 healthy adult controls.  There 
were no significant differences between 9 patients in remission and these control groups.   Figure 6.10:  Paired 
analysis in 9 individual patients, showed that the VEGFR2+ proportion of CD34+ PBMCs expressing VEGFR2 was 
not significantly different between active vasculitis and remission (p=0.15, median time to remission 4 months).   290 
 
VEGFR2  were  mirrored  in  6/10  individuals  by  the  changes  in  the  %  of  CD34+ 
expressing VEGFR2 and in 8/10 individuals by changes in the estimate of absolute 
number.    The  changes  in  the  estimate  of  absolute  number  were  mirrored  in  8/10 
individuals by the proportion of CD34+ cells expressing VEGFR2.   When 10 patients 
were followed up from disease onset, no significant differences were observed between 
pretreatment levels and median followup of 3 or 12 months for any of the three ways of 
expressing cell numbers (Figure 6.11a-c).  P values for the percentage of PBMCs were 
p = 0.5 and p = 0.3, for the percentage of CD34+ cells were p = 0.1 and p= 0.5 and for 
the estimate of absolute number p=0.2, p=0.15 respectively. 
 
6.4.2.5 CD34+CD144+ cells  
Another putative EPC combination described in a number of studies is CD34+CD144+ 
cells.  Using Kruskall Wallis testing revealed that the percentage of PBMCs expressing 
CD34  and  CD144  was  not  significantly  different  between  test  groups  (p=0.13).  
However, individual analysis revealed that 14 patients with active vasculitis (median 
value 0.05%) had significantly higher CD34+CD144+ PBMCs compared to 17 child 
controls (median value 0.019%, p=0.013), although not 4 febrile controls (median value 
0.09%) or 5 healthy adult controls (median value 0.03%).  There was no significant 
difference  between  8  patients  in  remission  (median  value  0.05%)  and  these  control 
groups.  Unpaired  analysis  between  active  vasculitis  and  patients  in  remission  also 
revealed no significant differences, a finding repeated when data pairing was considered 
in  the  analysis  (Figure  6.12b).    When  CD34+CD144+  cells  were  expressed  as  the 
proportion of CD34+ cells expressing CD144, Kruskall Wallis testing also revealed no 
overall significant differences between test groups (p=0.17).   
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Figure 6-11: CD34+VEGFR2+cells in vasculitis – responses to treatment 
 
Figure  6.11a-c:  Changes  in  the  %  of  PBMCs  expressing  CD34  and  VEGFR2  (Figure  6.11a),  the 
proportion of CD34 cells expressing VEGFR2 (Figure 6.11b) and the estimated absolute numbers of 
CD34+VEGFR2 cells (Figure 6.11c) were observed over time from disease onset in individual patients.   
Line colour reflects individual patients disease classification (as before) and the different line styles 
(solid/dashed/dotted)  represent  individual  patients.    Of  the  10  patients  followed  longitudinally,  the 
changes in the % of PBMCs expressing CD34, and VEGFR2 were mirrored by 6/10 individuals in the 
changes  in  the  proportion  of  CD34+  expressing  VEGFR2  an  in  8/10  individuals  in  changes  in  the 
estimate of absolute number.  The changes in the estimate of absolute number were mirrored in 8/10 
individuals by changes in the proportion of CD34+ cells expressing VEGFR2 and CD133.   When values 
at median followup of 3 and 12 months, were compared to disease onset, no significant differences were 
observed for any of the methods of enumeration. 292 
 
Individual  analysis  revealed  no  significant  differences  between  patients  with  active 
vasculitis (median value 38%) and any of the control groups (median values adults = 
35%, healthy children = 34%, febrile controls = 9%) or those in remission (median 
value 16%) (Figure 6.12c).  Unpaired analysis between active vasculitis and patients in 
remission  revealed  a  significantly  higher  proportion  of  CD144+  cells  during  active 
disease  (p=0.026),  however  when  paired  analysis  was  performed  on  9  individual 
patients, the data was no longer significant (p=0.19, Figure 6.12d). 
 
In order to determine if the % of PBMCs expressing CD34 and CD144 was comparable 
to  the proportion  of CD34+ PBMCs  expressing CD144 or the  absolute numbers  of 
CD34+ CD144+ cells, the changes observed in individual patients using the methods of 
expressing EPCs are shown in Figure 6.13a-c.   Of the 9 patients followed up form 
disease  onset,  the  changes  in  the  %  of  PBMCs  expressing  CD34  and  CD144  were 
mirrored in 6/9 individuals by the changes in the % of CD34+ expressing CD144 and in 
6/9 individuals by changes in the estimate of absolute number.  The changes in the 
estimate  of  absolute  number  were  mirrored  in  7/9  individuals  by  the  proportion  of 
CD34+ cells expressing CD144.    
 
When 9 patients were followed up from disease onset, no significant differences were 
observed between pretreatment levels and median followup of 3 or 12 months for any of 
the three ways of expressing cell numbers (Figure 6.13a-c).  P values for the percentage 
of PBMCs were p = 0.6 and p = 0.7, for the percentage of CD34+ cells were p = 0.5 and 
p= 0.8 and for the estimate of absolute number p=0.3, p=0.8 respectively. 
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Figure 6-12:  CD34+CD144+ cells in vasculitis 
 
Figure  6.12a:  Kruskall  Wallis  testing  indicated  no  overall  significant  differences  in  the  percentage  of  PBMCs 
expressing CD34 and CD144 between test groups (p=0.13).  However individual analysis revealed that 14 patients 
with active vasculitis had significantly higher CD34+CD144+ cells compared to 17 healthy child controls (p=0.013), 
although not 4 febrile controls or 5 healthy adult controls.  There were no significant differences between 9 patients 
in remission and these control groups.  Figure 6.12b:  In 8 individual patients, there was no significant difference 
between active vasculitis and remission (p=0.07, median time to remission 4 months).  Figure 6.12c: Kruskall Wallis 
testing indicated no overall significant difference in the proportion of CD34+ cells expressing CD144 between test 
groups (p=0.17).  However individual analysis revealed that 14 patients with active vasculitis had significantly 
higher CD34+CD144+ cells compared to 8 patients in remission, although not 17 healthy child controls, 4 febrile 
controls or 5 healthy adult control.    Figure 6.10: In 8 individual patients, there was no significant difference 
between active vasculitis and remission (p=0.19, median time to remission 4 months).  294 
 
Figure 6-13: CD34+CD144+ cell in vascultis – response to treatment 
 
   
Figure 6.13a-c: Changes in the % of PBMCs expressing CD34 and CD144 (Figure 6.13a), the proportion of CD34 
cells expressing CD144 (Figure 6.13b) and the estimated absolute numbers of CD34+CD144+ cells (Figure 6.13c) 
were observed over time from disease onset in individual patients.   Line colour reflects individual patients disease 
classification (as before) and the different line styles (solid/dashed/dotted) represent individual patients.  Of the 9 
patients followed longitudinally, the changes in the % of PBMCs expressing CD34 and CD144 were mirrored by 6/9 
individuals in the changes in the proportion of CD34+ expressing VEGFR2 an in 6/9 individuals in changes in the 
estimate of absolute number.  The changes in the estimate of absolute number were mirrored in 7/9 individuals by 
changes in the proportion of CD34+ cells expressing VEGFR2 and CD133.   When values at median followup of 3 
and 12 months, were compared to disease onset, no significant differences were observed for any of the methods of 
enumeration. 295 
 
6.4.2.6 CD34+CD144+CD133+ cells  
As CD34 and CD144 are both found on mature ECs, further discrimination is necessary 
and  thus  this  population  was  examined  in  combination  with  the  progenitor  marker 
CD133.    Using  Kruskall  Wallis  testing  revealed  that  the  percentage  of  PBMCs 
expressing  CD34  and  CD144  was  not  significantly  different  between  test  groups 
(p=0.17).    Individual  analysis  also  revealed  no  significant  differences  between  14 
patients with active vasculitis (median value 0.03%) and any of the control groups (17 
healthy  children, median value  = 0.01%, 4 febrile controls,  median value 0.01%, 5 
healthy adult controls, median value 0.02%).  8 patients in remission (median value 
0.01%) appeared to have lower CD34+CD144+CD133+ cells than patients with active 
vasculitis (unpaired analysis, p=0.07) and healthy child controls although this had not 
reached significance (p=0.051, Figure 6.14a).  When paired analysis was performed 
between active and inactive vasculitis in 8 individual patients there was no significant 
difference observed (p=0.1, Figure 6.14b).   
 
When CD34+CD144+CD133+ cells were expressed as the proportion of CD34+ cells 
expressing  CD144  and  CD133,  Kruskall  Wallis  testing  also  revealed  no  overall 
significant differences between test groups (p=0.12).  Individual analysis revealed no 
significant differences between patients with active vasculitis (median value 18.6%) and 
any of the control groups (median values adults = 17%, healthy children = 14%, febrile 
controls = 9%).  There was also no significant difference between patients in remission 
(median  value  8.5%)  and  these  control  groups,  although  values  appeared  lower  in 
patients in remission compared to healthy child controls, this failed to reach significance 
(p=0.07, Figure 6.14c).  Unpaired analysis between active and inactive disease revealed 
patients with active disease had significantly higher CD34+CD144+CD133+ cells than 296 
 
Figure 6-14 :CD34+CD144+CD133+ cells in vasculitis  
 
Figure  6.14a:  Kruskall  Wallis  testing  indicated  no  overall  significant  differences  in  the  percentage  of  PBMCs 
expressing CD34, CD144 and CD133 between test groups (p=0.17).  Individual analysis also revealed no significant 
difference between 14 patients with active vasculitis and 17 healthy child controls, 4 febrile controls or 5 healthy 
adult controls.  There were no significant differences between 8 patients in remission and these control groups.  
Figure 6.14b:  In 8 individual patients, there was no significant difference between active vasculitis and remission 
(p=0.1, median time to remission 4 months).  Figure 6.14c: Kruskall Wallis testing indicated no overall significant 
difference in the proportion of CD34+ cells expressing CD144 and CD133 between test groups (p=0.12).  However 
individual analysis revealed that 14 patients with active vasculitis had significantly higher CD34+CD144+CD133+ 
cells compared to 8 patients in remission, although not 17 healthy child controls, 4 febrile controls or 5 healthy adult 
control.  There were no significant differences between 8 patients in remission and these control groups  Figure 
6.14d: In 8 individual patients, there was no significant difference between active vasculitis and remission (p=0.1, 
median time to remission 4 months).  297 
 
patients in remission (p=0.023), although when paired analysis was performed on 8 
individual patients, the data was no longer significant (p=0.1, Figure 6.14d). 
 
In order to determine if the % of PBMCs expressing CD34, CD144 and CD133 was 
comparable to the proportion of CD34+ PBMCs expressing CD144 and CD133 or the 
absolute numbers of CD34+ CD144+CD133+ cells, the changes observed in individual 
patients using these methods of expressing EPCs are shown in Figure 6.13a-c.   Of the 9 
patients followed up from disease onset, the changes in the % of PBMCs expressing 
CD34 CD144 and CD133 were mirrored in 5/9 individuals by the changes in the % of 
CD34+ expressing CD144 and CD133 and in 8/9 individuals by changes in the estimate 
of absolute number.  The changes in the estimate of absolute number were mirrored in 
6/9 individuals by the proportion of CD34+ cells expressing CD144 and CD133 (Figure 
6.15a-c)    
 
When 9 patients were followed up from disease onset, no significant differences were 
observed between pretreatment levels and median followup of 3 or 12 months for any of 
the three ways of expressing cell numbers (Figure 6.15a-c).  P values for the percentage 
of PBMCs were p = 0.5 and p = 0.9, for the percentage of CD34+ cells were p = 0.3 and 
p= 0.25 and for the estimate of absolute number p=0.4, p=0.4 respectively. 
 
6.4.2.7 Other EPC related CD34 subpopulations 
In  a  small  number  of  individuals,  the  EPC  markers  CD34,  CD133,  VEGFR2  and 
CD144 were examined in combination with CD14, CD45, CD3 and CD146 to further 
establish the origins of CD34+ progenitor cells.   
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Figure  6-15:  CD34+CD144+CD133+  cells  in  vasculitis  –  response  to 
treatment 
 
 
 
Figure 6.15a-c: Changes in the % of PBMCs expressing CD34 CD144 and CD133 (Figure 6.15a), the proportion of 
CD34  cells  expressing  CD144  and  CD133  (Figure  6.15b)  and  the  estimated  absolute  numbers  of 
CD34+CD144+CD133+ cells (Figure 6.15c) were observed over time from disease onset in individual patients.   
Line  colour  reflects  individual  patients  disease  classification  (as  before)  and  the  different  line  styles 
(solid/dashed/dotted) represent individual patients.  Of the 9 patients followed longitudinally, the changes in the % of 
PBMCs expressing CD34,CD144 and CD133 were mirrored by 5/9 individuals in the changes in the proportion of 
CD34+  expressing  CD144  and CD133  in  8/9  individuals  in  changes in  the  estimate of  absolute number.    The 
changes in the estimate of absolute number were mirrored in 6/9 individuals by changes in the proportion of CD34+ 
cells expressing CD144 and CD133.   When values at median followup of 3 and 12 months, were compared to 
disease onset, no significant differences were observed for any of the methods of enumeration. 299 
 
The discrete CD34+ population gated on was frequently negative for CD45 or had only 
dim CD45 staining (Figure 6.16a).  Only a small proportion of CD34 cells expressed 
CD14 (Figure 6.16b) or the EC marker CD146 (Figure 6.16c).  CD146 as often at >1% 
in the blood, the majority of cells expressing it however were CD3+ T cells (Figure 
6.16d). In the small number of patients who were examined for CD34+CD14+CD133+ 
PBMCs, 6 patients with active vasculitis had a significantly higher percentage of this 
monocytic lineage cell expressing progenitor markers, compared to 16 healthy child 
controls  (p=0.035)  (Figure  6.17a).    There  were  no  significant  differences  for 
CD14+CD34+ (figure 6.17b) or CD146+CD34+ (Figure 6.17c) compared to healthy 
child controls.   Figure 6.17a-c only expresses these cell populations as percentage of 
PBMCs, other ways of expressing cell populations were also not significant. 
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Figure 6-16:Further CD34+ staining 
 
 
 
 
 
Figure 6.16a and b: The discrete CD34+ population, was frequently negative for CD45 (Figure 
6.16a) and CD14 (Figure 6.16b) or only exhibited dim staining of either of these markers. Figure 
6.16c: The discrete CD34 population was also predominantly negative for the endothelial marker 
CD146.  The majority of CD146+ cells were CD3 positive T cells. (Figure 6.16d).   
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Figure 6-17: CD34+CD14+CD146+ cells in vasculitis 
 
Figure 6.17a: The % of PBMCs expressing CD34, CD14 and  CD133 were significantly higher in 6 
patients with active vasculitis compared to 16 healthy child controls, although not 4 healthy adult 
controls (not enough data for comparison with febrile controls (n=2)). 6 patients in remission were 
not significantly different from these control groups Figure 6.17b: The % of PBMCs expressing 
CD34  and CD14  were  not  significantly  different  between  6  patients  with  active  vasculitis  or  6 
patients in remission compared  to16 healthy child controls or 4 healthy adult controls (not enough 
data for comparison with febrile controls (n=2)). Figure 6.17c:  The % of PBMCs expressing CD34 
and CD146 were not significantly different between 4 patients with active disease or 4 patients in 
remission compared to 4 healthy child controls. 
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6.4.3 Correlation of EPCs with disease activity 
Spearman Rank correlation coefficiant analysis was performed between the different 
combinations  of  EPCs  markers  (measured  as  %  of  PBMCs  and  %  of  the  CD34+ 
population) and the traditional markers of active disease; BVAS, CRP, ESR, platelet 
count, albumin, white cell count as well as the previously demonstrated novel markers 
of endothelial injury and cellular activation CEC count, EMPs and PMPs and the 4 
growth factors assessed in Chapter 5, in patients with vasculitis.  Tables 6.1 and 6.2 
summarises  the  results.    Table  6.3  shows  the  Holmn-Bonferroni  critical  values  to 
correct for multiple comparisons. 
 
When EPCs were expressed as a percentage of PBMCs, correlations were observed 
between  CD34+CD133+  PBMCs  and  white  cell  count  (r  =  0.444,  p  =  0.012), 
CD34+VEGFR2+ PBMCs and E-selectin +ve MPs (r = -0.516, p = 0.007) and total MP 
count (r = -0.460, p = 0.018) and CD34+ VEGFR2+CD133+ PBMCs and E-selectin 
+ve MPs  (r =  -0.496,  p = 0.010).  When EPCs  were  expressed as  a  percentage of 
CD34+ cells, correlations were observed between CD34+CD133+ PBMCs and white 
cell count (r = 0.364, p=0.044),  CD34+ VEGFR2+ CD133+ PBMCs and CD144 +ve 
MPs  (r = -0.233, p = 0.022*), CD34+VEGFR2+ PBMCs and CD144 +ve MPs (r = -
0.556, p = 0.003), CD14+ MMPs (r = -0.418, p = 0.034) and total MP population (r = -
0.529, p = 0.005).   CD34+CD144+ PBMCs correlated with levels of Ang-1 (r = 0.464, 
p = 0.046).  Interestingly all significant correlations for both methods of expressing 
putative EPC populations with MPs were negative.   
 
When  correction  for  multiple  comparisons  were  taken  into  account  non  of  the 
correlations observed remained significant (Table 6.3). 303 
 
Table 6-2: Spearman rank correlation coefficiants of putative EPC populations 
– expressed as percentage of PBMCs.  
 
 
Significant correlations highlighted in blue 
Marker  of 
disease 
activity/ 
growth 
factors 
%  of 
PBMCs 
expressing 
CD34 
% of PBMCs 
expressing 
CD34/CD133 
% of PBMCs 
expressing 
CD34/CD133/ 
VEGFR2 
%  of 
PBMCs 
expressing 
CD34/ 
VEGFR2 
%  of 
PBMCs 
expressing 
CD34/ 
/CD144 
% of PBMCs 
expressing 
CD34/CD133/ 
CD144 
BVAS  r = 0.18 
p = 0.39 
n = 30 
r = 0.266 
p = 0.149 
n = 31 
r = 0.152 
p = 0.42 
n = 30 
r = 0.080 
p = 0.68 
n = 30 
r = 0.131 
p = 0.515 
n = 27 
r = 0.164 
p = 0.40 
n = 28 
ESR  r = 0.229 
p = 0.231 
n = 29 
r = 0.296 
p = 0.112 
n = 29 
r = 0.221 
p = 0.25 
n = 29 
r = 0.186 
p = 0.34 
n = 29 
r = 0.118 
p = 0.57 
n = 26 
r = 0.152 
p = 0.42 
n = 27 
CRP  r = 0.335 
p = 0.075 
n = 29 
r = 0.325 
p = 0.080 
n = 30 
r = 0.090 
p = 0.64 
n = 29 
r = 0.177 
p = 0.58 
n = 29 
r = 0.025 
p = 0.90 
n = 26 
r = 0.177 
p = 0.38 
n = 27 
WCC  r = 0.274 
p = 0.113 
n = 30 
r = 0.444 
p = 0.012* 
n = 31 
r = 0.256 
p = 0.17 
n = 30 
r = 0.168 
p = 0.37 
n = 30 
r = -0.035 
p = 0.863 
n = 27 
r = 0.331 
p = 0.085 
n = 28 
Platelet 
count 
r =-0.04 
p = 0.83 
n = 29 
r = 0.118 
p = 0.53 
n = 30 
r = 0.053 
p = 0.79 
n = 29 
r = -0.121 
p = 0.53 
n = 29 
r = -0.093 
p = 0.63 
n = 27 
r = 0.088 
p = 0.67 
n = 24 
Albumin  r = -0.160 
p = 0.436 
n = 26 
r = -0.213 
p = 0.29 
n = 27 
r = -0.162 
p = 0.43 
n = 26 
r = -0.011 
p = 0.96 
n = 26 
r = -0.024 
p = 0.65 
n = 23 
r = -0.165 
p = 0.44 
n = 24 
CEC count  r = 0.209 
p = 0.34 
n = 23 
r = 0.340 
p = 0.113 
n = 23 
r = 0.232 
p = 0.29 
n = 23 
r = 0.160 
p = 0.47 
n = 23 
r = -0.026 
p = 0.91 
n = 20 
r = -0.014 
p = 0.96 
n = 20 
EMP 
(CD144+) 
r = 0.083 
p = 0.68 
n = 27 
r = 0.122 
p = 0.545 
n = 27 
r = -0.258 
p = 0.20 
n = 26 
r = -0.236 
p = 0.25 
n = 26 
r = -0.174 
p = 0.43 
n = 23 
r = -0.110 
p = 0.61 
n = 24 
EMP 
(CD105+) 
r = 0.003 
p = 0.988 
n = 27 
r = -0.084 
p = 0.68 
n = 27 
r = -0.233 
p = 0.25 
n = 26 
r = -0.234 
p = 0.25 
n = 26 
r = 0.167 
p = 0.45 
n = 23 
r = -0.220 
p = 0.92 
n = 24 
EMP 
(eselectin+) 
r = -0.184 
p = 0.359 
n = 27 
r = -0.261 
p = 0.188 
n = 27 
r = -0.496 
p = 0.010* 
n = 26 
r = -0.516 
p = 0.007* 
n = 26 
r = -0.303 
p = 0.159 
n = 23 
r = -0.186 
p = 0.39 
n = 24 
PMP 
(CD42a+) 
r = -0.816 
p = 0.354 
n = 27 
r = -0.127 
p = 0.528 
n = 27 
r = -0.120 
p = 0.56 
n = 26 
r = -0.342 
p = 0.087 
n = 26 
r = -0.060 
p = 0.79 
n = 23 
r = -0.007 
p = 0.97 
n = 24 
MMP 
(CD14+) 
r = -0.014 
p = 0.95 
n = 27 
r = -0.009 
p = 0.963 
n = 27 
r = -0.359 
p = 0.072 
n = 26 
r = -0.352 
p = 0.078 
n = 26 
r = -0.044 
p = 0.84 
n = 23 
r = -0.220 
p = 0.30 
n = 24 
Total MP  r = 0.217 
p = 0.32 
n = 23 
r = -0.007 
p = 0.96 
n = 27 
r = -0.296 
p = 0.141 
n = 26 
r = -0.460 
p = 0.018* 
n = 26 
r = 0.093 
p = 0.67 
n = 23 
r = -0.257 
p = 0.23 
n = 24 
VEGF  r = 0.1 
p = 0.62 
n = 26 
r = -0.029 
p = 0.89 
n = 26 
r = -0.068 
p = 0.75 
n = 25 
r = -0.068 
p = 0.748 
n = 25 
r = 0.039 
p = 0.86 
n = 22 
r = 0.299 
p = 0.17 
n = 23 
ANG-1  r = -0.357 
p = 0.112 
n = 21 
r = -0.196 
p = 0.394 
n = 21 
r = -0.050 
p = 0.83 
n = 21 
r = -0.050 
p = 0.830 
n = 21 
r = 0.027 
p = 0.91 
n = 19 
r = 0.012 
p = 0.96 
n = 19 
ANG-2  r = -0.101 
p = 0.61 
n = 28 
r = -0.003 
p = 0.989 
n = 28 
r = -0.204 
p = 0.31 
n = 27 
r = -0.204 
p = 0.308 
n = 27 
r = -0.276 
p = 0.19 
n = 24 
r = -0.117 
p = 0.58 
n = 25 
TB4  r = -0.205 
p = 0.387 
n = 20 
r = -0.015 
p = 0.95 
n = 20 
r = -0.228 
p = 0.35 
n = 19 
r = 0.1 
p = 0.63 
n = 25 
r = -0.382 
p = 0.14 
n = 16 
r = 0.042 
p = 0.87 
n = 17 304 
 
Table 6-3: Spearman rank correlation coefficiants of putative EPC populations 
– expressed as percentage of CD34+ PBMCs. 
 
Marker  of 
disease 
activity/ 
growth 
factors 
%  of  CD34+ 
cells  expressing 
CD133 
%  of  CD34+ 
cells  expressing 
CD133/VEGFR2 
%  of  CD34+ 
cells  expressing 
VEGFR2 
%  of  CD34+ 
cells  expressing 
CD144 
%  of  CD34+ 
cells  expressing 
CD133/CD144 
BVAS  r = 0.139 
p = 0.456 
n = 31 
r = 0.013 
p = 0.95 
n = 30 
r = 0.013 
p = 0.94 
n = 30 
r = 0.263 
p = 0.17 
n = 27 
r = 0.177 
p = 0.36 
n = 28 
ESR  r = 0.285 
p = 0.126 
n = 29 
r = 0.051 
p = 0.79 
n = 29 
r = 0.104 
p = 0.59 
n = 29 
r = 0.139 
p = 0.49 
n = 26 
r = 0.129 
p = 0.52 
n = 27 
CRP  r = 0.113 
p = 0.554 
n = 30 
r = -0.116 
p = 0.55 
n = 29 
r = -0.104 
p = 0.59 
n = 29 
r = 0.236 
p = 0.24 
n = 26 
r = 0.063 
p = 0.75 
n = 27 
WCC  r = 0.364 
p = 0.044* 
n = 31 
r = -0.105 
p = 0.58 
n = 30 
r = 0.216 
p = 0.25 
n = 30 
r = -0.259 
p = 0.18 
n = 27 
r = -0.133 
p = 0.50 
n = 28 
Platelet count  r = 0.290 
p = 0.12 
n = 30 
r = -0.001 
p = 0.99 
n = 29 
r = -0.164 
p = 0.40 
n = 29 
r = -0.181 
p = 0.34 
n = 27 
r = -0.076 
p = 0.70 
n = 24 
Albumin  r = -0.103 
p = 0.61 
n = 27 
r = 0.048 
p = 0.81 
n = 26 
r = 0.043 
p = 0.83 
n = 26 
r = -0.277 
p = 0.19 
n = 23 
r = -0.210 
p = 0.32 
n = 24 
CEC count  r = 0.146 
p = 0.51 
n = 23 
r = -0.174 
p = 0.42 
n = 23 
r = -0.282 
p = 0.19 
n = 23 
r = -0.276 
p = 0.24 
n = 20 
r = -0.229 
p = 0.33 
n = 20 
EMP 
(CD144+) 
r = -0.004 
p = 0.9 
n = 27 
r = -0.233 
p = 0.022* 
n = 26 
r = -0.556 
p = 0.003 
n = 26 
r = -0.239 
p = 0.26 
n = 24 
r = -0.262 
p = 0.22 
n = 24 
EMP 
(CD105+) 
r = -0.168 
p = 0.40 
n = 27 
r = -0.149 
p = 0.47 
n = 26 
r = -0.245 
p = 0.23 
n = 26 
r = 0.169 
p = 0.43 
n = 24 
r = -0.140 
p = 0.52 
n = 24 
EMP 
(eselectin+) 
r = -0.301 
p = 0.13 
n = 27 
r = -0.340 
p = 0.089 
n = 26 
r = -0.351 
p = 0.078 
n = 26 
r = 0.054 
p = 0.80 
n = 24 
r = 0.012 
p = 0.96 
n = 24 
PMP 
(CD42a+) 
r = -0.107 
p = 0.59 
n = 27 
r = 0.048 
p = 0.82 
n = 26 
r = -0.257 
p = 0.20 
n = 26 
r = -0.041 
p = 0.85 
n = 24 
r = -0.055 
p = 0.79 
n = 24 
MMP 
(CD14+) 
r = 0.007 
p = 0.98 
n = 27 
r = -0.26 
p = 0.2 
n = 26 
r = -0.418 
p = 0.034 
n = 26 
r = -0.074 
p = 0.26 
n = 24 
r = -0.377 
p = 0.069 
n = 23 
Total MP  r = 0.004 
p = 0.98 
n = 27 
r = -0.201 
p = 0.32 
n = 26 
r = -0.529 
p = 0.005* 
n = 26 
r = -0.179 
p = 0.40 
n = 24 
r = -0.336 
p = 0.11 
n = 23 
VEGF  r = -0.245 
p = 0.23 
n = 26 
r = -0.245 
p = 0.24 
n = 25 
r = -0.139 
p = 0.51 
n = 25 
r = 0.333 
p = 0.12 
n = 23 
r = 0.328 
p = 0.099 
n = 23 
ANG-1  r = -0.083 
p = 0.72 
n = 21 
r = 0.204 
p = 0.28 
n = 21 
r = 0.284 
p = 0.21 
n = 21 
r = 0.464 
p = 0.046 
n = 19 
r = 0.489 
p = 0.034 
n = 19 
ANG-2  r = 0.310 
p = 0.109 
n = 28 
r = 0.252 
p = 0.21 
n = 27 
r = 0.098 
p = 0.63 
n = 27 
r = 0.228 
p = 0.27 
n = 24 
r = 0.227 
p = 0.27 
n = 25 
TB4  r = -0.180 
p = 0.45 
n = 20 
r = -0.170 
p = 0.23 
n = 19 
r = -0.205 
p = 0.40 
n = 25 
r = 0.145 
p = 0.58 
n = 17 
r = -0.042 
p = 0.87 
n = 17 
 
Significant correlations highlighted in blue 
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Table 6-4:  Holm-Bonferroni critical values for significant correlations between 
EPCs and markers of disease activity 
Test  P value  Adjusted  critical  value 
(Holm-Bonferroni) 
EMP  (eselectin+)  vs  %  of 
PBMCs expressing CD34  0.007  0.00049 
EMP  (eselectin+)  vs  %  of 
PBMCs expressing CD34  0.01  0.000495 
WCC  vs  %  of  PBMCs 
expressing CD34/CD133  0.012  0.0005 
Total  MP  vs  %  of  PBMCs 
expressing CD34/CD133  0.018  0.000505 
     
EMP (CD144+) vs % of CD34+ 
cells expressing VEGFR2  0.003  0.000588 
Total MP vs % of CD34+ cells 
expressing VEGFR2  0.005  0.000595 
EMP (CD144+) vs % of CD34+ 
cells  expressing 
CD133/VEGFR2  0.022  0.000602 
MMP  vs  %  of  CD34+  cells 
expressing VEGFR2  0.034  0.00061 
ANG-1  vs  %  of  CD34+  cells 
expressing CD133/CD144  0.034  0.000617 
WCC  vs  %  of  CD34+  cells 
expressing CD133  0.044  0.000625 
ANG-1  vs  %  of  CD34+  cells 
expressing CD144  0.046  0.000633 
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6.5 Detection of EPCs using cell culture 
While  the  main  focus  of  this  chapter  has  been  on  using  flow  cytometry  to  detect 
populations of EPCs, culture methodologies may give some insight into the functional 
capacity  of  EPCs,  and  although  time  limitations  (and  blood  volume  limitations  as 
previously  mentioned)  of  this  project  did  not  permit  extensive  assessment  of  the 
vasculitis cohort, the preliminary observations relating to methodology performed in 4 
adult controls and 2 patients bears mention.   
 
As  discussed  in  the  introduction  to  this  chapter,  many  groups  have  used  a  colony 
counting  methodology  to  assess  EPCs  in  vitro.    While  the  non-adherent  population 
isolated after 1-2 days in culture gives rise to a colony phenotype which correlates with 
endothelial function (Hill et al., 2003) and mortality (Werner et al., 2005), as yet the 
colonies  derived  from  the  non-adherent  cells  have  not  shown  such  a  clear  cut 
relationship (Xiao et al., 2007b), yet this population contains a cell population which 
can go on to form endothelial-like monolayers after 2-3 weeks in culture (notably the 
non-adherent  population  has  not  been documented to  do this).    The aim of these 
preliminary studies was to develop a methodology where it would be possible to analyse 
both adherent and non-adherent colonies as well as using the non-adherent population in 
matrigel tubule experiments, based on techniques previously established in our group 
but minimizing the volume of blood necessary.  As has been apparent throughout this 
study,  it  is  frequently  a  problem  to  obtain  greater  than  10-15mls  total  volume  of 
research blood from small children.  In the following series of preliminary experiments 
blood was obtained from 4 healthy adult controls and 2 children with vasculitis (one 
individual had PAN, the other an unclassified small vessel vasculitis, both were on 
immunosuppressive treatment and disease was in remission). 307 
 
6.5.1 Colony counting 
The  protocol  for  enumeration  of  colonies  derived  from  the  non-adherent  culture 
population as described in the section 2.6.3 was based on the protocol described by Hill 
et al (Hill et al., 2003).  Briefly 2.5 x 10
6 cells were added per well on a 12 well 
fibronectin coated plate and cultured for 48hrs in RPMI with 20% FCS and antibiotics.  
After 48hrs the supernatant was removed and the  non-adherent cells contained in it 
were counted and replated at a concentration of 1 x10
6 cells per well on a second 12 
well fibronectin coated plate and cultured in EPC media for 7 days (section 2.6.3).  The 
remaining  adherent  populations  on  the  original  culture  plate  were  also  cultured 
concurrently  in  EPC  mix  to  see  if  the  two  populations  differed  considerably  when 
colonies were counted.   
 
In 5 individuals (2 patients, 3 adult controls) each initial culture well gave enough non-
adherent cells for 1 well of second stage non-adherent culture.  In 1 healthy control, 
however, 3 wells only gave sufficient non-adherent cells for 2 wells.  Thus in order to 
get a minimum of 2 non-adherent cultures for enumeration of colonies, at least 3 initial 
wells  would  be  necessary  using  this  methodology  (a  total  of  7.5x10
6  cells, 
approximately 7-10mls of blood).  Figure 6.18a-d demonstrates the typical phenotype of 
both  the  non-adherent  and  adherent  colonies  observed  in  this  experiment  and  the 
number of colonies counted for both the patients and controls.   As can be seen from 
Figure 6.18, more colonies were formed in non-adherent cell cultures and both patients 
had less colonies than 3 of 4 healthy adults studied.   
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Figure 6-18: EPC colony culture 
 
 
Figure 6.18a and b: When PBMCs were cultured in EPC mix the non-adherent colonies were often 
large (formed after 5-9 days) (figure 6.18a) and in 6 individuals (4 healthy adult controls and 2 
vasculitis  patients  –  one  with  PAN,  one  with  an  unclassified  small  vessel  vasculitis,  both  on 
immunosuppressive treatment) colony count at day 9 ranged from 0-86 colonies per well. Figure 
6.18c and d: When the non-adherent population was removed after an initial 48 hours in culture and 
replated, colonies formed after 5-7 days in culture (figure 6.18c) and in 6 individuals (4 healthy 
adult controls and 2 vasculitis patients as before) colony count at day 7 ranged from 0-42 colonies 
per well. 
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6.5.2 Matrigel 
When endothelial cells such as HUVEC are grown on the extracellular matrix scaffold - 
Matrigel
TM, they form tubule networks (Figure 6.19a).  In this system, the ability of 
EPCs  to  incorporate  and  influence  EC  growth  (and  repair)  can  be  assessed.    As 
mentioned above, culturing of PBMCs in EGM-2 can lead to the development of late-
outgrowth EC-like monolayers.  Thus earlier cultures must include the putative EPC 
population, thus EGM-2 cultures in which colonies have formed (herein described as 
EPC enriched) are used in these in vitro assays.  
 
In order to generate sufficient adherent cells for matrigel assays (as described in section 
2.6.4) 5 x 10
6 cells per well were cultured on fibronectin coated 12 well plates in EGM-
2 for 9 days. Cells from these EPC enriched cultures were then lifted and 40,000 cells 
were combined with 40,000 HUVEC in EGM-2 on a Matrigel
TM coated 12 well plate 
and cultured for a further 18 hours.  In all of the 6 individuals studied (4 adult controls, 
2 patients), 1 well of initial culture was more than sufficient to generate enough cells for 
1  well  of  Matrigel
TM  culture.    However  even  in  the  small  numbers  studied  it  was 
immediately apparent that the cultures obtained from patients grew poorly compared to 
the adults.  After 9 days, all of the healthy adult cultures were confluent with cells, 
making it impossible to distinguish colonies (Figure 6.19b).  In both patients, however, 
there were much fewer cells and neither culture appeared confluent, individual colonies 
could be readily counted (Figure 6.19d).  Thus in order to generate enough cells for a 
Matrigel
TM assay using this methodology, at least 2 wells would be necessary (10 x 10
6 
cells, approximately 10-15mls of blood). 
 
The  extent  of  incorporation  and the influence that EPC enriched cultures can  have on  310 
 
endothelial cells, can be readily assessed in this system.  EPC enriched culture cells can 
be distinguished from HUVEC by using a metabolic dye such as diI labeled-acetylated 
low density lipoprotein as described in section 2.6.5 (Figure 6.19d) to determine the 
extent of incorporation.  Growth characteristics such as total tubule length and number 
of branch point in a random field can also be readily determined (highlighted in Figure 
6.19a).   
 
The  changes  in  growth  characteristics  attributable  to  EPC  enriched  cells  were 
determined  by  comparing  mixed  EPC  enriched/HUVEC  cultures  to  a  control  well 
containing only 40,000 HUVEC.  This is an important comparison as it controls for 
variations  in  HUVEC  growth  between  different  experiments.    Figures  6.20a-c 
demonstrate the preliminary results obtained in the individuals studied.  In this series of 
experiments  5  out  of  the  6  EPC  enriched  cultures  studied  (3  healthy  adults  and  2 
patients) exerted a slightly negative effect on HUVEC tubule length (Figure 6.20a) and 
number of branch points (Figure 6.20b) when compared to the control well of HUVEC 
alone.  The range of tubule length (expressed as a ratio of HUVEC cultured with EPC 
enriched cells to HUVEC alone) was 0.75 – 1.25 in healthy adults and 0.3-0.75 in the 
two patients.  When branch points were considered the range (as before expressed as a 
ratio) was 0.4-1.25 in healthy adults and 0.4-0.5 in the two patients.  Incorporation of 
EPC  enriched  cultures  was  low  in  all  cultures  (5-14  cells  per  random  field,  Figure 
6.20c).  
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Figure 6-19: Matrigel EPC culture 
 
 
 
 
Figure 6.19a: When HUVEC were cultured on Matrigel
TM, they formed tubule networks.  Growth of 
these tubules were assessed by counting of branch points (arrowed) and measuring total tubule 
length within a random field.  Figure 6.19b:  To assess how EPC enriched cells could influence 
HUVEC  tubule  formation,  PBMCs  were  cultured  for  9  days  in  EGM-2  before  combining  with 
HUVEC in Matrigel
TM.  All of the EPC enriched cultures from healthy adults were confluent with 
cells making it impossible to count colonies (figure 6.19b).  In the 2 patients studied both had much 
fewer  cells  (Figure  6.19c).  Figure  6.19d:  DiI-acetylated  LDL  could  be  used  to  stain  cultured 
PBMCs to allow them to be distinguished from the HUVEC they incorporated into.  312 
 
Figure 6-20: Matrigel assay results 
 
 
 
Figure 6.20a-c: 40,000 PBMCs cultured for 9 days in EGM-2 were lifted and mixed with 40,000 HUVEC 
and cultured on Matrigel
TM for 18 hours.  These were compared to HUVEC cultured alone.  Figure 
6.20a: In 6 individuals (4 healthy adult controls and 2 patients on treatment) the ratio of total tubule 
length  between  mixed  cultures  and  HUVEC  alone  ranged  from  0.3  to  1.25.    Figure  6.20b:  In  6 
individuals (4 healthy adult controls and 2 patients on treatment) the ratio of total branch points between 
mixed cultures and HUVEC alone ranged from 0.4 to 1.2.  Figure 6.20c: Incorporation of cells was low 
in all cultures, ranging from 2-14 cells per random field.  313 
 
6.6 Discussion 
EPCs have been enumerated in a number of different ways and as yet no consensus has 
been reached as to which culture techniques or flow cytometric protocols best describes 
this population of cells.  In this chapter flow cytometry was used to investigate the 
different  CD34+  populations  within  which  EPCs  are  thought  to  reside  and  some 
preliminary data relating to optimization of culture methodologies for detection of EPCs 
was  also  presented.    The  latter  are  important,  but  were  not  applied  widely  to  the 
paediatric vasculitis cohort because the blood volumes required were too great to obtain 
from children concurrently with the other tests described in this thesis.    
 
Using flow cytometry the proportion of PBMCs expressing a number of combinations 
of  EPC  markers  (CD34+CD133+,  CD34+CD133+VEGFR2+  and  CD34+CD144+) 
were  significantly  higher  in  patients  with  active  disease  compared  to  healthy  child 
controls.  Two different combinations of cell surface markers which other groups have 
used  to  define  EPCs  (CD34+VEGFR2+  and  CD34+CD144+CD133+)  were  not.  10 
individual patients were studied from disease onset and no significant differences were 
observed in any of the combinations of cell surface markers between active and inactive 
disease (although CD133+CD34+ was close to significance with p=0.054) or at median 
followup of 3 or 12 months from disease onset.  This is undoubtedly influenced by the 
small numbers studied.  
 
As described earlier in this chapter, concerns were raised as to whether enumeration of 
putative EPCs  as  a proportion  of a viable cell gate (a protocol  which is  frequently 
described  within  EPC  literature)  was  appropriate  in  this  cohort.    While  this  is  an 
acceptable definition of an EPC for some studies, and has been widely published, in the 314 
 
context of vasculitis, immunosuppressive treatment might be skewing the population by 
reducing the absolute number of cells within the gate.   In order to determine if this was 
a  major  limitation  of  this  study,  putative  EPC  populations  were  enumerated  in  3 
different ways.  Firstly using the widely published percentage of the broad PBMC gate, 
secondly as a percentage of a smaller more defined population (CD34+ cells).  Both of 
these were compared to an estimate of absolute number in individual patients followed 
up from disease onset.  In order to estimate the absolute number of EPCs, the leukocyte 
count derived from the routine bloods taken in the vasculits patients was utilized in a 
methodology  adapted  from  the  dual  platform  ISHAGE  protocol  for  enumeration  of 
CD34+ cells (Gajkowska et al., 2006).    
 
For each combination of putative EPC markers, when these 3 enumeration methods 
were compared, the majority of changes in EPC number over time in individual patients 
was  comparable.    However  in  a  small  number  of  patients,  there  were  obvious 
differences;  for  example  where  EPCs  enumerated  as  a  percentage  of  PBMCs  had 
increased, absolute number may have declined.  Enumerating EPCS as a proportion of 
CD34+ cells did not mirror the changes occurring in the estimate of absolute number 
any better than enumerating them as a percentage of the PBMC gate.  However when 
differences between active disease and controls groups for this method of enumeration 
were examined, p values for the groups where a significant difference was observed 
were  smaller  (for  CD34+CD133+  and  CD34+VEGFR2+CD133+  populations).    The 
exception to this was the CD34+CD144+ population which was significantly different 
between active disease and controls when expressed as a percentage of PBMCs, but not 
when expressed as a percentage of CD34+ cells.      315 
 
While  this  could  be  consided  over-interpretation  of  the  available  data,  it  raises  an 
interesting question relating to what is the most appropriate way to quantify an EPC 
population.    When  considered  alone  absolute  number  seems  to  a  more  intuitive 
measure,  however  when  the  relationship  between  EPCs  and  haematopeotic  cells  is 
considered matters become more complicated.  The measure of EPCs which has been 
shown to most closely reflect endothelial function (non-adherent colonies) is actually a 
measure of the interaction between haematopoeitic cells and presumanbly EPCs (the 
majority  of  cells  making  up  these  colonies  staining  postiviely  for  CD3  or  CD14).  
Therefore the ratio (or percentage) of EPCs within this population may actually be more 
informative.    For  future  studies,  it  would  be  important  to  consider  both,  thus 
optimization of whole blood flow cytometry from which both an absolute number and a 
% of the mononuclear cells expressing these markers could be derived would be an 
obvious future direction of this work.  It would also allow a much smaller amount of 
blood to be used, allowing culture work to be carried out in parallel on these samples. 
 
Despite questions relating to the best way to enumerate EPCs, significant increases were 
observed  during  active  disease  in  CD34+VEGFR2+CD133+  and  CD133+CD34+ 
populations in the two methods that could be compared with healthy child controls.  
This  is  comparable  with  the  study  by  Nakatani  et  al  who  observed  increased  EPC 
number in patients with active  KD compared to healthy controls, with highest levels 
being  found  in  patients  with  coronary  artery  lesions  (Nakatani  et  al.,  2003).      The 
increase in EPCs number seen in these children with vasculitis also corresponds with 
the findings from Chapter 5, where it was determined that growth factors associated 
with vasculogenesis are also elevated in active disase, particularly at disease onset, and 
decline with remission inducing therapy.   316 
 
When the putative EPC populations observed in this chapter with correlated with other 
markers  of  disease  activity,  including  growth  factors,  no  striking  correlations  were 
observed, however numbers were small (>30 events) and a larger study population may 
be needed, also the large number of tests performed meant the significant correlations 
observed did not withstand multiple comparison corrections.  Interestingly the majority 
of EPC markers studied actually correlated negatively with endothelial microparticles, 
perhaps this is indicative of EPCs being targeting towards activated endothelium, hence 
being at lower levels.       
 
In adults however, the situation is in contrast to that observed in children.  Adults with 
active  AAV  have  comparable  levels  of  CD34+  PBMCs  to  healthy  controls,  which 
increase on treatment (de groot et al., 2007).  This interesting observation indicates that 
perhaps children have a different response to vasculitic injury than adults.  Further study 
will however be necessary to clarify this.  While increases in EPC number may well be 
relevant to attempted reparative responses, the function of these EPCs in children, could 
conceivably  be  impaired.    Studies  which  have  utilized  colony  formation  assays    in 
adults with active AAV have demonstrated decreased formation of colonies which may 
(Holmen et al., 2005) or may not improve with treatment (Zavada et al., 2008) .  
 
Considering the underwhelming differences in the different EPC populations between 
disease and the various controls, and the lack of consistency within the literature as to 
what constitutes an EPC, EPC functional assays in this cohort may indeed give more 
informative data  and is  an avenue of considerable future interest.    Using the EPC 
culture methodologies that have been previously established within the group (Arrigoni 
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of blood  necessary for  generating informative  data was  prohibitive in  the vasculitis 
cohort, particularly if any of the other assays described in this thesis were to be carried 
out in parallel. Thus further optimization would be necessary.  Currently performing 
assays to assess non-adherent colonies and Matrigel
TM would require a minimum of 15-
20mls of blood (to obtain 17.5x10
6 PBMCs in total).  This is too much blood to obtain 
from small children, especially when a further 5-10mls is required for the other assays 
described in this thesis.  The methodologies for these assays described in this chapter 
were  preliminarily  investigated  because  they  are  based  on  techniques  previously 
published which have provided the most informative data relating to endothelial health 
(in the case of the non-adherent colonies which correlate with FMD) or in the case of 
the  EPC  enriched  population  which  can  integrate  into  endothelium  (the  matrigel 
experiments).    The  first  obvious  optimization  would  be  to  combine  the  two  above 
mentioned culture assays in order to generate one culture from which both the non-
adherent culture and the adherent cells for Matrigel
TM could be derived.  This would 
require  extensive  investigation  into  the  effects  that  slight  changes  to  culture  media, 
number of cells plated and protocols may make however and time restraints meant that 
this could not be done within the remit of this thesis.   
 
In order to examine both adherent and non-adherent colonies, one possible protocol 
would be to establish the EGM-2 matrigel cultures, removing the non-adherent cells at 
day 2.   In order to ascertain whether changes to methodology (including media used, 
number  of  cells  initially  plated)  influences  the  colonies  formed,  cultures  using  the 
different  protocols  must  be  grown  in  parallel  and  compared.    Phenotypic 
characterization  using  flow  cytometry  would  be  one  way  of  doing  this,  however 
comparing colony counts between cultures would also be necessary.  While this may be 318 
 
time consuming, if the end result was a robust assay, which could use a small volume of 
blood  (<10mls)  to  enumerate  both  the  non-adherent  colonies  which  correlate  with 
endothelial function and to investigate the interaction of EPC cultures with HUVEC the 
effort would be rewarded.   
 
In conclusion, this chapter has described the different CD34+ subpopulations that may 
constitute a population of cells which are involved in vascular repair.  A number of 
these populations are elevated at disease onset, corresponding with a time when growth 
factors involved in their recruitment are also elevated.  Thus children with vasculitis in 
contrast to adults with the disease may be instigating a reparative response, whether this 
is of functional significance remains unknown and is an avenue of future work. 
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Discussion 
The vasculitides are a rare and heterogeneous group of disorders that are characterized 
by  the  presence  of  inflammation  in  blood  vessel  walls.    As  has  been  discussed 
previously, robust classification of the vasculitides has proven difficult; to date there are 
no specific diagnostic tests and patients frequently exhibit complex and overlapping 
symptoms.  Consequently the most commonly used classification criteria (CHCC) is 
based on the size of the vessels predominantly affected.  In relation to children however, 
these criteria have now been formally shown to have poor sensitivity and specificity 
(Ozen, Brogan et al, manuscript in preparation 2009), highlighting the need to consider 
children differently to adults.  A number of the vasculitides are also associated with the 
risk of disease recurrence and patients require careful monitoring long term to allow 
detection of flaring disease.   
 
It was with these concepts in mind that this thesis was undertaken, to investigate assays 
which could indicate the presence of active systemic vasculitis irrespective of causal 
pathology  and  disease  classification  and  would  be  of  relevance  in  adults,  but  more 
importantly in children, where small sample volumes are an issue.  Although causal 
pathology  remains  poorly  defined  in  many  conditions,  one  common  downstream 
consequence  of  inappropriate  inflammation  within  the  vasculature,  which  may  be 
relevant to virtually all of the vasculitides, is injury to the endothelium.  This concept 
underlies  all  of  the  work  described  within  this  thesis.    Moreover,  the  damaged 
endothelium releases factors into the blood, thus allowing testing in a relatively non 
invasive manner from small volumes of peripheral blood. 
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The  first  putative  biomarkers  of  disease  activity  described  within  this  thesis  were 
circulating endothelial cells (CECs, Chapter 3).  At the time of establishing the assay it 
was apparent that two techniques were being interchangeably used within the literature 
for  enumeration  of  CECs,  namely  flow  cytometry  (FC)  and  immunomagnetic  bead 
extraction (IBE).  It had even been reported that the two techniques gave comparable 
results in adult controls and patients with breast cancer or acute coronary syndromes 
(Goon et  al.,  2006).  Thus  initially both  techniques were utilised within the GOSH 
cohort to determine which was the most appropriate method for examining CECs in this 
population (Section 3.5).  In contrast to the study by Goon et al, it was soon apparent 
that IBE and FC did not give comparable results in children with vasculitis, although the 
IBE data obtained was comparable with previous studies in adults with vasculitis which 
had utilized the IBE methodology (Woywodt et al., 2003b).   
 
Subsequently a number of experiments were performed in order to determine why the 
FC protocol, as described by Goon et al, was not appropriate for enumeration of CECs 
in children with vasculitis.  The following conclusions were reached: firstly that size 
matters – whilst Goon et al had gated on a mononuclear cell FSC SSC region, light 
microscopy had indicated that CECs were of comparable sizes to HUVEC and PAEC 
which exhibited a different FSC SSC profile. Thus a much larger gate was necessary to 
include this; secondly, factors that are inherent to FC also limited CEC recovery.  These 
included sensitivity of detection of rare events and the ability of the flow cytometer to 
resolve individual events.  Most importantly it was found that the lysis necessary for 
removal of red cells significantly limited recovery of CECs (Clarke et al., 2008).   
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an  ongoing  area  of  debate  within  the  CEC  literature  –  how  best  to  quantify  CECs 
(Shantsila and Lip, 2008).  Currently new methodologies utilizing IBE and automated 
microscopy (Rowand et al., 2007) or IBE enriched FC (Widemann et al., 2008) have 
now  been  described  which  may  provide  a  more  automated  approach  to  CEC 
enumeration, bringing it closer to clinical utilization.  It is also likely that an approach to 
FC based around previously published protocols for detection of apoptotic and necrotic 
cells may also provide another methodology by which FC could be utilized to detect 
CECs in patients with vasculitis and would be an obvious future direction of this study 
(discussed in Chapter 3).   However, as demonstrated herein any techniques developed 
for CEC enumeration need to be carefully validated in individuals where CECs may be 
fragile in nature.  While data was not presented in this thesis to indicate why CECs may 
be  less  robust  on  handling  than  in  other  conditions,  Woywodt  et  al  had  already 
convincingly demonstrated in adults with AAV that 84% of cells obtained from patients 
with  active  disease  stained  positive  for  annexin  V/propidium  iodide  indicating  a 
necrotic phenotype (Woywodt et al., 2003b).  Whilst repeating this work in children 
would be an important next step, the limiting blood volumes and rarity of patients meant 
this was not possible during this project.    
 
Despite the methodological controversies IBE enumeration of CECs proved robust in 
this  particular  cohort  (Section  3.7)  and  demonstrated  significantly  higher  CECs  in 
patients with active vasculitis than in all control groups studied (healthy and disease 
control  children,  and  adults)  as  well  as  compared  to  patients  in  remission.    Of 
considerable interest was the indication that CECs were elevated during active disease 
irrespective  of  treatment  status,  declined  with  remission  inducing  therapy  and  were 
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with clinical scores of disease activity but not with inflammatory markers such as ESR 
and CRP (which are influenced by treatment).  Therefore in this context CECs are a 
particularly  useful  biomarker  of  disease  activity,  although  the  current  methodology 
limits use to a research tool. 
 
In a number of individuals, when CECs were enumerated, small ULEX-bright staining 
particles were frequently seen alongside the larger CECs, which could be indicative of 
fragile CECs fragmenting or possibly of endothelial MPs.   Chapter 4 therefore went on 
to describe MPs in the same group of patients.  Because FC was utilized to enumerate 
MPs, several different populations could easily be studied within this project and these 
included MPs of endothelial, platelet, neutrophil, monocyte and lymphocyte origins.  As 
indicated in Chapter 3, FC for rare event analysis requires careful optimization and thus 
this chapter also contained a significant proportion of optimization work, particularly as 
MPs  are  at  the  lower  limits  of  detection  of  the  flow  cytometer.    A  major  step  in 
optimising the technique was limiting the background noise, which had been shown to 
adversely influence accuracy of detection of latex counting beads and thus presumably 
MPs themselves.  As the MPs of interest were AnV positive it was decided to utilize the 
AnV staining, by using a fluoresence threshold, below which events were not counted, 
thereby  removing  the  majority  of  electrical  noise  and  any  debris  in  the  fluidics, 
increasing  the  recovery  of  MP  events.    Although  this  greatly  improved  sensitivity 
(Figure 4.7), the major downside to this approach was that post-hoc analysis of AnV 
negative populations could not be performed if required at a later date.   
 
The utilization of a threshold to reduce background noise has been widely used by 
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studies performed in vasculitis difficult.  Despite this the results obtained were similar 
to other studies.  The previous study from our group indicated higher EMPs (CD105+ 
and E-selectin+) during active disease compared to patients in remission and controls 
(Brogan et al., 2004a).  In the present study CD144+ EMPs were also significantly 
higher  in  patients  with  active  vasculitis  compared  to  controls  and  declined  when 
individual patients entered remission, although CD105+ EMPs and E-selectin + EMPs 
were  not.    Interestingly  in  this  study  CD105+  EMPs  were  significantly  higher  in 
patients in remission compared to controls.   Although this contrasts with the previous 
study from within our group it could be explained by the higher proportion of KD 
patients within the previously studied cohort - preliminary data indicates that patients 
with acute KD may have higher EMPs than other vasculitis patients (Figure 4.27).   As 
before PMPs were not significantly different between patients and controls, although 
they did correlate inversely with markers of disease activity (white cell count, BVAS, 
ESR and CRP) indicating that PMPs may indeed be lower during active disease.   MPs 
of monocytic origin (CD14+) were also found to be elevated during active disease.   
 
The differences in MP numbers between active disease and remission or the control 
groups were not particularly striking even when significant differences were observed 
and it may be that changes in individual patients provide more informative data than 
broad studies within a heterogenous population.  Whilst MPs may not be as robust a 
biomarker of disease activity as CEC, they may provide more informative data relating 
to cellular activation in individual patients, which could be of particular importance 
when predicting whether a patient is likely to enter disease flare.  Further prospective 
studies in larger cohorts will be required to truly clarify whether MPs could provide a 
way of monitoring patients cellular activation profiles.  325 
 
Another interesting finding in this study (although preliminary) was that in a number of 
individual patients with active disease prior to treatment MPs were low (particularly 
apparent for EMPs and PMPs), suggesting that in active untreated disease there may be 
sequestering of MPs to activated cells within the blood or to the endothelium.  As MPs 
of a number of different phenotypes have been demonstrated to influence cell function 
(discussed  in  detail  in  the  introduction  Chapter  4),  in  this  context  they  could  be 
contributing  to  the  pathogenesis  of  the  disease  and  thus  future  studies  concurrently 
investigating  MP-cell  complexes  would  also  be  an  interesting  direction  to  take  this 
study.   
 
Whilst  EMPs  and  CECs  reflect  the  activation  and  injury  of  the  endothelium,  it  is 
possible that reparative responses maybe underway in an attempt to repair the damaged 
vessels.  Thus the latter chapters of this thesis focused on possible repair mechanisms, 
firstly by measuring growth factors associated with angiogenesis and vasculogenesis  - 
the signals of repair and secondly by enumerating endothelial progenitor cells, the cells 
believed to play a key role in orchestrating repair.  As a downstream consequence of 
endothelial  injury,  these  could  also  be  utilized  as  biomarkers  of  disease  activity.  
However  as  the  results  from  these  studies  indicate,  this  highly  controversial  and 
complex  field  is  likely  influenced  by  treatment  and  thus  although  their  use  as 
biomarkers  is  limited,  the  data  presented  herein  raises  some  interesting  questions 
relating to the long term potential for damage repair in vasculitis.  
 
In Chapter 5, the relationship between the growth factors VEGF, Ang-1, Ang-2 and Tβ4 
and disease activity was considered.  Whilst Tβ4 was not significantly different between 
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previously unpublished finding, perhaps indicative of ongoing growth.  When patients 
with active disease prior to treatment were considered it was apparent that with the 
exception of Tβ4, growth factors were elevated, when compared to controls and patients 
in remission.  In individual patients, levels declined with treatment, however whether 
this is due to patients being in remission or due to therapy is unclear.  Growth factor 
levels  appear  to  be  influenced  by  treatment  and  preliminary  data  demonstrated  that 
when  patients  had  an  active  disease  flare  while  on  routine  maintenance  therapy 
(corticosteroids, with azathioprine) their levels of VEGF, Ang-1 and Ang-2 were lower 
when compared to treatment naive patients (Figure 5.6).  This finding could thus limit 
growth factors usefulness as biomarkers of disease activity and is in contrast to the 
conclusions reached in the recent publication by Kumpers et al, whereby Ang-2 was 
considered to be a good biomarker of disease activity in adults with AAV (Kumpers et 
al., 2009).  However as discussed in Chapter 5, the influence of treatment status was not 
studied in depth as in this study.   
 
Regardless of the usefulness of growth factors as putative biomarkers,  these studies 
indicate that angiogenic and vasculogenic pathways are activated in patients with active 
disease  and  therefore  there  may  be  an  attempted  reparative  response  occurring.  
Conversely, when one considers the tightly regulated systems that control angiogenesis 
and vasculogenesis, these elevations in several interlinked growth factors (a “growth 
factor  storm”)  could  also  be  of  pathological  consequence,  propagating  further 
dysfunction  and  injury  to  the  endothelium.    Rather  than  viewing  growth  factors  as 
targets for influencing repair, their double edged sword action could indeed make them 
novel therapeutic targets.  In this context a recent publication has indicated that PDGF 
receptor inhibition using imatinib (Gleevec
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the cell responses necessary for the development of intimal hyperplasia characteristic of 
giant cell arteritis and TD using an in vitro system.  In vivo data is eagerly awaited 
(Lozano et al., 2008).  While an attractive hypothesis, this avenue of research would 
require  extensive  in  vivo  justification  before  clinical  trials  could  be  performed, 
particularly in children.    
 
While Chapter 5 indicated there may indeed be changes in reparative responses, Chapter 
6 went on to investigate the controversial topic of endothelial progenitor cells (EPCs).  
As discussed previously while this cell population has received much interest, as yet 
there is no consensus relating to cell surface marker expression or culture methodology 
for their detection.  As with the other FC techniques described in this thesis, technical 
difficulties associated with rare event analysis had to be considered, as did the gating 
strategy and way of enumerating EPCs.  What was apparent from the data obtained 
however, was that EPCs (defined as cells expressing CD34, CD133 and VEGFR2) and 
“early” progenitor cells not necessarily of endothelial lineage (expressing CD34 and 
CD133) were elevated at disease onset when compared to controls and declined with 
treatment in individual patients.  This is in striking contrast to the data published in 
adults  (de  Groot  et  al.,  2007),  whereby  treatment  increased  EPC  number,  further 
hilighting  the  need  to  consider  children  as  different  from  adults,  particular  when 
considering vascular growth and repair.   
 
Whilst EPC number may be elevated, function cannot be determined in FC assays and 
thus the latter part of the chapter described some preliminary data in order to establish 
culture assays.  While time constraints and the low blood volumes available meant that 
patients could not be studied concurrently with the other biomarkers in this thesis, even 328 
 
preliminary data in 2 individuals on maintenance therapy indicated that cultured cell 
growth may be impaired when compared to healthy adults (Figures 6.18 and 6.19).  
Extensive study is required to determine whether EPC function as determined using 
these culture assays is impaired and whether this relates to EPC number.  However this 
is an avenue of ongoing work within the group, which on the basis of the preliminary 
data described in this thesis has now been funded by the Arthritis Research Campaign.   
 
Because  of  the  nature  of  this  study,  one  recurrent  theme  throughout  related  to  the 
statistical interpretation of data, particularly when multiple comparisons were performed 
simultaneously.    The  purpose  of  tests  such  as  the  Bonferroni  is  to  correct  for  the 
familywise  error  that  occurs  when  multiple  statistical  tests  are  performed 
simultaneously.  A test is considered significant when the likelyhood of it occurring by 
chance is less than 5%.  Conversely this means that the likelyhood of a rare event 
occurring randomly is thus 5% and therefore when multiple comparisons are performed 
5% of these could be occurring by chance.  Corrections such as the Holm Bonferroni 
have been developed to attempt to correct this.  However there remains much debate to 
the valididity of these rigid statistical tests particularly when relating to heterogenous 
patient populations such as those studied herein.  While interesting observations were 
made  relating  to  the  putative  biomarkers  studied  in  this  project  in  order  to  clarify 
whether these are in fact truly significant effects rather than false positives resulting 
from  multiple  comparisons  further  study  in  more  patients  of  those  interesting 
observations is required.  This is work is ongoing within the group. 
  
The term biomarker was defined as an objectively measured characteristic which could 
be utilized as  a clinical outcome or endpoint in trials.  Currently  clinical  outcomes 329 
 
which can be utilized in clinical trials of vasculitis are limited and include parameters 
such as mortality, although in the short term and in children particularly this is not a 
useful outcome as it is so low.  In the three years of this study only one individual died, 
this individual had had preexisting TD for several years prior to enrolling in the study 
and at the time of study was considered to have inactive vasculitis, being well into the 
late “fibrotic” phase of this disease.   
 
Thus biomarkers such as those described herein must be utilized in the future to allow 
more realistic clinical endpoints in trials.  Alongside blood biomarkers, other possible 
endpoints could include more longterm responses to disease such as the assessment of 
structural  changes  in  arteries  and  overall  vascular  function,  using  non  invasive 
techniques  such  as  assessment  of  flow  mediated  dilatation,  pulse  wave  velocity  or 
intima media thickness.  These changes ultimately would reflect the balance between 
extent of injury and the ability to repair and may not be as influenced by treatment as 
some  of  the  rapidly  changing  blood  biomarkers  described  herein.    Assessment  of 
structure and function is an ongoing avenue of work within the group.   
 
Concluding remarks 
This study has been underlined by the common pathology of all the vasculitiides  – 
endothelial  injury.    By  focusing  on  this  pivotal  consequence  of  innappropriate  and 
sustained inflammation in the vessel wall, a number of putative biomarkers which have 
potential to be utilised clinically to assess disease activity, (particularly that which may 
not have overt clinical symptoms) have been assessed.  Of those studied CECs have 
proven the most robust to date, however methodological limitations restrict their use 330 
 
clinically to a research tool.  During this study it also became apparent that children may 
have differences relating to vasculogenic responses when compared to adults and that 
therapy necessary to promote disease remission may be influencing pathways involved 
in reparitive responses and thus could impact on the long term health of the vasculature.  
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Appendix 1 - Classification and definitions of Vasculitis  
Chapel Hill Consensus Criteria  (Jennette et al., 1994) 
Large vessel vasculitis 
 
Giant  cell 
(temporal) arteritis  
 
Granulomatous  arteritis  of  the  aorta  and  its  major  branches,  with  a 
predilection for the extracranial branches of the carotid artery. Often involves 
the  temporal  artery.  Usually  occurs  in  patients  older  than  50  and  often  is 
associated with polymyalgia rheumatica.  
 
Takayasu arteritis  
 
Granulomatous  inflammation  of  the  aorta  and  its  major  branches.  Usually 
occurs in patients younger than 50.  
 
Medium-sized vessel vasculitis 
 
Polyarteritis 
nodosa  (classic 
PAN)  
 
Necrotizing  inflammation  of  medium-sized  or  small  arteries  without 
glomerulonephritis or vasculitis in arterioles, capillaries, or venules. 
 
Kawasaki disease  
 
Arteritis  involving  large,  medium-sized,  and  small  arteries,  and  associated 
with  muco-cutaneous  lymph  node  syndrome.  Coronary  arteries  are  often 
involved. Aorta and veins may be involved. Usually occurs in children.  
Small vessel vasculitis 
 
Wegener’s 
granulomatosis  
 
Granulomatous inflammation involving the respiratory tract, and necrotizing 
vasculitis affecting small to medium-sized vessels (e.g., capillaries, venules, 
arterioles, and arteries). Necrotizing glomerulonephritis is common.  
 
Churg-Strauss 
syndrome  
 
Eosinophil-rich  and  granulomatous  inflammation  involving  the  respiratory 
tract, and necrotizing vasculitis affecting small to medium-sized vessels, and 
associated with asthma and eosinophilia.  
 
Microscopic 
polyangiitis 
(microscopic 
polyarteritis) 
 
Necrotizing  vasculitis,  with  few  or  no  immune  deposits,  affecting  small 
vessels (i.e., capillaries, venules, or arterioles). Necrotizing arteritis involving 
small  and  medium-  sized  arteries  may  be  present.  Necrotizing 
glomerulonephritis is very common. Pulmonary capillaritis often occurs.  
 
Henoch-Schönlein 
purpura  
 
Vasculitis, with IgA-dominant immune deposits, affecting small vessels (i.e., 
capillaries, venules, or arterioles). Typically involves skin, gut, and glomeruli, 
and is associated with arthralgias or arthritis.  
 
Essential 
cryoglobulinemic 
vasculitis  
 
Vasculitis, with cryoglobulin immune deposits, affecting small vessels (i.e., 
capillaries, venules, or arterioles), and associated with cryoglobulins in serum. 
Skin and glomeruli are often involved.  
 
Cutaneous 
leukocytoclastic 
angiitis  
 
Isolated  cutaneous  leukocytoclastic  angiitis  without  systemic  vasculitis  or 
glomerulonephritis.  
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American College of Rheumatology (ACR) Criteria, 1990  
Polyarteritis nodosa  
(Lightfoot, Jr. et al., 1990) modified for children (Brogan et al., 2002). The presence of 3 
or more of the criteria defines a patient as having PAN. Arteriography or biopsy are mandatory 
criteria 
  Weight loss of 5% or more (not due to diet or other factors) or failure to thrive 
  Livedo reticularis 
  Testicular pain or tenderness 
  Myalgias, weakness, or leg tenderness 
  Mononeuropathy or polyneuropathy 
  Systemic hypertension 
  Elevated blood urea nitrogen or creatinine 
  Hepatitis B virus -  presence of hepatitis B surface antigen or antibody in serum 
  Arteriographic abnormality -  aneurysms or occlusions of the visceral arteries, 
not  caused  by  arteriosclerosis,  fibromuscular  dysplasia,  or  other  non-
inflammatory causes 
  Biopsy of small- or medium-sized artery containing granulocytes/mononuclear 
leukocytes in vessel wall 
 
Wegener’s Granulomatosis   (Leavitt et al., 1990) 
Diagnosis requires the presence of two of the four criteria. The presence of any two or more 
criteria has a sensitivity of 88.2% and a specificity of 92.0%.  
  Nasal or oral inflammation – ulcers, nasal discharge 
  Abnormal-appearing chest radiograph  - Nodules, fixed infiltrates or cavities 
  Abnormal  urinary  sediment  -  Microhematuria  (>5  RBC/hpf)  or  RBC  casts 
(RBC- red blood cell) 
  Granulomatous inflammation within artery wall 
 
Takayasu’s disease  (Arend et al., 1990) 
The  presence  of  3  or  more  of  these  6  criteria  gives  a  sensitivity  of  90.5%  and  a 
specificity of 97.8%. 
  Onset at less than 40 years of age 
  Claudication of an extremity 
  Decreased brachial artery pulse 
  > 10mm Hg difference in blood pressure between arms 
  A bruit over the subclavian arteries or the aorta  
  Arteriographic  evidence  of  narrowing  or  occlusion  of  the  entire  aorta,  its 
primary branches, or large arteries in the proximal upper or lower extremities 
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Hypersensitivity vasculitis   (Calabrese et al., 1990) 
For classification, hypersensitivity vasculitis is defined if at least three of these criteria 
are present. The presence of any three or more criteria yields a sensitivity of 71.0% and 
specificity of 83.9%.  
  Age at onset >16 yr  (not relevant for children) 
  Medication  at  disease  onset  (agents  that  may  have  been  factor  in  disease 
development) 
  Palpable purpura – elevated rash over one of more areas of skin  – does not 
blanch with pressure 
  Maculopapular rash – flat raised lesions 
  Biopsy (including arteriole and venule) - showing granulocytes in perivascular 
of extravascular location 
 
Henoch-Schönlein purpura  (Mills et al., 1990) 
For classification, Henöch- Schonlein purpura is defined  if at least two of these criteria 
are present. The presence of any two or more criteria yields a sensitivity of 87.1% and 
specificity of 87.7%.  
  Palpable purpura 
  Age </=20 yr at onset 
  Bowel angina - diffuse abdominal pain, worse after meals, or the diagnosis of 
bowel ischemia, usually including bloody diarrhoea 
  Wall granulocytes on biopsy 
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EULAR/PReS endorsed consensus criteria for the classification 
of childhood vasculitides (Ozen et al., 2006) 
 
Predominantly large vessel vasculitis 
Takayasu arteritis 
Predominantly medium sized vessel vasculitis 
 
Childhood polyarteritis nodosa 
Cutaneous polyarteritis 
Kawasaki disease 
Predominantly small vessel vasculitis 
 
Granulomatous 
 
 
Wegener’s granulomatosis 
 Churg-Strauss syndrome 
 
Non-Granulomatous 
 
Microscopic polyangiitis 
Henoch-Schönlein purpura  
Isolated cutaneous leucocytoclastic 
vasculitis 
Hypocomplementic urticarial vasculitis 
 
Other vasculitides 
 
Behçet disease 
Vasculitis secondary to infection (including hepatitis B associatedpolyarteritis nodosa), 
malignancies, and drugs, including hypersensitivity vasculitis 
Vasculitis associated with connective tissue diseases 
 Isolated vasculitis of the central nervous system 
Cogan syndrome 
Unclassified 
 
 
Classification criteria:  
 
Henoch-Schönlein purpura 
 
Palpable purpura (mandatory criterion) in the presence of at least one of the following four 
features: 
  Diffuse abdominal pain 
  Any biopsy showing predominant IgA deposition 
  Arthritis (acute any joint) or arthralgia 
  Renal involvement (any haematuria and/or proteinuria) 335 
 
Kawasaki disease 
Fever persisting for at least five days (mandatory criterion) plus four of thefollowing five 
features: 
  Changes in peripheral extremities or perineal area 
  Polymorphous exanthema 
  Bilateral conjunctival injection 
  Changes of lips and oral cavity: injection of oral and pharyngeal mucosa 
  Cervical lymphadenopathy 
In the presence of coronary artery involvement (detected on echocardiography) and fever, fewer 
than four of the remaining five criteria are sufficient (the exact number of criteria 
 
Polyarteritis nodosa 
A systemic illness characterised by the presence of either a biopsy showing small and mid-size 
artery necrotising vasculitis OR angiographic abnormalities* (aneurysms or occlusions) 
(mandatory criteria), plus at least two of the following: 
  Skin involvement (livedo reticularis, tender subcutaneous nodules,other vasculitic 
lesions) 
  Myalgia or muscle tenderness 
  Systemic hypertension, relative to childhood normative data 
  Mononeuropathy or polyneuropathy 
  Abnormal urine analysis and/or impaired renal function (Glomerular filtration rate of 
less than 50% normal for age) 
  Testicular pain or tenderness 
  Signs or symptoms suggesting vasculitis of any other major organ system 
(gastrointestinal, cardiac, pulmonary, or central nervous system) 
*Should include conventional angiography if magnetic resonance angiography is negative. 
 
Wegener’s granulomatosis 
Three of the following six features should be present: 
  Abnormal urinalysis* (Haematuria and/or significant proteinuria.) 
  Granulomatous inflammation on biopsy_ 
  Nasal sinus inflammation 
  Subglottic, tracheal, or endobronchial stenosis 
  Abnormal chest x ray or CT 
  PR3 ANCA or C-ANCA staining 
*If a kidney biopsy is done it characteristically shows necrotising pauciimmune 
glomerulonephritis. 
 
Takayasu’s arteritis 
Angiographic abnormalities (conventional, CT, or MR) of the aorta or its main branches 
(mandatory criterion), plus at least one of the following four features: 
  Decreased peripheral artery pulse(s) and/or claudication of extremities 
  Blood pressure difference >10 mm Hg 
  Bruits over aorta and/or its major branches 
  Hypertension (related to childhood normative data) 
  CT, computed tomography; MR, magnetic resonance.
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Appendix 2 - The Birmingham Vasculitis Activity Score 
(Luqmani et al., 1994) 
Tick box only if abnormality is newly present or worsening within the previous 4 weeks 
and ascribable to vasculitis (changes from adult BVAS are in bold)  
 
1. SYSTEMIC           3 (maximum total)  
none             0 
malaise            1 
myalgia            1 
arthralgia/arthritis         1 
fever (<38.5°C)          1  
fever (>38.5°C)          2  
wt loss (1-2 kg) within past month    2  
wt loss (>2 kg) within past month     3  
 
2. CUTANEOUS         6 (maximum total)  
none            0  
infarct            2  
purpura            2 
other skin vasculitis         2 
ulcer             4 
gangrene           6 
multiple digit gangrene         6 
 
3. MUCOUS MEMBRANES/EYES     6 (maximum total)  
none             0 
mouth ulcers           1 
genital ulcers          1  
conjunctivitis           1 
episcleritis           2 
uveitis             6 
retinal exudates          6  
retinal haemorrhage         6 
 
 
4. ENT            6 (maximum total)  
nil             0 
nasal discharge/obstruction       2 
sinusitis            2 
epistaxis           4 
crusting            4 
aural discharge          4 
otitis media           4 
new deafness           6 
hoarseness/laryngitis         2 
subglottic involvement         6 
 
5. CHEST           6 (maximum total)  
none            0  
dyspnoea or wheeze         2 
nodules or fibrosis         2 
pleural effusion/pleurisy         4 
infiltrate           4 
haemoptysis/haemorrhage         4 337 
 
massive haemoptysis         6 
 
6. CARDIOVASCULAR      6 (maximum total) 
none             0 
bruits             2 
new loss of pulses         4 
aortic incompetence         4 
pericarditis           4 
new coronary artery lesions      4 
new myocardial infarct         6 
CCF/cardiomyopathy         6 
 
7. ABDOMINAL         9 (maximum total) 
none            0  
abdominal pain           3 
bloody diarrhoea          6 
gall bladder perforation         9 
gut infarction           9 
pancreatitis          9 
 
8. RENAL           12 (maximum total)  
none            0  
hypertension (systolic >95
th centile)     4 
proteinuria (>1 + or >20mmol/mg)     4 
haematuria (> 1 + or >10 rbc/ml)        8 
cGFR 50-80 mls/min/1.73m2      8 
cGFR 15-49 mls/min/1.73m2      10 
cGFR <15 mls/min/1.73m2        12 
rise in creatinine >10%         12 
 
9. NERVOUS SYSTEM        9 (maximum total) 
none            0            
organic confusion/dementia      3  
seizures (not hypertensive)        9  
stroke            9  
cord lesion           9           
peripheral neuropathy         6 
motor mononeuritis multiplex       9 
 
MAXIMUM SCORE       63 338 
 
Appendix 3 – Flow cytometry plans 
Microparticles tube plan 
 
22 tube plan – samples >200ul 
1.  Unstained MPs 
2.  AnV (beads) 
3.  AnV + IgG PE (BD) 
4.  AnV + IgG PE (Serotec) 
5.  AnV + IgG PE (ebiosciences) 
6.  AnV + IgG PE (Biolegend) 
7.  AnV + IgG CY5 (BD) 
8.  AnV + IgG PerCP (BD) 
9.  AnV + E-selectin PE (BD) 
10. AnV + P-selectin PE (BD) 
11. AnV + CD15 PE (Biolegend) 
12. AnV + CD144 PE (BD) 
13. AnV + CD105 PE (BD) 
14. AnV + CD66b PE (BD) 
15. AnV + CD42a PerCP (BD) 
16. AnV + ICAM-1 CY5 (BD) 
17. AnV + CD11b CY5 (BD) 
18. AnV + L-selectin PE (BD) 
19. AnV + TF PE (BD) 
20. AnV + CD14 PE (BD) 
21. AnV + CD3 CY5 PE (BD) 
22. AnV (beads) 
12  tube  plan  –  samples 
<200ul 
1.  Unstained MPs 
2.  AnV (beads) 
3.  AnV + IgG PE (BD) 
4.  AnV + IgG PE (Serotec) 
5.  AnV + IgG PE (ebiosciences) 
6.  AnV + IgG PerCP (BD) 
7.  AnV + E-selectin PE (BD) 
8.  AnV + CD144 PE (BD) 
9.  AnV + CD105 PE (BD) 
10. AnV + CD42a PerCP (BD) 
11. AnV + CD14 PE (BD) 
12. AnV (beads) 339 
 
EPC tube plan for frozen PBMCs 
23 tube plan 
1.  Unstained PBMCs 
2.  VEGFR2 isotype control 
3.  VEGFR2 
4.  CD144 isotype controls 
5.  CD144 
6.  CD45 isotype control 
7.  CD45 
8.  CD14 isotype contro*l 
9.  CD14* 
10. CD133 PE control 
11. CD133 
12. CD146 PE control 
13. CD146 
14. CD34 controls 
15. CD34  
16. CD3 control* 
17. CD3* 
18. VEGFR2/CD133/CD34 
19. CD144/CD133/CD34 
20. CD14/CD133/CD34* 
21. CD144/CD146/CD34* 
22. CD45/CD146/CD34 
23.  CD45/CD146/CD3*
12 tube plan  
1.  Unstained PBMCs 
2.  VEGFR2 isotype control 
3.  VEGFR2 
4.  CD144 isotype controls 
5.  CD144 
6.  CD133 PE control 
7.  CD133 
8.  CD34 controls 
9.  CD34  
10. VEGFR2/CD133/CD34 
11. CD144/CD133/CD34 
 
 
 
The 23 tube plan was used when samples have large numbers of PBMCs 
The 16 tube plan (same as the 23 plan, excluding tubes with *) was used for samples 
with between 5x10
6 and 10x10
6 frozen PBMCs  
The 11 well tube plan was used for samples with less than 5x10
6 frozen PBMCs 
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Appendix 4 – MP generation  
MPs were generated from paternt cells as described in section 4.3.2. 
 
Neutrophil MP generation – activation of parent cells 
 341 
 
Neutrophil MP generation – phenotype of MPs 
 342 
 
MPs  generated  from  TNFα  stimulated  PBMCS  - 
phenotype
 
Nb. PBMC samples isolated were lymphoprep often had platelet contamination, hence 
the high CD42a and P-selectin expression in this individual.   343 
 
MPs generated from TNFα stimulated endothelial cells -
activation of parent cells 
 
 
 344 
 
MPs generated from TNFα stimulated endothelial cells 
– phenotype 345 
 
Appendix 5 –  Standard graphs for ELISAs 
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Appendix 6 – Changes in CECs and MPs with disease 
activity in individual patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 1 – A 13 year old male with PAN, patient was not treatment naïve at onset of 
study and was followed from a flare (t=0). 348 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 2 – A 9 year old male with systemic vasculitis and colitis.  Patient was treatment 
naïve at onset of study. 349 
 
 
 
Patient 3 – A 10 year old male with PAN, patient was treatment naïve at start of study, 
at first presentation of disease. Notably this individual entered a period of disease flare 
at 23 months from disease onset. 350 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 4 - A 12 year old female with ANCA+ WG, this patient was treatment naïve at 
onset of study at disease presentation. Changes in this individual relating to CECs and 
MPS were highlighted in Figures  3.19  and 4.24.  Notably this  individual entered a 
period of systemic flare 12 months into their disease. 351 
 
Patient 5 - An 11 year old female with WG. This patient was treatment naïve at onset of 
study  at  disease  presentation.  Changes  in  this  individuals  CECs  and  MPs  were 
highlighted in figures 3.20 and 4.25.  Notably this patient had an episode of localized 
granulomatous flare 28 months into their disease (orbital). 352 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 6 – A 2 year old female with PAN who suffered a stroke at disease onset. Patient 
was treatment naïve at onset of study at presentation of disease. 353 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 7 -  A 6 year old male with PAN, this patient was treatment naïve at onset of 
study at disease presentation.   
   354 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 8 – A 15 year old male with WG, patient was treatment naïve at onset of study.  
15 months into treatment patient exhibited localized nasal symptoms.  By 19 months 
symptoms were more systemic, although CECs remained low. 
   355 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 9 – a 6 year old female with PAN. Patient was treatment naïve at onset of study 
at disease onset. 
 356 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 10 – a 1 year old female with PAN.  Patient was treatment naïve  at onset of 
study at disease onset. 357 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 11 – a 10 year female with PAN, presented with gastrointestinal inflammation. 
Patient was undergoing immunosuppression for this at onset of study. 358 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 12 – a 14 year old female with WG. Treatment had been instigated prior to 
study, although patient was observed at first presentation of disease. 359 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 13 -  a 12 year old male with PAN, patient was followed from a disease flare. 360 
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